PT J
AU Kollberg, G
   Jansson, M
   Pérez-Bercoff, Å
   Melberg, A
   Lindberg, C
   Holme, E
   Moslemi, AR
   Oldfors, A
AF Kollberg, G
   Jansson, M
   Pérez-Bercoff, Å
   Melberg, A
   Lindberg, C
   Holme, E
   Moslemi, AR
   Oldfors, A
TI Low frequency of mtDNA point mutations in patients with PEO associated with <i>POLG1</i> mutations
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mtDNA point mutations; multiple deletions; mitochondrial myopathy; polymerase gamma; progressive external ophthalmoplegia
ID progressive external ophthalmoplegia; mitochondrial-dna polymerase; autosomal-dominant; neurogastrointestinal encephalomyopathy; multiple deletions; gamma-a; twinkle; disorder; defects; muscle
AB Mitochondrial myopathy in progressive external ophthalmoplegia (PEO) has been associated with POLG1 mutations. POLG1 encodes the catalytic a subunit of polymerase c and is the only polymerase known to be involved in mtDNA replication. It has two functionally different domains, one polymerase domain and one exonuclease domain with proofreading activity. In this study we have investigated whether mtDNA point mutations are involved, directly or indirectly, in the pathogenesis of PEO. Muscle biopsy specimens from patients with POLG1 mutations, affecting either the exonuclease or the polymerase domain, were investigated. Single cytochrome c oxidase (COX)-deficient muscle fibers were dissected and screened for clonally expanded mtDNA point mutations using a sensitive denaturing gradient gel electrophoresis analysis, in which three different regions of mtDNA, including five different tRNA genes, were investigated. To screen for randomly distributed mtDNA point mutations in muscle, two regions of mtDNA including deletion breakpoints were investigated by high-fidelity PCR, followed by cloning and sequencing. Long-range PCR revealed multiple mtDNA deletions in all the patients but not the controls. No point mutations were identified in single COX-deficient muscle fibers. Cloning and sequencing of muscle homogenate identified randomly distributed point mutations at very low frequency in patients and controls (<1: 50 000). We conclude that mtDNA point mutations do not appear to be directly or indirectly involved in the pathogenesis of mitochondrial disease in patients with different POLG1 mutations.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Uppsala University; Uppsala University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@pathology.gu.se
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Domínguez BM, 2002, ARCH LATINOAM NUTR, V52, P219
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 26
TC 25
Z9 26
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD APR 15
PY 2005
VL 13
IS 4
BP 463
EP 469
DI 10.1038/sj.ejhg.5201341
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 909KF
UT WOS:000227858100015
PM 15702133
DA 2024-11-01
ER

PT J
AU Mohlke, KL
   Jackson, AU
   Scott, LJ
   Peck, EC
   Suh, YD
   Chines, PS
   Watanabe, RM
   Buchanan, TA
   Conneely, KN
   Erdos, MR
   Narisu, N
   Enloe, S
   Valle, TT
   Tuomilehto, J
   Bergman, RN
   Boehnke, M
   Collins, FS
AF Mohlke, KL
   Jackson, AU
   Scott, LJ
   Peck, EC
   Suh, YD
   Chines, PS
   Watanabe, RM
   Buchanan, TA
   Conneely, KN
   Erdos, MR
   Narisu, N
   Enloe, S
   Valle, TT
   Tuomilehto, J
   Bergman, RN
   Boehnke, M
   Collins, FS
TI Mitochondrial polymorphisms and susceptibility to type 2 diabetes-related traits in Finns
SO HUMAN GENETICS
LA English
DT Article
ID major noncoding region; insulin-resistance; skeletal-muscle; mapping genes; dna mutation; d-loop; mellitus; variant; prevalence; population
AB Mitochondria play an integral role in ATP production in cells and are involved in glucose metabolism and insulin secretion, suggesting that variants in the mitochondrial genome may contribute to diabetes susceptibility. In a study of Finnish families ascertained for type 2 diabetes mellitus (T2DM), we genotyped single nucleotide polymorphisms (SNPs) based on phylogenetic networks. These SNPs defined eight major haplogroups and subdivided groups H and U, which are common in Finns. We evaluated association with both diabetes disease status and up to 14 diabetes-related traits for 762 cases, 402 non-diabetic controls, and 465 offspring of genotyped females. Haplogroup J showed a trend toward association with T2DM affected status (OR 1.69, P=0.056) that became slightly more significant after excluding cases with affected fathers (OR 1.77, P=0.045). We also genotyped non-haplogroup-tagging SNPs previously reported to show evidence for association with diabetes or related traits. Our data support previous evidence for association of T16189C with reduced ponderal index at birth and also show evidence for association with reduced birthweight but not with diabetes status. Given the multiple tests performed and the significance levels obtained, this study suggests that mitochondrial genome variants may play at most a modest role in glucose metabolism in the Finnish population. Furthermore, our data do not support a reported maternal inheritance pattern of T2DM but instead show a strong effect of recall bias.
C1 Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA.
   Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
   Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA USA.
   Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Dept Epidemiol & Hlth Promot, Helsinki, Finland.
   Natl Publ Hlth Inst, Dept Biochem, Helsinki, Finland.
   Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   So Ostrobothnia Cent Hosp, Seinajoki, Finland.
C3 University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; University of Southern California; University of Southern California; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki
RP Univ N Carolina, Dept Genet, 4109-F Neurosci Res Bldg,103 Mason Farm Rd,CB 726, Chapel Hill, NC 27599 USA.
EM mohlke@med.unc.edu
FU Intramural NIH HHS Funding Source: Medline; NHGRI NIH HHS [HG00376] Funding Source: Medline; NIDDK NIH HHS [DK62370, DK27619, DK29867] Funding Source: Medline
CR Alcolado JC, 2002, DIABETIC MED, V19, P89, DOI 10.1046/j.1464-5491.2002.00675.x
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790
   Barrett TG, 2001, BEST PRACT RES CL EN, V15, P325, DOI 10.1053/beem.2001.0149
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Casteels K, 1999, LANCET, V353, P1499, DOI 10.1016/S0140-6736(98)05817-6
   Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Florez JC, 2003, ANNU REV GENOM HUM G, V4, P257, DOI 10.1146/annurev.genom.4.070802.110436
   Ghosh S, 2000, AM J HUM GENET, V67, P1174, DOI 10.1016/S0002-9297(07)62948-6
   Gill-Randall R, 2001, DIABETIC MED, V18, P413, DOI 10.1046/j.1464-5491.2001.00477.x
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Littell RC, 1996, SAS SYSTEMS MIXED MO, V0, P0
   Maca-Meyer N, 2001, BMC GENET, V2, P0, DOI 10.1186/1471-2156-2-13
   Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Marchington DR, 1996, HUM MOL GENET, V5, P473, DOI 10.1093/hmg/5.4.473
   McCarthy MI, 2004, HUM MOL GENET, V13, PR33, DOI 10.1093/hmg/ddh057
   Mohlke KL, 2002, P NATL ACAD SCI USA, V99, P16928, DOI 10.1073/pnas.262661399
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   NEWMAN B, 1987, DIABETOLOGIA, V30, P763
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622
   Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866
   Poulton J, 2004, J MED GENET, V41, P957, DOI 10.1136/jmg.2004.019208
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Poulton J, 2002, DIABETIC MED, V19, P969, DOI 10.1046/j.0742-3071.2002.00836.x
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315
   Richards M, 1996, AM J HUM GENET, V59, P185
   Richards MB, 1998, ANN HUM GENET, V62, P241, DOI 10.1046/j.1469-1809.1998.6230241.x
   Sbisà E, 1997, GENE, V205, P125, DOI 10.1016/S0378-1119(97)00404-6
   SHERROD LR, 1999, NATL HEAD START ASS, V2, P412
   Silander K, 2004, DIABETES, V53, P821, DOI 10.2337/diabetes.53.3.821
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121
   Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166
   Suzuki Y, 1997, METABOLISM, V46, P1019, DOI 10.1016/S0026-0495(97)90272-9
   Tawata M, 1998, DIABETES, V47, P276, DOI 10.2337/diab.47.2.276
   Tawata M, 2000, DIABETES, V49, P1269, DOI 10.2337/diabetes.49.7.1269
   Thomas AW, 1996, J MED GENET, V33, P253, DOI 10.1136/jmg.33.3.253
   Torroni A, 1996, GENETICS, V144, P1835
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   TUOMILEHTO J, 1991, INT J EPIDEMIOL, V20, P1010, DOI 10.1093/ije/20.4.1010
   Valle T, 1998, DIABETES CARE, V21, P949, DOI 10.2337/diacare.21.6.949
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 56
TC 65
Z9 68
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD NOV 15
PY 2005
VL 118
IS 2
BP 245
EP 254
DI 10.1007/s00439-005-0046-4
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 993YN
UT WOS:000233996300010
PM 16142453
DA 2024-11-01
ER

PT J
AU Elpeleg, O
   Miller, C
   Hershkovitz, E
   Bitner-Glindzicz, M
   Bondi-Rubenstein, G
   Rahman, S
   Pagnamenta, A
   Eshhar, S
   Saada, A
AF Elpeleg, O
   Miller, C
   Hershkovitz, E
   Bitner-Glindzicz, M
   Bondi-Rubenstein, G
   Rahman, S
   Pagnamenta, A
   Eshhar, S
   Saada, A
TI Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID nucleoside-diphosphate kinase; thymidine kinase; mutations; gene; synthetases; thiokinase; expression; eukaryotes; proteins; diseases
AB The mitochondrial DNA (mtDNA) depletion syndrome is a quantitative defect of mtDNA resulting from dysfunction of one of several nuclear-encoded factors responsible for maintenance of mitochondrial deoxyribonucleoside triphosphate (dNTP) pools or replication of mtDNA. Markedly decreased succinyl-CoA synthetase activity due to a deleterious mutation in SUCLA2, the gene encoding the beta subunit of the ADP-forming succinyl-CoA synthetase ligase, was found in muscle mitochondria of patients with encephalomyopathy and mtDNA depletion. Succinyl-CoA synthetase is invariably in a complex with mitochondrial nucleotide diphosphate kinase; hence, we propose that a defect in the last step of mitochondrial dNTP salvage is a novel cause of the mtDNA depletion syndrome.
C1 Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel.
   Ben Gurion Univ Negev, Fac Med, Soroka Med Ctr, Dept Pediat, IL-84105 Beer Sheva, Israel.
   UCL, Inst Child Hlth, Clin & Mol Genet Unit, London, England.
   UCL, Inst Child Hlth, Biochem Endocrinol & Metab Unit, London, England.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Ben Gurion University; Soroka Medical Center; University of London; University College London; University of London; University College London
RP Elpeleg, O (corresponding author), Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
EM Elpeleg@cc.huji.ac.il
CR ALLEN DA, 1986, FEBS LETT, V194, P171, DOI 10.1016/0014-5793(86)80071-0
   Andreoli C, 2004, NUCLEIC ACIDS RES, V32, PD459, DOI 10.1093/nar/gkh137
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200
   BRADSHAW PC, 2005, AM J PHYSL CELL PHYS, V0, P0
   CHA S, 1964, J BIOL CHEM, V239, P1961
   Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391
   DOOIJEWAARD G, 1976, BIOCHIM BIOPHYS ACTA, V440, P1, DOI 10.1016/0005-2728(76)90109-2
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8
   Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580
   Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573
   KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S
   KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264
   Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Parks RE, 1973, ENZYMES, VVIII, P307
   Rustin P, 1997, BBA-MOL BASIS DIS, V1361, P185, DOI 10.1016/S0925-4439(97)00035-5
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SANADI DR, 1954, BIOCHIM BIOPHYS ACTA, V14, P434, DOI 10.1016/0006-3002(54)90205-X
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   WEITZMAN PDJ, 1986, FEBS LETT, V199, P57, DOI 10.1016/0014-5793(86)81223-6
NR 33
TC 240
Z9 259
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN 15
PY 2005
VL 76
IS 6
BP 1081
EP 1086
DI 10.1086/430843
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 925IX
UT WOS:000229047900014
PM 15877282
DA 2024-11-01
ER

PT J
AU Chaturvedi, S
   Bala, K
   Thakur, R
   Suri, V
AF Chaturvedi, S
   Bala, K
   Thakur, R
   Suri, V
TI Mitochondrial encephalomyopathies: advances in understanding
SO MEDICAL SCIENCE MONITOR
LA English
DT Review
DE encephalomyopathies; mitochondrial disorders
ID ragged-red fibers; hereditary optic neuropathy; cytochrome-c-oxidase; clinical-features; necrotizing encephalomyelopathy; myoclonic epilepsy; dna; disease; mtdna; mutation
AB Mitochondrial encephatomyopathies encompass a group of disorders that have impaired oxidative metabolism in skeletal muscles and central nervous system. As the field of mitochondrial medicine takes shape and physicians in all specialties become increasingly aware of respiratory chain or oxidative phosphorylation (OXPHOS) related disorders, their prevalence remains largely unknown. The unique features of the mitochondrial genome and tire dual control over this important cellular apparatus makes the clinical presentation variable and diagnosis difficult. There is a confounding variation in phenotype and genotype, and the natural history of the disorders in individual patients is not accurately predictable. Only recently have things begun to fall into place and some phenotypes defined. Diagnosis requires a complex battery of clinical studies coupled with diagnostic findings on muscle biopsy (abnormal structure, histochemistry, or enzyme studies) or DNA testing. However, a reasonably confident diagnosis can be made by viewing the clinical presentation in the light of family history and some basic, routinely available laboratory investigations. This review tries to give a brief account of mitochondrial structure, function and genetics, and clinical presentation, evaluation, and treatment in suspected cases of mitochondrial encephalomyopathies.
C1 Inst Human Behav & Allied Sci, Dept Pathol, Delhi, India.
   Inst Human Behav & Allied Sci, Dept Neurol, Delhi, India.
   Inst Human Behav & Allied Sci, Dept Microbiol, Delhi, India.
RP GTB Hosp, D-2, Delhi 110095, India.
EM cysujata@hotmail.com
CR BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   BYRNE E, 1985, J NEUROL SCI, V71, P273, DOI 10.1016/0022-510X(85)90065-6
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAVID E, 1998, NEUROPATHOLOGY, V0, P0
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   FUKUHARA N, 1985, ANN NEUROL, V18, P368, DOI 10.1002/ana.410180323
   GEYER CA, 1988, J COMPUT ASSIST TOMO, V12, P40, DOI 10.1097/00004728-198801000-00006
   Ghosh SS, 1996, AM J HUM GENET, V58, P325
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   HALL K, 1978, NEURORADIOLOGY, V16, P48, DOI 10.1007/BF00395200
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P1371
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   JENITH JP, 1996, NAT GENET, V14, P146
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kimura S, 1997, BRAIN DEV-JPN, V19, P535, DOI 10.1016/S0387-7604(97)00074-0
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KURIYAMA M, 1984, NEUROLOGY, V34, P72, DOI 10.1212/WNL.34.1.72
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MUKOYAMA M, 1986, J NEUROL, V233, P228, DOI 10.1007/BF00314025
   MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   NEVILLE BGR, 1993, BRAINS DIS NERVOUS S, V0, P453
   Newman NJ, 1993, OPHTHALMOL CLIN N AM, V4, P431
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   PETERSON PL, 1988, NEUROL CLIN, V6, P529, DOI 10.1016/S0733-8619(18)30859-4
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   POULTON J, 1995, AM J HUM GENET, V57, P224
   ROBINSON BH, 1989, METABOLIC BASIS INHE, V1, P869
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Shoffner JM, 2000, NEUROL CLIN, V18, P105, DOI 10.1016/S0733-8619(05)70180-8
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 1998, CURR OPIN NEUROL, V11, P491, DOI 10.1097/00019052-199810000-00012
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace Douglas C, 1993, P63, V0, P0
   ZEMAN J, 1998, MED SCI MONITOR, V4, P436
   Zeviani M, 1997, CURR OPIN NEUROL, V10, P160, DOI 10.1097/00019052-199704000-00015
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
NR 52
TC 10
Z9 12
U1 0
U2 0
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
EI 
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUL 15
PY 2005
VL 11
IS 7
BP RA238
EP RA246
DI 
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 945ZK
UT WOS:000230541300024
PM 15990701
DA 2024-11-01
ER

PT J
AU Seneca, S
   Goemans, N
   Van Coster, R
   Givron, P
   Reybrouck, T
   Sciot, R
   Meulemans, A
   Smet, J
   Van Hove, JLK
AF Seneca, S
   Goemans, N
   Van Coster, R
   Givron, P
   Reybrouck, T
   Sciot, R
   Meulemans, A
   Smet, J
   Van Hove, JLK
TI A mitochondrial tRNA Aspartate mutation causing isolated mitochondrial myopathy
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE mitochondrial myopathy; exercise intolerance; mitochondrial DNA; tRNA genes; tRNA(Asp)
ID respiratory-chain; anaerobic threshold; diagnostic-criteria; familial myopathy; gas-exchange; exercise; gene; children; disorders; muscle
AB Several mutations in mitochondrial transfer RNA (tRNA) genes can cause mitochondrial myopathy. We describe a young girl who presented with pronounced exercise intolerance. The anaerobic threshold and the maximal oxygen consumption were decreased. She had decreased complex I and IV enzyme activity and ragged red fibers on muscle biopsy. An A to G transition at nucleotide position 7526 in tRNA Aspartate (tRNA(Asp)) gene was heteroplasmic in several of the patient's tissues. We were unable to detect the mutation in muscle tissue from the patient's mother. This case adds a new genetic etiology for mitochondrial myopathy. It also illustrates for patients with combined deficiency of the complex I and IV enzyme activity the value of sequencing in the affected tissue muscle, and not only in blood, all mitochondrial tRNA genes including those not commonly affected, such as in this case mt tRNA(Asp). (c) 2005 Wiley-Liss, Inc.
C1 Free Univ Brussels, Ctr Med Genet, Brussels, Belgium.
   Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Pediat, Louvain, Belgium.
   State Univ Ghent, Dept Pediat, B-9000 Ghent, Belgium.
   Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Pathol, Louvain, Belgium.
   Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80202 USA.
C3 Universite Libre de Bruxelles; KU Leuven; University Hospital Leuven; Ghent University; KU Leuven; University Hospital Leuven; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver
RP Childrens Hosp, Dept Pediat, Box B153,Tammen Hall 7T-26,1056 E 19th Ave, Denver, CO 80218 USA.
EM Johan.Vanhove@uchsc.edu
CR BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   HUGHSON RL, 1991, COMPUT BIOMED RES, V24, P118, DOI 10.1016/0010-4809(91)90024-Q
   JANKE A, 1994, GENETICS, V137, P243
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MILLER DL, 1981, J BIOL CHEM, V256, P9774
   *MIT, 2005, HUM MIT GEN DAT, V0, P0
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   REYBROUCK T, 1985, EUR J APPL PHYSIOL, V54, P278, DOI 10.1007/BF00426145
   Reybrouck T, 2001, EUR HEART J, V22, P1052, DOI 10.1053/euhj.2000.2425
   Rowland TW, 1997, CHEST, V111, P327, DOI 10.1378/chest.111.2.327
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Seneca S, 1998, J MED GENET, V35, P963, DOI 10.1136/jmg.35.11.963
   Shoffner JM, 2001, METABOLIC MOL BASES, V0, P2367
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   van Beekvelt MCP, 1999, ANN NEUROL, V46, P667, DOI 10.1002/1531-8249(199910)46:4<667::AID-ANA19>3.0.CO;2-D
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
NR 38
TC 27
Z9 28
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD AUG 30
PY 2005
VL 137A
IS 2
BP 170
EP 175
DI 10.1002/ajmg.a.30854
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 961AP
UT WOS:000231634600009
PM 16059939
DA 2024-11-01
ER

PT J
AU Arpa-Gutiérrez, FJ
   Cruz-Martínez, A
   Campos-González, Y
   Gutiérrez-Molina, M
   Santiago-Pérez, S
   Pérez-Conde, MC
   López-Pajares, MR
   Martín-Casarrubias, MA
   Rubio-Muñoz, JC
   del Hoyo, P
   Arpa-Fernández, A
   Arenas-Barbero, J
AF Arpa-Gutiérrez, FJ
   Cruz-Martínez, A
   Campos-González, Y
   Gutiérrez-Molina, M
   Santiago-Pérez, S
   Pérez-Conde, MC
   López-Pajares, MR
   Martín-Casarrubias, MA
   Rubio-Muñoz, JC
   del Hoyo, P
   Arpa-Fernández, A
   Arenas-Barbero, J
TI Mitochondrial respiratory chain diseases.: Evaluation and variability in 52 patients
SO REVISTA DE NEUROLOGIA
LA English
DT Article
DE electromyography; encephalopathy; genetics; mitochondrial disease; muscle biopsy; myopathy; neuropathy; respiratory chain disease
ID ragged-red fibers; mutation; dna; neuropathy; muscle; encephalomyopathy; epidemiology; deficiency; diagnosis; family
AB Introduction. Clinical, electrophysiological, genetic and biochemical deficiencies variability were evaluated in 52 patients diagnosed of mitochondrial respiratory chain diseases (MRCD). Patients and methods. 26 men and 26 women, aged 19 to 79 years, were tested by clinical examination, electrophysiological techniques, muscle biopsy and genetic and biochemical studies. Results. The patients were classified into seven phenotypes: myopathy, chronic progressive external ophthalmoplegia, progressive ophthalmoplegia plus ataxia, Kearns-Sayre syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke episodes (MELAS), myoclonic encephalopathy with ragged-red fibers (MERRF), and encephalopathies. Each phenotype may begin by different ways. The electromiography showed myopathy in 39 cases and various types of neuropathy in 10. Ragged-red COX negative fibers or widespread electron microscopic abnormalities were found in 47 cases. Simple deletions, multiple deletions and three different point mutations were observed. Deficiency of complexes I, II, III and IV were found alone or in different associations. Conclusions. MRCD shows wide variations in clinical, genetic and biochemical studies. Some patients with nonspecific manifestations, mainly of central nervous system, need careful attention and to be on account of diagnostic suspicion.
C1 Hosp Univ La Paz, Serv Neurol, E-28046 Madrid, Spain.
   Hosp Severo Ochoa, Madrid, Spain.
   Hosp 12 Octubre, E-28041 Madrid, Spain.
C3 Hospital Universitario La Paz; Severo Ochoa University Hospital; Hospital Universitario 12 de Octubre
RP Hosp Univ La Paz, Serv Neurol, Paseo Castellana,261, E-28046 Madrid, Spain.
EM jarpag@ctv.es
CR Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Birch-Machin M, 1993, MITOCHONDRIAL DYSFUN, V0, P51
   Blanco-Barca O, 2004, REV NEUROLOGIA, V39, P618
   CALABRESI PA, 1994, MUSCLE NERVE, V17, P943, DOI 10.1002/mus.880170815
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Castro-Gago M, 2000, REV NEUROLOGIA, V31, P263, DOI 10.33588/rn.3103.2000074
   CESEN W, 1972, ARCH NEUROL-CHICAGO, V26, P193
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P11697
   FAWCETT PRW, 1982, J NEUROL SCI, V53, P397, DOI 10.1016/0022-510X(82)90021-1
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   GEYER CA, 1988, J COMPUT ASSIST TOMO, V12, P40, DOI 10.1097/00004728-198801000-00006
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUBBARD JI, 1973, PHYSIOL REV, V53, P674, DOI 10.1152/physrev.1973.53.3.674
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   NAGEL T, 1993, PEDRIATR NEUROL, V9, P151
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   PAULAKIS SG, 1984, ANN NEUROL, V16, P481
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   PEYRONNARD JM, 1980, ANN NEUROL, V7, P262, DOI 10.1002/ana.410070310
   Pineda M, 2004, REV NEUROLOGIA, V38, P1023, DOI 10.33588/rn.3811.2004019
   Raspall-Chaure M, 2004, REV NEUROLOGIA, V39, P1129, DOI 10.33588/rn.3912.2004296
   Ricoy-Campo JR, 2003, REV NEUROLOGIA, V37, P775, DOI 10.33588/rn.3708.2002596
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   SMITH SJM, 1993, J NEUROL, V240, P367, DOI 10.1007/BF00839969
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   TEENER JW, 1994, ANN NEUROL, V36, P508
   TORBERGSEN T, 1991, MUSCLE NERVE, V14, P35
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Vladutiu GD, 2002, MUSCLE NERVE, V25, P649, DOI 10.1002/mus.10104
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
NR 50
TC 5
Z9 5
U1 1
U2 2
PU REVISTA DE NEUROLOGIA
PI BARCELONA
PA C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN
SN 0210-0010
EI 1576-6578
J9 REV NEUROLOGIA
JI Rev. Neurologia
PD OCT 16
PY 2005
VL 41
IS 8
BP 449
EP 454
DI 10.33588/rn.4108.2005206
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 979ZQ
UT WOS:000232984100001
PM 16224730
DA 2024-11-01
ER

PT J
AU Chuenkongkaew, WL
   Lertrit, P
   Limwongse, C
   Nilanont, Y
   Boonyapisit, K
   Sangruchi, T
   Chirapapaisan, N
   Suphavilai, R
AF Chuenkongkaew, WL
   Lertrit, P
   Limwongse, C
   Nilanont, Y
   Boonyapisit, K
   Sangruchi, T
   Chirapapaisan, N
   Suphavilai, R
TI An unusual family with Leber's hereditary optic neuropathy and facioscapulohumeral muscular dystrophy
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE 11778 mutation; 4q35 subtelomere; a Thai family; facioscapulohumeral muscular dystrophy; Leber's hereditary optic neuropathy
ID fshd
AB We performed an observational prospective analysis to study the clinical characteristics as well as a molecular genetic analysis of 17 members of a Thai family who had visual loss and/or muscle weakness. Their blood mitochondrial DNA were examined for the presence of the G11778A Leber's hereditary optic neuropathy (LHON) mutation. Facioscapulolmmeral muscular dystrophy (FSHD) DNA analysis was performed in four members who had visual loss. Of 17 family members, the eight members who had the 11778 LHON mutation were all from branch 'a'. Three of these eight members had FSHD with a 17-27-kb deletion of a tandem repeat in the 4q35 subtelomere, and two had been clinically diagnosed as FSHD. Four of six examined members in branch V showed muscular dystrophy clinically diagnosed as FSHD. No correlation of blood DNA analysis between LHON and FSHD in affected members was found. We describe the first family with FSHD and G11778A LHON in which a mutation in mitochondrial DNA at nucleotide position 11778 of branch 'a' was found to be the origin of the mutation.
C1 Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Bangkok 10700, Thailand.
   Mahidol Univ, Siriraj Hosp, Dept Biochem, Bangkok 10700, Thailand.
   Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok 10700, Thailand.
   Mahidol Univ, Siriraj Hosp, Dept Pathol, Bangkok 10700, Thailand.
C3 Mahidol University; Mahidol University; Mahidol University; Mahidol University
RP Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, 2 Prannok Rd, Bangkok 10700, Thailand.
EM siwck@mahidol.ac.th
CR DESAI UR, 1990, AM J OPHTHALMOL, V110, P568, DOI 10.1016/S0002-9394(14)77885-7
   FITZSIMONS RB, 1987, BRAIN, V110, P631, DOI 10.1093/brain/110.3.631
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Laforêt P, 2001, NEUROMUSCULAR DISORD, V11, P616
   LUNT PW, 1995, HUM MOL GENET, V4, P1243
   LUNT PW, 1995, HUM MOL GENET, V4, P951, DOI 10.1093/hmg/4.5.951
   NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4
   Orrell RW, 1999, NEUROLOGY, V52, P1822, DOI 10.1212/WNL.52.9.1822
   PADBERG GW, 1995, MUSCLE NERVE, V0, PS73
   PADBERG GW, 1997, DIAGNOSTIC CRITERIA, V0, P9
   RIODANEVA P, 1995, BRAIN, V118, P319
   SMITH KH, 1993, ARCH OPHTHALMOL-CHIC, V111, P1486, DOI 10.1001/archopht.1993.01090110052022
NR 12
TC 10
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAY 15
PY 2005
VL 12
IS 5
BP 388
EP 391
DI 10.1111/j.1468-1331.2004.01060.x
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 918EV
UT WOS:000228526000010
PM 15804271
DA 2024-11-01
ER

PT J
AU Kirino, Y
   Goto, Y
   Campos, Y
   Arenas, J
   Suzuki, T
AF Kirino, Y
   Goto, Y
   Campos, Y
   Arenas, J
   Suzuki, T
TI Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE mitochondrial tRNA; taurine modification
ID stroke-like episodes; transfer rnaleu(uur) gene; cells lacking mtdna; lactic-acidosis; point mutation; transcription termination; melas subgroup; dna mutations; encephalopathy; myopathy
AB Mutations in mtDNA are responsible for a variety of mitochondrial diseases, where the mitochondrial tRNA(Leu(UUR)) gene has especially hot spots for pathogenic mutations. Clinical features often depend on the tRNA species and/or positions of the mutations; however, molecular pathogenesis elucidating the relation between the location of the mutations and their leading phenotype are not fully understood. We report here that mitochondrial tRNAS(Leu(UUR)) harboring one of five mutations found in tissues from patients with symptoms of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (A3243G, G3244A, T3258C, T3271C, and T32911C) lacked the normal taurine-containing modification (5-taurinomethyluridine) at the anticodon wobble position. In contrast, mitochondrial tRNASLeu(UUR) with different mutations found in patients that have mitochondrial diseases but do not show the MELAS symptoms (G3242A, T3250C, C3254T, and A3280G) had the normal 5-taurinomethyluridine modifications. These observations were made by using a modified primer extension technique that can detect the modification deficiency in the extremely limited quantities of mutant tRNAs obtainable from patient tissues. These results strongly suggest deficient wobble modification could be a key molecular factor responsible for the phenotypic features of MELAS, which can explain why the different MELAS-associated mutations result in indistinguishable clinical features.
C1 Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan.
   Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1878502, Japan.
   Hosp 12 Octubre, Ctr Invest, E-28041 Madrid, Spain.
C3 University of Tokyo; University of Tokyo; National Center for Neurology & Psychiatry - Japan; Hospital Universitario 12 de Octubre
RP Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM ts@chembio.t.u-tokyo.ac.jp
CR Bjork GR, 1995, TRNA, V0, P165
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Grosjean H, 1998, MODIFICATION AND EDITING OF RNA, V0, P21
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOGA Y, 1988, ANN NEUROL, V24, P749, DOI 10.1002/ana.410240609
   MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4
   MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0
   RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki T, 2005, TOP CURR GENET, V12, P23, DOI 10.1007/b106361
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yokoyama Shigeyuki, 1995, P207, V0, P0
   2003, 1900, V13, V0, P277
NR 35
TC 138
Z9 165
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 17
PY 2005
VL 102
IS 20
BP 7127
EP 7132
DI 10.1073/pnas.0500563102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 928SO
UT WOS:000229292200015
PM 15870203
DA 2024-11-01
ER

PT J
AU Luo, NG
   Kaguni, LS
AF Luo, NG
   Kaguni, LS
TI Mutations in the Spacer region of <i>Drosophila</i> mitochondrial DNA polymerase affect DNA binding, processivity, and the balance between Pol and Exo function
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID i klenow fragment; progressive external ophthalmoplegia; crystal-structure; biochemical-characterization; frameshift fidelity; accessory subunit; catalytic subunit; 3'-5' exonuclease; thumb subdomain; active-site
AB The catalytic subunit (alpha) of mitochondrial DNA polymerase (poly) shares conserved DNA polymerase and 3'-5' exonuclease active site motifs with Escherichia coli DNA polymerase I and bacteriophage T7 DNA polymerase. A major difference between the prokaryotic and mitochondrial proteins is the size and sequence of the region between the exonuclease and DNA polymerase domains, referred to as the spacer in pol gamma-alpha. Four gamma-specific conserved sequence elements are located within the spacer region of the catalytic subunit in eukaryotic species from yeast to humans. To elucidate the functional roles of the spacer region, we pursued deletion and site-directed mutagenesis of Drosophila poly. Mutant proteins were expressed from baculovirus constructs in insect cells, purified to near homogeneity, and analyzed biochemically. We find that mutations in three of the four conserved sequence elements within the spacer alter enzyme activity, processivity, and/or DNA binding affinity. In addition, several mutations affect differentially DNA polymerase and exonuclease activity and/or functional interactions with mitochondrial single-stranded DNA-binding protein. Based on these results and crystallographic evidence showing that the template-primer binds in a cleft between the exonuclease and DNA polymerase domains in family A DNA polymerases, we propose that conserved sequences within the spacer of pol gamma may position the substrate with respect to the enzyme catalytic domains.
C1 Michigan State Univ, Grad Program Genet, E Lansing, MI 48823 USA.
   Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48823 USA.
C3 Michigan State University; Michigan State University
RP Michigan State Univ, Grad Program Genet, E Lansing, MI 48823 USA.
EM lskaguni@msu.edu
FU NIGMS NIH HHS [GM45295] Funding Source: Medline
CR Bailey MF, 2004, J MOL BIOL, V336, P673, DOI 10.1016/j.jmb.2003.11.023
   BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397
   COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Doublié S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0
   Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h
   Fansler B S, 1974, METHODS ENZYMOL, V29, P53
   Farr Carol L, 2002, METHODS MOL BIOL, V197, P273, DOI 10.1385/1-59259-284-8:273
   Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045
   Iyengar B, 1999, GENETICS, V153, P1809
   JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777
   JOYCE CM, 1982, J BIOL CHEM, V257, P1958
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693
   KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0
   KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264
   Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181
   Lam WC, 2002, BIOCHEMISTRY-US, V41, P3943, DOI 10.1021/bi0120603
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389
   Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954
   Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0
   OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972
   Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860
   WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2
NR 45
TC 33
Z9 39
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 28
PY 2005
VL 280
IS 4
BP 2491
EP 2497
DI 10.1074/jbc.M411447200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 889NG
UT WOS:000226449100015
PM 15537632
DA 2024-11-01
ER

PT J
AU Hinttala, R
   Uusimaa, J
   Remes, AM
   Rantala, H
   Hassinen, IE
   Majamaa, K
AF Hinttala, R
   Uusimaa, J
   Remes, AM
   Rantala, H
   Hassinen, IE
   Majamaa, K
TI Sequence analysis of nuclear genes encoding functionally important complex I subunits in children with encephalomyopathy
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE NADH ubiquinone oxidoreductase; mitochondria; nuclear genes
ID leigh-syndrome; ubiquinone oxidoreductase; liver mitochondria; aqdq subunit; ndufs4 gene; mutations; deficiency; patient; nadh; cardiomyopathy
AB Complex I has a vital role in the energy production of the cell, and the clinical spectrum of complex I deficiency varies from severe lactic acidosis in infants to muscle weakness in adults. It has been estimated that the cause of complex I deficiency, especially in children, is often a mutation in the nuclear-encoded genes and, more rarely, in the genes encoded by mitochondrial DNA. We sequenced nine complex I subunit coding genes, NDUFAB1, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFV1 and NDUFV2, in 13 children with defined complex I deficiency. Two novel substitutions were found: a synonymous replacement 201A > T in NDUFV2 and a non-synonymous base exchange 52C > T in NDUFS8. The 52C > T substitution produced the replacement Arg18Cys in the leading peptide of the TYKY subunit. This novel missense mutation was found as a heterozygote in one patient and her mother, but not among 202 healthy controls nor among 107 children with undefined encephalomyopathy. Bioinformatic analyses suggested that Arg18Cys could lead to marked changes in the physicochemical properties of the mitochondrial-targeting peptide of TYKY, but we could not see changes in the assembly or activity of complex I or in the transcription of NDUFS8 in the fibroblasts of our patient. We suggest that Arg18Cys in the leading peptide of the TYKY subunit is not solely pathogenic, and that other genetic factors contribute to the disease-causing potential of this mutation.
C1 Univ Oulu, Dept Neurol, Oulu 90014, Finland.
   Univ Oulu Hosp, Clin Res Ctr, Oulu 90014, Finland.
   Univ Oulu, Dept Pediat, Oulu 90014, Finland.
   Univ Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland.
C3 University of Oulu; University of Oulu; University of Oulu
RP Univ Oulu, Dept Neurol, POB 5000, Oulu 90014, Finland.
EM kari.majamaa@oulu.fi
CR Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   CHRZANOWSKALIGHTOWLERS ZMA, 1993, ANAL BIOCHEM, V214, P45, DOI 10.1006/abio.1993.1454
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2
   COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665
   Crane FL, 1971, METHODS IN ENZYMOLOGY, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6
   Dichgans M, 2000, EUR J HUM GENET, V8, P280, DOI 10.1038/sj.ejhg.5200460
   Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0
   Guénebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518
   Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   PFANNER N, 1997, CURR BIOL, V7, P100
   Procaccio V, 1997, BBA-GENE STRUCT EXPR, V1351, P37, DOI 10.1016/S0167-4781(97)00020-1
   Procaccio V, 2004, NEUROLOGY, V62, P1899, DOI 10.1212/01.WNL.0000125251.56131.65
   ROISE D, 1988, J BIOL CHEM, V263, P4509
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Sutton A, 2003, PHARMACOGENETICS, V13, P145, DOI 10.1097/00008571-200303000-00004
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   van den Heuvel LP, 2004, MITOCHONDRION, V4, P395, DOI 10.1016/j.mito.2004.07.005
   VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535
   VUOKILA PT, 1988, BIOCHEM J, V249, P339, DOI 10.1042/bj2490339
NR 38
TC 15
Z9 16
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD OCT 15
PY 2005
VL 83
IS 10
BP 786
EP 794
DI 10.1007/s00109-005-0712-y
PG 9
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 971RL
UT WOS:000232401600005
PM 16142472
DA 2024-11-01
ER

PT J
AU Sandhu, JK
   Sodja, C
   McRae, K
   Li, Y
   Rippstein, P
   Wei, YH
   Lach, B
   Lee, F
   Bucurescu, S
   Harper, ME
   Sikorska, M
AF Sandhu, JK
   Sodja, C
   McRae, K
   Li, Y
   Rippstein, P
   Wei, YH
   Lach, B
   Lee, F
   Bucurescu, S
   Harper, ME
   Sikorska, M
TI Effects of nitric oxide donors on cybrids harbouring the mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) A3243G mitochondrial DNA mutation
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE caspase-independent; electron transport chain; MELAS; mitochondrial DNA mutation; nitric oxide donor; reactive nitrogen and oxygen species
AB Reactive nitrogen and oxygen species (O-2(center dot-) H2O2, NO center dot and ONOO-) have been strongly implicated in the pathophysiology of neurodegenerative and mitochondrial diseases. In the present study, we examined the effects of nitrosative and/or nitrative stress generated by DETA-NO {(Z)-1-[2-aminoethyl-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate}, SIN-1 (3-morpholino-sydnonimine hydrochloride) and SNP (sodium nitroprusside) on U87MG glioblastoma cybrids carrying wt (wild-type) and mutant [A3243G (Ala(3243) -> Gly)] mtDNA (mitochondrial genome) from a patient suffering from MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). The mutant cybrids had reduced activity of cytochrome c oxidase, significantly lower ATP level and decreased mitochondrial membrane potential. However, endogenous levels of reactive oxygen species were very similar in all cybrids regardless of whether they carried the mtDNA defects or not. Furthermore, the cybrids were insensitive to the nitrosative and/or nitrative stress produced by either DETA-NO or SIN-1 alone. Cytotoxicity, however, was observed in response to SNP treatment and a combination of SIN-1 and glucose-deprivation. The mutant cybrids were significantly more sensitive to these insults compared with the wt controls. Ultrastructural examination of dying cells revealed several characteristic features of autophagic cell death. We concluded that nitrosative and/or nitrative stress alone were insufficient to trigger cytotoxicity in these cells, but cell death was observed with a combination of metabolic and nitrative stress. The vulnerability of the cybrids to these types of injury correlated with the cellular energy status, which were compromised by the MELAS mutation.
C1 Natl Res Council Canada, Inst Biol Sci, Neurogenesis & Brain Repair Grp, Ottawa, ON K1A 0R6, Canada.
   Ottawa Hosp, Dept Lab Med & Pathol, Ottawa, ON K1Y 4E9, Canada.
   Natl Yang Ming Univ, Dept Biochem, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Ctr Cellular & Mol Biol, Taipei 112, Taiwan.
   King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Riyadh 11211, Saudi Arabia.
   Hlth Canada, Banting Res Ctr, Ottawa, ON K1A 0L2, Canada.
   Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
C3 National Research Council Canada; University of Ottawa; Ottawa Hospital Research Institute; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; King Faisal Specialist Hospital & Research Center; Health Canada; University of Ottawa
RP Natl Res Council Canada, Inst Biol Sci, Neurogenesis & Brain Repair Grp, M54,1200 Montreal Rd, Ottawa, ON K1A 0R6, Canada.
EM jagdeep.sandhu@nrc.ca; marianna.sikorska@nrc.ca
CR AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0
   Baker MA, 2000, ANTIOXID REDOX SIGN, V2, P197, DOI 10.1089/ars.2000.2.2-197
   BATES JN, 1991, BIOCHEM PHARMACOL, V42, PS157, DOI 10.1016/0006-2952(91)90406-U
   Beltrán B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602
   Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001
   Candé C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200
   Fass U, 2004, BRAIN RES, V1005, P90, DOI 10.1016/j.brainres.2004.01.046
   GHADIALLY FN, 1997, ULTRASTRUCT PATHOL, V0, P195
   Ghafourifar P, 2001, BIOL SIGNAL RECEPT, V10, P57
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HARRISON DG, 1993, CIRCULATION, V87, P1461, DOI 10.1161/01.CIR.87.5.1461
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Keefer LK, 2003, ANNU REV PHARMACOL, V43, P585, DOI 10.1146/annurev.pharmtox.43.100901.135831
   King M P, 1996, METHODS ENZYMOL, V264, P313, DOI 10.1016/S0076-6879(96)64030-0
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282
   Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0
   Land SC, 1999, J EXP BIOL, V202, P211
   LARM JA, 1994, J BIOL CHEM, V269, P30097
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   LAWEN A, 1994, MOL ASPECTS MED, V15, P13
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702
   Niknahad H, 1996, BIOCHEM PHARMACOL, V51, P1031, DOI 10.1016/0006-2952(96)85086-6
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5
   Ramachandran A, 2002, P NATL ACAD SCI USA, V99, P6643, DOI 10.1073/pnas.102019899
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   SATOH MS, 1993, J BIOL CHEM, V268, P5480
   Tarnopolsky MA, 2004, MUSCLE NERVE, V29, P537, DOI 10.1002/mus.20020
   Thyagarajan B, 2002, BRIT J PHARMACOL, V137, P821, DOI 10.1038/sj.bjp.0704949
   Weber K, 2002, BIOL CHEM, V383, P283, DOI 10.1515/BC.2002.030
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Wiesner RJ, 1997, NEWS PHYSIOL SCI, V12, P178
   Williams AJ, 1999, J CHILD NEUROL, V14, P518, DOI 10.1177/088307389901400807
   Yamamoto T, 2000, P SOC EXP BIOL MED, V225, P200, DOI 10.1046/j.1525-1373.2000.22525.x
   Yasuda Masahiro, 1998, JOURNAL OF TOXICOLOGICAL SCIENCES, V23, P389
   Zigova T, 2001, DEV BRAIN RES, V127, P63, DOI 10.1016/S0165-3806(01)00107-9
NR 45
TC 22
Z9 23
U1 0
U2 1
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 2005
VL 391
IS 
BP 191
EP 202
DI 10.1042/BJ20050272
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 980DF
UT WOS:000232993400005
PM 15969653
DA 2024-11-01
ER

PT J
AU Finsterer, J
   Haberler, C
   Schmiedel, J
AF Finsterer, J
   Haberler, C
   Schmiedel, J
TI Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia
SO CLINICAL NEUROPHARMACOLOGY
LA English
DT Review
DE respiratory chain; local anesthetic; neuromuscular; side effect; adverse reaction
ID mitochondrial energy-metabolism; bupivacaine
AB Worsening of the neuromuscular manifestations in Kearns-Sayre syndrome after administering local anesthesia with articaine has not been reported. The authors describe a severe adverse reaction to local anesthesia with articaine for tooth extraction in a 28-year-old woman with Kearns-Sayre syndrome due to a 5.9-kb mitochondrial DNA deletion. The patient was subjected to local anesthesia with 1.5 mL (60 mg) articaine in the left submandibular nerve for tooth extraction. Five minutes after the injection the patient developed weakness of the limb muscles, extreme fatigue with increased desire to sleep, a feeling of heat, inappetence, and frequent urination. The adverse reaction resolved spontaneously within 48 hours without sequelae. Administration of articaine may cause severe side effects in patients with Kearns-Sayre syndrome. Articaine should be used with caution in these patients.
C1 Krankenanstalt Rudolfstiftung Wien, Dept Neurol, Vienna, Austria.
   Univ Vienna, Gen Hosp, Clin Inst Neurol, Sch Med, Vienna, Austria.
   Carl Gustav Carus Univ Dresden, Dept Neurol, Dresden, Germany.
C3 Rudolfstiftung Hospital; University of Vienna; Technische Universitat Dresden; Carl Gustav Carus University Hospital
RP Postfach 20, A-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200
   Nouette-Gaulain K, 2002, ANESTHESIOLOGY, V97, P1507, DOI 10.1097/00000542-200212000-00024
   Peñarrocha-Diago M, 2000, ORAL SURG ORAL MED O, V90, P21, DOI 10.1067/moe.2000.107506
   Scutari G, 1998, BIOCHEM PHARMACOL, V56, P1633, DOI 10.1016/S0006-2952(98)00192-0
   Sztark F, 1997, BIOCHEM MOL BIOL INT, V43, P997
   Tsutsumi Y, 2001, ANESTHESIOLOGY, V95, P766, DOI 10.1097/00000542-200109000-00032
NR 6
TC 20
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-5664
EI 1537-162X
J9 CLIN NEUROPHARMACOL
JI Clin. Neuropharmacol.
PD MAY-JUN 15
PY 2005
VL 28
IS 3
BP 148
EP 149
DI 10.1097/01.wnf.0000165352.10841.21
PG 2
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 941ND
UT WOS:000230220600012
PM 15965317
DA 2024-11-01
ER

PT J
AU Ishikawa, K
   Kasahara, A
   Watanabe, N
   Nakada, K
   Sato, A
   Suda, Y
   Aizawa, S
   Hayashi, JI
AF Ishikawa, K
   Kasahara, A
   Watanabe, N
   Nakada, K
   Sato, A
   Suda, Y
   Aizawa, S
   Hayashi, JI
TI Application of ES cells for generation of respiration-deficient mice carrying mtDNA with a large-scale deletion
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mouse Delta mtDNA; intercellular mtDNA transfer; ES cells; mitochondrial diseases; disease model mice
ID inter-mitochondrial complementation; protein-synthesis; mouse mtdna; dna; elimination; embryogenesis; dysfunction; myopathy; defects; mutant
AB In a previous study, we used mouse zygotes as recipients of mtDNA with a large-scale deletion mutation (Delta mtDNA) and generated respiration-deficient mice (mito-mice) carrying Delta mtDNA. In this study, we used mouse ES cells as recipients of Delta mtDNA, and generated mito-mice with Delta mtDNA only when the ES cells carried 17% Delta mtDNA. No chimera mice or their F, progenies were obtained from ES cells carrying more than 61% Delta mtDNA. These observations suggest that respiratory defects of ES cells inhibit their normal differentiation into chimera mice and mito-mice, and that ES cells are more effective than zygotes for generation of mito-mice carrying mtDNAs without significant pathogenic mutations. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058572, Japan.
   RIKEN, CDB, Lab Vertebrate Body, Kobe, Hyogo 6500047, Japan.
C3 University of Tsukuba; University of Tsukuba; RIKEN
RP Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
EM jib45@sakura.cc.tsukuba.ac.jp
CR Attardi G, 2002, NAT GENET, V30, P360, DOI 10.1038/ng0402-360
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Hayashi J, 2002, NAT GENET, V30, P361, DOI 10.1038/ng0402-361
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   McKenzie M, 2004, P NATL ACAD SCI USA, V101, P1685, DOI 10.1073/pnas.0303184101
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749
NR 20
TC 7
Z9 7
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2005
VL 333
IS 2
BP 590
EP 595
DI 10.1016/j.bbrc.2005.05.155
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 944HU
UT WOS:000230418700043
PM 15953585
DA 2024-11-01
ER

PT J
AU Levin, BC
   Sekiguchi, K
   Tully, LA
   Chen, TLJ
   Gropman, A
AF Levin, BC
   Sekiguchi, K
   Tully, LA
   Chen, TLJ
   Gropman, A
TI The common deletion found in patient reexamined after 33 years and comparison with complete mtDNA sequences of maternal relatives
SO MITOCHONDRION
LA English
DT Article
DE chronic progressive external ophthalmoplegia; CPEO; haplogroup K; mitochondrial DNA (mtDNA); mitochondrial disease; ptosis; ragged-red fibers
ID human mitochondrial-dna; mutation
AB In 1966, a male (17 years old) was clinically examined at the National Institutes of Health (NIH) and diagnosed with Idiopathic Progressive External Ophthalmoplegia (IPEO). A muscle biopsy showing ragged-red fibers implicated mitochondrial involvement. Since the sequence of human mitochondrial DNA (mtDNA) was not determined until 1981, no genetic confirmation of the disease was possible at that time. In 1999, clinical reexamination and sequencing the entire mtDNA of the patient and living maternal relatives (mother and brother) indicated a progressive mitochondrial myopathy and the presence of the 4977 base pair (bp) deletion (the common deletion) in the patient. Published by Elsevier B.V. on behalf of Mitochondria Research Society.
C1 Natl Inst Stand & Technol, Div Biotechnol, Gaithersburg, MD 20899 USA.
   Natl Res Inst Police Sci, Kashiwa, Chiba, Japan.
   Natl Inst Justice, Invest & Forens Sci Div, Washington, DC USA.
   Penn State Univ, Milton S Hershey Med Ctr, Dept Surg, Hershey, PA 17033 USA.
   Georgetown Univ, Ctr Funct & Mol Imaging, Washington, DC USA.
   NHGRI, NIH, Bethesda, MD 20892 USA.
C3 National Institute of Standards & Technology (NIST) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)
RP Levin, BC (corresponding author), Natl Inst Stand & Technol, Div Biotechnol, 100 Bur Dr,MS 8311, Gaithersburg, MD 20899 USA.
EM barbara.levin@nist.gov
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lee MS, 2002, MITOCHONDRION, V1, P321, DOI 10.1016/S1567-7249(01)00031-9
   Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Ro LS, 2003, MUSCLE NERVE, V28, P737, DOI 10.1002/mus.10504
   Thayer RE, 2003, EXP GERONTOL, V38, P567, DOI 10.1016/S0531-5565(03)00033-0
   WALLACE DC, 1996, EMERY RIMOINS PRINCI, V1, P277
   WEI YH, 1992, MUTAT RES, V275, P145, DOI 10.1016/0921-8734(92)90019-L
   Zullo Steven J, 2002, METHODS MOL BIOL, V197, P119, DOI 10.1385/1-59259-284-8:119
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD DEC 15
PY 2005
VL 5
IS 6
BP 403
EP 410
DI 10.1016/j.mito.2005.08.001
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 997HL
UT WOS:000234236000003
PM 16172025
DA 2024-11-01
ER

PT J
AU Coulbault, L
   Herlicoviez, D
   Chapon, F
   Read, MH
   Penniello, MJ
   Reynier, P
   Fayet, G
   Lombès, A
   Jauzac, P
   Allouche, S
AF Coulbault, L
   Herlicoviez, D
   Chapon, F
   Read, MH
   Penniello, MJ
   Reynier, P
   Fayet, G
   Lombès, A
   Jauzac, P
   Allouche, S
TI A novel mutation in the mitochondrial tRNA<SUP>Asn</SUP> gene associated with a lethal disease
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE lethal infantile mitochondrial disease; mtDNA; tRNA(Asn) gene mutation; respiratory chain deficiency; cytochrome c oxidase deficiency
ID myopathy; sequence; rna
AB We describe a lethal mitochondrial disease in a 10-month-old child who presented with encephalomyopathy. Histochemical and electron microscopy examinations of skeletal muscle biopsy revealed abnormal mitochondria associated with a combined deficiency of complexes I and IV. After excluding mitochondrial DNA deletions and depletion, direct sequencing was used to screen for mutation in all transfer RNA (tRNA) genes. A T-to-C Substitution at position 5693 in the tRNA(Asn) gene was found in blood and muscle. Microdissection of muscle biopsy and its analysis revealed the highest level of this mutation in cytochrome c oxidase (COX)-negative fibres. We suggest that this novel mutation would affect the anticodon loop structure of the tRNA(Asn) and cause a fatal mitochondrial disease. (c) 2005 Elsevier Inc. All rights reserved.
C1 Ctr Hosp, Biochim Lab A, F-14033 Caen, France.
   Univ Caen, F-14033 Caen, France.
   Ctr Hosp, Serv Anat Pathol, F-14033 Caen, France.
   Ctr Hosp, Dept Genet & Reprod, F-14033 Caen, France.
   Ctr Hosp, Dept Pediat, F-14033 Caen, France.
   Ctr Hosp, Lab Biochim & Biol Mol, INSERM, U694, F-14033 Caen, France.
   Ctr Hosp, Inst Myol, INSERM, U582, F-75013 Paris, France.
   Univ Pitie Salpetriere, F-75013 Paris, France.
C3 CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen NORMANDIE; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; Sorbonne Universite
RP Ctr Hosp, Biochim Lab A, Ave Cote Nacre, F-14033 Caen, France.
EM allouche-s@chu-caen.fr
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Malgat M, 1999, MITOCHONDRIAL DISEASES, V0, PP357, DOI 10.1007/978-3-642-59884-5_27
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   REYNIER P, 1999, MITOCHONDRIAL DIS, V0, P379
   Romero NB, 1999, MITOCHONDRIAL DISEASES- MODELS AND METHODS, V0, P343
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
NR 13
TC 13
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 15
PY 2005
VL 329
IS 3
BP 1152
EP 1154
DI 10.1016/j.bbrc.2005.02.083
PG 3
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 909UI
UT WOS:000227885800048
PM 15752774
DA 2024-11-01
ER

PT J
AU Davidzon, G
   Mancuso, M
   Ferraris, S
   Quinzii, C
   Hirano, M
   Peters, HL
   Kirby, D
   Thorburn, DR
   DiMauro, S
AF Davidzon, G
   Mancuso, M
   Ferraris, S
   Quinzii, C
   Hirano, M
   Peters, HL
   Kirby, D
   Thorburn, DR
   DiMauro, S
TI <i>POLG</i> mutations and Alpers syndrome
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID mitochondrial-dna depletion; progressive external ophthalmoplegia; polymerase-gamma-a; thymidine kinase; degeneration; disease; gene; childhood; deficiency; features
AB Alpers-Huttenlocher syndrome (AHS) an autosomal recessive hepatocerebral syndrome of early onset, has been associated with mitochondrial DNA (mtDNA) depletion and mutations in polymerase gamma gene (POLG). We have identified POLG mutations in four patients with hepatocerebral syndrome and mtDNA depletion in liver, who fulfilled. criteria for AHS. All were compound heterozygous for the G848S and W748S mutations, previously reported in patients with progressive external ophtalmoplegia or ataxia. We conclude that AHS should be included in the clinical spectrum of mtDNA depletion and is often associated with POLG mutations, which can cause either multiple mtDNA deletions or mtDNA depletion.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Univ Pisa, Inst Neurol, Dept Neurosci, Pisa, Italy.
   Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   Victoria Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   Victoria Royal Childrens Hosp, Genet Hlth Serv, Melbourne, Vic, Australia.
C3 Columbia University; University of Pisa; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne
RP Columbia Univ, Coll Phys & Surg 4 420, 630 West 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   PRICK MJJ, 1983, CLIN NEUROL NEUROSUR, V85, P57, DOI 10.1016/0303-8467(83)90024-0
   Rasmussen M, 2000, J CHILD NEUROL, V15, P473, DOI 10.1177/088307380001500709
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
NR 20
TC 102
Z9 107
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JUN 15
PY 2005
VL 57
IS 6
BP 921
EP 923
DI 10.1002/ana.20498
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 931XH
UT WOS:000229518300019
PM 15929042
DA 2024-11-01
ER

PT J
AU Lee, CF
   Liu, CY
   Chen, SM
   Sikorska, M
   Lin, CY
   Chen, TL
   Wei, YH
AF Lee, CF
   Liu, CY
   Chen, SM
   Sikorska, M
   Lin, CY
   Chen, TL
   Wei, YH
TI Attenuation of UV-induced apoptosis by coenzyme Q<sub>10</sub> in human cells harboring large-scale deletion of mitochondrial DNA
SO ROLE OF THE MITOCHONDRIA IN HUMAN AGING AND DISEASE: FROM GENES TO CELL SIGNALING
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; mutation; apoptosis; UV irradiation; coenzyme Q(10)
ID oxidative stress; molecular-mechanisms; encephalomyopathy; activation; mutations; increase; diseases; coq(10); pathway
AB Chronic progressive external ophthalmoplegia (CPEO) syndrome is one of the mitochondrial diseases caused by large-scale deletions in mitochundrial DNA (mtDNA) that impair the respiratory function of mitochondria and result in decreased production of ATP in affected tissues. In order to investigate whether CPEO-associated mtDNA mutations (i.e., 4,366-bp and 4,977bp large-scale deletions) render human cells more vulnerable to apoptosis, we constructed cybrids carrying the deleted mtDNA. Assays for cell viability, DNA fragmentation, cytochrome c release, and caspase 3 activation revealed that UV irradiation at 20 J/m(2) triggered apoptosis in all the cybrids. This treatment also produced elevated intracellular levels of reactive oxygen species (ROS). The rate of UV-induced cell death was more pronounced in the cybrids harboring mtDNA deletions than in the control cybrid with wild-type mtDNA. Subsequently, we evaluated the effect of coenzyme Q10 on the UV-triggered apoptosis. The results showed that after pretreatment of the cybrids with 100 mu M coenzyme Q10 the UV-induced cell damage (i.e., ROS production and activation of caspase 3) was significantly reduced. Taken together, these findings suggest that large-scale deletions of mtDNA increased the susceptibility of human cells to the UV-triggered apoptosis and that coenzyme Q10 mitigated the damage; hence, it might potentially serve as a therapeutic agent to treat mitochondrial diseases resulting from mtDNA deletions.
C1 Natl Yang Ming Univ, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Ctr Cellular & Mol Biol, Taipei 112, Taiwan.
   Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Research Council Canada
RP Natl Yang Ming Univ, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
CR Beal MF, 2002, FREE RADICAL RES, V36, P455, DOI 10.1080/10715760290021315
   BOROWYBOROWSKI M, 2004, PATENT NO. 6045826, V0, P0
   BOROWYBOROWSKI M, 2004, PATENT NO. 6191172, V0, P0
   Chuang YC, 2003, SHOCK, V19, P427, DOI 10.1097/01.shk.0000048900.46342.37
   FORSMARKANDREE P, 1994, MOL ASPECTS MED, V15, P73, DOI 10.1016/0098-2997(94)90015-9
   HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x
   Langsjoen PH, 1999, BIOFACTORS, V9, P273, DOI 10.1002/biof.5520090224
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425
   LIN FH, 1992, BIOCHEM BIOPH RES CO, V182, P238, DOI 10.1016/S0006-291X(05)80136-6
   Liou CW, 2000, EUR NEUROL, V43, P54, DOI 10.1159/000008130
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   McCarthy S, 2004, TOXICOL APPL PHARM, V201, P21, DOI 10.1016/j.taap.2004.04.019
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6
   Sandhu JK, 2003, J NEUROSCI RES, V72, P691, DOI 10.1002/jnr.10579
   Shiah SG, 1999, CANCER RES, V59, P391
   Sikorska M, 2003, BIOFACTORS, V18, P173, DOI 10.1002/biof.5520180220
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
NR 25
TC 16
Z9 27
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2005
VL 1042
IS 
BP 429
EP 438
DI 10.1196/annals.1338.036
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics
GA BCR22
UT WOS:000230893400050
PM 15965089
DA 2024-11-01
ER

PT J
AU Bayona-Bafaluy, MP
   Blits, B
   Battersby, BJ
   Shoubridge, EA
   Moraes, CT
AF Bayona-Bafaluy, MP
   Blits, B
   Battersby, BJ
   Shoubridge, EA
   Moraes, CT
TI Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE gene therapy; mitochondria
ID central-nervous-system; mtdna; vectors; transduction; expression; therapy; disease; muscle; mice; replication
AB Frequently, mtDNA with pathogenic mutations coexist with wildtype genomes (mtDNA heteroplasmy). Mitochondrial dysfunction and disease ensue only when the proportion of mutated mtDNAs is high, thus a reduction in this proportion should provide an effective therapy for these disorders. We developed a system to decrease specific mtDNA haplotypes by expressing a mitochondrially targeted restriction endonuclease, ApaLI, in cells of heteroplasmic mice. These mice have two mtDNA haplotypes, of which only one contains an ApaLI site. After transfection of cultured hepatocytes with mitochondrially targeted ApaLI, we found a rapid, directional, and complete shift in mtDNA heteroplasmy (2-6 h). We tested the efficacy of this approach in vivo, by using recombinant viral vectors expressing the mitochondrially targeted ApaLI. We observed a significant shift in mtDNA heteroplasmy in muscle and brain transduced with recombinant viruses. This strategy could prevent disease onset or reverse clinical symptoms in patients harboring certain heteroplasmic pathogenic mutations in mtDNA.
C1 Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.
   McGill Univ, Montreal Neurol Inst, Dept Human Genet, Montreal, PQ H3A B34, Canada.
C3 University of Miami; University of Miami; University of Miami; McGill University
RP Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU NEI NIH HHS [P30 EY014801, R01 EY010804, EY014801, R01 EY010804-08, EY10804, R01 EY010804-07] Funding Source: Medline; NINDS NIH HHS [NS41777, R56 NS041777, R01 NS041777] Funding Source: Medline
CR Amalfitano A, 2004, METHODS, V33, P173, DOI 10.1016/j.ymeth.2003.11.006
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200
   Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024
   Cao HB, 2004, VIRAL IMMUNOL, V17, P327, DOI 10.1089/vim.2004.17.327
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197
   De Giorgi F, 1999, METHOD CELL BIOL, V58, P75
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   Passini MA, 2003, J VIROL, V77, P7034, DOI 10.1128/JVI.77.12.7034-7040.2003
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Santos MAS, 2004, TRENDS GENET, V20, P95, DOI 10.1016/j.tig.2003.12.009
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Taylor RW, 2000, NEUROL SCI, V21, PS909, DOI 10.1007/s100720070002
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Wang YL, 2000, ADV PHARMACOL, V47, P343
NR 32
TC 127
Z9 152
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 4
PY 2005
VL 102
IS 40
BP 14392
EP 14397
DI 10.1073/pnas.0502896102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 971OD
UT WOS:000232392900049
PM 16179392
DA 2024-11-01
ER

PT J
AU Anitori, R
   Manning, K
   Quan, F
   Weleber, RG
   Buist, NRM
   Shoubridge, EA
   Kennaway, NG
AF Anitori, R
   Manning, K
   Quan, F
   Weleber, RG
   Buist, NRM
   Shoubridge, EA
   Kennaway, NG
TI Contrasting phenotypes in three patients with novel mutations in mitochondrial tRNA genes
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mitochondrial myopathy; mitochondrial encephalomyopathy; pigmentary retinopathy; mitochondrial DNA; mitochondrial tRNA mutation; complex I deficiency; complex IV deficiency; cytochrome c oxidase negative fibers; hair root analysis; pathogenesis of mitochondrial tRNA mutations
ID mtdna point mutation; dna mutations; diabetes-mellitus; protein-synthesis; skeletal-muscle; wild-type; myopathy; exercise; deficiency; melas
AB We studied three patients, each harboring a novel mutation at a highly conserved position in a different mitochondrial tRNA gene. The mutation in patient 1 (T5543C) was associated with isolated mitochondrial myopathy, and occurred in the anticodon loop of tRNA(Trp). In patient 2, with mitochondrial myopathy and marked retinopathy, the mutation (G14710A) resulted in an anticodon swap (Glu to Lys) in tRNA. Patient 3, who manifested mitochondrial encephalomyopathy and moderate retinal dysfunction, harbored a mutation (C3287A) in the TpsiC loop of tRNA(Leuf(UUR)). The mutations were heteroplasmic in muscle in all cases, and sporadic in two cases. PCR-RFLP analysis in all patients showed much higher amounts of mutated mtDNA in affected tissue (muscle) than unaffected tissue (blood), and significantly higher levels of mutated mtDNA in cytochrome c oxidase (COX)-negative muscle fibers than in COX-positive fibers, confirming the pathogenicity of these mutations. The mutation was also detected in single hair roots from all three patients, indicating that each mutation must have arisen early in embryonic development or in maternal germ cells. This suggests that individual hair root analyses may reflect a wider tissue distribution of mutated mtDNA than is clinically apparent, and might be useful in predicting prognosis and, perhaps, the risk of transmitting the mutation to offspring. Our data suggest a correlation between clinical phenotype and distribution of mutated mtDNA in muscle versus hair roots. Furthermore, the high threshold for phenotypic expression in single muscle fibers (92-96%) suggests that therapies may only need to increase the percentage of wildtype mtDNA by a small amount to be beneficial. (C) 2004 Elsevier Inc. All rights reserved.
C1 Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
C3 Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; McGill University
RP Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
EM kennaway@ohsu.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   ANITORI RP, 1999, P 4 EUR M MIT PATH, V0, P73
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   LI H, 1991, METHODS (ORLANDO), V2, P49, DOI 10.1016/S1046-2023(05)80125-2
   *MITOMAP, 2004, HUM MIT GEN DAT, V0, P0
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Pallanck Leo, 1995, P371, V0, P0
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Raha S, 1999, HUM MUTAT, V13, P245, DOI 10.1002/(SICI)1098-1004(1999)13:3<245::AID-HUMU9>3.0.CO;2-B
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   SHOFFNER JM, 2001, METABOLIC MOL BASES, V2, P2367
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Suzuki Y, 1997, DIABETES CARE, V20, P1138, DOI 10.2337/diacare.20.7.1138
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   VILARINHO L, 2001, P 5 EUR M MIT PATH V, V0, P297
   WASSERMAN K, 1985, J APPL PHYSIOL, V59, P935, DOI 10.1152/jappl.1985.59.3.935
   WILICHOWSKI E, 2001, P 5 EUR M MIT PATH V, V0, P307
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 55
TC 36
Z9 37
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD FEB 15
PY 2005
VL 84
IS 2
BP 176
EP 188
DI 10.1016/j.ymgme.2004.10.003
PG 13
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 901RP
UT WOS:000227299900011
PM 15670724
DA 2024-11-01
ER

PT J
AU Yokoi, F
   Dang, MT
   Mitsui, S
   Li, YQ
AF Yokoi, F
   Dang, MT
   Mitsui, S
   Li, YQ
TI Exclusive paternal expression and novel alternatively spliced variants of ε-sarcoglycan mRNA in mouse brain
SO FEBS LETTERS
LA English
DT Article
DE epsilon-sarcoglycan; epsilon-sarcoglycan gene; imprinting; PDZ-binding motif; myoclonus-dystonia
ID myoclonus-dystonia-syndrome; nitric-oxide synthase; mitochondrial-dna; alpha-sarcoglycan; gene; mutations; cre; identification; recombinase; muscle
AB Mutations of SGCE encoding epsilon-sarcoglycan cause myoclonus-dystonia. SGCE is paternally expressed; however, 5-10% of patients show maternal inheritance of the disease. We found Sgce was exclusively paternally expressed in mice by using a novel polymorphism marker. The result was confirmed in Sgce heterozygous knockout mice. This finding suggests that maternally inherited myoclonus-dystonia may not result from maternal expression of SGCE. Furthermore, we report a new family of alternatively spliced Sgce mRNA expressed in the brain coding for different C-terminal sequences possessing a PDZ-binding motif. Our results provide a better basis for diagnosis and understanding of the pathogenesis of myoclonus-dystonia. (c) 2005 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
C1 Univ Illinois, Beckman Inst Adv Sci & Technol, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign
RP Univ Illinois, Beckman Inst Adv Sci & Technol, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.
EM y-li4@uiuc.edu
CR Asmus F, 2002, ANN NEUROL, V52, P489, DOI 10.1002/ana.10325
   Asmus Friedrich, 2004, ADV NEUROL, V94, P113
   Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3
   Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364
   Ettinger AJ, 1998, J BIOL CHEM, V273, P19922
   Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534
   Fahn S, 1988, ADV NEUROL, V50, P1
   Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T
   Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893
   Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893
   Furukawa Y, 2002, NEUROLOGY, V59, P1130, DOI 10.1212/WNL.59.8.1130
   Grabowski M, 2003, EUR J HUM GENET, V11, P138, DOI 10.1038/sj.ejhg.5200938
   Grundmann K, 2004, MOVEMENT DISORD, V19, P1294, DOI 10.1002/mds.20128
   Guo HL, 2000, BIOCHEM BIOPH RES CO, V269, P149, DOI 10.1006/bbrc.2000.2263
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   Han F, 2003, NEUROLOGY, V61, P244, DOI 10.1212/01.WNL.0000073142.40185.C1
   Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Klein C, 2002, CURR OPIN NEUROL, V15, P491, DOI 10.1097/00019052-200208000-00014
   Leung JC, 2001, NEUROGENETICS, V3, P133, DOI 10.1007/s100480100111
   Matise MP, 2000, PRACT APPROACH SER, V212, P101
   McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7
   Müller B, 2002, AM J HUM GENET, V71, P1303, DOI 10.1086/344531
   Németh AH, 2002, BRAIN, V125, P695, DOI 10.1093/brain/awf090
   Nishiyama A, 2004, MOL BRAIN RES, V125, P1, DOI 10.1016/j.molbrainres.2004.01.012
   Ono R, 2003, GENOME RES, V13, P1696, DOI 10.1101/gr.906803
   Papaioannou V, 2000, PRACT APPROACH SER, V212, P133
   Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000
   SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166
   Schüle B, 2004, J NEUROL NEUROSUR PS, V75, P1181, DOI 10.1136/jnnp.2003.027177
   Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080
   Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1
   Smallwood A, 2003, BIOL REPROD, V69, P286, DOI 10.1095/biolreprod.102.013078
   SNAITH MR, 1995, GENE, V166, P173, DOI 10.1016/0378-1119(95)00579-8
   Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989
   Valente EM, 2005, NEUROLOGY, V64, P737, DOI 10.1212/01.WNL.0000151979.68010.9B
   Valente EM, 2003, MOVEMENT DISORD, V18, P1047, DOI 10.1002/mds.10476
   Zimprich A, 2001, NAT GENET, V29, P66, DOI 10.1038/ng709
NR 38
TC 25
Z9 30
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD AUG 29
PY 2005
VL 579
IS 21
BP 4822
EP 4828
DI 10.1016/j.febslet.2005.07.065
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 960XF
UT WOS:000231625800045
PM 16099459
DA 2024-11-01
ER

PT J
AU Longley, MJ
   Graziewicz, MA
   Bienstock, RJ
   Copeland, WC
AF Longley, MJ
   Graziewicz, MA
   Bienstock, RJ
   Copeland, WC
TI Consequences of mutations in human DNA polymerase γ
SO GENE
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA replication; PEO; Alpers syndrome; POLG
ID progressive external ophthalmoplegia; p55 accessory subunit; mitochondrial-dna; polg mutations; autosomal-dominant; multiple deletions; male-infertility; alpers-syndrome; mtdna; gene
AB DNA polymerase gamma is responsible for replication and repair of the mitochondrial genome. Human DNA polymerase gamma is composed of a 140-kDa catalytic subunit and a 55-kDa accessory subunit. Mutations in the gene for the catalytic subunit (POLG) have been shown to be a frequent cause of mitochondrial disorders. To date over 40 disease mutations and 9 nonsynonymous polymorphisms in POLG have been found to be associated with autosomal recessive and dominant progressive external ophthalmoplegia (PEO), Alpers syndrome, sensory ataxia, neuropathy, dysarthria and ophthalmoparesis (SANDO), Parkinsonism, and male infertility. In this paper we review the literature of POLG mutations and discuss their impact on mitochondrial diseases. We also describe a public access web database to annotate POLG mutations for the research community. (c) 2005 Elsevier B.V. All rights reserved.
C1 NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
   NIEHS, Comp Sci Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   GONZALEZ E, 2004, POLG TWINKLE MUTATIO, V6, P1
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Rovio AT, 2004, MAMM GENOME, V15, P492, DOI 10.1007/s00335-004-3049-x
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 45
TC 125
Z9 136
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 
J9 GENE
JI Gene
PD JUL 18
PY 2005
VL 354
IS 
BP 125
EP 131
DI 10.1016/j.gene.2005.03.029
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 959DN
UT WOS:000231497200019
PM 15913923
DA 2024-11-01
ER

PT J
AU Winkler-Stuck, K
   Kirches, E
   Mawrin, C
   Dietzmann, K
   Lins, H
   Wallesch, CW
   Kunz, WS
   Wiedemann, FR
AF Winkler-Stuck, K
   Kirches, E
   Mawrin, C
   Dietzmann, K
   Lins, H
   Wallesch, CW
   Kunz, WS
   Wiedemann, FR
TI Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinsons disease
SO JOURNAL OF NEURAL TRANSMISSION
LA English
DT Article
DE mitochondria; mitochondrial DNA; oxidative phosphorylation; Parkinsons disease; skeletal muscle
ID oxidative-phosphorylation defects; amyotrophic-lateral-sclerosis; cytochrome-c-oxidase; complex-i; repair activity; dna-repair; fibers; disorders; brain; mtdna
AB The origin and tissue distribution of the mitochondrial dysfunction in Parkinson's disease (PD) remains still a matter of controversy. To re-evaluate a probably free radical-born, generalized mitochondrial impairment in PD, we applied optimized enzymatic assays, high resolution oxygraphic measurements of permeabilized muscle fibers, and application of metabolic control analysis to skeletal muscle samples of 19 PD patients and 36 age-matched controls. We detected decreased activities of respiratory chain complexes I and IV being accompanied by increased flux control coefficients of complexes I and IV on oxygen consumption of muscle fibers. We further investigated if randomly distributed point mutations in two discrete regions of the mitochondrial DNA are increased in PD muscle, and if they could contribute to the mitochondrial impairment. Our data confirm the previously debated presence of a mild mitochondrial defect in skeletal muscle of patients with PD which is accompanied with an about 1.5 to 2-fold increase of point mutated mtDNA.
C1 Univ Klinikum Magdeburg, Neurol Klin, Leipziger Str 44, D-39120 Magdeburg, Germany.
   Otto Von Guericke Univ, Neurol Klin, Magdeburg, Germany.
   Otto Von Guericke Univ, Inst Neuropathol, Magdeburg, Germany.
   Univ Bonn, Klin Epileptol, D-5300 Bonn, Germany.
C3 University Hospital Magdeburg; Otto von Guericke University; Otto von Guericke University; University of Bonn
RP Otto Von Guericke Univ, Neurol Klin, Magdeburg, Germany.
EM falk.wiedemann@medizin.uni-magdeburg.de
CR ANDERSON JJ, 1993, J NEUROL NEUROSUR PS, V56, P477, DOI 10.1136/jnnp.56.5.477
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bergmeyer HU, 1974, IN METHODS OF ENZYMATIC ANALYSIS, V0, P727
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BINDOFF LA, 1989, LANCET, V2, P49, DOI 10.1016/S0140-6736(89)90291-2
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   Byrne E, 2002, J CLIN NEUROSCI, V9, P497, DOI 10.1054/jocn.2001.0991
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   Chen DX, 2002, J NEUROCHEM, V81, P1273, DOI 10.1046/j.1471-4159.2002.00916.x
   DIDONATO S, 1993, NEUROLOGY, V43, P2262, DOI 10.1212/WNL.43.11.2262
   DIMONTE DA, 1993, NEURODEGENERATION, V2, P275
   Dubowitz V, 1973, MUSCLE BIOPSY MODERN, V0, P0
   Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066
   Grishko VI, 1999, NUCLEIC ACIDS RES, V27, P4510, DOI 10.1093/nar/27.22.4510
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x
   Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jenner P, 2003, ANN NEUROL, V53, PS26, DOI 10.1002/ana.10483
   KACSER H, 1973, RATE CONTROL BIOL PR, V0, P0
   Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com
   Kirches EJF, 1998, J INHERIT METAB DIS, V21, P400, DOI 10.1023/A:1005306725644
   Koutsilieri E, 2002, J NEUROL, V249, P111, DOI 10.1007/S00415-002-1201-7
   KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F
   Kuznetsov AV, 1997, BBA-MOL BASIS DIS, V1360, P142, DOI 10.1016/S0925-4439(96)00072-5
   Kuznetsov AV, 1998, J CELL BIOL, V140, P1091, DOI 10.1083/jcb.140.5.1091
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Miró O, 1998, J NEUROSCI METH, V80, P107, DOI 10.1016/S0165-0270(97)00204-5
   *MITOMAP, 2004, HUM MIT GEN DAT, V0, P0
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   NAKAGAWAHATTORI Y, 1992, J NEUROL SCI, V107, P29, DOI 10.1016/0022-510X(92)90205-Y
   Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   REICHMANN H, 1994, EUR NEUROL, V34, P263, DOI 10.1159/000117053
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Richter G, 2002, J NEURAL TRANSM, V109, P721, DOI 10.1007/s007020200060
   Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257
   Saxowsky TT, 2002, J BIOL CHEM, V277, P37201, DOI 10.1074/jbc.M206654200
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   SINGER TP, 1995, BBA-MOL BASIS DIS, V1271, P211, DOI 10.1016/0925-4439(95)00030-8
   Sperl W, 1997, MOL CELL BIOCHEM, V174, P71, DOI 10.1023/A:1006880529195
   TAYLOR I, 1994, ENGL LANG NOTES, V31, P77
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VANKUILENBURG ABP, 1991, EUR J BIOCHEM, V199, P615
   Vielhaber S, 2003, ANN NEUROL, V53, P686, DOI 10.1002/ana.10564
   Wharton DC, 1967, METHODS ENZYMOL, V10, P245, DOI 10.1016/0076-6879(67)10048-7
   Wiedemann FR, 1998, J NEUROL SCI, V156, P65, DOI 10.1016/S0022-510X(98)00008-2
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   Wiedemann FR, 1999, ANN NY ACAD SCI, V893, P426, DOI 10.1111/j.1749-6632.1999.tb07870.x
   ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158
NR 57
TC 51
Z9 62
U1 0
U2 6
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0300-9564
EI 1435-1463
J9 J NEURAL TRANSM
JI J. Neural Transm.
PD APR 15
PY 2005
VL 112
IS 4
BP 499
EP 518
DI 10.1007/s00702-004-0195-y
PG 20
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 910BW
UT WOS:000227905400004
PM 15340872
DA 2024-11-01
ER

PT J
AU Zeharia, A
   Fischel-Ghodsian, N
   Casas, K
   Bykhovskaya, Y
   Tamari, H
   Lev, D
   Mimouni, M
   Lerman-Sagie, T
AF Zeharia, A
   Fischel-Ghodsian, N
   Casas, K
   Bykhovskaya, Y
   Tamari, H
   Lev, D
   Mimouni, M
   Lerman-Sagie, T
TI Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis:: An autosomal recessive syndrome in Persian Jews caused by a mutation in the <i>PUS1</i> gene
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID marrow-pancreas syndrome; multiple deletions; respiratory-chain; wolfram-syndrome; disorder; dna; infancy; region; defect
AB We report the seventh case of autosomal recessive inherited mitochondrial myopathy, lactic acidosis, and sideroblastic anemia. The patient, a product of consanguineous Persian Jews, had the association of mental retardation, dysmorphic features, lactic acidosis, myopathy, and sideroblastic anemia. Muscle biopsy demonstrated low activity of complexes 1 and 4 of the respiratory chain. Electron microscopy revealed paracrystalline inclusions in most mitochondria. Southern blot of the mitochondrial DNA did not show any large-scale rearrangements. The patient was found to be homozygous for the 656C -> T mutation in the pseudouridine synthase 1 gene (PUS1). Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia is an oxidative phosphorylation disorder causing sideroblastic anemia, myopathy, and, in some cases, mental retardation that is due to mutations in the nuclear-encoded PUS1 gene. This finding provides additional evidence that mitochondrial ribonucleic acid modification impacts the phenotypic expression of oxidative phosphorylation disorders.
C1 United Arab Emirates Univ, Fac Med, Dept Paediat, Al Ain, U Arab Emirates.
   United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Radiol, Al Ain, U Arab Emirates.
   United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Nucl Med, Al Ain, U Arab Emirates.
   United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Paediat, Al Ain, U Arab Emirates.
C3 United Arab Emirates University; United Arab Emirates University; United Arab Emirates University; United Arab Emirates University
RP United Arab Emirates Univ, Fac Med, Dept Paediat, POB 17666, Al Ain, U Arab Emirates.
EM asagie@post.tau.ac.il
FU NIDCD NIH HHS [R01DC01402] Funding Source: Medline
CR Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   Barrientos A, 1996, J CLIN INVEST, V97, P1570, DOI 10.1172/JCI118581
   BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   BORGNAPIGNATTI C, 1989, J PEDIATR-US, V114, P405, DOI 10.1016/S0022-3476(89)80558-X
   BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031
   Bridges KR, 1997, J PEDIAT HEMATOL ONC, V19, P274, DOI 10.1097/00043426-199707000-00002
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Bykhovskaya Y, 2004, MOL GENET METAB, V82, P27, DOI 10.1016/j.ymgme.2004.01.020
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Casas K, 2004, AM J MED GENET A, V127A, P44, DOI 10.1002/ajmg.a.20652
   Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368
   CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAY A, 1994, BAILLIERE CLIN HAEM, V7, P851, DOI 10.1016/S0950-3536(05)80128-3
   NUSBAUM NJ, 1991, AM J HEMATOL, V37, P41, DOI 10.1002/ajh.2830370109
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   RAWLES JM, 1974, AM J MED, V56, P891, DOI 10.1016/0002-9343(74)90820-1
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SHERRATT HSA, 1988, METHOD BIOCHEM ANAL, V33, P243
   Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 24
TC 59
Z9 61
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD MAY 15
PY 2005
VL 20
IS 5
BP 449
EP 452
DI 10.1177/08830738050200051301
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 932TI
UT WOS:000229575900013
PM 15971356
DA 2024-11-01
ER

PT J
AU Khaidakov, A
   Chavannes-Turesky, N
   Cooney, CA
   Dupont-Versteegden, EE
   Kennedy, RH
   Siegel, ER
   Khaidakova, G
   Reis, RJS
AF Khaidakov, A
   Chavannes-Turesky, N
   Cooney, CA
   Dupont-Versteegden, EE
   Kennedy, RH
   Siegel, ER
   Khaidakova, G
   Reis, RJS
TI Contribution of de novo point mutations to the overall mutational burden in mitochondrial DNA of adult rats
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE mitochondrial DNA; point mutations; aging; rats; brain; muscle
ID parkinsons-disease; glucose-metabolism; alzheimers-disease; clonal expansions; oxidative damage; brain; accumulation; degeneration; involvement; impairment
AB This study analyzed the incidence of point mutations in mitochondrial DNA of brain and muscle tissues from young (6-month) and old (24-month) male F344 rats. Coding sequence mutations in subunit 5 of the NADH dehydrogenase gene were detected after high-fidelity PCR amplification and cloning by denaturing gradient gel electrophoresis (DGGE) assay followed by sequencing of detected mutants. In total, almost a thousand individual clones were analyzed both in brain and muscle samples. On average, mtDNA from brain tissue showed a 66% increase with age in mutation frequencies (2.3 +/- 1.9 vs. 3.8 +/- 4.5 X 10(-4) mutations/bp, mean +/- SD), which failed to reach statistical significance (p=0.45). Muscle tissues yielded substantially fewer mutants with average mutant frequencies for both young and old rats almost 10 times lower than the corresponding values in the brain tissue (0.3 +/- 0.4 and 0.5 +/- 0.6 X 10-4, respectively). The difference in mutation accumulation between muscle and brain was highly significant in both the younger group (Chi-squared = 9.7, p <= 0.01) and in older animals (Chi-squared = 10.9, p <= 0.001). Molecular analysis of the mutated sequences revealed that almost half were identical sequences recurring in different samples and tissues. Our findings indicate that the process of mutation accumulation in mitochondria begins in the germ-line and/or during earlier stages of life, contributing up to half of the total mutational burden, whereas de novo spontaneous formation of point mutations in adulthood is far less than was anticipated. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Arkansas Med Sci, John L McClellan Mem Vet Hosp, Dept Geriatr, Little Rock, AR 72205 USA.
   Univ Arkansas Med Sci, John L McClellan Mem Vet Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.
   Univ Arkansas Med Sci, John L McClellan Mem Vet Hosp, Dept Pharm & Biostat, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences
RP Univ Arkansas Med Sci, John L McClellan Mem Vet Hosp, Dept Geriatr, GB-100,4300 W 7th St, Little Rock, AR 72205 USA.
EM khaidakovmagomed@uams.edu
FU NIA NIH HHS [P01AG20641] Funding Source: Medline
CR Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389
   Coller HA, 2002, ANN NY ACAD SCI, V959, P434, DOI 10.1111/j.1749-6632.2002.tb02113.x
   CORBISIER P, 1990, EUR J CELL BIOL, V51, P173
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fantel AG, 2002, ANN NY ACAD SCI, V959, P424, DOI 10.1111/j.1749-6632.2002.tb02112.x
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   FERRANDIZ ML, 1994, BRAIN RES, V644, P335, DOI 10.1016/0006-8993(94)91699-3
   HARMAN D, 1972, AM J CLIN NUTR, V25, P839
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   KLEIN CB, 2004, COMMUNICATION, V0, P0
   Kovalenko SA, 1998, ANN NY ACAD SCI, V854, P171, DOI 10.1111/j.1749-6632.1998.tb09900.x
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   MACKLER B, 1973, ARCH BIOCHEM BIOPHYS, V158, P662, DOI 10.1016/0003-9861(73)90558-4
   MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Orr WC, 2003, J BIOL CHEM, V278, P26418, DOI 10.1074/jbc.M303095200
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Shepard TH, 1998, ANAT REC, V252, P383, DOI 10.1002/(SICI)1097-0185(199811)252:3<383::AID-AR6>3.0.CO;2-Z
   Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Spencer CC, 2003, AGING CELL, V2, P123, DOI 10.1046/j.1474-9728.2003.00044.x
   TANIMURA T, 1970, P SOC EXP BIOL MED, V135, P51
   Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015
   Vinson RK, 2002, MUTAT RES-FUND MOL M, V509, P79, DOI 10.1016/S0027-5107(02)00223-3
   Wallace DR, 2004, MITOMAP: A HUMAN MITOCHONDRIAL DATABASE, V0, P0
   Wetter TJ, 1999, AM J PHYSIOL-ENDOC M, V276, P0
NR 31
TC 8
Z9 11
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD MAY 15
PY 2005
VL 40
IS 5
BP 396
EP 402
DI 10.1016/j.exger.2005.02.007
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 935WN
UT WOS:000229814200007
PM 15919591
DA 2024-11-01
ER

PT J
AU Kowald, A
   Jendrach, M
   Pohl, S
   Bereiter-Hahn, J
   Hammerstein, P
AF Kowald, A
   Jendrach, M
   Pohl, S
   Bereiter-Hahn, J
   Hammerstein, P
TI On the relevance of mitochondrial fusions for the accumulation of mitochondrial deletion mutants: A modelling study
SO AGING CELL
LA English
DT Article
DE aging; computer simulations; free radicals; mitochondrial fusion; mitochondrial mutants
ID dna mutations; muscle-fibers; copy number; human liver; human heart; mtdna; replication; fission; organelles; disease
AB The molecular mechanisms underlying the aging process are still unclear, but the clonal accumulation of mitochondrial deletion mutants is one of the prime candidates. An important question for the mitochondrial theory of aging is to discover how defective organelles might be selected at the expense of wild-type mitochondria. We propose that mitochondrial fission and fusion events are of critical importance for resolving this apparent contradiction. We show that the occurrence of fusions removes the problems associated with the idea that smaller DNA molecules accumulate because they replicate in a shorter time - the survival of the tiny (SOT) hypothesis. Furthermore, stochastic simulations of mitochondrial replication, mutation and degradation show that two important experimental findings, namely the overall low mosaic pattern of oxidative phosphorylation (OXPHOS) impaired cells in old organisms and the distribution of deletion sizes, can be reproduced and explained by this hypothesis. Finally, we make predictions that can be tested experimentally to further verify our explanation for the age-related accumulation of mitochondrial deletion mutants.
C1 Max Planck Inst Mol Genet, Kinet Modeling Grp, D-14195 Berlin, Germany.
   Goethe Univ Frankfurt, Kinemat Cell Res Grp, D-6000 Frankfurt, Germany.
   Humboldt Univ, Inst Theoret Biol, Berlin, Germany.
C3 Max Planck Society; Goethe University Frankfurt; Humboldt University of Berlin
RP Max Planck Inst Mol Genet, Kinet Modeling Grp, Ihnestr 73, D-14195 Berlin, Germany.
EM kowald@molgen.mpg.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arimura S, 2004, P NATL ACAD SCI USA, V101, P7805, DOI 10.1073/pnas.0401077101
   Berdanier CD, 2001, MUTAT RES-FUND MOL M, V475, P169, DOI 10.1016/S0027-5107(01)00068-9
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Clayton DA, 2003, IUBMB LIFE, V55, P213, DOI 10.1080/1521654031000134824
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   de Grey ADJ, 1999, MITOCHONDRIAL FREE R, V0, P0
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Díez-Sánchez C, 2003, BIOL REPROD, V68, P180, DOI 10.1095/biolreprod.102.005140
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015
   HUEMER RP, 1971, EXP GERONTOL, V6, P327, DOI 10.1016/0531-5565(71)90001-5
   Jendrach M, 2005, MECH AGEING DEV, V126, P813, DOI 10.1016/j.mad.2005.03.002
   Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   KIRKWOOD TBL, 1992, ANN NY ACAD SCI, V663, P412, DOI 10.1111/j.1749-6632.1992.tb38685.x
   Korr H, 1998, BRAZ J MED BIOL RES, V31, P289, DOI 10.1590/S0100-879X1998000200012
   Kowald A, 2000, J THEOR BIOL, V202, P145, DOI 10.1006/jtbi.1999.1046
   Kowald A, 1999, J ANTI-AGING MED, V2, P243
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   LINNANE AW, 1990, BIOCHEM INT, V22, P1067
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   MENZIES RA, 1971, J BIOL CHEM, V246, P2425
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345
   MullerHocker J, 1997, HEPATOLOGY, V26, P709
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233
   RAMSEY S, 2005, J BIOINF COMPUT BIOL, V3, P1
   Randerath Kurt, 1996, P198, V0, P0
   RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4
   SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030
   Shenkar R, 1996, AM J HUM GENET, V59, P772
   Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028
   TAPPER DP, 1981, J BIOL CHEM, V256, P5109
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Yoon Y, 2001, CURR BIOL, V11, PR67, DOI 10.1016/S0960-9822(01)00011-2
NR 55
TC 31
Z9 32
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD OCT 15
PY 2005
VL 4
IS 5
BP 273
EP 283
DI 10.1111/j.1474-9726.2005.00169.x
PG 11
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 964SE
UT WOS:000231900000005
PM 16164426
DA 2024-11-01
ER

PT J
AU Turner, CJ
   Granycome, C
   Hurst, R
   Pohler, E
   Juhola, MK
   Juhola, MI
   Jacobs, HT
   Sutherland, L
   Holt, IJ
AF Turner, CJ
   Granycome, C
   Hurst, R
   Pohler, E
   Juhola, MK
   Juhola, MI
   Jacobs, HT
   Sutherland, L
   Holt, IJ
TI Systematic segregation to mutant mitochondrial DNA and accompanying loss of mitochondrial DNA in human NT2 teratocarcinoma cybrids
SO GENETICS
LA English
DT Article
ID protein-synthesis; mtdna mutation; point mutation; cell-lines; expression; selection; myopathy; defects; gene; organization
AB In this study a well-characterized pathological mutation at nucleotide position 3243 of human mitochondrial DNA was introduced into human rho(0) teratocarcinoma (NT2) cells. In cloned and mixed populations of NT2 cells heteroplasmic for the mutation, mitotic segregation toward increasing levels of mutant mitochondrial DNA always occurred. Rapid segregation was frequently followed by complete loss of mitochondrial DNA. These findings support the idea that pathological mitochondrial DNA mutations are particularly deleterious in specific cell types, which can explain some of the tissue-specific aspects of mitochondrial DNA diseases. Moreover, these findings suggest that mitochondrial DNA depletion may be an important and widespread feature of mitochondrial DNA disease.
C1 MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England.
   Ninewells Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.
   Univ Tampere, Tampere Univ Hosp, FI-33014 Tampere, Finland.
   Univ Tampere, Inst Med Technol, FI-33014 Tampere, Finland.
C3 UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Dundee; Tampere University; Tampere University Hospital; Tampere University
RP MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.
EM holt@mrc-dunn.cam.ac.uk
FU Medical Research Council [MC_U105663140] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI
CR Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   BOURGERON T, 1993, J BIOL CHEM, V268, P19369
   Chadalavada Rajendrakumar SV, 2005, FUNCTIONAL & INTEGRATIVE GENOMICS, V5, P59, DOI 10.1007/s10142-005-0132-7
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   El Meziane A, 1998, NAT GENET, V18, P350
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAYASHI J, 1992, J INHERIT METAB DIS, V15, P448
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Lehtinen SK, 2000, GENETICS, V154, P363
   Loktionov A, 2001, CARCINOGENESIS, V22, P1053, DOI 10.1093/carcin/22.7.1053
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   MATTHEWS PM, 1995, HUM GENET, V96, P261
   POULTON J, 1995, DIABETOLOGIA, V38, P868, DOI 10.1007/s001250050366
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Sambrook J, 1990, MOL CLONING LAB MANU, V0, P0
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOUBRIDGE EA, 1995, BIOCHEM BIOPH RES CO, V213, P189, DOI 10.1006/bbrc.1995.2115
   Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vergani L, 1999, HUM MOL GENET, V8, P1751, DOI 10.1093/hmg/8.9.1751
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174
NR 40
TC 24
Z9 29
U1 0
U2 5
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD AUG 15
PY 2005
VL 170
IS 4
BP 1879
EP 1885
DI 10.1534/genetics.105.043653
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 966PO
UT WOS:000232033300037
PM 15944344
DA 2024-11-01
ER

PT J
AU Liu, JR
AF Liu, JR
TI Precipitation of stroke-like event by chickenpox in a child with MELAS syndrome
SO NEUROLOGY INDIA
LA English
DT Article
DE apparent diffusion coefficient mapping; chickenpox; diffusion weighted MRI; MELAS syndrome; stroke-like episode
ID lactic-acidosis; encephalopathy; varicella; episodes
AB The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS) is a rare congenital disorder of mitochondrial DNA (mtDNA). Herein we report a case of MELAS, whose second stroke-like episode was provoked by chickenpox. A point mutation at nucleotide (nt) 3243 in mtDNA supported the diagnosis of MELAS in this case. History of myopathy, the presence of lesions that did not conform to accepted distributions of vascular territories on cranial magnetic resonance imaging (MRI), normal result of cranial magnetic resonance angiography, hyperintensity on diffusion weighted MRI and apparent diffusion coefficient mapping indicating the presence of vasogenic edema in the fresh stroke-like lesion, and mitochondrial DNA analysis helped to exclude the diagnosis of ischemic cerebral infarction which can also be induced by chickenpox.
C1 Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurol, Hangzhou, Peoples R China.
C3 Zhejiang University
RP Liu, JR (corresponding author), 88 Jie Fang Rd, Hangzhou 310009, Peoples R China.
EM liujianren@medmail.com.cn
CR Abe K, 2004, NEURORADIOLOGY, V46, P113, DOI 10.1007/s00234-003-1138-2
   Dashe JF, 1998, NEW ENGL J MED, V339, P1914, DOI 10.1056/NEJM199812243392608
   Kolb SJ, 2003, J NEUROL SCI, V216, P11, DOI 10.1016/S0022-510X(03)00218-1
   McKee DH, 2000, J NEUROL NEUROSUR PS, V68, P765, DOI 10.1136/jnnp.68.6.765
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Sébire G, 1999, ANN NEUROL, V45, P679, DOI 10.1002/1531-8249(199905)45:5<679::AID-ANA22>3.0.CO;2-E
   Sharfstein SR, 1999, ARCH NEUROL-CHICAGO, V56, P241, DOI 10.1001/archneur.56.2.241
   Ueno M, 2002, BRAIN DEV-JPN, V24, P106, DOI 10.1016/S0387-7604(02)00005-0
NR 8
TC 11
Z9 13
U1 0
U2 2
PU NEUROL SOC INDIA
PI CHANDIGARH
PA C/O J S CHOPRA, PGIMER, DEPT NEUROLOGY, CHANDIGARH 160 012, INDIA
SN 0028-3886
EI 
J9 NEUROL INDIA
JI Neurol. India
PD SEP 15
PY 2005
VL 53
IS 3
BP 323
EP 325
DI 10.4103/0028-3886.16932
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA 979TG
UT WOS:000232967100021
PM 16230801
DA 2024-11-01
ER

PT J
AU Kang, DC
   Hamasaki, N
AF Kang, DC
   Hamasaki, N
TI Alterations of mitochondrial DNA in common diseases and disease states: Aging, neurodegeneration, heart failure, diabetes and cancer
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE mitochondria; mitochondrial DNA; reactive oxygen species (ROS); oxidative stress; aging; DNA damage; DNA repair
ID dependent lipid-peroxidation; nadh-ubiquinone reductase; 1-methyl-4-phenylpyridinium ion mpp+; manganese superoxide-dismutase; oxidative stress; friedreichs-ataxia; respiratory-chain; parkinsons-disease; escherichia-coli; human mtdna
AB It has long been considered that mitochondrial DNA disease is a rare genetic disorder causing neuromyopathy. However, alterations of mitochondrial DNA recently have been recognized to play an important role in the pathogenesis of so-called common diseases such as heart failure, diabetes, and cancer. Although some of these alterations are inherited, more and more attention is being focused on the accumulation of mitochondrial DNA mutations in somatic cells, particularly terminally differentiated cells such as cardiomyocytes and neurons that occurs with age. Mitochondrial DNA is more vulnerable to alteration than nuclear DNA, mainly for two reasons. First, mitochondria are a major source of intracellular reactive oxygen species (ROS). Therefore mitochondrial DNA is under much stronger oxidative stress than is nuclear DNA. Second, mitochondria have a matrix-side negative membrane potential for oxidative phosphorylation. This membrane potential concentrates lipophilic cations inside mitochondria up to similar to1,000-fold. Unfortunately, some therapeutic reagents are lipophilic cations, and such exogenously added chemicals are prone to damage mitochondria. AZT, an anti-HIV drug, causes mitochondrial myopathy as a side effect, which is a typical example of how chemotherapeutics adversely affect metabolism of mitochondrial DNA. In this review, we focus on ROS and chemical damage of mitochondrial DNA in common diseases.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Kang, DC (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM kang@mailserver.med.kyushu-u.ac.jp
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9
   Bauer MF, 1999, CLIN CHEM LAB MED, V37, P855, DOI 10.1515/CCLM.1999.129
   Beckman K B, 1996, METHODS ENZYMOL, V264, P442, DOI 10.1016/S0076-6879(96)64040-3
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Cossée M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219
   DEGREY A, 1997, BIOESSAYS, V19, P0
   Delatycki MB, 2000, J MED GENET, V37, P1, DOI 10.1136/jmg.37.1.1
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068
   DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981
   ETO Y, 1992, ARCH BIOCHEM BIOPHYS, V295, P101, DOI 10.1016/0003-9861(92)90493-G
   FELLOUS R, 1988, CANCER RES, V48, P6542
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5
   Gorogawa S, 2002, DIABETES RES CLIN PR, V57, P1, DOI 10.1016/S0168-8227(02)00005-0
   GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E
   Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7
   Hasegawa E, 1997, ARCH BIOCHEM BIOPHYS, V337, P69, DOI 10.1006/abbi.1996.9726
   HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300
   Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3
   Ide T, 2000, CIRC RES, V86, P152, DOI 10.1161/01.RES.86.2.152
   Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529
   Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357
   Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446
   Iwaasa M, 2002, DNA SEQUENCE, V13, P251, DOI 10.1080/1042517021000011654
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kang D, 1997, ARCH BIOCHEM BIOPHYS, V337, P75, DOI 10.1006/abbi.1996.9727
   Kang D, 2002, CURR GENET, V41, P311, DOI 10.1007/s00294-002-0312-0
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   Kang D, 1998, MITOCHONDRIAL DNA MU, V0, P1
   KANG DC, 1983, J BIOCHEM, V94, P1301, DOI 10.1093/oxfordjournals.jbchem.a134475
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Kinugawa S, 2000, CIRC RES, V87, P392
   LeProust EM, 2000, J MOL BIOL, V302, P1063, DOI 10.1006/jmbi.2000.4073
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lodi R, 2001, ANN NEUROL, V49, P590
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3
   MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0
   Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536
   MCMURRAY J, 1993, EUR HEART J, V14, P1493, DOI 10.1093/eurheartj/14.11.1493
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159
   MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miquel J, 1998, EXP GERONTOL, V33, P113, DOI 10.1016/S0531-5565(97)00060-0
   MIQUEL J, 1984, EXP GERONTOL, V19, P31, DOI 10.1016/0531-5565(84)90029-9
   Miyako K, 1999, EUR J BIOCHEM, V259, P412, DOI 10.1046/j.1432-1327.1999.00056.x
   Miyako K, 1997, J BIOL CHEM, V272, P9605
   MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x
   MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637
   Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843
   Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355
   OTABE S, 1994, J CLIN ENDOCR METAB, V79, P768, DOI 10.1210/jc.79.3.768
   Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Przedborski S, 1998, MOVEMENT DISORD, V13, P35
   PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658
   PZEDOBRSKI S, 1996, P NATL ACAD SCI USA, V93, P4565
   Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010
   RAMSAY RR, 1986, J BIOL CHEM, V261, P7585
   Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   SAKUMI K, 1993, J BIOL CHEM, V268, P23524
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9
   SCHATZ G, 1995, BBA-MOL BASIS DIS, V1271, P123, DOI 10.1016/0925-4439(95)00018-Y
   SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982
   Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R
   SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F
   Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B
   Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099
   TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853
   TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129
   TAKESHIGE K, 1980, BIOCHEM J, V192, P861, DOI 10.1042/bj1920861
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tsutsui H, 2001, CIRCULATION, V104, P2883, DOI 10.1161/hc4901.101347
   TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0
   Umeda S, 2000, EUR J BIOCHEM, V267, P200, DOI 10.1046/j.1432-1327.2000.00990.x
   Urata M, 1998, CLIN CHEM, V44, P2088
   vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197
   Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352
   Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696
NR 113
TC 104
Z9 122
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 0929-8673
EI 
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUN 15
PY 2005
VL 12
IS 4
BP 429
EP 441
DI 10.2174/0929867053363081
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 897IO
UT WOS:000226997500005
PM 15720251
DA 2024-11-01
ER

PT J
AU Viljoen, S
   Griep, MA
   Nelson, M
   Viljoen, H
AF Viljoen, S
   Griep, MA
   Nelson, M
   Viljoen, H
TI A macroscopic kinetic model for DNA polymerase elongation and high-fidelity nucleotide selection
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE biochemical engineering; molecular biology; polymerase chain reaction; mathematical model
ID deoxyribonucleoside triphosphate pool; double-strand breaks; mitochondrial-dna; replication fidelity; uracil recognition; depletion myopathy; imbalance; cells; mutant; asymmetry
AB The enzymatically catalyzed template-directed extension of ssDNA/primer complex is an important reaction of extraordinary complexity. The DNA polymerase does not merely facilitate the insertion of dNMP, but it also performs rapid screening of substrates to ensure a high degree of fidelity. Several kinetic studies have determined rate constants and equilibrium constants for the elementary steps that make up the overall pathway. The information is used to develop a macroscopic kinetic model, using an approach described by Ninio [Ninio J., 1987. Alternative to the steady-state method: derivation of reaction rates from first-passage times and pathway probabilities. Proc. Natl. Acad. Sci. U.S.A. 84, 663-667]. The principle idea of the Ninio approach is to track a single template/primer complex over time and to identify the expected behavior. The average time to insert a single nucleotide is a weighted sum of several terms, including the actual time to insert a nucleotide plus delays due to polymerase detachment from either the ternary (template-primer-polymerase) or quaternary (+nucleotide) complexes and time delays associated with the identification and ultimate rejection of an incorrect nucleotide from the binding site. The passage times of all events and their probability of occurrence are expressed in terms of the rate constants of the elementary steps of the reaction pathway. The model accounts for variations in the average insertion time with different nucleotides as well as the influence of G + C content of the sequence in the vicinity of the insertion site. Furthermore the model provides estimates of error frequencies. If nucleotide extension is recognized as a competition between successful insertions and time delaying events, it can be described as a binomial process with a probability distribution. The distribution gives the probability to extend a primer/template complex with a certain number of base pairs and in general it maps annealed complexes into extension products. 2005 Elsevier Ltd. All rights reserved.
C1 Univ Nebraska, Dept Chem Engn, Lincoln, NE 68588 USA.
   Nebraska Wesleyan Univ, Dept Biochem, Lincoln, NE 68540 USA.
   Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.
   Megabase Res Prod, Lincoln, NE 68540 USA.
C3 University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln
RP Viljoen, H (corresponding author), Univ Nebraska, Dept Chem Engn, Lincoln, NE 68588 USA.
EM hviljoen1@unl.edu
CR Ahmed A, 2003, J ANTI-AGING MED, V6, P315, DOI 10.1089/109454503323028911
   AKERBLOM L, 1982, J BIOL CHEM, V257, P6776
   Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338
   Chimploy K, 2000, J BIOL CHEM, V275, P39267, DOI 10.1074/jbc.M006233200
   Connolly BA, 2003, BIOCHEM SOC T, V31, P699, DOI 10.1042/BST0310699
   DAS SK, 1983, BIOCHEM BIOPH RES CO, V114, P458, DOI 10.1016/0006-291X(83)90802-1
   Fogg MJ, 2002, NAT STRUCT BIOL, V9, P922, DOI 10.1038/nsb867
   Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045
   GRUNBERGMANAGO M, 1955, SCIENCE, V122, P907, DOI 10.1126/science.122.3176.907
   HEINEMANN V, 1995, SEMIN ONCOL, V22, P11
   Jager Joachim, 1999, CURRENT OPINION IN STRUCTURAL BIOLOGY, V9, P21, DOI 10.1016/S0959-440X(99)80004-9
   JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471
   JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345
   Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z
   Julias JG, 1998, J VIROL, V72, P7941, DOI 10.1128/JVI.72.10.7941-7949.1998
   KASAHARA Y, 1993, MUTAT RES, V319, P143, DOI 10.1016/0165-1218(93)90073-M
   Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693
   Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200
   Lehman IR, 2003, J BIOL CHEM, V278, P34733, DOI 10.1074/jbc.X300002200
   Li Y, 2001, CURR ORG CHEM, V5, P871, DOI 10.2174/1385272013375067
   LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035
   Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4
   MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502
   Melnyk S, 1999, CANCER LETT, V146, P35, DOI 10.1016/S0304-3835(99)00213-X
   Michaelis L, 1913, BIOCHEM Z, V49, P333
   Miura S, 2004, CURR DRUG TARGETS, V5, P191, DOI 10.2174/1389450043490578
   NINIO J, 1987, P NATL ACAD SCI USA, V84, P663, DOI 10.1073/pnas.84.3.663
   PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SAIKI RK, 1985, SCIENCE, V230, P0
   Shuttleworth G, 2004, J MOL BIOL, V337, P621, DOI 10.1016/j.jmb.2004.01.021
   Smith A J, 1980, METHODS ENZYMOL, V65, P560
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   SUZUKI K, 1983, MUTAT RES, V122, P293, DOI 10.1016/0165-7992(83)90009-X
   Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WATAYA Y, 1988, NUCL ACIDS S SER, V53, P0
   Whitney SE, 2004, COMPUT BIOL CHEM, V28, P195, DOI 10.1016/j.compbiolchem.2004.03.001
   YAMATO M, 1992, JPN J CANCER RES, V83, P661, DOI 10.1111/j.1349-7006.1992.tb00141.x
   YOSHIOKA A, 1987, J BIOL CHEM, V262, P8235
NR 40
TC 8
Z9 9
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476-9271
EI 
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD APR 15
PY 2005
VL 29
IS 2
BP 101
EP 110
DI 10.1016/j.compbiolchem.2005.02.003
PG 10
WC Biology; Computer Science, Interdisciplinary Applications
SC Life Sciences & Biomedicine - Other Topics; Computer Science
GA 921KU
UT WOS:000228764000004
PM 15833438
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Haller, RG
AF Taivassalo, T
   Haller, RG
TI Exercise and training in mitochondrial myopathies
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE mtDNA defects; exercise intolerance; treatment; endurance training; resistance training; satellite cells
ID cytochrome-c-oxidase; skeletal-muscle; satellite cells; point mutation; mtdna; adaptations; expression; accumulation; metabolism; responses
AB The intriguing concept of exercise training as therapy for mitochondrial disease is currently unsettled: in the unique setting of mitochondrial heteroplasmy, what are the effects of chronic exercise on skeletal muscle containing a mixture of mutated and wild-type mitochondrial DNA (mtDNA)? Furthermore, what are the consequences of habitual physical inactivity on mitochondrial heteroplasmy? In patients with mtDNA defects, deleterious effects of limited physical activity likely magnify the mitochondrial oxidative impairment contributing to varying degrees of exercise intolerance. Normal adaptive responses to endurance training offer the potential to increase levels of functional mitochondria, improving exercise tolerance. The few clinical studies assessing such training effects in patients with mtDNA defects have unequivocally demonstrated physiologic and biochemical adaptations that improve exercise tolerance and quality of life. Uncertain, however, is the training effect on mitochondrial heteroplasmy. To determine therapeutic advisability of endurance training, it remains imperative to establish whether: reported increases in mutant mtDNA levels can be offset by increases in absolute wild-type mtDNA levels; and chronic physical inactivity leads to a selective down-regulation of wild-type mtDNA. Resistance exercise training offers an alternate, innovative therapeutic approach in patients with sporadic mtDNA mutations; exercise-induced transfer of normal mtDNA templates from muscle satellite cells to mature myofibers, thereby lowering mutation load (increasing functional mitochondrial load). Efficacy and safety of this approach needs to be replicated in a larger group of patients. Currently, appropriate recommendation (either in support or against) exercise training in mitochondrial disease is lacking, which is frustrating for physicians and disheartening for patients. Although considerable progress has been made, an immediate urgency exists to resolve the effects of chronic exercise on skeletal muscle in patients with heteroplasmic mtDNA mutations.
C1 Neuromusc Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA.
   Dallas VA Med Ctr, Dallas, TX USA.
C3 University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas
RP McGill Univ, Dept Kinesiol & Phys Educ, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.
EM tanjataivassalo@yahoo.com
CR Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505
   BISCHOFF R, 1994, MYOGENESIS, V2, P97
   BOOTH FW, 1977, J BIOL CHEM, V252, P416
   CHEEK DB, 1985, EARLY HUM DEV, V12, P211, DOI 10.1016/0378-3782(85)90144-6
   Chinnery P F, 2003, NEUROMUSCUL DISORD, V13, P757, DOI 10.1016/S0960-8966(03)00097-X
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Essig D A, 1996, EXERC SPORT SCI REV, V24, P289
   FAULKNER JA, 1977, MED SCI SPORT EXER, V9, P148
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   HALLER RG, 1983, NEUROLOGY, V33, P1283, DOI 10.1212/WNL.33.10.1283
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   HALLER RG, 1994, MYOLOGY, V0, P807
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   HE L, 2002, NUCLEIC ACIDS RES, V15, P30
   HENRIKSSON J, 1992, DIABETES CARE, V15, P1701, DOI 10.2337/diacare.15.11.1701
   Heslop L, 2000, J CELL SCI, V113, P2299
   Hikida RS, 2000, J GERONTOL A-BIOL, V55, PB347, DOI 10.1093/gerona/55.7.B347
   Hood D A, 2000, EXERC SPORT SCI REV, V28, P68
   Ivey FM, 2000, J GERONTOL A-BIOL, V55, PM641, DOI 10.1093/gerona/55.11.M641
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   MCCOMAS AJ, 1994, MED SCI SPORT EXER, V26, P1498
   MITCHELL JH, 1971, NEW ENGL J MED, V284, P1018, DOI 10.1056/NEJM197105062841809
   MOORE RL, 1987, J APPL PHYSIOL, V63, P1719, DOI 10.1152/jappl.1987.63.5.1719
   Mujika I, 2001, MED SCI SPORT EXER, V33, P1297, DOI 10.1097/00005768-200108000-00009
   NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004
   Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032
   Roth SM, 2001, J GERONTOL A-BIOL, V56, PB240, DOI 10.1093/gerona/56.6.B240
   SALE DG, 1988, MED SCI SPORT EXER, V20, PS135, DOI 10.1249/00005768-198810001-00009
   SALTIN B, 1980, FED PROC, V39, P1506
   Saltin B, 1983, COMPREHENSIVE PHYSIOLOGY, V0, P555
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2002, MEDICINE & SCIENCE IN SPORTS & EXERCISE, V34, PS169, DOI 10.1097/00005768-200205001-00943
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   TESCH PA, 1989, J APPL PHYSIOL, V83, P67
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 52
TC 64
Z9 68
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD DEC 15
PY 2005
VL 37
IS 12
BP 2094
EP 2101
DI 10.1249/01.mss.0000177446.97671.2a
PG 8
WC Sport Sciences
SC Sport Sciences
GA 992DY
UT WOS:000233865800012
PM 16331135
DA 2024-11-01
ER

PT J
AU Srivastava, S
   Moraes, CT
AF Srivastava, S
   Moraes, CT
TI Double-strand breaks of mouse muscle mtDNA promote large deletions similar to multiple mtDNA deletions in humans
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID human mitochondrial-dna; large-scale deletions; skeletal actin gene; restriction-endonuclease; homologous recombination; direct repeats; replication; deficiency; initiation; mutations
AB Mitochondrial DNA (mtDNA) deletions are a common cause of mitochondrial disorders and have been found to accumulate during normal aging. Despite the fact that hundreds of deletions have been characterized at the molecular level, their mechanisms of genesis are unknown. We tested the effect of double-strand breaks of muscle mtDNA by developing a mouse model in which a mitochondrially targeted restriction endonuclease (PstI) was expressed in skeletal muscle of mice. Because mouse mtDNA harbors two PstI sites, transgenic founders developed a mitochondrial myopathy associated with mtDNA depletion. The founders showed a chimeric pattern of transgene expression and their residual level of wild-type mtDNA in muscle was similar to 40% of controls. We were able to identify the formation of large mtDNA deletions in muscle of transgenic mice. A family of mtDNA deletions was identified, and most of these rearrangements involved one of the PstI sites and the 3' end of the D-loop region. The deletions had no or small direct repeats at the breakpoint region. These features are essentially identical to the ones observed in humans with multiple mtDNA deletions in muscle, suggesting that double-strand DNA breaks mediate the formation of large mtDNA deletions.
C1 Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Univ Miami, Sch Med, Dept Cell Biol & Anat, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU NEI NIH HHS [EY 10804, R01 EY010804] Funding Source: Medline; NIGMS NIH HHS [GM 55766] Funding Source: Medline; NIMH NIH HHS [R01 MH085801] Funding Source: Medline; NINDS NIH HHS [NS 041777, R01 NS041777, R56 NS041777] Funding Source: Medline
CR Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210
   BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BRENNAN KJ, 1993, J BIOL CHEM, V268, P719
   Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399
   Dudás A, 2004, MUTAT RES-REV MUTAT, V566, P131, DOI 10.1016/j.mrrev.2003.07.001
   Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9
   IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616
   Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614
   Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798
   Miller DL, 2001, ANAT HISTOL EMBRYOL, V30, P253, DOI 10.1046/j.1439-0264.2001.00330.x
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Oshima J, 2002, CANCER RES, V62, P547
   Ozawa T, 1999, J BIOENERG BIOMEMBR, V31, P377, DOI 10.1023/A:1005479920097
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 28
TC 131
Z9 161
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2005
VL 14
IS 7
BP 893
EP 902
DI 10.1093/hmg/ddi082
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 911BJ
UT WOS:000227975800002
PM 15703189
DA 2024-11-01
ER

PT J
AU Alexanderson, H
   Lundberg, IE
AF Alexanderson, H
   Lundberg, IE
TI The role of exercise in the rehabilitation of idiopathic inflammatory myopathies
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE dermatomyositis; exercise; idiopathic inflammatory myopathies; inclusion body myositis; outcome measures; polymyositis; rehabilitation
ID inclusion-body myositis; mitochondrial-dna deletions; resonance spectroscopy; skeletal-muscle; class-i; polymyositis; dermatomyositis; strength; program; safety
AB Purpose of review The objective of this review is to provide an update on exercise and clinical assessment in the idiopathic inflammatory myopathies. Recent findings Polymyositis, dermatomyositis and inclusion body myositis are rare conditions with muscle weakness as a common prominent feature. Earlier, these patients were discouraged from active exercise due to a fear of increased muscle inflammation with recommendations to rest, perform range of motion exercises and in some cases, isometric exercises. However, beginning in the 1990s, studies reported reduced disability in patients with chronic polymyositis/dermatomyositis following resistive mild/moderate to intensive muscular training and aerobic endurance training, without signs of increased muscle inflammation. Patients with active, recent onset disease seem to benefit from mild/moderate muscular exercise without signs of increased muscle inflammation. There is no evidence of increased muscle inflammation following exercise in inclusion body myositis. However, the beneficial effects are unclear as one study report increased muscle strength, while the other could not achieve impairment reduction. Summary Studies evaluating active exercise in IIM support the notion of safety and benefits. However, large multi-center studies are needed to fully establish the safety and benefits of different types of exercise. Data indicate that active exercise, adapted to disease activity and disability should be included in the rehabilitation of patients in all stages of IIM. The newly developed and validated outcome measures for patients with polymyositis and dermatomyositis help assess the effects of interventions on disease activity and disability in clinical trials and in clinical practice. However, there are no sensitive and valid outcome measure for patients with inclusion body myositis.
C1 Karolinska Univ Hosp, Dept Phys Therapy, Rheumatol Unit, SE-17176 Stockholm, Sweden.
   Karolinska Univ Hosp, Dept Med, Rheumatol Unit, Karolinska Inst, SE-17176 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital
RP Karolinska Univ Hosp, Dept Phys Therapy, Rheumatol Unit D2 07, SE-17176 Stockholm, Sweden.
EM helene.alexandersson@karolinska.se
CR Alexanderson H, 2000, SCAND J RHEUMATOL, V29, P295
   Alexanderson H, 1999, RHEUMATOLOGY, V38, P608, DOI 10.1093/rheumatology/38.7.608
   Alexanderson H, 2002, J RHEUMATOL, V29, P2386
   [Anonymous], 2001, PHYSIOTHERAPY, V0, P0, DOI DOI 10.1016/S0031-9406(05)60764-X
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Arnardottir S, 2003, J REHABIL MED, V35, P31, DOI 10.1080/16501970306110
   Askanas V, 2003, J CHILD NEUROL, V18, P185, DOI 10.1177/08830738030180030401
   Brandt EN, 1997, ENABLING AMERICA: ASSESSING THE ROLE OF REHABILITATION SCIENCE AND ENGINEERING, V0, P0
   Cea G, 2002, BRAIN, V125, P1635, DOI 10.1093/brain/awf163
   Christopher-Stine L, 2004, BEST PRACT RES CL RH, V18, P331, DOI 10.1016/j.berh.2004.02.009
   Chung YL, 2001, CLIN EXP RHEUMATOL, V19, P447
   CLARKE AE, 1995, ARTHRITIS RHEUM, V38, P1218, DOI 10.1002/art.1780380907
   CROSBY CA, 1995, AM J HAND SURG, V19, P665
   Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1
   Dorph C, 2001, J RHEUMATOL, V28, P1591
   EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402
   Englund P, 2002, ARTHRITIS RHEUM, V46, P1044, DOI 10.1002/art.10140
   ESCALANTE A, 1993, J RHEUMATOL, V20, P1340
   Felice KJ, 1998, MUSCLE NERVE, V21, P659, DOI 10.1002/(SICI)1097-4598(199805)21:5<659::AID-MUS17>3.0.CO;2-Q
   FRESE E, 1987, PHYS THER, V67, P1072, DOI 10.1093/ptj/67.7.1072
   HENRIKSSON KG, 1990, PROG NEUROBIOL, V35, P181, DOI 10.1016/0301-0082(90)90026-D
   HENRIKSSON KG, 1982, ACTA NEUROL SCAND, V65, P280, DOI 10.1111/j.1600-0404.1982.tb03087.x
   HICKS JE, 1993, J RHEUMATOL, V20, P1399
   Josefson A, 1996, J RHEUMATOL, V23, P1380
   Lodi R, 1998, BRAIN, V121, P2119, DOI 10.1093/brain/121.11.2119
   Macey AC, 1995, J HAND SURG-BRIT EUR, V20B, P841, DOI 10.1016/S0266-7681(95)80059-X
   Marie I, 2001, J RHEUMATOL, V28, P2230
   Mastaglia FL, 2003, MUSCLE NERVE, V27, P407, DOI 10.1002/mus.10313
   Mastaglia FL, 2002, RHEUM DIS CLIN N AM, V28, P723, DOI 10.1016/S0889-857X(02)00021-2
   Miller FW, 2001, RHEUMATOLOGY, V40, P1262, DOI 10.1093/rheumatology/40.11.1262
   Minor MA, 1999, RHEUM DIS CLIN N AM, V25, P233, DOI 10.1016/S0889-857X(05)70062-4
   Nagi SZ, 1965, SOCIOLOGY REHABILITA, V0, P0
   Nyberg P, 2000, J RHEUMATOL, V27, P940
   ODDIS CV, 1988, J RHEUMATOL, V15, P807
   ODDIS CV, 1990, J RHEUMATOL, V17, P1329
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   PARK JH, 1995, ARTHRITIS RHEUM, V38, P68, DOI 10.1002/art.1780380111
   PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402
   PETERSEN P, 1989, AM J OCCUP THER, V43, P444, DOI 10.5014/ajot.43.7.444
   Pfleiderer B, 2004, RHEUMATOLOGY, V43, P696, DOI 10.1093/rheumatology/keh182
   PLOTZ PH, 1995, ANN INTERN MED, V122, P715, DOI 10.7326/0003-4819-122-9-199505010-00010
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Schroder JM, 1997, MOL CELL BIOCHEM, V174, P277, DOI 10.1023/A:1006829129079
   SEKUL EA, 1993, SEMIN NEUROL, V13, P256, DOI 10.1055/s-2008-1041132
   Spector SA, 1997, MUSCLE NERVE, V20, P1242, DOI 10.1002/(SICI)1097-4598(199710)20:10<1242::AID-MUS6>3.3.CO;2-X
   Stenström CH, 2003, ARTHRIT RHEUM-ARTHR, V49, P428, DOI 10.1002/art.11051
   Sultan SM, 2002, RHEUMATOLOGY, V41, P22, DOI 10.1093/rheumatology/41.1.22
   *US DEP HHS, 1993, PLAN NAT CTR MED REH, V0, P0
   Varjú C, 2003, CLIN REHABIL, V17, P83, DOI 10.1191/0269215503cr572oa
   Vencovsky J, 2000, SCAND J RHEUMATOL, V29, P95, DOI 10.1080/030097400750001897
   Wiesinger GF, 1998, BRIT J RHEUMATOL, V37, P196
   Wiesinger GF, 1998, BRIT J RHEUMATOL, V37, P1338
   Wiesinger GF, 2000, ARCH PHYS MED REHAB, V81, P1, DOI 10.1016/S0003-9993(00)90212-0
   World Health Organization, 2001, ICF: INTERNATIONAL CLASSIFICATION OF FUNCTIONING, V0, P0
NR 54
TC 32
Z9 40
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD MAR 15
PY 2005
VL 17
IS 2
BP 164
EP 171
DI 10.1097/01.bor.0000152665.41493.49
PG 8
WC Rheumatology
SC Rheumatology
GA 912LH
UT WOS:000228079200010
PM 15711230
DA 2024-11-01
ER

PT J
AU Hirano, M
   Lagier-Tourenne, C
   Valentino, ML
   Martí, R
   Nishigaki, Y
AF Hirano, M
   Lagier-Tourenne, C
   Valentino, ML
   Martí, R
   Nishigaki, Y
TI Thymidine phosphorylase mutations cause instability of mitochondrial DNA
SO GENE
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; thymidine phosphorylase; MNGIE; nucleoside; nucleotide
ID cell growth-factor; neurogastrointestinal encephalomyopathy mngie; multiple deletions; tissue distribution; autosomal-dominant; gene-mutations; expression; depletion; fidelity; mtdna
AB Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder characterized by ptosis and progressive external ophthalmoplegia, peripheral neuropathy, severe gastrointestinal dysmotility, cachexia and leukoencephalopathy. Muscle biopsies of MNGIE patients have revealed morphologically abnormal mitochondria and defects of respiratory chain enzymes. In addition, patients harbor depletion, multiple deletions, and point mutations of mitochondrial DNA (mtDNA). This disorder is caused by loss-of-function mutations in the gene encoding thymidine phosphorylase (TP) a cytosolic enzyme. In MNGIE patients, TP activity is very low or absent resulting in dramatically elevated levels of plasma thymidine and deoxyuridine. We have hypothesized that the increased levels of thymidine and deoxyuridine cause mitochondrial nucleotide pool imbalances that, in turn, generate mtDNA alterations. (c) 2005 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Spain.
   Natl Inst Neurosci, Dept Neuromuscular Res, Natl Ctr Neurol & Psychiat, Tokyo, Japan.
C3 Columbia University; Hospital Universitari Vall d'Hebron; National Center for Neurology & Psychiatry - Japan
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.
EM mh29@columbia.edu
CR Brown NS, 1998, BIOCHEM J, V334, P1
   BUROKER NE, 1990, GENETICS, V124, P157
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946
   Focher F, 2001, CURR CANCER DRUG TAR, V1, P141, DOI 10.2174/1568009013334232
   FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212
   Gamez J, 2005, J NEUROL SCI, V228, P35, DOI 10.1016/j.jns.2004.09.034
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   Hirano M, 2004, TOP CURR GENET, V8, P177
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Kocaefe YÇ, 2003, EUR J HUM GENET, V11, P102, DOI 10.1038/sj.ejhg.5200908
   KUNKEL TA, 1988, J BIOL CHEM, V263, P14784
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Martín MA, 2004, NEUROLOGY, V63, P1536
   Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   PHEAR G, 1987, P NATL ACAD SCI USA, V84, P4450, DOI 10.1073/pnas.84.13.4450
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O
   YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604
NR 40
TC 41
Z9 42
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JUL 18
PY 2005
VL 354
IS 
BP 152
EP 156
DI 10.1016/j.gene.2005.04.041
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 959DN
UT WOS:000231497200023
PM 15975738
DA 2024-11-01
ER

PT J
AU Hattori, Y
   Takeoka, M
   Nakajima, K
   Ehara, T
   Koyama, M
AF Hattori, Y
   Takeoka, M
   Nakajima, K
   Ehara, T
   Koyama, M
TI A heteroplasmic mitochondrial DNA 3310 mutation in the ND1 gene in a patient with type 2 diabetes, hypertrophic cardiornyopathy, and mental retardation
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE type 2 diabetes; hypertrophic cardiomyopathy; left ventricular hypertrophy; ND1 gene; heteroplasmic mutation
ID hereditary optic neuropathy; nadh dehydrogenase; complex-i; mutation; mellitus; lhon
AB A mentally retarded 57-year-old Japanese man with maternally-inherited type 2 diabetes was found to have hypertrophic cardiomyopathy (HCM) that was associated with pathological changes in the myocardial mitochondria. The mitochondrial DNA (mtDNA) of this patient was examined and a C3310T mutation was found in the ND1 gene, which resulted in the substitution of serine for proline. The normal 3310 mtDNA band could not be detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in mtDNA from his myocardium, pancreas, cerebral tissue, skeletal muscle, and lymphocytes. However two clones sequenced from his pancreatic tissue did not show this C3310T mutation while forty-eight did. Mitochondria isolated from the lymphocytes of his two sisters also had this mutation. mtDNA point mutations in the ND1 gene region reported thus far have been mostly homoplasmic. However, the C3310T point mutation that was found in this patient was heteroplasmic, which is a high level of mutation and may represent the pathogenic gene that was responsible for causing mitochondrial disease.
C1 Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol,Div Mol & Cellular Biol, Matsumoto, Nagano 390, Japan.
   Asama Gen Hosp, Dept Internal Med, Saku, Japan.
   Shinshu Univ, Sch Med, Dept Histopathol, Matsumoto, Nagano 390, Japan.
   Komoro Kosei Gen Hosp, Dept Pathol, Komoro, Japan.
C3 Shinshu University; Shinshu University
RP Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol,Div Mol & Cellular Biol, Asahi 3-1-1, Matsumoto, Nagano 390, Japan.
EM u-chan@avis.ne.jp
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   EARLEY FGP, 1984, BIOCHEM J, V224, P525, DOI 10.1042/bj2240525
   FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HANZLIKOVA V, 1977, J ULTRA MOL STRUCT R, V60, P121, DOI 10.1016/S0022-5320(77)80048-8
   Hattori Y, 2003, DIABETES CARE, V26, P952, DOI 10.2337/diacare.26.3.952
   Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324
   Howell N, 1997, VISION RES, V37, P3495, DOI 10.1016/S0042-6989(96)00167-8
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KARPATI G, 1974, J NEUROL SCI, V23, P129, DOI 10.1016/0022-510X(74)90148-8
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   Mackey DA, 1996, AM J HUM GENET, V59, P481
   Momiyama Y, 2001, DIABETES CARE, V24, P604, DOI 10.2337/diacare.24.3.604
   NAKAGAWA Y, 1995, BIOCHEM BIOPH RES CO, V209, P664, DOI 10.1006/bbrc.1995.1550
   NIKOSKELAINEN EK, 1994, CLIN NEUROSCI, V2, P115
   RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   SHOFFNER JM, 1998, METABOLIC MOL BASES, V0, P1535
   STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089
   Torroni A, 1997, AM J HUM GENET, V60, P1107
NR 23
TC 14
Z9 15
U1 0
U2 1
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0947-7349
EI 1439-3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD JUN 15
PY 2005
VL 113
IS 6
BP 318
EP 323
DI 10.1055/s-2005-865646
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 939KX
UT WOS:000230072700002
PM 15977098
DA 2024-11-01
ER

PT J
AU Remes, AM
   Majamaa-Voltti, K
   Kärppä, M
   Moilanen, JS
   Uimonen, S
   Helander, H
   Rusanen, H
   Salmela, PI
   Sorri, M
   Hassinen, IE
   Majamaa, K
AF Remes, AM
   Majamaa-Voltti, K
   Kärppä, M
   Moilanen, JS
   Uimonen, S
   Helander, H
   Rusanen, H
   Salmela, PI
   Sorri, M
   Hassinen, IE
   Majamaa, K
TI Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population
SO NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; tissue distribution; epidemiology; mutation; a3243g; mtdna
AB Background: Large-scale mitochondrial DNA ( mtDNA) deletions are associated with clinical conditions such as Kearns - Sayre syndrome and chronic progressive external ophthalmoplegia in adults and Pearson syndrome in children. Reported case series have suggested that deletions are not uncommon in the population, but their prevalence has not been documented. Methods: The authors ascertained patients with clinical features associated with mtDNA deletions in a defined adult population in northern Finland. Buccal epithelial samples were requested from each patient fulfilling the selection criteria, and full-length mtDNA was amplified using the long PCR method. Deletion breakpoints were identified using sequencing. Patients with deletions were examined clinically. Results: The authors identified four patients with single large-scale mtDNA deletions. The prevalence of deletions was calculated to be 1.6/ 100,000 in the adult population in the province of Northern Ostrobothnia ( 0.0 to 3.2; 95% CI). Analysis of incident cases from a neighboring province revealed two patients with deletions and yielded a similar population frequency. Conclusions: The frequency of large- scale mitochondrial DNA deletions is similar among populations, suggesting that there is a constant rate of new deletions.
C1 Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Otorhinolaryngol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Internal Med, FIN-90014 Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu
RP Univ Oulu, Dept Neurol, POB 5000, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
CR Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   DEVRIES DD, 1992, NEUROMUSCULAR DISORD, V2, P185, DOI 10.1016/0960-8966(92)90005-Q
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GERBITZ KD, 1990, J CLIN CHEM CLIN BIO, V28, P241
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Harrison TJ, 1997, AM J OPHTHALMOL, V124, P217, DOI 10.1016/S0002-9394(14)70787-1
   Hartl DL, 2000, A PRIMER OF POPULATION GENETICS, V3rd ed., P0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Lehtonen MS, 2000, EUR J HUM GENET, V8, P315, DOI 10.1038/sj.ejhg.5200455
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Moilanen JS, 2001, EUR J HUM GENET, V9, P59, DOI 10.1038/sj.ejhg.5200550
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nishino I, 2000, ANN NEUROL, V47, P792
   PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   REMES AM, 1994, J AM COLL CARDIOL, V23, P935, DOI 10.1016/0735-1097(94)90640-8
   Remes AM, 2003, J NEUROL NEUROSUR PS, V74, P1158, DOI 10.1136/jnnp.74.8.1158
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Simon DK, 1999, ANNU REV MED, V50, P111
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
NR 31
TC 38
Z9 41
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 22
PY 2005
VL 64
IS 6
BP 976
EP 981
DI 10.1212/01.WNL.0000154518.31302.ED
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 908RH
UT WOS:000227806600009
PM 15781811
DA 2024-11-01
ER

PT J
AU Pulkes, T
   Liolitsa, D
   Eunson, LH
   Rose, M
   Nelson, IP
   Rahman, S
   Poulton, J
   Marchington, DR
   Landon, DN
   Debono, AG
   Morgan-Hughes, JA
   Hanna, MG
AF Pulkes, T
   Liolitsa, D
   Eunson, LH
   Rose, M
   Nelson, IP
   Rahman, S
   Poulton, J
   Marchington, DR
   Landon, DN
   Debono, AG
   Morgan-Hughes, JA
   Hanna, MG
TI New phenotypic diversity associated with the mitochondrial tRNA <SUP>Ser(UCN)</SUP> gene mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE exercise intolerances; MERRF; respiratory chain disease; mitochondrial DNA
ID respiratory-chain; dna; mtdna; proportion; myopathy; genotype; epilepsy; oocytes; stroke; merrf
AB We performed detailed clinical, histopathological, biochemical, in vitro translation and molecular genetic analysis in patients from two unrelated families harbouring the tRNA(Ser(UCN)) 7472C-insertion mutation. Proband I developed a progressive neurodegenerative phenotype characterised by myoclonus, epilepsy, cerebellar ataxia and progressive hearing loss. Proband 2 had a comparatively benign phenotype characterised by isolated myopathy with exercise intolerance. Both patients had the 7472C-insertion mutation in identical proportions and they exhibited a similar muscle biochemical and histopathological phenotype. However, proband 2 also had a previously unreported homoplasmic A to C transition at nucleotide position 7472 in the tRNA(Ser(UCN)) gene. This change lengthens further the homopolymeric C run already expanded by the 7472C-insertion. These data extend the phenotypic range associated with the 7472C-insertion to include isolated skeletal myopathy, as well as a MERRF-like phenotype. (c) 2005 Elsevier B.V. All rights reserved.
C1 UCL, Ctr Neuromuscular Dis, Inst Neurol, London WC1N 3BG, England.
   UCL, Dept Mol Neurosci, Inst Neurol, London WC1N 3BG, England.
   Inst Neurol, Dept Neuropathol, London WC1N 3BG, England.
   Kings Neurosci Ctr, Dept Neurol, Reg Neuromuscular Dis Unit, London, England.
   Inst Child Hlth, Metab Unit, London, England.
   John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England.
   St Lukes Hosp, Dept Med, Guardamangia, Malta.
C3 University of London; University College London; University of London; University College London; University of London; University College London; University of London; King's College London; University of London; University College London; University of Oxford
RP UCL, Ctr Neuromuscular Dis, Inst Neurol, Queen Sq, London WC1N 3BG, England.
EM mhanna@ion.ucl.ac.uk
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BOLANOS JP, 1994, J NEUROCHEM, V63, P910
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hanna MG, 1999, CELL MOL LIFE SCI, V55, P691, DOI 10.1007/s000180050327
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   KADENBACB, 1967, BIOCHIM BIOPHYS ACTA, V138, P651, DOI 10.1016/0005-2787(67)90574-6
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Marchington DR, 1997, AM J HUM GENET, V60, P408
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   PAYNE CM, 1975, J NEUROL SCI, V25, P99, DOI 10.1016/0022-510X(75)90190-2
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   SJOSTROM M, 1982, MUSCLE NERVE, V5, P538, DOI 10.1002/mus.880050708
   SJOSTROM M, 1982, J HISTOCHEM CYTOCHEM, V30, P1, DOI 10.1177/30.1.7054271
   SWEENEY MG, 1994, J NEUROL SCI, V121, P57, DOI 10.1016/0022-510X(94)90157-0
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 24
TC 25
Z9 26
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY 15
PY 2005
VL 15
IS 5
BP 364
EP 371
DI 10.1016/j.nmd.2005.01.006
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 923EW
UT WOS:000228893000008
PM 15833431
DA 2024-11-01
ER

PT J
AU Chabi, B
   Adhihetty, PJ
   Ljubicic, V
   Hood, DA
AF Chabi, B
   Adhihetty, PJ
   Ljubicic, V
   Hood, DA
TI How is mitochondrial biogenesis affected in mitochondrial disease?
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE mitochondrial myopathy; exercise; DNA mutations; skeletal muscle; mitochondrial DNA
ID transcription factor-a; c-oxidase deficiency; progressive external ophthalmoplegia; gamma coactivator-1-alpha expression; hereditary optic neuropathy; skeletal-muscle cells; kearns-sayre syndrome; protein import; contractile activity; gene-expression
AB Mitochondrial biogenesis occurs when the tissue energy demand is chronically increased to stress the ATP producing capacity of the preexisting mitochondria. In muscle, endurance training is a metabolic stress that is capable of inducing mitochondrial biogenesis, the consequence of which is improved performance during exercise. Expansion of the mitochondrial volume requires the coordinated response of the nuclear and mitochondrial genomes. During acute exercise, the initial signaling events are the perturbations in ATP turnover and calcium (Ca2+) concentrations caused by the contractile process. These alterations activate signal transduction pathways which target transcription factors involved in gene expression. Nuclear gene products are then posttranslationally imported into mitochondria. One of these, Tfam, is important for the regulation of mitochondrial DNA (mtDNA) gene expression. In muscle, a broad range of mitochondrial-specific diseases due to mutations in nuclear DNA or mtDNA exist, termed mitochondrial myopathies. These mutations result in dysfunctional mitochondrial assembly which ultimately leads to reduced ATP production. Mitochondrial myopathy patients exhibit a variety of compensatory responses which attempt to reconcile this energy deficiency, but the extent and the type of compensatory adaptations are disease-specific. Understanding the role of exercise in mediating these compensatory responses leading to mitochondrial biogenesis could help us in prescribing exercise designed to improve mitochondrial function in patients with mitochondrial myopathies. In addition, numerous other diseases (e.g., neurological disorders, cancer, diabetes, and cardiomyopathies), as well as the aging process, have etiologies or consequences attributed, in part, to mitochondrial dysfunction. Thus, insight gained by investigating the steps involved in exercise-induced mitochondrial biogenesis may help us to understand the underlying basis of these other disease states.
C1 York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
   York Univ, Dept Biol, N York, ON M3J 1P3, Canada.
C3 York University - Canada; York University - Canada
RP York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
EM dhood@yorku.ca
CR Adhihetty PJ, 2003, BAM PADOVA, V13, P171
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com
   Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628
   Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, PE1340, DOI 10.1152/ajpendo.2001.281.6.E1340
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Chin ER, 2004, P NUTR SOC, V63, P279, DOI 10.1079/PNS2004335
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305
   Freyssenet D, 2004, AM J PHYSIOL-CELL PH, V286, PC1053, DOI 10.1152/ajpcell.00418.2003
   Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grey JY, 2000, AM J PHYSIOL-CELL PH, V279, PC1393, DOI 10.1152/ajpcell.2000.279.5.C1393
   Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100
   Hood DA, 2004, P NUTR SOC, V63, P293, DOI 10.1079/PNS2004342
   Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137
   Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, PC1669, DOI 10.1152/ajpcell.00409.2002
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, PC867, DOI 10.1152/ajpcell.00191.2003
   Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374
   Khrapko K, 2003, MUTAT RES-FUND MOL M, V522, P13, DOI 10.1016/S0027-5107(02)00306-8
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   LESTIENNE P, 1988, LANCET, V1, P885
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   LI K, 1995, AM J PHYSIOL-CELL PH, V269, PC1265, DOI 10.1152/ajpcell.1995.269.5.C1265
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   Miura S, 2003, J BIOL CHEM, V278, P31385, DOI 10.1074/jbc.M304312200
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nisoli E, 2004, BIOCHEM PHARMACOL, V67, P1, DOI 10.1016/j.bcp.2003.10.015
   Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072
   Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com
   ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2
   Rungi AA, 2002, BBA-MOL BASIS DIS, V1586, P146, DOI 10.1016/S0925-4439(01)00072-2
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, PC1380, DOI 10.1152/ajpcell.1998.274.5.C1380
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WICKS KL, 1991, AM J PHYSIOL, V260, PC841, DOI 10.1152/ajpcell.1991.260.4.C841
   Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 80
TC 29
Z9 36
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD DEC 15
PY 2005
VL 37
IS 12
BP 2102
EP 2110
DI 10.1249/01.mss.0000177426.68149.83
PG 9
WC Sport Sciences
SC Sport Sciences
GA 992DY
UT WOS:000233865800013
PM 16331136
DA 2024-11-01
ER

PT J
AU Spinazzola, A
   Zeviani, M
AF Spinazzola, A
   Zeviani, M
TI Disorders of nuclear-mitochondrial intergenomic signaling
SO GENE
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; multiple deletions; depletion; autosomal
ID progressive external ophthalmoplegia; polymerase-gamma mutations; autosomal-dominant; multiple deletions; dna depletion; polg mutations; thymidine kinase; genetic features; myopathy; involvement
AB Depletion and multiple deletions of mitochondrial DNA (mtDNA) have been associated with a number of autosomal disorders classified as defects of nuclear-mitochondrial intergenomic signaling. The mendelian forms of progressive external ophthalmoplegia (PEO) are clinically and genetically heterogeneous disorders characterized by the accumulation of multiple deletions of mtDNA in postmitotic patient's tissues. Most of the autosomal dominant PEO (adPEO) families carry heterozygous mutations in either one of three genes: ANTI, Twinkle, and POLG1. Mutations in POLG1 can also cause autosomal recessive PEO (arPEO) and apparently sporadic cases. In addition, recessive POLG1 mutations are responsible for sensory-atactic neuropathy, dysarthria and ophthalmoplegia (SANDO), juvenile spino-cerebellar ataxia-epilepsy syndrome (SCAE) and Alpers-Huttenlocher hepatopathic poliodystrophy. Mutations in thymidine phosphorylase gene (TP) are linked to mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive disorder in which PEO is associated with gastrointestinal dysmotility and leukodystrophy. Finally, mitochondrial DNA depletion syndromes (MDS), defined by tissue-reduction in mtDNA copy number, have been linked to mutations in two genes involved in deoxyribonucleotide (dNTP) metabolism: thymidine kinase 2 (TK2) and deoxyguanosine kinase (DGUOK). (c) 2005 Elsevier B.V. All rights reserved.
C1 Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   FERRARI G, 2005, UNPUB BRAIN, V21, P0
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MIZUSAWA H, 1988, J NEUROL SCI, V86, P171, DOI 10.1016/0022-510X(88)90096-2
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 89
Z9 98
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 
J9 GENE
JI Gene
PD JUL 18
PY 2005
VL 354
IS 
BP 162
EP 168
DI 10.1016/j.gene.2005.03.025
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 959DN
UT WOS:000231497200025
PM 15921863
DA 2024-11-01
ER

PT J
AU Goios, A
   Nogueira, C
   Pereira, C
   Vilarinho, L
   Amorim, A
   Pereira, L
AF Goios, A
   Nogueira, C
   Pereira, C
   Vilarinho, L
   Amorim, A
   Pereira, L
TI mtDNA single macrodeletions associated with myopathies: Absence of haplogroup-related increased risk
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID mitochondrial-dna; region sequences; mutations; deletions; network; disease
AB As for any non-recombining genome, any mutation at mtDNA, if not recurrent, appears on a particular haplotype background, allowing its detection by haplogroup association studies. It has been shown that the propensity for occurrence of single macrodeletions at a level beyond the pathological threshold is associated with super-haplogroup U/K. However, in this report, we present evidence for the absence of preferential haplogroup backgrounds for single macrodeletions. We have analysed how haplogroup diagnostic polymorphisms could disrupt direct repeats usually flanking the deleted segment, and we have concluded that for the Common Deletion, no such polymorphisms are observed in humans, but they do occur in other primates. Furthermore, we also report five new single macrodeletions.
C1 Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal.
   IGM, Oporto, Portugal.
   Univ Porto, Fac Ciencias, P-4100 Oporto, Portugal.
C3 Universidade do Porto; Universidade do Porto
RP Univ Porto, Inst Patol & Imunol Mol, R Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.
EM aalmeida@ipatimup.pt
CR Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Crimi M, 2003, EUR J HUM GENET, V11, P896, DOI 10.1038/sj.ejhg.5201056
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hou JH, 1996, BIOCHEM J, V318, P1065, DOI 10.1042/bj3181065
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204
   Mohri I, 1998, J NEUROL SCI, V158, P106, DOI 10.1016/S0022-510X(98)00082-3
   Pereira L, 2004, INT J LEGAL MED, V118, P132, DOI 10.1007/s00414-003-0424-1
   PEREIRA L, 2005, IN PRESS INT J ANDRO, V0, P0
   Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
NR 19
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD JUN 15
PY 2005
VL 28
IS 5
BP 769
EP 778
DI 10.1007/s10545-005-0023-z
PG 10
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 962VA
UT WOS:000231759900017
PM 16151908
DA 2024-11-01
ER

PT J
AU Moslemi, AR
   Darin, N
   Tulinius, M
   Oldfors, A
   Holme, E
AF Moslemi, AR
   Darin, N
   Tulinius, M
   Oldfors, A
   Holme, E
TI Two new mutations in the <i>MTATP6</i> gene associated with Leigh syndrome
SO NEUROPEDIATRICS
LA English
DT Article
DE Leigh syndrome; mtDNA; MTATP6; complex V; ATP synthase
ID atpase 6 gene; mitochondrial-dna deletions; c-oxidase deficiency; escherichia-coli; t9176c mutation; muscle-fibers; synthase; disease; encephalomyopathy; childhood
AB In this study we have analyzed the mtDNA encoded ATPase 6 and 8 genes (MTATP6 and MTATP8) in two children with Leigh syndrome (LS) and reduced Mg2+ ATPase activity in muscle mitochondria. In patient 1, with a mild and reversible phenotype, mutational analysis revealed a heteroplasmic T -> C mutation at nt position 9185 (T9185C) in the MTATP6. The mutation resulted in substitution of a highly conserved leucine to proline at codon 220. The proportion of the mutation was > 97% in the patient's blood and muscle and 85% in blood of his asymptomatic mother. Patient 2, with severe clinical phenotype and death at 2 years of age, exhibited a novel heteroplasmic T9191C missense mutation in the MTATP6, which converted a highly conserved leucine to a proline at position 222 of the polypeptide. The proportion of the mutation was 90% in fibroblasts and 94% muscle tissue. This mutation was absent in the patient's parents and sister suggesting that the mutation was de novo. Our findings expand the spectrum of mutations causing LS and emphasize the role of MTATP6 gene mutations in pathogenesis of LS.
C1 Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Paediat, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Moslemi, AR (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@pathology.gu.se
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DAVIS PC, 1987, AM J NEURORADIOL, V8, P71
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Dionisi-Vici C, 1998, J INHERIT METAB DIS, V21, P2, DOI 10.1023/A:1005397227996
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   HARTZOG PE, 1993, J BIOL CHEM, V268, P12250
   Hartzog PE, 1999, INT J BIOCHEM CELL B, V31, P769, DOI 10.1016/S1357-2725(99)00029-1
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Ogilvie I, 1999, FEBS LETT, V453, P179, DOI 10.1016/S0014-5793(99)00605-5
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Santorelli FM, 1996, PEDIATR RES, V39, P914, DOI 10.1203/00006450-199605000-00028
   SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   TULINIUS MH, 1995, HUM GENET, V96, P290
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
NR 25
TC 52
Z9 60
U1 0
U2 5
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD OCT 15
PY 2005
VL 36
IS 5
BP 314
EP 318
DI 10.1055/s-2005-872845
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 976RG
UT WOS:000232750300005
PM 16217706
DA 2024-11-01
ER

PT J
AU Ma, YS
   Chen, YC
   Lu, CY
   Liu, CY
   Wei, YH
AF Ma, YS
   Chen, YC
   Lu, CY
   Liu, CY
   Wei, YH
TI Upregulation of matrix metalloproteinase 1 and disruption of mitochondrial network in skin fibroblasts of patients with MERRF syndrome
SO ROLE OF THE MITOCHONDRIA IN HUMAN AGING AND DISEASE: FROM GENES TO CELL SIGNALING
LA English
DT Article; Proceedings Paper
DE MERRF syndrome; mitochondrial disease; matrix metalloproteinase; reactive oxygen species; oxidative stress
ID manganese superoxide-dismutase; oxidative stress; dna mutations; hydrogen-peroxide; human-cells; apoptosis; expression; increases; diseases; muscle
AB By using cDNA microarray and RT-PCR techniques, we investigated the genome-wide alteration of gene expression in skin fibroblasts from patients with myoclonic epilepsy and ragged-red fibers (MERRF) syndrome. By screening for, the genes with altered levels of expression, we first discovered that matrix metalloproteinase 1 (MMPI) was highly induced in the primary culture of skin fibroblasts of a female patient in a four-generation family with MERRF syndrome. This phenomenon was confirmed in skin fibroblasts from three other MERRIF patients harboring about 85% of mtDNA with A8344G mutation. A further study revealed that the expression of MMP1 could be further induced by treatment of the skin fibroblasts with 200 mu M hydrogen peroxide (H2O2) and inhibited by 1 mM N-acetyleysteine. Moreover, the intracellular level of H2O2 in skin fibroblasts of the female MERRF patient was higher than those of the asymptomatic family members and age-matched healthy controls. These findings imply that the increase in the expression of MMP1 may represent one of the responses to the increased oxidative stress in the skin fibroblasts of MERRF patients. We suggest that in affected tissues the oxidative stress-elicited overexpression of MMP1, and probably other matrix metalloproteinases involved in cytoskeleton remodeling, may play an important role in the pathogenesis and progression of mitochondrial encephalomyopathies such as MERRF syndrome.
C1 Natl Yang Ming Univ, Dept Biochem, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Ctr Cellular & Mol Biol, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University
RP Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
CR Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2
   COLLIER NC, 1993, J CELL BIOCHEM, V52, P297, DOI 10.1002/jcb.240520306
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Filosto M, 2002, ACTA NEUROPATHOL, V103, P215, DOI 10.1007/s004010100455
   Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1007/BF02254978
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   Lu CY, 2002, CLIN CHIM ACTA, V318, P97, DOI 10.1016/S0009-8981(01)00809-9
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200
   Rusanen H, 2002, CELL MOTIL CYTOSKEL, V53, P231, DOI 10.1002/cm.10066
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, PC53, DOI 10.1152/ajpcell.2001.280.1.C53
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wei YH, 2003, ADV CLIN CHEM, V37, P83, DOI 10.1016/S0065-2423(03)37007-6
   Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 23
TC 25
Z9 26
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2005
VL 1042
IS 
BP 55
EP 63
DI 10.1196/annals.1338.006
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics
GA BCR22
UT WOS:000230893400006
PM 15965045
DA 2024-11-01
ER

PT J
AU Manczak, M
   Jung, YS
   Park, BS
   Partovi, D
   Reddy, PH
AF Manczak, M
   Jung, YS
   Park, BS
   Partovi, D
   Reddy, PH
TI Time-course of mitochondrial gene expressions in mice brains:: implications for mitochondrial dysfunction, oxidative damage, and cytochrome <i>c</i> in aging
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE aging; ATPase 6; C57BL6 mice; cytochrome c; 8-hydroxyguanosine; mitochondrial dysfunction
ID alzheimers-disease; skeletal-muscle; dna deletions; phosphorylation; metabolism; tissue; stress; restriction; mutations; nuclear
AB The study of aging is critical for a better understanding of many age-related diseases. The free radical theory of aging, one of the prominent aging hypotheses, holds that during aging, increasing reactive oxygen species in mitochondria causes mutations in the mitochondrial DNA and damages mitochondrial components, resulting in senescence. Understanding a mitochondrial gene expression profile and its relationship to mitochondrial function becomes an important step in understanding aging. The objective of the present study was to determine mRNA expression of mitochondrial-encoded genes in brain slices from C57BL6 mice at four ages (2, 12, 18, and 24 months) and to determine how these altered mitochondrial genes influence age-related changes, including oxidative damage and cytochrome c in apoptosis. Using northern blot analysis, in situ hybridization, and immunofluorescence analyses, we analyzed changes in the expression of mitochondrial RNA encoding the mitochondrial genes, oxidative damage marker, 8-hydroxyguanosine (8-OHG), and cytochrome c in brain slices from the cortex of C57BL6 mice at each of the four ages. Our northern blot analysis revealed an increased expression of mitochondrial-encoded genes in complexes I, III, IV, and V of the respiratory chain in 12- and 18-month-old C57BL6 mice compared to 2-month-old mice, suggesting a compensatory mechanism that allows the production of proteins involved in the electron transport chain. In contrast to the up-regulation of mitochondrial genes in 12- and 18-month-old C57BL6 mice, mRNA expression in 24-month-old C57BL6 mice was decreased, suggesting that compensation maintained by the up-regulated genes cannot be sustained and that the down-regulation of expression results in the later stage of aging. Our in situ hybridization analyses of mitochondrial genes from the hippocampus and the cortex revealed that mitochondrial genes were over-expressed, suggesting that these brain areas are critical for mitochondrial functions. Our immunofluorescence analysis of 8-OHG and cytochrome c revealed increased 8-OHG and cytochrome c in 12-month-old C57BL6 mice, suggesting that age-related mitochondrial oxidative damage and apoptosis are associated with mitochondrial dysfunction. Our double-labeling analysis of in situ hybridization of ATPase 6 and our immunofluorescence analysis of 8-OHG suggest that specific neuronal populations undergo oxidative damage. Further, double-labeling analysis of in situ hybridization of ATPase 6 and immunofluorescence analysis of cytochrome c suggest cytochrome c release is related to mitochondrial dysfunction in the aging C57BL6 mouse brain. This study also suggests that these mitochondrial gene expression changes may relate to the role of mitochondrial dysfunction, oxidative damage, and cytochrome c in aging and in age-related diseases such as Alzheimer's disease and Parkinson's disease.
C1 Oregon Hlth & Sci Univ, Inst Neurol Sci, Neurogenet Lab, Beaverton, OR 97006 USA.
   Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University
RP Oregon Hlth & Sci Univ, Inst Neurol Sci, Neurogenet Lab, 505 NW 185th Ave, Beaverton, OR 97006 USA.
EM reddyh@ohsu.edu
FU NIA NIH HHS [AG 22643] Funding Source: Medline
CR Aksenov MY, 1999, NEUROCHEM RES, V24, P767, DOI 10.1023/A:1020783614031
   [Anonymous], 1900, DOI 10.1089/REJ.1.1999.2.15, V0, P0
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Beers MH, 2004, THE MERCK MANUAL OF HEALTH AGING, V0, P0
   Biesalski HK, 2002, CURR OPIN CLIN NUTR, V5, P5, DOI 10.1097/00075197-200201000-00002
   Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Cadenas Enrique, 2004, MOLECULAR ASPECTS OF MEDICINE, V25, P17, DOI 10.1016/j.mam.2004.02.005
   Chandrasekaran K, 1997, MOL BRAIN RES, V44, P99, DOI 10.1016/S0169-328X(96)00191-X
   CHANDRASEKARAN K, 1994, NEUROBIOL AGING, V14, P343
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   de Carvalho CV, 2000, BIOGERONTOLOGY, V1, P357, DOI 10.1023/A:1026542618182
   DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208
   FERNANDEZSILVA P, 1991, BIOCHEM BIOPH RES CO, V176, P645, DOI 10.1016/S0006-291X(05)80233-5
   Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7
   Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   Navarro A, 2004, AM J PHYSIOL-REG I, V286, PR505, DOI 10.1152/ajpregu.00208.2003
   Navarro A, 2002, AM J PHYSIOL-REG I, V282, PR985, DOI 10.1152/ajpregu.00537.2001
   Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9
   PIKO L, 1984, MECH AGEING DEV, V26, P113, DOI 10.1016/0047-6374(84)90170-2
   PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1
   Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Shoffner JM, 1997, NEUROGENETICS, V1, P13, DOI 10.1007/s100480050002
   SOONG NW, 1992, NAT GENET, V2, P318
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vijg J, 2000, MUTAT RES-FUND MOL M, V447, P117, DOI 10.1016/S0027-5107(99)00202-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 37
TC 165
Z9 188
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB 15
PY 2005
VL 92
IS 3
BP 494
EP 504
DI 10.1111/j.1471-4159.2004.02884.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 888VI
UT WOS:000226401900007
PM 15659220
DA 2024-11-01
ER

PT J
AU Naidu, S
   Bibat, G
   Lin, D
   Burger, P
   Barker, P
   Rosemberg, S
   Braverman, N
   Arroyo, H
   Dowling, M
   Hamosh, A
   Kimonis, V
   Blank, C
   Fiumara, A
   Facchini, S
   Singhal, B
   Moser, H
   Kelley, R
   DiMauro, S
AF Naidu, S
   Bibat, G
   Lin, D
   Burger, P
   Barker, P
   Rosemberg, S
   Braverman, N
   Arroyo, H
   Dowling, M
   Hamosh, A
   Kimonis, V
   Blank, C
   Fiumara, A
   Facchini, S
   Singhal, B
   Moser, H
   Kelley, R
   DiMauro, S
TI Progressive cavitating leukoencephalopathy: A novel childhood disease
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID acute disseminated encephalomyelitis; acute necrotizing encephalopathy; hemophagocytic lymphohistiocytosis; children; adrenoleukodystrophy; spectroscopy; mutations; features; lesions; form
AB We report 19 patients with a previously undelineated neurodegenerative syndrome characterized by episodic acute onset of irritability or neurological deficits between 2 months and 3.5 years of age, followed by steady or intermittent clinical deterioration. Seven children died between 11 months and 14 years of age. Cranial magnetic resonance imaging (MRI) shows patchy leukoencephalopathy with cavities, and vascular permeability, in actively affected regions. Early lesions affect corpus callosum and centrum semiovale, with or without cerebellar or cord involvement. After repeated episodes, areas of tissue loss coalesce with older lesions to become larger cystic regions in brain or spinal cord. Diffuse spasticity, dementia, vegetative state, or death ensues. Gray matter is spared until late in the course. In some, incomplete clinical or MRI recovery occurs after episodes. The clinical course varies from rapid deterioration to prolonged periods of stability that are unpredictable by clinical or MRI changes. Elevated levels of lactate in brain, blood, and cerebrospinal fluid, abnormal urine organic acids, and changes in muscle respiratory chain enzymes are present but inconsistent, without identifiable mitochondrial DNA mutations or deletions. Pathological studies show severe loss of myelin sparing U-fibers, axonal disruption, and cavitary lesions without inflammation. Familial occurrence and consanguinity suggest autosomal recessive inheritance of this distinct entity.
C1 Kennedy Krieger Inst, Neurogenet Dept, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Radiol, Baltimore, MD 21205 USA.
   Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   Univ Sao Paulo, Hosp Clin, Dept Pathol, Sao Paulo, Brazil.
   Johns Hopkins Med Inst, Inst Med Genet, Baltimore, MD 21205 USA.
   Hosp Pediat, Dept Neurol, Buenos Aires, DF, Argentina.
   Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA.
   Childrens Hosp, Dept Genet, Boston, MA 02115 USA.
   Gettysburg Pediat, Gettysburg, PA USA.
   Univ Catania, Pediat Clin, Dept Neurol, I-95124 Catania, Italy.
   Baylor Coll Med, Div Pediat Neurol, Houston, TX 77030 USA.
   Bombay Hosp & Med Res Ctr, Inst Med Sci, Med Res Ctr, Bombay, Maharashtra, India.
   Columbia Univ, Dept Neurol, New York, NY USA.
C3 Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Universidade de Sao Paulo; Johns Hopkins University; Johns Hopkins Medicine; University of Buenos Aires; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas Dallas; Harvard University; Boston Children's Hospital; University of Catania; Baylor College of Medicine; Bombay Hospital & Medical Research Centre; Columbia University
RP Naidu, S (corresponding author), Kennedy Krieger Inst, Neurogenet Dept, 707 N Broadway,5th Floor Tower, Baltimore, MD 21205 USA.
EM naidu@kennedykrieger.org
CR Bizzi A, 2001, AM J NEURORADIOL, V22, P1125
   Canavan MM, 1931, NEUROLOGY, V15, P299
   deRecondo A, 1997, J NEUROL NEUROSUR PS, V63, P15, DOI 10.1136/jnnp.63.1.15
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9
   Golay X, 2002, MAGNET RESON MED, V47, P384, DOI 10.1002/mrm.10038
   Gorospe JR, 2004, NEUROLOGY, V62, P878, DOI 10.1212/01.WNL.0000115106.88813.5B
   Henneke M, 2005, NEUROLOGY, V64, P1411, DOI 10.1212/01.WNL.0000158472.82823.01
   Henter JI, 1997, J PEDIATR-US, V130, P358, DOI 10.1016/S0022-3476(97)70196-3
   Hynson JL, 2001, NEUROLOGY, V56, P1308, DOI 10.1212/WNL.56.10.1308
   Johnson AB, 2003, J CHILD NEUROL, V18, P625, DOI 10.1177/08830738030180090901
   Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61
   Lim KE, 2003, CLIN IMAG, V27, P281, DOI 10.1016/S0899-7071(02)00552-1
   LOY TS, 1991, SEMIN ONCOL, V18, P34
   Mizuguchi M, 1997, BRAIN DEV-JPN, V19, P81, DOI 10.1016/S0387-7604(96)00063-0
   Neilson DE, 2004, ANN NEUROL, V55, P291, DOI 10.1002/ana.10849
   Pouwels PJW, 1998, NEUROPEDIATRICS, V29, P254, DOI 10.1055/s-2007-973571
   Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957
   Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007
   TZIKA AA, 1993, RADIOLOGY, V189, P467, DOI 10.1148/radiology.189.2.8210375
   VANDERKNAAP MS, 1995, ANN NEUROL, V37, P324, DOI 10.1002/ana.410370308
   zur Stadt U, 2005, HUM MOL GENET, V14, P827, DOI 10.1093/hmg/ddi076
NR 22
TC 27
Z9 28
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0364-5134
EI 
J9 ANN NEUROL
JI Ann. Neurol.
PD DEC 15
PY 2005
VL 58
IS 6
BP 929
EP 938
DI 10.1002/ana.20671
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 989WE
UT WOS:000233703900015
PM 16315274
DA 2024-11-01
ER

PT J
AU Taylor, RW
AF Taylor, RW
TI Gene therapy for the treatment of mitochondrial DNA disorders
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE complementation; exercise training; gene therapy; heteroplasmy; mitochondrial DNA; treatment
ID transfer-rna; in-vitro; saccharomyces-cerevisiae; prenatal-diagnosis; point mutation; muscle-fibers; ribosomal-rna; plasmid dna; wild-type; mtdna
AB Despite recent epidemiological studies confirming that mitochondrial respiratory chain disorders due to mutations in either the mitochondrial or nuclear genome are amongst the most common inherited human diseases, realistic therapeutic strategies for these patients remain limited. The disappointing response to various vitamins, cofactors and electron acceptors that have been administered to patients in an attempt to bypass the underlying respiratory chain defect, coupled with the complexities of human mitochondrial genetics, means that novel and innovative means are required to offer realistic treatments. Several 'gene therapy' strategies have therefore been proposed to treat patients with pathogenic mitochondrial DNA mutations, and although these are not without their own inherent problems, several exciting approaches promise much in the near future. This review will provide a basic background to mitochondrial genetics and mitochondrial DNA disorders before introducing the various strategies being tested in vitro at present, in cell culture and animal models, and, in the example of therapeutic exercise, in patients themselves.
C1 Newcastle Univ, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Bayona-Bafaluy MP, 2003, AM J HUM GENET, V73, P627
   BIGGER B, 2003, GENETICS MITOCHRONDR, V0, P327
   Bigger BW, 2001, J BIOL CHEM, V276, P23018, DOI 10.1074/jbc.M010873200
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Chinnery P F, 2003, NEUROMUSCUL DISORD, V13, P757, DOI 10.1016/S0960-8966(03)00097-X
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CHRZANOWSKALIGHTOWLERS ZMA, 1995, GENE THER, V2, P311
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Collombet JM, 1997, J BIOL CHEM, V272, P5342, DOI 10.1074/jbc.272.8.5342
   DSouza GGM, 2004, CURR GENE THER, V4, P317
   DSouza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168-3659(03)00297-9
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Dean NL, 2003, MOL HUM REPROD, V9, P631, DOI 10.1093/molehr/gag077
   Delage L, 2003, MOL CELL BIOL, V23, P4000, DOI 10.1128/MCB.23.11.4000-4012.2003
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Entelis NS, 2001, J BIOL CHEM, V276, P45642, DOI 10.1074/jbc.M103906200
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   Flierl A, 2003, MOL THER, V7, P550, DOI 10.1016/S1525-0016(03)00037-6
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Funes S, 2002, J BIOL CHEM, V277, P6051, DOI 10.1074/jbc.M109993200
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   HARDING AE, 1992, AM J HUM GENET, V50, P629
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Khan SM, 2004, J BIOENERG BIOMEMBR, V36, P387, DOI 10.1023/B:JOBB.0000041773.20072.9e
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Koulintchenko M, 2003, EMBO J, V22, P1245, DOI 10.1093/emboj/cdg128
   LeBlanc AJ, 1999, J BIOL CHEM, V274, P21071, DOI 10.1074/jbc.274.30.21071
   Leshinsky-Silver E, 2003, PRENATAL DIAG, V23, P31, DOI 10.1002/pd.516
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Magalhaes PJ, 1998, MOL BIOL CELL, V9, P2375, DOI 10.1091/mbc.9.9.2375
   Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   McGregor A, 2003, BBA-GENE STRUCT EXPR, V1629, P73, DOI 10.1016/j.bbaexp.2003.08.005
   McGregor A, 2001, MOL GENET GENOMICS, V265, P721, DOI 10.1007/s004380100469
   Meirelles FV, 1997, GENETICS, V145, P445
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091
   Oca-Cossio J, 2003, GENETICS, V165, P707
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Puranam RS, 2001, MOL CELL BIOL, V21, P548, DOI 10.1128/MCB.21.2.548-561.2001
   Roberts RM, 1999, AM J MED GENET, V87, P265, DOI 10.1002/(SICI)1096-8628(19991126)87:3<265::AID-AJMG14>3.0.CO;2-S
   Ross GF, 2003, BIOCONJUGATE CHEM, V14, P962, DOI 10.1021/bc034050f
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200
   Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x
   TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, P3404, DOI 10.1093/nar/29.16.3404
   Taylor RW, 1997, J BIOENERG BIOMEMBR, V29, P195, DOI 10.1023/A:1022646215643
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Weber K, 1997, AM J HUM GENET, V60, P373
   Weissig V, 2000, DRUG DELIV, V7, P1, DOI 10.1080/107175400266722
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 101
TC 6
Z9 9
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD FEB 15
PY 2005
VL 5
IS 2
BP 183
EP 194
DI 10.1517/14712598.5.2.183
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 908FH
UT WOS:000227772300005
PM 15757380
DA 2024-11-01
ER

PT J
AU Feng, YQ
   Guo, N
   Huang, F
   Li, L
   Yao, XL
   Li, XH
   Zhang, C
   Liang, XL
AF Feng, YQ
   Guo, N
   Huang, F
   Li, L
   Yao, XL
   Li, XH
   Zhang, C
   Liang, XL
TI Clinical, pathological and genetic study of a kindred of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE mitochondrial encephalornyopathy with lactic acidosis; stroke-like episodes pathology gene sequencing
ID mutation; melas; dna; diagnosis; myopathy
AB he first description of a syndrome including stroke-like episodes, lactic acidaemia, and ragged red fibres, was reported by Shapira et al in 1975.(1) Pavlakis et al(2) described further cases, introduced the acronym MELAS (mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes), and suggested that this represented a distinct mitochondrial disease phenotype. In 1990, Goto et al(3) identified A3243G mutation in the transfer RNA (tRNA) leucine (UUR) gene in some patients with MELAS. Although this mutation has now been established to be the commonest mtDNA defect it is often misdiagnosed. Here we report a kindred of MELAS including a mother and a son. Clinical, pathological and genetic studies are proceeding.
C1 Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
C3 Sun Yat Sen University
RP Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
EM fyqgz@sina.com
CR GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Smith ML, 1997, J CLIN ENDOCR METAB, V82, P2826, DOI 10.1210/jc.82.9.2826
   Song DL, 2001, CHINESE MED J-PEKING, V114, P1273
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   Wang ZX, 2002, CHINESE MED J-PEKING, V115, P995
   Wong LJC, 1997, CLIN CHEM, V43, P1241
NR 12
TC 0
Z9 0
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
EI 
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD APR 20
PY 2005
VL 118
IS 8
BP 695
EP 698
DI 
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 920HH
UT WOS:000228679500014
PM 15899127
DA 2024-11-01
ER

PT J
AU Blakely, EL
   de Silva, R
   King, A
   Schwarzer, V
   Harrower, T
   Dawidek, G
   Turnbull, DM
   Taylor, RW
AF Blakely, EL
   de Silva, R
   King, A
   Schwarzer, V
   Harrower, T
   Dawidek, G
   Turnbull, DM
   Taylor, RW
TI LHON/MELAS overlap syndrome associated with a mitochondrial <i>MTND1</i> gene mutation
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; LHON; MELAS; overlap syndrome; complex I
ID mtdna mutation; nd5; diagnosis
AB Pathogenic point mutations in the mitochondrial MTND1 gene have previously been described in association with two distinct clinical phenotypes - Leber hereditary optic neuropathy (LHON) and mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes ( MELAS). Here we report the first heteroplasmic mitochondrial DNA ( mtDNA) point mutation (3376G>A) in the MTND1 gene associated with an overlap syndrome comprising the clinical features of both LHON and MELAS. Muscle histochemistry revealed subtle mitochondrial abnormalities, while biochemical analysis showed an isolated complex I deficiency. Our findings serve to highlight the growing importance of mutations in mitochondrial complex I structural genes in MELAS and its associated overlap syndromes.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Oldchurch Hosp, Dept Neurol, Romford RM7 0BE, Essex, England.
   Oldchurch Hosp, Dept Neuropathol, Romford RM7 0BE, Essex, England.
   Oldchurch Hosp, Dept Ophthalmol, Romford RM7 0BE, Essex, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   *MITOMAP, 1907, HUM MIT GEN DAT, V0, P0
   Musumeci O, 2000, AM J HUM GENET, V66, P1900, DOI 10.1086/302927
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040
NR 19
TC 69
Z9 78
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAY 15
PY 2005
VL 13
IS 5
BP 623
EP 627
DI 10.1038/sj.ejhg.5201363
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 920LX
UT WOS:000228692000019
PM 15657614
DA 2024-11-01
ER

PT J
AU Munakata, K
   Iwamoto, K
   Bundo, M
   Kato, T
AF Munakata, K
   Iwamoto, K
   Bundo, M
   Kato, T
TI Mitochondrial DNA 3243A&gt;G mutation and increased expression of <i>LARS2</i> gene in the brains of patients with bipolar disorder and schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE DNA microarray; leucyl-tRNA synthetase 2; mitochondrial (LARS2); aminoacylation; mitochondrial DNA 3243A > G; peptide nucleic acid (PNA)-clamped PCR; postmortem brain
ID magnetic-resonance spectroscopy; stroke-like episodes; lactic-acidosis; external ophthalmoplegia; diabetes-mellitus; mental-disorders; point mutations; human-cells; melas; nucleotide
AB Background. Accumulating evidence suggests mitochondrial dysfunction in bipolar disorder. Analyses of mitochondria-related genes using DNA microarray showed significantly increased LARS2 (mitochondrial leucyl-tRNA synthetase) in the postmortem prefrontal cortices of patients with bipolar disorder provided by the Stanley Foundation Brain Collection. LARS2 is a nuclear gene encoding the enzyme catalyzing the aminoacylation of mitochondrial tRNA(Leu). A well-studied mitochondrial DNA point mutation, 3243A>G, in the region of tRNA(Leu (UUR)), related with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), is known to decrease the efficiency of aminoacylation of tRNA(Leu (UUR)). Methods. The steady state level of LARS2 was examined in the transmitochondrial cybrids carrying 3243A>G. We examined the 3243A>G mutation in these brains using the peptide nucleic acid-clamped polymerase chain reaction restriction fragment length polymorphism method. Results. LARS2 was upregulated in the transmitochrondrial cybrids carrying 3243A>G. The 3243A>G was detected in the postmortem brains of two patients with bipolar disorder and one with schizophrenia. These patients also showed higher levels of the mutation in their livers and significantly higher gene expression of LARS2 compared with other subjects. Conclusions: These results suggest that upregulation of LARS2 is a hallmark of 324A>G mutation. The accumulation of 3243A>G mutation in the brain may have a pathophysiologic role in bipolar disorder and schizophrenia.
C1 RIKEN, Brain Sci Inst, Lab Mol Dynam Met Disorders, Wako, Saitama 3510198, Japan.
C3 RIKEN
RP RIKEN, Brain Sci Inst, Lab Mol Dynam Met Disorders, Hirosawa 2-1, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.go.jp
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ben-Shachar D, 1999, INT J NEUROPSYCHOPH, V2, P245, DOI 10.1017/S1461145799001649
   Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273
   CHOMYN A, 1994, AM J HUM GENET, V54, P966
   Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Iwamoto K, 2004, MOL PSYCHIATR, V9, P406, DOI 10.1038/sj.mp.4001437
   James R, 2004, MOL CELL NEUROSCI, V26, P112, DOI 10.1016/j.mcn.2004.01.013
   Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, PC867, DOI 10.1152/ajpcell.00191.2003
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   King L, 1999, SYNAPSE, V31, P67, DOI 10.1002/(SICI)1098-2396(199901)31:1<67::AID-SYN9>3.0.CO;2-#
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Liu VWS, 1997, HUM MUTAT, V9, P265, DOI 10.1002/(SICI)1098-1004(1997)9:3<265::AID-HUMU8>3.3.CO;2-6
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Maurer I, 2001, SCHIZOPHR RES, V48, P125, DOI 10.1016/S0920-9964(00)00075-X
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   Miyaoka H, 1997, BIOL PSYCHIAT, V42, P524, DOI 10.1016/S0006-3223(97)00280-1
   MullerHocker J, 1997, HEPATOLOGY, V26, P709
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Odawara M, 1998, HUM GENET, V102, P708, DOI 10.1007/s004390050768
   Odawara M, 1997, DIABETIC MED, V14, P503, DOI 10.1002/(SICI)1096-9136(199706)14:6<503::AID-DIA394>3.0.CO;2-1
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Onishi H, 1997, BIOL PSYCHIAT, V41, P1137, DOI 10.1016/S0006-3223(97)00005-X
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   PETTEGREW JW, 1991, ARCH GEN PSYCHIAT, V48, P563
   Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511
   Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P978
   Prince JA, 1999, NEUROPSYCHOPHARMACOL, V21, P372, DOI 10.1016/S0893-133X(99)00016-0
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   SHANSKE AL, 1993, NEUROMUSCULAR DISORD, V3, P191, DOI 10.1016/0960-8966(93)90058-R
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Sohm N, 2004, J MOL BIOL, V339, P17, DOI 10.1016/j.jmb.2004.03.066
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suzuki Y, 1997, MOL ASPECTS MED, V18, P0
   Tanaka M, 2004, ANN NY ACAD SCI, V1011, P7, DOI 10.1196/annals.1293.002
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9
   Ueda Y, 2004, PEDIATR NEPHROL, V19, P107, DOI 10.1007/s00467-003-1318-7
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Washizuka S, 2004, BIOL PSYCHIAT, V56, P483, DOI 10.1016/j.biopsych.2004.07.004
   Washizuka S, 2003, AM J MED GENET B, V120B, P72, DOI 10.1002/ajmg.b.20041
   Whatley SA, 1996, NEUROCHEM RES, V21, P995, DOI 10.1007/BF02532409
   Yamazaki M, 1991, RINSHO SHINKEIGAKU, V31, P1219
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
NR 54
TC 108
Z9 121
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAR 1
PY 2005
VL 57
IS 5
BP 525
EP 532
DI 10.1016/j.biopsych.2004.11.041
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 903HB
UT WOS:000227415400012
PM 15737668
DA 2024-11-01
ER

PT J
AU Luoma, PT
   Luo, NG
   Löscher, WN
   Farr, CL
   Horvath, R
   Wanschitz, J
   Kiechl, S
   Kaguni, LS
   Suomalainen, A
AF Luoma, PT
   Luo, NG
   Löscher, WN
   Farr, CL
   Horvath, R
   Wanschitz, J
   Kiechl, S
   Kaguni, LS
   Suomalainen, A
TI Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; autosomal-dominant; polg mutations; multiple deletions; drosophila-melanogaster; catalytic subunit; strand synthesis; gamma-a; mtdna; neuropathy
AB Defects of mitochondrial polymerase gamma (POLG) underlie neurological diseases ranging from myopathies to parkinsonism and infantile Alpers syndrome. The most severe manifestations have been associated with mutations of the 'spacer' region of POLG, the function of which has remained unstudied in humans. We identified a family, segregating three POLG amino acid variants, A467T, R627Q and Q1236H. The first two affect the spacer region and the third is a polymorphism, allelic with R627Q. Three grades of disease severity appeared to correlate with the genotypes. The patient with the most severe outcome, cerebellar ataxia syndrome, had all three variants, those with R627Q and Q1236H had juvenile-onset ptosis and gait disturbance and those with a single A467T allele had late-onset ptosis. To evaluate the molecular pathogenesis of these spacer defects, we expressed and purified the mutant proteins and studied their catalytic properties in vitro. The A467T substitution resulted in clearly decreased activity, DNA binding and processivity of the polymerase. Our biochemical data, the dominant manifestation of A467T and its previously reported high frequency in the Belgian population (0.6%), emphasize the role of this mutation as a common cause of neurological disease. Further, biochemical evidence that a polymorphic variant may modify the function of a mutant POLG, if occurring in the same polypeptide, is shown here. Finally, and surprisingly, other pathogenic spacer mutants showed DNA-binding affinities and processivities similar to or higher than the controls, suggesting that the disease-causing mechanisms of spacer mutations extend beyond the basic catalytic functions of POLG.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
   Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA.
   Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria.
   Acad Hosp Schwabing, Metab Dis Ctr, Munich, Germany.
   Acad Hosp Schwabing, Dept Clin Chem, Munich, Germany.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Michigan State University; Michigan State University; Medical University of Innsbruck
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Room C523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU NIGMS NIH HHS [GM45295] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brobby GW, 1998, NEW ENGL J MED, V338, P548, DOI 10.1056/NEJM199802193380813
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Iyengar B, 1999, GENETICS, V153, P1809
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kajander OA, 1999, NAT MED, V5, P965, DOI 10.1038/12379
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Löffler J, 2001, EUR J HUM GENET, V9, P226, DOI 10.1038/sj.ejhg.5200607
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   SCHMITT ME, 1993, CURR OPIN GENET DEV, V3, P769, DOI 10.1016/S0959-437X(05)80097-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972
   Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 42
TC 88
Z9 96
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 15
PY 2005
VL 14
IS 14
BP 1907
EP 1920
DI 10.1093/hmg/ddi196
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 941HL
UT WOS:000230205800001
PM 15917273
DA 2024-11-01
ER

PT J
AU McComsey, GA
   Paulsen, DM
   Lonergan, JT
   Hessenthaler, SM
   Hoppel, CL
   Williams, VC
   Fisher, RL
   Cherry, CL
   White-Owen, C
   Thompson, KA
   Ross, ST
   Hernandez, JE
   Ross, LL
AF McComsey, GA
   Paulsen, DM
   Lonergan, JT
   Hessenthaler, SM
   Hoppel, CL
   Williams, VC
   Fisher, RL
   Cherry, CL
   White-Owen, C
   Thompson, KA
   Ross, ST
   Hernandez, JE
   Ross, LL
TI Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine
SO AIDS
LA English
DT Article
DE stavudine; abacavir; mitochondrial DNA; mitochondrial toxicity; electron transport chain; apoptosis; lipoatrophy
ID reverse-transcriptase inhibitors; hiv-infected patients; subcutaneous adipocyte apoptosis; active antiretroviral therapy; antiviral nucleoside analogs; adipose-tissue; toxicity; lipodystrophy; myopathy; substitution
AB Objective: To determine if stavudine (alpha4T)-associated mitochondrial toxicity could be reversed by substitution with another nucleoside reverse transcriptase inhibitor. As apoptosis and dysfunction of electron transport chain (ETC) activities may underlie mitochondrial toxicity, these parameters were also evaluated. Design: The 16 participants (on d4T for >3 years; with lipoatrophy and/or hyperlactatemia) substituted abacavir or zidovudine for stavudine in their antiretroviral regimen. Key parameters including dual-energy X-ray absorptiometry (DEXA) scans, fat apoptosis, mitochondrial DNA (mtDNA) content in peripheral blood mononuclear cells (PBMC), skeletal muscle and fat, as well as skeletal muscle mitochondrial ETC activities were evaluated at study entry and at 48 weeks after the substitution. Methods: Quantitative PCR was used to evaluate mtDNA levels and the presence of deletions/rearrangements; CLIA-validated methods for ETC activities; terminal deoxynucleotidyl transferase dUTP-digoxigenin nick-end labeling assays to evaluate adipocyte apoptosis; and DEXA scans to measure changes in body fat. Results: MtDNA was depleted at study entry in muscle, adipose tissue and PBMC but levels rebounded with respective mean increases of 141%, 146%, and 369% at week 48. Corresponding fat improvements were noted with DEXA increases of 21%, 11%, and 16% in arm, leg, and trunk, respectively. Quantitative adipocyte apoptosis were significantly increased at baseline (P < 0.01 versus HIV-negative controls), with a significant reduction at week 48 (P < 0.05 versus baseline). Mean values for seven mitochondrial enzyme activities assays at entry indicated substantial loss of function (48% to 85% of controls) with significant improvement of complex I activity by week 48. Conclusions: Substitution of stavudine with abacavir or zidovudine improves mitochondrial indices and fat apoptosis in the setting of lipoatrophy. (C) 2005 Lippincott Williams Wilkins.
C1 Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.
   Case Sch Med Ctr AIDS Res, Cleveland, OH 44106 USA.
   GlaxoSmithKline, San Diego, CA USA.
   Univ Calif San Diego, San Diego, CA 92103 USA.
   Monash Univ, Melbourne, Vic 3004, Australia.
   Burnet Inst, Melbourne, Vic, Australia.
C3 University System of Ohio; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Ohio; Case Western Reserve University; GlaxoSmithKline; University of California System; University of California San Diego; Monash University; Burnet Institute
RP McComsey, GA (corresponding author), 11100 Euclid Ave,Mailstop 8A, Cleveland, OH 44106 USA.
EM mccomsey.grace@clevelandactu.org
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Bhat HK, 1999, CIRCULATION, V99, P807, DOI 10.1161/01.CIR.99.6.807
   Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4
   Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Canevari L, 1999, FEBS LETT, V457, P131, DOI 10.1016/S0014-5793(99)01028-5
   Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207
   CHEN CH, 1991, MOL PHARMACOL, V39, P625
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008
   Domingo P, 2001, J INFECT DIS, V184, P1197, DOI 10.1086/323805
   Gahan ME, 2001, J CLIN VIROL, V22, P241, DOI 10.1016/S1386-6532(01)00195-0
   HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   JOHNSON JA, 2002, 14 INT AIDS C BARC S, V0, P0
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002
   MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743
   Masini A, 1999, J NEUROL SCI, V166, P131, DOI 10.1016/S0022-510X(99)00126-4
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790
   Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   PAULSEN DM, 2002, 14 INT C AIDS BARC J, V0, P0
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
   ZINN AB, 1986, NEW ENGL J MED, V315, P469, DOI 10.1056/NEJM198608213150801
NR 34
TC 125
Z9 132
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 
J9 AIDS
JI Aids
PD JAN 3
PY 2005
VL 19
IS 1
BP 15
EP 23
DI 10.1097/00002030-200501030-00002
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 887MR
UT WOS:000226310700002
PM 15627029
DA 2024-11-01
ER

PT J
AU Sharer, JD
AF Sharer, JD
TI The adenine nucleotide translocase type 1 (ANT1): A new factor in mitochondrial disease
SO IUBMB LIFE
LA English
DT Review
DE adenine nucleotide translocase; mitochondrial disorders; autosomal dominant progressive external ophthalmoplegia; Senger's syndrome
ID progressive external ophthalmoplegia; facioscapulohumeral muscular-dystrophy; defective oxidative-phosphorylation; permeability transition pore; autosomal-dominant; multiple deletions; hypertrophic cardiomyopathy; saccharomyces-cerevisiae; congenital cataract; nuclear genes
AB Mitochondrial disorders of oxidative phosphorylation (OXPHOS) comprise a growing list of potentially lethal diseases caused by mutations in either mitochondrial (mtDNA) or nuclear DNA (nDNA). Two such conditions, autosomal dominant progressive external ophthalmoplegia (adPEO) and Senger's Syndrome, are associated with dysfunction of the heart and muscle-specific isoform of the adenine nucleotide translocase (ANT1), a nDNA gene product that facilitates transport of ATP and ADP across the inner mitochondrial membrane. AdPEO is a mtDNA deletion disorder broadly characterized by pathology involving the eyes, skeletal muscle, and central nervous system. In addition to ANT1 , mutations in at least two other nuclear genes, twinkle and POLG , have been shown to cause mtDNA destabilization associated with adPEO. Senger's syndrome is an autosomal recessive condition characterized by congenital heart defects, abnormalities of skeletal muscle mitochondria, cataracts, and elevated circulatory levels of lactic acid. This syndrome is associated with severe depletion of ANT1, which may be the result of an as yet unidentified ANT1-specific transcriptional or translational processing error. ANT1 has also been associated with a third condition, autosomal dominant facioscapulohumeral muscular dystrophy (FSHD), an adult onset disorder characterized by variable muscle weakness in the face, feet, shoulders, and hips. FSHD patients possess specific DNA deletions on chromosome 4, which appear to cause derepression of several nearby genes, including ANT1 . Early development of FSHD may involve mitochondrial dysfunction and increased oxidative stress, possibly associated with overexpression of ANT1.
C1 Univ Alabama, Dept Genet, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Sharer, JD (corresponding author), Univ Alabama, Dept Genet, Kaul 652A,720 20th St S, Birmingham, AL 35294 USA.
EM dsharer@genetics.uab.edu
CR Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Belzacq AS, 2003, CANCER RES, V63, P541
   Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chevrollier A, 2005, M S-MED SCI, V21, P156, DOI 10.1051/medsci/2005212156
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   CRUYSBERG JRM, 1986, AM J OPHTHALMOL, V102, P740, DOI 10.1016/0002-9394(86)90402-2
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2003, BASIC APPL MYOL, V13, P145
   DIMAURO S, 2003, GENETESTS, V0, P0
   Flierl A, 2005, GENE THER, V12, P570, DOI 10.1038/sj.gt.3302443
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Laoudj-Chenivesse D, 2005, J MOL MED, V83, P216, DOI 10.1007/s00109-004-0583-7
   Law AKT, 2004, BMC NEUROSCI, V5, P0, DOI 10.1186/1471-2202-5-1
   Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   Morava E, 2004, EUR J PEDIATR, V163, P467, DOI 10.1007/s00431-004-1465-2
   MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603
   Muthumani K, 2003, BIOCHEM BIOPH RES CO, V304, P583, DOI 10.1016/S0006-291X(03)00631-4
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Padberg G W, 1991, NEUROMUSCUL DISORD, V1, P231, DOI 10.1016/0960-8966(91)90094-9
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   Sharer JD, 2002, MOL BIOL CELL, V13, P71, DOI 10.1091/mbc.01-05-0245
   Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553
   Shoffner JM, 1995, METABOLIC MOL BASES, V7th, P1535
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smythe GM, 2000, MOL THER, V1, P304, DOI 10.1006/mthe.2000.0049
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   van den Heuvel L, 2001, BIOESSAYS, V23, P518, DOI 10.1002/bies.1071
   van der Maarel SM, 2005, AM J HUM GENET, V76, P375, DOI 10.1086/428361
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26
   Winokur ST, 2003, NEUROMUSCULAR DISORD, V13, P322, DOI 10.1016/S0960-8966(02)00284-5
   Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287
   Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 54
TC 39
Z9 46
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1521-6543
EI 
J9 IUBMB LIFE
JI IUBMB Life
PD SEP 15
PY 2005
VL 57
IS 9
BP 607
EP 614
DI 10.1080/15216540500217735
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 970WF
UT WOS:000232342400002
PM 16203679
DA 2024-11-01
ER

PT J
AU Güçer, S
   Talim, B
   Asan, E
   Korkusuz, P
   Özen, S
   Ünal, S
   Kalkanoglu, SH
   Kale, G
   Çaglar, M
AF Güçer, S
   Talim, B
   Asan, E
   Korkusuz, P
   Özen, S
   Ünal, S
   Kalkanoglu, SH
   Kale, G
   Çaglar, M
TI Focal segmental glomerulosclerosis associated with mitochondrial cytopathy:: Report of two cases with special emphasis on podocytes
SO PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
LA English
DT Article
DE focal segmental glomerulosclerosis; mitochondrial cytopathy; childhood; electron microscopy; podocyte
ID debre-fanconi-syndrome; dna; mutations; deletion; disease
AB We report two children with focal segmental glomerulosclerosis (FSGS) associated with mitochondrial cytopathy (MC). Case 1 was diagnosed as MC with the findings of ptosis, ophthalmoplegia, failure to thrive, high serum lactate and pyruvate levels, ragged red fibers in muscle biopsy and the common 4.9 kb deletion in mtDNA when she was four years old. She subsequently developed FSGS four years later. Case 2 was a four month-old girl presenting with feeding difficulty from birth, with vomiting, seizures and nystagmoid eye movements, nephrotic proteinuria and hematuria. Renal biopsy revealed FSGS. Ultrastructural study demonstrated markedly pleomorphic mitochondria in podocytes with a severe effacement of foot processes. The analyses of muscle biopsy and skin fibroblasts for respiratory chain enzymes were found to be normal, while mitochondrial DNA analysis revealed the population of a single deleted mtDNA in the heteroplasmic state. The present cases illustrate FSGS as a rare renal complication of mitochondrial disease and provide further evidence of podocytes possessing abnormal mitochondria which may cause glomerular epithelial cell damage leading to glomerulosclerosis.
C1 Hacettepe Univ, Fac Med, Dept Pediat, Pathol Unit, TR-06100 Ankara, Turkey.
   Hacettepe Univ, Fac Med, Dept Histol & Embryol, TR-06100 Ankara, Turkey.
   Hacettepe Univ, Fac Med, Dept Pediat, Nephrol & Rheumatol Unit, TR-06100 Ankara, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University
RP Hacettepe Univ, Fac Med, Dept Pediat, Pathol Unit, TR-06100 Ankara, Turkey.
EM sgucer@hacettepe.edu.tr
CR Borisov VB, 2002, MOL ASPECTS MED, V23, P385, DOI 10.1016/S0098-2997(02)00013-4
   Buemi M, 1997, NEPHRON, V76, P249, DOI 10.1159/000190188
   DEGIROLAMI U, 2000, DIAGNOSTIC ELECT MIC, V0, P912
   Doleris LM, 2000, KIDNEY INT, V58, P1851, DOI 10.1046/j.1523-1755.2000.00356.x
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456
   Kurogouchi F, 1998, AM J NEPHROL, V18, P551, DOI 10.1159/000013406
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Mochizuki H, 1996, CLIN NEPHROL, V46, P347
   MORRIS AAM, 1995, PEDIATR NEPHROL, V9, P407, DOI 10.1007/BF00866711
   NAGATA M, 1992, KIDNEY INT, V42, P148, DOI 10.1038/ki.1992.272
   NIAUDET P, 1994, PEDIATR NEPHROL, V8, P164, DOI 10.1007/BF00865468
   Niaudet P, 1997, KIDNEY INT, V51, P1000, DOI 10.1038/ki.1997.140
   Patterson K, 2004, PEDIATR DEVEL PATHOL, V7, P629, DOI 10.1007/s10024-004-5051-4
   Rutledge JC, 2004, PEDIATR DEVEL PATHOL, V7, P641, DOI 10.1007/s10024-004-5049-y
   Scaglia F, 2003, AM J MED GENET A, V123A, P172, DOI 10.1002/ajmg.a.20315
   SPERL W, 1988, EUR J PEDIATR, V147, P418, DOI 10.1007/BF00496424
   THORNER P S, 1985, PEDIATRIC PATHOLOGY, V4, P25
   Unal S, 2005, J CHILD NEUROL, V20, P83, DOI 10.1177/08830738050200011304
   Yamagata K, 2002, J AM SOC NEPHROL, V13, P0, DOI 10.1097/01.ASN.0000019772.17954.F8
NR 23
TC 53
Z9 59
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1093-5266
EI 1615-5742
J9 PEDIATR DEVEL PATHOL
JI Pediatr. Dev. Pathol.
PD DEC 15
PY 2005
VL 8
IS 6
BP 710
EP 717
DI 10.1007/s10024-005-0058-z
PG 8
WC Pathology; Pediatrics
SC Pathology; Pediatrics
GA 995ZY
UT WOS:000234145400017
PM 16328667
DA 2024-11-01
ER

PT J
AU Slama, A
   Glurgea, I
   Debrey, D
   Bridoux, D
   de Lonlay, P
   Levy, P
   Chretien, D
   Brivet, M
   Legrand, A
   Rustin, P
   Munnich, A
   Rötig, A
AF Slama, A
   Glurgea, I
   Debrey, D
   Bridoux, D
   de Lonlay, P
   Levy, P
   Chretien, D
   Brivet, M
   Legrand, A
   Rustin, P
   Munnich, A
   Rötig, A
TI Deoxyguanosine kinase mutations and combined deficiencies of the mitochondrial respiratory chain in patients with hepatic involvement
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mitochondrial DNA depletion; deoxyguanosine kinase; respiratory chain defect
ID dna depletion syndrome; gene; myopathy; expression; diseases
AB The activity of deoxyguanosine kinase (DGUOK), a mitochondrial enzyme involved in the anabolism of mitochondrial (mt) deoxyribo-nucleotides, governs the maintenance of the mtDNA. Deleterious mutations of the DGUOK gene are thus associated with mtDNA depletion and result in combined deficiencies of mtDNA-encoded respiratory chain enzymes. With the aim to estimate the prevalence of DGUOK mutations in a cohort of 30 patients with hepatocerebral disease and combined respiratory chain deficiencies, we studied the DGUOK gene and identified previously unreported mutations in five families. Two patients and their affected sibs, born to non-consanguineous parents, were homozygous for a missense mutation (M1T, and L250S, respectively). One patient presented a homozygous 4 pb insertion (796 insT-GAT) and two other patients, and their affected sibs, were compound heterozygous (E165V/L266R and E211G/L266R, respectively). These findings allowed us to propose prenatal diagnosis in two families. In conclusion, we observed a high prevalence of DGUOK mutations (17%) in patients with hepatic involvement and combined respiratory chain deficiencies with hepatic involvement. (c) 2005 Elsevier Inc. All rights reserved.
C1 Hop Bicetre, Lab Biochim 1, AP HP, Le Kremlin Bicetre, France.
   Hop Bicetre, Serv Hepatol Pediat, AP HP, Le Kremlin Bicetre, France.
   Hop Necker Enfants Malad, Serv Genet Med, AP HP, Paris, France.
   Hop Necker Enfants Malad, INSERM U 393, Paris, France.
   Hop Robert Debre, INSERM, U676, F-75019 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Universite Paris Saclay; Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Hopital Universitaire Antoine-Beclere - APHP; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP
RP Slama, A (corresponding author), Hop Bicetre, Lab Biochim 1, AP HP, Le Kremlin Bicetre, France.
EM abdel.slama@bct.aphp.fr
CR Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 15
TC 29
Z9 34
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD DEC 15
PY 2005
VL 86
IS 4
BP 462
EP 465
DI 10.1016/j.ymgme.2005.09.006
PG 4
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 997XP
UT WOS:000234282500007
PM 16263314
DA 2024-11-01
ER

PT J
AU Patton, JR
   Bykhovskaya, Y
   Mengesha, E
   Bertolotto, C
   Fischel-Ghodsian, N
AF Patton, JR
   Bykhovskaya, Y
   Mengesha, E
   Bertolotto, C
   Fischel-Ghodsian, N
TI Mitochondrial myopathy and sideroblastic anemia (MLASA) -: Missense mutation in the pseudouridine synthase 1 (<i>PUS1</i>) gene is associated with the loss of tRNA pseudouridylation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID u2 snrna; dyskeratosis-congenita; ribosomal-rna; in-vivo; conserved pseudouridine; anticodon loop; chain-reaction; dna invitro; biogenesis; stabilization
AB A missense mutation in the PUS1 gene affecting a highly conserved amino acid has been associated with mitochondrial myopathy and sideroblastic anemia (MLASA), a rare autosomal recessive oxidative phosphorylation disorder. The PUS1 gene encodes the enzyme pseudouridine synthase 1 (Pus1p) that is known to pseudouridylate tRNAs in other species. Total RNA was isolated from lymphoblastoid cell lines established from patients, parents, unaffected siblings, and unrelated controls, and the tRNAs were assayed for the presence of pseudouridine (Psi) at the expected positions. Mitochondrial and cytoplasmic tRNAs from MLASA patients are lacking modification at sites normally modified by Pus1p, whereas tRNAs from controls, unaffected siblings, or parents all have Psi at these positions. In addition, there was no Pus1p activity in an extract made from a cell line derived from a patient with MLASA. Immunohistochemical staining of Pus1p in cell lines showed nuclear, cytoplasmic, and mitochondrial distribution of the protein, and there is no difference in staining between patients and unaffected family members. MLASA is thus associated with absent or greatly reduced tRNA pseudouridylation at specific sites, implicating this pathway in its molecular pathogenesis.
C1 Univ S Carolina, Sch Med, Dept Pathol & Microbiol, Columbia, SC 29209 USA.
   Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Med Genet,David Geffen Sch Med, Ahmanson Dept Pediat,Steven Spielberg Pediat Res, Los Angeles, CA 90048 USA.
C3 University of South Carolina System; University of South Carolina Columbia; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Ste 1165 WT, Los Angeles, CA 90048 USA.
EM nathan.fischel@cshs.org
FU NIDCD NIH HHS [R01DC01402] Funding Source: Medline
CR Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941
   Auffinger P, 2014, MODIFICATION EDITING, V0, PP103, DOI 10.1128/9781555818296.ch6
   Auffinger P, 1998, MODIFICATION EDITING, V0, P569
   Bakin AV, 1998, METH MOL B, V77, P297
   Baumstark T, 2001, RNA, V7, P1652
   Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368
   Chen JG, 2000, BIOCHEMISTRY-US, V39, P12723, DOI 10.1021/bi001109m
   Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591
   Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020
   Davis DR, 1998, J BIOMOL STRUCT DYN, V15, P1121, DOI 10.1080/07391102.1998.10509006
   DAVIS DR, 1991, BIOCHEMISTRY-US, V30, P4223, DOI 10.1021/bi00231a017
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dönmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504
   GRIFFEY RH, 1985, J BIOL CHEM, V260, P9734
   Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200
   Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32
   Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604
   Helm M, 2004, J MOL BIOL, V337, P545, DOI 10.1016/j.jmb.2004.01.036
   Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+
   Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316
   MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035
   Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141
   Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396
   MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   Newby MI, 2002, NAT STRUCT BIOL, V9, P958, DOI 10.1038/nsb873
   Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308
   Nishimura S, 1972, PROG NUCLEIC ACID RES MOL BIOL, V12, P49
   Patton JR, 2003, BIOCHEM J, V372, P595, DOI 10.1042/BJ20021938
   Ramamurthy V, 1999, J BIOL CHEM, V274, P22225, DOI 10.1074/jbc.274.32.22225
   Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447
   SAMBROOK J, 2001, MOL CLONING LAB MANU, V0, P776
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589
   Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783
   Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461
   Zhao XL, 2004, RNA, V10, P681, DOI 10.1261/rna.5159504
   Zhao XS, 2004, MOL CELL, V15, P549, DOI 10.1016/j.molcel.2004.06.044
NR 43
TC 108
Z9 123
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 20
PY 2005
VL 280
IS 20
BP 19823
EP 19828
DI 10.1074/jbc.M500216200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 926HH
UT WOS:000229113700049
PM 15772074
DA 2024-11-01
ER

PT J
AU Masuyama, M
   Iida, R
   Takatsuka, H
   Yasuda, T
   Matsuki, T
AF Masuyama, M
   Iida, R
   Takatsuka, H
   Yasuda, T
   Matsuki, T
TI Quantitative change in mitochondrial DNA content in various mouse tissues during aging
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE mitochondrial DNA; aging; real-time PCR; gene expression; mouse tissue
ID fluorescence differential display; human skeletal-muscle; copy number; m-lp; expression; age; abnormality; deletion; disease; protein
AB In order to systematically characterize age-related changes in the mtDNA content of various tissues during aging, we analyzed the mtDNA content of eight tissues from mice at five different ages from young to senescent by quantitative real-time PCR analysis. Obvious variations of mtDNA content among the tissues were detected: There was a 20-fold range in 2-week-old mice and a 50-fold range in 15-month-old mice. The mtDNA contents of the heart, lung, kidney, spleen and skeletal muscle increased gradually with age, whereas those of bone marrow and brain showed no age-related pattern. The expression patterns of mitochondrial transcription factor A (mtTFA) and mitochondrial single-strand DNA binding protein (mtSSB), possible regulatory factors of the mtDNA copy number, were not necessarily linked with the age-related pattern of the mtDNA content, suggesting the existence of other factors that affect the mtDNA content. The Western blot analysis of mtDNA-encoded cytochrome c oxidase subunit III (MTCO3) demonstrated that the expression levels of this protein in the heart and skeletal muscle increase with age in parallel with the mtDNA content. These findings confirm that the mtDNA content of tissues changes during aging. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Fukui, Fac Med Sci, Dept Forens Med, Matsuoka, Fukui 9101193, Japan.
   Univ Fukui, Fac Med Sci, Dept Med Genet & Biochem, Matsuoka, Fukui 9101193, Japan.
C3 University of Fukui; University of Fukui
RP Univ Fukui, Fac Med Sci, Dept Forens Med, Matsuoka, Fukui 9101193, Japan.
EM ireiko@fmsra.fukui-med.ac.jp
CR Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7
   Barrientos A, 1997, BIOCHEM MOL MED, V62, P165, DOI 10.1006/bmme.1997.2647
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Iida R, 2003, J BIOL CHEM, V278, P6301, DOI 10.1074/jbc.M210886200
   Iida R, 2000, MECH AGEING DEV, V113, P135, DOI 10.1016/S0047-6374(99)00104-9
   Iida R, 2002, EXP GERONTOL, V37, P1121, DOI 10.1016/S0531-5565(02)00066-9
   Iida R, 2001, BIOCHEM BIOPH RES CO, V283, P292, DOI 10.1006/bbrc.2001.4769
   Kornberg A, 1992, DNA REPLICATION, V0, P0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee HC, 1998, FEBS LETT, V441, P292, DOI 10.1016/S0014-5793(98)01564-6
   Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1
   Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
NR 25
TC 71
Z9 86
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD MAY 25
PY 2005
VL 1723
IS 1-3
BP 302
EP 308
DI 10.1016/j.bbagen.2005.03.001
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 934FI
UT WOS:000229691900035
PM 15820144
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Ferraris, S
   Nishigaki, Y
   Azan, G
   Mauro, A
   Sammarco, P
   Krishna, S
   Tay, SKH
   Bonilla, E
   Romansky, SG
   Hirano, M
   DiMauro, S
AF Mancuso, M
   Ferraris, S
   Nishigaki, Y
   Azan, G
   Mauro, A
   Sammarco, P
   Krishna, S
   Tay, SKH
   Bonilla, E
   Romansky, SG
   Hirano, M
   DiMauro, S
TI Congenital or late-onset myopathy in patients with the T14709C mtDNA mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondrial myopathy; diabetes mellitus; maternal inheritance; mtDNA
ID mitochondrial-dna mutations; diabetes-mellitus
AB Three patients with different clinical phenotypes harbored the same point mutation at nucleotide 14109 (T14709C) in the tRNA(Gto) of mitochondrial DNA (mtDNA). The first patient was a 21-month-old child with severe congenital myopathy. respiratory distress and mild mental retardation. Muscle biopsy showed about 12% cytochrome c oxidase (COX)-negative ragged-red fibers (RRFs), and markedly decreased activities of mitochondrial respiratory chain complexes I, III and IV The other two patients were 51- and 55-year-old siblings with slowly progressive myopathy and diabetes mellitus. Muscle biopsy showed focal COX-negative RRFs and decreased activities of complexes I, III and IV. In all three patients, the T14709C mutation was abundant in muscle but present at lower levels in accessible tissues. Previously described patients with the same mutation also showed congenital or late-onset myopathy Diabetes is frequently associated with both phenotypes and is a clinical clue to the molecular diagnosis. (C) 2004 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10003 USA.
   Ist Auxol Italiano, Div Neurol, Verbania, Italy.
   Osped V Cervello, Palermo, Italy.
   Long Beach Mem Med Ctr, Long Beach, CA 90801 USA.
C3 Columbia University; IRCCS Istituto Auxologico Italiano
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10003 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Carelli V, 2002, MITOCHONDRIAL DISORD, V0, P115
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DIMAURO S, 2003, GENEREVIEWS GENE TES, V0, P0
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HOA H, 1995, AM J HUM GENET, V56, P1017
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Schon EA, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2, P69
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
NR 15
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2005
VL 228
IS 1
BP 93
EP 97
DI 10.1016/j.jns.2004.10.018
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 889JJ
UT WOS:000226439000016
PM 15607216
DA 2024-11-01
ER

PT J
AU Schröder, JM
   Züchner, S
   Dichgans, M
   Nagy, Z
   Molnar, MJ
AF Schröder, JM
   Züchner, S
   Dichgans, M
   Nagy, Z
   Molnar, MJ
TI Peripheral nerve and skeletal muscle involvement in CADASIL
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE CADASIL; notch3 mutations; neuropathy; myopathy; mitochondrial DNA
ID autosomal-dominant arteriopathy; human mitochondrial-dna; human sural nerves; subcortical infarcts; notch3 mutations; blood-vessels; leukoencephalopathy cadasil; skin biopsy; hereditary; neuropathy
AB Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is characterized by degeneration of vascular smooth muscle cells (VSMC) of nearly all tissues studied so far. The clinical phenotype of CADASIL shows great variability. The disease is caused by mutations of the Notch3 gene encoding the transmembrane receptor Notch3, which is expressed predominantly in VSMC. In some patients, neuromuscular symptoms have been described. To investigate the fine structural features of peripheral nerve and muscle biopsy specimens in more cases and greater detail, seven electron microscopically confirmed CADASIL patients showing a variable amount of granular osmiophilic material on the surface of VSMC were included in this study. Pathogenic mutations within the cluster region (exon 3 and 4) of the Notch3 gene were identified in six cases. Degeneration and regeneration of nerve fibers in the sural nerves, studied in four cases, was present, although moderate, in all nerve biopsy specimens, whereas an intramuscular nerve fascicle showed more severe changes. Enlarged mitochondria with needle-like calcium precipitates were repeatedly seen. In muscle biopsy specimens, some degree of neurogenic atrophy was apparent in addition to myopathic changes, including occasional ragged red fibers with abnormally large mitochondria, focal tubular aggregates, abnormal terminal cisternae, and myofibrillary abnormalities. Automated sequence analysis of the whole mitochondrial DNA performed in one patient revealed several nucleotide polymorphisms, which were not considered pathogenic. The findings suggest that in CADASIL degeneration of small blood vessels is initiated by defects of the surface membrane of VSMC. Dysfunction of these blood vessels may cause low-grade chronic ischemia with secondary hypoxidosis and a large variety of structural changes noted in skeletal muscle and peripheral nerves, although a primary influence of the underlying genetic defect can not be excluded.
C1 Univ Hosp Aachen, Dept Neuropathol, Rhein Westfal TH Aachen, D-52074 Aachen, Germany.
   Natl Inst Psychiat & Neurol, H-1021 Budapest, Hungary.
   Univ Munich, Dept Neurol, Klinikum Grosshadern, Munich, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of Munich
RP Univ Hosp Aachen, Dept Neuropathol, Rhein Westfal TH Aachen, Pauwelstr 30, D-52074 Aachen, Germany.
EM molnarm@opni.hu
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   [Anonymous], 2001, PATHOLOGY PERIPHERAL, V0, P0
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122
   Bergmann M, 1996, ACTA NEUROPATHOL, V92, P341, DOI 10.1007/s004010050528
   CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5
   Chawda SJ, 2000, NEURORADIOLOGY, V42, P249, DOI 10.1007/s002340050880
   CHEN YS, 1995, AM J HUM GENET, V57, P133
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dichgans M, 2000, EUR J HUM GENET, V8, P280, DOI 10.1038/sj.ejhg.5200460
   Dichgans M, 2002, J NEUROL SCI, V203, P77, DOI 10.1016/S0022-510X(02)00270-8
   Dichgans M, 1998, ANN NEUROL, V44, P731, DOI 10.1002/ana.410440506
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Goebel HH, 1997, MUSCLE NERVE, V20, P625, DOI 10.1002/(SICI)1097-4598(199705)20:5<625::AID-MUS17>3.0.CO;2-V
   GREHL H, 1991, ACTA NEUROPATHOL, V81, P680, DOI 10.1007/BF00296380
   Haritoglou C, 2004, AM J OPHTHALMOL, V138, P302, DOI 10.1016/j.ajo.2004.02.073
   Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047
   Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506
   Joutel A, 2001, LANCET, V358, P2049, DOI 10.1016/S0140-6736(01)07142-2
   Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kalaria RN, 2004, J NEUROL SCI, V226, P35, DOI 10.1016/j.jns.2004.09.008
   Kalimo H, 2002, BRAIN PATHOL, V12, P371
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   MARZUKI S, 1991, HUM GENET, V88, P139
   Mawrin C, 2001, ACTA NEUROPATHOL, V102, P364
   Mayer M, 1999, J NEUROL, V246, P526, DOI 10.1007/s004150050398
   Müller HD, 2001, ACTA NEUROPATHOL, V102, P27
   Nukada H, 1996, BRAIN, V119, P1449, DOI 10.1093/brain/119.5.1449
   Oberstein SAJL, 2003, ACTA NEUROPATHOL, V106, P107, DOI 10.1007/s00401-003-0701-6
   Opherk C, 2004, BRAIN, V127, P2533, DOI 10.1093/brain/awh282
   Peters N, 2004, EXP CELL RES, V299, P454, DOI 10.1016/j.yexcr.2004.06.004
   Prakash N, 2002, EXP CELL RES, V278, P31, DOI 10.1006/excr.2002.5544
   Rafalowska J, 2003, ACTA NEUROPATHOL, V106, P569, DOI 10.1007/s00401-003-0764-4
   Rubio A, 1997, ACTA NEUROPATHOL, V94, P247, DOI 10.1007/s004010050700
   Ruchoux MM, 1998, NEUROPATH APPL NEURO, V24, P60
   RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500
   Ruchoux MM, 2002, ANN NY ACAD SCI, V977, P224, DOI 10.1111/j.1749-6632.2002.tb04819.x
   Ruchoux MM, 2003, AM J PATHOL, V162, P329, DOI 10.1016/S0002-9440(10)63824-2
   SCHRODER JM, 1995, ACTA NEUROPATHOL, V89, P116, DOI 10.1007/BF00296354
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   SCHRODER JM, 1991, ACTA NEUROPATHOL, V82, P471, DOI 10.1007/BF00293381
   SCHRODER JM, 1986, ACTA NEUROPATHOL, V72, P29, DOI 10.1007/BF00687944
   Schutz G, 1997, CELL TISSUE RES, V290, P31, DOI 10.1007/s004410050904
   Senderek J, 1998, ACTA NEUROPATHOL, V95, P443, DOI 10.1007/s004010050823
   SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297
   TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256
   Vielhaber S, 2001, J NEUROPATH EXP NEUR, V60, P1032, DOI 10.1093/jnen/60.11.1032
   Walsh JS, 2000, J AM ACAD DERMATOL, V43, P1125, DOI 10.1067/mjd.2000.110895
NR 51
TC 27
Z9 30
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD DEC 15
PY 2005
VL 110
IS 6
BP 587
EP 599
DI 10.1007/s00401-005-1082-9
PG 13
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 992AW
UT WOS:000233857200007
PM 16328531
DA 2024-11-01
ER

PT J
AU Iizuka, T
   Sakai, F
AF Iizuka, T
   Sakai, F
TI Pathogenesis of stroke-like episodes in MELAS: Analysis of neurovascular cellular mechanisms
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Review
DE MELAS; stroke-like episodes; neuronal hyperexcitability; pathogenesis
ID magnetic-resonance-spectroscopy; mitochondrial-dna mutation; anticodon wobble nucleotide; cerebral-blood-flow; lactic-acidosis; point mutation; creatine monohydrate; mtdna mutation; nicotinamide treatment; modification defect
AB The pathogenesis of stroke-like episodes in mitochondrial encephalopathy, myopathy, lactic acidosis and stroke-like episodes (MELAS) is not fully understood although two main theories have been proposed; ischemic vascular hypothesis caused by "mitochondrial angiopathy" and generalized cytopathic hypothesis caused by "mitochondrial cytopathy". Crucial molecular mechanism includes the lack of taurine modification at the wobble uridine of mutant transfer RNAS(Leu(UUR)) resulting in defective translation of cognate codons due to a defect in codon-anticodon interaction. Whereas recent clinical studies have shed light on the neuronal hyperexcitability, which may potentially initiate a cascade of stroke-like events. Stroke-like episodes are characterized by neuronal hyperexcitability, neuronal vulnerability, increased capillary permeability, and focal hyperaemia. It is recognized that stroke-like lesions not only evolve in the area incongruent to a vascular territory, but also potentially spread into the surrounding cortex with concomitant vasogenic edema presumably provoked by prolonged epileptic activities. Based on the clinical observations, we speculate that stroke-like episodes appear to be non-ischemic neurovascular events; once neuronal hyperexcitability developed in a localized brain region as a result from either mitochondrial dysfunction in the capillary endothelial cells, or in neurons or astrocytes, epileptic activities may depolarize the adjacent neurons leading to propagation of epileptic activities in the surrounding cortex. Increased capillary permeability provoked by epileptic activities in the presence of mitochondrial capillary angiopathy may cause unique, edematous brain lesions predominantly involving the cortex. As a consequence, susceptible neuronal population in the cortex may result in neuronal loss with a laminar or pseudo-laminar distribution.
C1 Kitasato Univ, Sch Med, Dept Med Neurol, Sagamihara, Kanagawa 2288555, Japan.
C3 Kitasato University
RP Kitasato Univ, Sch Med, Dept Med Neurol, 1-15-1 Kitasato, Sagamihara, Kanagawa 2288555, Japan.
EM takahiro@med.kitasato-u.ac.jp
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   Amagasaki K, 2001, J NEUROSURG, V94, P133, DOI 10.3171/jns.2001.94.1.0133
   Barisic N, 2002, NEUROPEDIATRICS, V33, P157, DOI 10.1055/s-2002-33679
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   Berbel-Garcia A, 2004, CLIN NEUROPHARMACOL, V27, P187, DOI 10.1097/01.wnf.0000137862.67131.bf
   Betts J, 2004, NEUROCHEM RES, V29, P505, DOI 10.1023/B:NERE.0000014821.07269.8d
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   BRENINGSTALL GN, 1988, PEDIATR NEUROL, V4, P366, DOI 10.1016/0887-8994(88)90085-9
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   CAMPISTOL J, 2000, REV NEUROL S, V1, P105
   Campos Y, 1997, BIOCHEM BIOPH RES CO, V238, P323, DOI 10.1006/bbrc.1997.7166
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P493, DOI 10.1016/S0960-8966(00)00107-3
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Clark JM, 1996, NEUROLOGY, V46, P223, DOI 10.1212/WNL.46.1.223
   Cock H, 1999, EPILEPSIA, V40, P33, DOI 10.1111/j.1528-1157.1999.tb00897.x
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889
   Curran J, 1998, MODIFIED NUCLEOSIDES, V0, P493
   DANKS RA, 1988, AUST NZ J MED, V18, P69, DOI 10.1111/j.1445-5994.1988.tb02245.x
   Dashe JF, 1998, NEW ENGL J MED, V339, P1914, DOI 10.1056/NEJM199812243392608
   de Toledo M, 2001, REV NEUROLOGIA, V33, P148, DOI 10.33588/rn.3302.2001016
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DURCAN L, 1992, NEUROLOGY, V42, P282
   El Idrissi A, 2004, NEUROCHEM RES, V29, P189, DOI 10.1023/B:NERE.0000010448.17740.6e
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Feddersen B, 2003, NEUROLOGY, V61, P1149, DOI 10.1212/01.WNL.0000092497.53706.1B
   FUJII T, 1990, PEDIATR NEUROL, V6, P253, DOI 10.1016/0887-8994(90)90116-I
   Funakawa I, 1997, ELECTROEN CLIN NEURO, V103, P370, DOI 10.1016/S0013-4694(97)00020-9
   Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   GROPEN TI, 1994, STROKE, V25, P1873, DOI 10.1161/01.STR.25.9.1873
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Hart PE, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2, P35
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hattori Y, 2001, RINSHO SHINKEIGAKU, V41, P668
   Hirano M, 2000, BRAIN PATHOL, V10, P451
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Iizuka T, 2003, NEUROLOGY, V61, P577, DOI 10.1212/01.WNL.0000078931.87815.B3
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Ikejiri Y, 1996, NEUROLOGY, V47, P583, DOI 10.1212/WNL.47.2.583
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Kamada K, 2001, J NEUROL NEUROSUR PS, V70, P675, DOI 10.1136/jnnp.70.5.675
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   KEEP RF, 1993, ADV EXP MED BIOL, V331, P43
   Kim IO, 1996, AM J ROENTGENOL, V166, P641, DOI 10.2214/ajr.166.3.8623642
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827
   Kolb SJ, 2003, J NEUROL SCI, V216, P11, DOI 10.1016/S0022-510X(03)00218-1
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   LOVE S, 1993, J PATHOL, V170, P9, DOI 10.1002/path.1711700103
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Majamaa K, 1996, LIFE SCI, V58, P691, DOI 10.1016/0024-3205(95)02338-0
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Menotti Francesca, 2004, ITAL HEART J, V5, P460
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Miyamoto A, 1997, NEURORADIOLOGY, V39, P427, DOI 10.1007/s002340050438
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   Möller HE, 2002, MUSCLE NERVE, V25, P593, DOI 10.1002/mus.10084
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   Mörl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Napolitano A, 2000, NEUROL SCI, V21, PS981, DOI 10.1007/s100720070015
   Nishino I, 1996, MUSCLE NERVE, V19, P1603, DOI 10.1002/(SICI)1097-4598(199612)19:12<1603::AID-MUS10>3.0.CO;2-S
   Oguro H, 2004, INTERNAL MED, V43, P427, DOI 10.2169/internalmedicine.43.427
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohshita T, 2000, NEURORADIOLOGY, V42, P651, DOI 10.1007/s002340000335
   Okatani Y, 2003, EUR J PHARMACOL, V465, P163, DOI 10.1016/S0014-2999(03)01463-8
   OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502
   Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446
   Oppenheim C, 2000, J NEUROL NEUROSUR PS, V69, P248, DOI 10.1136/jnnp.69.2.248
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   Rajesh KG, 2003, AM J PHYSIOL-HEART C, V285, PH2171, DOI 10.1152/ajpheart.00143.2003
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Remes AM, 2002, NEUROLOGY, V59, P1275, DOI 10.1212/WNL.59.8.1275
   Rossi FH, 2002, NEUROLOGIST, V8, P313, DOI 10.1097/00127893-200209000-00004
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Sano M, 1995, ACTA NEUROL SCAND, V92, P497
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050
   SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100
   Schon EA, 2003, CURR MED CHEM, V10, P2523, DOI 10.2174/0929867033456503
   Schürer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sue CM, 2000, BRAIN PATHOL, V10, P442
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Suzuki T, 2001, NUCLEIC ACIDS RES SUPPL, V0, P257
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Takahashi S, 1998, J NEUROL SCI, V158, P58, DOI 10.1016/S0022-510X(98)00105-1
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Thambisetty M, 2004, EXPERT REV MOL DIAGN, V4, P631, DOI 10.1586/14737159.4.5.631
   Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001
   Toyoda K, 2004, J NEUROL SCI, V221, P11, DOI 10.1016/j.jns.2004.03.002
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   Valanne L, 1996, NEUROPEDIATRICS, V27, P154, DOI 10.1055/s-2007-973767
   VEGGIOTTI P, 1995, NEUROPHYSIOL CLIN, V25, P158, DOI 10.1016/0987-7053(96)80168-7
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Watanabe Y, 1998, J NUCL MED, V39, P961
   Welch KMA, 2003, NEUROLOGY, V61, PS2, DOI 10.1212/WNL.61.8_suppl_4.S2
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
   Yonemura K, 2001, AM J NEURORADIOL, V22, P269
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
NR 157
TC 77
Z9 99
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD JAN 15
PY 2005
VL 2
IS 1
BP 29
EP 45
DI 10.2174/1567202052773544
PG 17
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 904UD
UT WOS:000227522300005
PM 16181098
DA 2024-11-01
ER

PT J
AU Chan, SSL
   Longley, MJ
   Copeland, WC
AF Chan, SSL
   Longley, MJ
   Copeland, WC
TI The common A467T mutation in the human mitochondrial DNA polymerase (<i>POLG</i>) compromises catalytic efficiency and interaction with the accessory subunit
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID multiple deletions; spacer-region; gamma; identification; disorders; defects; processivity; depletion; binding; ataxia
AB dAmong the nearly 50 disease mutations in the gene for the catalytic subunit of human DNA polymerase gamma, POLG, the A467T substitution is the most common and has been found in 0.6% of the Belgian population. The A467T mutation is associated with a wide range of mitochondrial disorders, including Alpers syndrome, juvenile spinocerebellar ataxia-epilepsy syndrome, and progressive external ophthalmoplegia, each with vastly different clinical presentations, tissue specificities, and ages of onset. The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in k(cat) with minimal effect on exonuclease function. Human DNA polymerase gamma (pol gamma) requires association of a 55-kDa accessory subunit for enhanced DNA binding and highly processive DNA synthesis. However, the A467T mutant enzyme failed to interact with and was not stimulated by the accessory subunit, as judged by processivity, heat inactivation, and N-ethylmaleimide protection assays in vitro. Thermolysin digestion and immunoprecipitation experiments further indicate weak association of the subunits for A467T pol gamma. This is the first example of a mutation in POLG that disrupts physical association of the pol gamma subunits. We propose that reduced polymerase activity and loss of accessory subunit interaction are responsible for the depletion and deletion of mitochondrial DNA observed in patients with this POLG mutation.
C1 NIEHS, NIH, Lab Mol Genet, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP NIEHS, NIH, Lab Mol Genet, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bienstock RJ, 2004, MITOCHONDRION, V4, P203, DOI 10.1016/j.mito.2004.05.018
   CHAN SSL, 2005, IN PRESS DNA REPAIR, V0, P0
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HUBER HE, 1987, J BIOL CHEM, V262, P16224
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley Matthew J, 2002, METHODS MOL BIOL, V197, P245, DOI 10.1385/1-59259-284-8:245
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702
   LONGLEY MJ, 2005, IN PRESS GENE, V0, P0
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   NGUYEN KV, 2005, IN PRESS NEUROLOGY, V0, P0
   POLESKY AH, 1990, J BIOL CHEM, V265, P14579
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   SPINAZZOLA A, 2005, IN PRESS GENE, V0, P0
   TABOR S, 1987, J BIOL CHEM, V262, P16212
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 35
TC 111
Z9 116
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 9
PY 2005
VL 280
IS 36
BP 31341
EP 31346
DI 10.1074/jbc.M506762200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 961LZ
UT WOS:000231665200002
PM 16024923
DA 2024-11-01
ER

PT J
AU Park, SY
   Choi, GH
   Choi, HI
   Ryu, JW
   Jung, CY
   Lee, W
AF Park, SY
   Choi, GH
   Choi, HI
   Ryu, JW
   Jung, CY
   Lee, W
TI Depletion of mitochondrial DNA causes impaired glucose utilization and insulin resistance in L6 GLUT4myc myocytes
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID human skeletal-muscle; phosphatidylinositol 3-kinase; diabetes-mellitus; ethidium bromide; rat adipocytes; receptor substrate-1; signaling pathways; transporter glut4; plasma-membrane; niddm subjects
AB Mitochondrial dysfunction contributes to a number of human diseases, such as hyperlipidemia, obesity, and diabetes. The mutation and reduction of mitochondrial DNA (mtDNA) have been suggested as factors in the pathogenesis of diabetes. To elucidate the association of cellular mtDNA content and insulin resistance, we produced L6 GLUT4myc myocytes depleted of mtDNA by long term treatment with ethidium bromide. L6 GLUT4myc cells cultured with 0.2 mu g/ml ethidium bromide (termed depleted cells) revealed a marked decrease in cellular mtDNA and ATP content, concomitant with a lack of mRNAs encoded by mtDNA. Interestingly, the mtDNA-depleted cells showed a drastic decrease in basal and insulin-stimulated glucose uptake, indicating that L6 GLUT4myc cells develop impaired glucose utilization and insulin resistance. The repletion of mtDNA normalized basal and insulin-stimulated glucose uptake. The mRNA level and expression of insulin receptor substrate (IRS)-1 associated with insulin signaling were decreased by 76 and 90% in the depleted cells, respectively. The plasma membrane (PM) GLUT4 in the basal state was decreased, and the insulin-stimulated GLUT4 translocation to the PM was drastically reduced by mtDNA depletion. Moreover, insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B were drastically reduced in the depleted cells. Those changes returned to control levels after mtDNA repletion. Taken together, our data suggest that PM GLUT4 content and insulin signal pathway intermediates are modulated by the alteration of cellular mtDNA content, and the reductions in the expression of IRS-1 and insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B are associated with insulin resistance in the mtDNA-depleted L6 GLUT4myc myocytes.
C1 Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea.
   SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Vet Affairs Med Ctr,Biophys Lab, Buffalo, NY 14215 USA.
C3 Dongguk University; State University of New York (SUNY) System; University at Buffalo, SUNY; US Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea.
EM wanlee@mail.dongguk.ac.kr
CR Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104
   Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524
   Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782
   CHEN LB, 1989, METHOD CELL BIOL, V29, P103
   CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91
   Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113
   GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329
   Han JC, 2003, ARCH BIOCHEM BIOPHYS, V413, P213, DOI 10.1016/S0003-9861(03)00120-6
   HANSEN PA, 1995, J BIOL CHEM, V270, P1679
   Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300
   HERZBERG NH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P63, DOI 10.1016/0925-4439(93)90091-E
   Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791
   Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5
   Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090
   JHUN BH, 1992, J BIOL CHEM, V267, P17710
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KANAI F, 1993, J BIOL CHEM, V268, P14523
   Kanzaki M, 2003, CURR BIOL, V13, PR574, DOI 10.1016/S0960-9822(03)00478-0
   Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374
   Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872
   Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7
   Khayat ZA, 2000, J CELL SCI, V113, P279
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7
   Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021
   Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755
   Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200
   Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200
   Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806
   MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x
   Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, PE1007, DOI 10.1152/ajpendo.2001.280.6.E1007
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803
   Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   SERRADAS P, 1995, ENDOCRINOLOGY, V136, P5623, DOI 10.1210/en.136.12.5623
   Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051
   SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930
   Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166
   Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096
   SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542
   Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071
   Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI200112348
   Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, PE572, DOI 10.1152/ajpendo.1999.277.3.E572
   Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2
   Wang QH, 1999, MOL CELL BIOL, V19, P4008
   Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175
   White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952
   Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4
   Yamauchi T, 1996, MOL CELL BIOL, V16, P3074
   Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8
   ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8
NR 66
TC 51
Z9 56
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 18
PY 2005
VL 280
IS 11
BP 9855
EP 9864
DI 10.1074/jbc.M409399200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 905HQ
UT WOS:000227559600015
PM 15764607
DA 2024-11-01
ER

PT J
AU Sarnat, HB
   Marín-García, J
AF Sarnat, HB
   Marín-García, J
TI Pathology of mitochondrial encephalomyopathies
SO CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
ID kearns-sayre-syndrome; c-oxidase deficiency; human skeletal-muscle; spinal muscular-atrophy; ragged-red fibers; dna depletion; respiratory-chain; neuromuscular disorders; thymidine kinase; mtdna deletions
AB Muscle biopsy provides the best tissue to confirm a mitochondrial cytopathy. Histochemical features often correlate with specific syndromes and facilitate the selection of biochemical and genetic studies. Ragged-red fibres nearly always indicate a combination defect of respiratory complexes I and IV. Increased punctate lipid within myofibers is a regular feature of Kearns-Sayre and PEO, but not of MELAS and MERRF. Total deficiency of succinate dehydrogenase indicates a severe defect in Complex 11; total absence of cytochrome-c-oxidase activity in all myofibres correlates with a severe deficiency of Complex IV or of coenzyme-Q10. The selective loss of cytochrome-c-oxidase activity in scattered myofibers, particularly if accompanied by strong succinate dehydrogenase staining in these same fibres, is good evidence of mitochondrial cytopathy and often of a significant mtDNA mutation, though not specific for Complex IV disorders. Glycogen may be excessive in ragged-red zones. Ultrastructure provides morphological evidence of mitochondrial cytopathy, in axons and endothelial cells as well as myocytes. Abnormal axonal mitochondria may contribute to neurogenic atrophy of muscle, a secondary chronic feature. Quantitative determinations of respiratory chain enzyme complexes, with citrate synthase as an internal control, confirm the histochemical impressions or may be the only evidence of mitochondrial disease. Biological and technical artifacts may yield falsely low enzymatic activities. Genetic studies screen common point mutations in mtDNA. The brain exhibits characteristic histopathological alterations in mitochondrial diseases. Skin biopsy is useful for mitochondrial ultrastructure in smooth erector pili muscles and axons; skin fibroblasts may be grown in culture. Mitochondrial alterations occur in many nonmitochondrial diseases and also may be induced by drugs and toxins.
C1 Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada.
   Univ Calgary, Fac Med, Calgary, AB, Canada.
   Mol Cardiol & Neuromuscular Inst, Highland Pk, NJ USA.
C3 Alberta Childrens Hospital; University of Calgary; University of Calgary
RP Sarnat, HB (corresponding author), Alberta Childrens Prov Gen Hosp, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
CR Arnon S, 2002, PRENATAL DIAG, V22, P34, DOI 10.1002/pd.232
   Berger A, 2003, ACTA NEUROPATHOL, V105, P245, DOI 10.1007/s00401-002-0638-1
   BHAWAT AG, 1971, ARCH PATHOL, V91, P70
   BONILLA E, 1975, J ULTRA MOL STRUCT R, V51, P404, DOI 10.1016/S0022-5320(75)80103-1
   Brierley EJ, 1997, ANN NEUROL, V41, P114, DOI 10.1002/ana.410410120
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   CARPENTER S, 1992, NEUROLOGY, V42, P388
   Carpenter S, 2001, PATHOLOGY SKELETAL M, V0, P453
   Castro-Gago M, 2000, REV NEUROLOGIA, V31, P838, DOI 10.33588/rn.3109.2000325
   Chow CK, 2001, BIOL SIGNAL RECEPT, V10, P112
   Darin N, 2003, NEUROPEDIATRICS, V34, P311
   DeCoo IFM, 1997, J NEUROL SCI, V149, P37, DOI 10.1016/S0022-510X(97)05366-5
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DiMauro S, 2002, ADV NEUROL, V89, P217
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Fardeau M, 1981, ACTA NEUROPATHOL SUPPL, V7, P279
   Fernández R, 1999, NEUROMUSCULAR DISORD, V9, P136, DOI 10.1016/S0960-8966(98)00117-5
   Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2
   GRAU JM, 1995, ANN NEUROL, V38, P273, DOI 10.1002/ana.410380225
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P7, DOI 10.1023/A:1015104910239
   Holmuhamedov E, 2003, MITOCHONDRION, V3, P13, DOI 10.1016/S1567-7249(03)00053-9
   Huang CC, 2002, J NEURO-OPHTHALMOL, V22, P66, DOI 10.1097/00041327-200203000-00036
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   JORDAN J, 2003, REV NEUROLOGIA, V37, P1058
   KELLEY RI, 1983, AM J MED GENET, V16, P503, DOI 10.1002/ajmg.1320160409
   Kimata KG, 1998, ARCH NEUROL-CHICAGO, V55, P722, DOI 10.1001/archneur.55.5.722
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Kubota Y, 1999, J AM ACAD DERMATOL, V41, P469, DOI 10.1016/S0190-9622(99)70123-4
   Kyriakides T, 2003, ACTA MYOL, V22, P48
   LAKE BD, 2002, GREENFIELDS NEUROPAT, V0, P0
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Li X, 2003, MITOCHONDRION, V3, P29, DOI 10.1016/S1567-7249(03)00058-8
   Linnane AW, 2002, FREE RADICAL RES, V36, P445, DOI 10.1080/10715760290021306
   Lorenc A, 2003, MITOCHONDRION, V3, P119, DOI 10.1016/S1567-7249(03)00106-5
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   Marin-Garcia J, 2000, J CHILD NEUROL, V15, P555, DOI 10.1177/088307380001500812
   Marin-Garcia J, 2000, PEDIATR NEUROL, V22, P122, DOI 10.1016/S0887-8994(99)00117-4
   Marín-García J, 2003, PEDIATR NEUROL, V29, P26, DOI 10.1016/S0887-8994(03)00013-4
   Marín-García J, 2002, PEDIATR NEUROL, V27, P213, DOI 10.1016/S0887-8994(02)00426-5
   MarinGarcia J, 1997, J INHERIT METAB DIS, V20, P674, DOI 10.1023/A:1005322409330
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Melegh B, 1997, NEUROPEDIATRICS, V28, P257, DOI 10.1055/s-2007-973710
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MILES L, 2003, LAB INVEST, V0, P0
   Mitsui T, 2002, ACTA NEUROPATHOL, V104, P260, DOI 10.1007/s00401-002-0553-5
   NAUMANN M, 1995, ACTA NEUROPATHOL, V89, P152
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 1997, GENOMICS, V39, P185, DOI 10.1006/geno.1996.4465
   NIKALI K, 2003, EUR J PAEDIATR NEURO, V7, P285
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   PEYRONNARD JM, 1980, ANN NEUROL, V7, P262, DOI 10.1002/ana.410070310
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   POULTON J, 1991, CLIN GENET, V39, P33
   Ricoy-Campo JR, 2003, REV NEUROLOGIA, V37, P775, DOI 10.33588/rn.3708.2002596
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   SARNAT HB, 1983, CAN J NEUROL SCI, V10, P170, DOI 10.1017/S0317167100044863
   Schapira A, 2003, MITOCHONDRIAL FUNCTION AND DYSFUNCTION, V0, P0
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Silver MA, 2003, BIOFACTORS, V18, P125, DOI 10.1002/biof.5520180214
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543
   Tanji K, 2003, J NEUROPATH EXP NEUR, V62, P567
   TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   THOMAS L, 1974, LIVES CELL, V0, P72
   Tsao CY, 2000, J CHILD NEUROL, V15, P445, DOI 10.1177/088307380001500704
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   Vielhaber S, 2002, J NEUROPATH EXP NEUR, V61, P885, DOI 10.1093/jnen/61.10.885
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wada H, 1996, BRAIN DEV-JPN, V18, P263, DOI 10.1016/0387-7604(96)00017-4
   Wu SP, 2004, EPILEPSIA, V45, P204, DOI 10.1111/j.0013-9580.2004.29603.x
   Yerroum M, 2000, ACTA NEUROPATHOL, V100, P82, DOI 10.1007/s004010051196
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
NR 88
TC 63
Z9 72
U1 0
U2 1
PU CANADIAN J NEUROL SCI INC
PI CALGARY
PA PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA
SN 0317-1671
EI 
J9 CAN J NEUROL SCI
JI Can. J. Neurol. Sci.
PD MAY 15
PY 2005
VL 32
IS 2
BP 152
EP 166
DI 10.1017/S0317167100003929
PG 15
WC Clinical Neurology
SC Neurosciences & Neurology
GA 930GF
UT WOS:000229403100004
PM 16018150
DA 2024-11-01
ER

PT J
AU Taanman, JW
   Schapira, AHV
AF Taanman, JW
   Schapira, AHV
TI Analysis of the trinucleotide CAG repeat from the DNA polymerase γ gene (<i>POLG</i>) in patients with Parkinson's disease
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE DNA polymerase gamma; POLG; Parkinson's disease; CAG repeat; polyglutamine tract; mitochondria
ID progressive external ophthalmoplegia; mitochondrial complex-i; huntingtons-disease; mtdna deletions; mutations; features; family; defect; brain
AB The human gene for the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase (POLG) contains a trinucleotide CAG repeat encoding a polyglutamine tract near the amino-terminus of the protein. Expansions of similar polyglutamine-encoding CAG microsatellite repeats in other genes are known to cause neurodegenerative disorders. As mitochondrial dysfunction has been implicated in the aetiology of Parkinson's disease, we determined the POLG CAG repeat length in DNA samples extracted from 22 idiopathic Parkinson's disease patients and 31 control subjects. The distribution of the POLG CAG repeat length in the control samples matched the distribution reported for control samples by others. Comparison between the CAG repeat length distribution of control and Parkinson's disease samples revealed no evidence of either germ line or somatic POLG CAG repeat instability in Parkinson's disease patients. Our results rule out POLG CAG repeat instability as a common pathogenic mechanism in idiopathic Parkinson's disease. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 UCL, Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, London NW3 2PF, England.
   UCL, Inst Neurol, London WC1N 3BG, England.
C3 University of London; University College London; University of London; University College London
RP Taanman, JW (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.
EM j.taanman@rfc.ucl.ac.uk
CR ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BOLDEN A, 1977, J BIOL CHEM, V252, P3351
   Bonifati V, 2003, NEUROL SCI, V24, P159, DOI 10.1007/s10072-003-0108-0
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Champy P, 2004, J NEUROCHEM, V88, P63, DOI 10.1046/j.1471-4159.2003.02138.x
   CHECCARELLI N, 1994, J NEUROL SCI, V123, P74, DOI 10.1016/0022-510X(94)90206-2
   Cordato DJ, 2004, J CLIN NEUROSCI, V11, P119, DOI 10.1016/j.jocn.2003.10.009
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352
   Kennedy L, 2000, HUM MOL GENET, V9, P2539, DOI 10.1093/hmg/9.17.2539
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
NR 31
TC 34
Z9 38
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0304-3940
EI 
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD MAR 7
PY 2005
VL 376
IS 1
BP 56
EP 59
DI 10.1016/j.neulet.2004.11.023
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 898UI
UT WOS:000227101300012
PM 15694274
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Moslemi, AR
   Lindberg, C
   Holme, E
   Oldfors, A
AF Kollberg, G
   Moslemi, AR
   Lindberg, C
   Holme, E
   Oldfors, A
TI Mitochondrial myopathy and rhabdomyolysis associated with a novel nonsense mutation in the gene encoding cytochrome <i>c</i> oxidase subunit I
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE COX; mtDNA; mitochondrial myopathy; mutation; rhabdomyolysis
ID progressive external ophthalmoplegia; recurrent myoglobinuria; dna deletions; exercise intolerance; myogenic progenitors; metabolic causes; skeletal-muscle; b gene; patient; microdeletion
AB Mitochondrial DNA (mtDNA) mutations associated with rhabdomyolysis are rare but have been described in sporadic cases with mutations in the cytochrome b and cytochrome c oxidase (COX) genes and in 3 cases with tRNA(Leu) mutation. We report a novel heteroplasmic G6708A nonsense mutation in the mtDNA COI gene encoding COX subunit I in a 30-year-old woman with muscle weakness, pain, fatigue, and one episode of rhabdomyolysis. Histochemical examination of muscle biopsy specimens revealed reduced COX activity in the majority of the muscle fibers (similar to90%) and frequent ragged red fibers. Biochemical analysis showed a marked and isolated COX deficiency. Analysis of DNA extracted from single fibers revealed higher levels of the mutation in COX-deficient fibers (> 95%) compared with COX-positive fibers (1%-80%). The mutation was not detected in a skin biopsy, cultured myoblasts, or blood leukocytes. Nor was it identified in blood leukocytes from the asymptomatic mother, indicating a de novo mutation that arose after germ layer differentiation. Western blot analysis and immunohistochemical staining revealed that reduced levels of COX subunit I were accompanied by reduced levels of other mtDNA encoded subunits, as well as nuclear DNA encoded subunit IV, supporting the concept that COX subunit I is essential for the assembly of complex IV in the respiratory chain.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@pathology.gu.se
CR Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092
   Bischoff R, 1994, SATELLITE CELL MUSCL, V0, P97
   Bonavaud S, 1997, BIOL CELL, V89, P233, DOI 10.1016/S0248-4900(97)80039-1
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kwon JH, 2003, EUR NEUROL, V50, P123, DOI 10.1159/000072517
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Melberg A, 1998, NEUROLOGY, V50, P299, DOI 10.1212/WNL.50.1.299
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   TONIN P, 1990, ANN NEUROL, V27, P181, DOI 10.1002/ana.410270214
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053
NR 31
TC 35
Z9 37
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD FEB 15
PY 2005
VL 64
IS 2
BP 123
EP 128
DI 10.1093/jnen/64.2.123
PG 6
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 898WK
UT WOS:000227106700004
PM 15751226
DA 2024-11-01
ER

PT J
AU Thajeb, P
   Wu, MC
   Shih, BF
   Tzen, CY
   Chiang, MF
   Yuan, RY
AF Thajeb, P
   Wu, MC
   Shih, BF
   Tzen, CY
   Chiang, MF
   Yuan, RY
TI Brain single photon emission computed tomography in patients with A3243G mutation in mitochondrial DNA tRNA
SO ROLE OF THE MITOCHONDRIA IN HUMAN AGING AND DISEASE: FROM GENES TO CELL SIGNALING
LA English
DT Article; Proceedings Paper
DE mitochondrial disease; A3243G mutation; MELAS; brain SPECT; CPEO; diaschisis; hypoperfusion; migraine
ID melas syndrome; trna(leu) a3243g; lactic-acidosis; diffusion; encephalopathy; myopathy; features; episodes
AB Brain single photon emission computed tomography (SPECT) studies were conducted in three patients with A3243G mutation of the mitochondrial (mt) DNA tRNA. All were born to mothers suffering from chronic progressive external ophthalmoplegia (CPEO) with the same A3243G point mutation of the mtDNA tRNA. The first case manifested clinically with MELAS, the second case manifested with CPEO, and third case was characterized by recurrent migraine-like headache, tremor, and epilepsy. Brain SPECT of all patients, regardless of whether they had or had not suffered from stroke-like episodes, showed multiple areas of asymmetrical decreased perfusion, particularly in the posterior and lateral head regions, especially the temporal lobes. Crossed-cerebellar diaschisis may occur. Conventional brain magnetic resonance images failed to show some of the lesions. Decreased regional cerebral blood flow, rather than previously proposed hyperemia, is likely to be the cause. We conclude that mitochondrial vasculopathy with regional cerebral hypoperfusion may be seen on brain SPECT in patients with mitochondrial disorders and A3243G mutations, regardless of whether they have or have not suffered from stroke-like episodes.
C1 Mackay Mem Hosp, Dept Neurol, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Nucl Med, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Pathol, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Neurosurg, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Med Res, Taipei 11499, Taiwan.
   Taipei Med Univ Hosp, Sect Neurol, Taipei, Taiwan.
C3 Mackay Memorial Hospital; Mackay Memorial Hospital; Mackay Memorial Hospital; Mackay Memorial Hospital; Mackay Memorial Hospital; Taipei Medical University Hospital; Taipei Medical University
RP Thajeb, P (corresponding author), Mackay Mem Hosp, Dept Neurol & Med Res, POB Nei Hu 6-30, Taipei 11499, Taiwan.
EM thajebp@hotmail.com
CR CHIEN D, 1992, AM J NEURORADIOL, V13, P1097
   DiMauro S, 1997, MOL GENETIC BASIS NE, V0, P201
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HSU CC, 1995, ACTA NEUROL SCAND, V92, P252
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   MUNNICH A, 2001, METABOLIC MOL BASES, V2, P2261
   Ohshita T, 2000, NEURORADIOLOGY, V42, P651, DOI 10.1007/s002340000335
   Parry A, 2003, J NEUROIMAGING, V13, P293, DOI 10.1177/1051228403254783
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373
   SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   THAJEB P, 1997, CHIN MED J BEIJING, V110, P726
   THAJEB P, 2000, CHIN MED J TAIPEI, V63, P71
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Wallace DC, 2001, THE METABOLIC AND MOLECULAR BASIS OF INHERITED DISEASE, V0, P2425
   Yonemura K, 2001, AM J NEURORADIOL, V22, P269
   ZHANG Y, 2001, CHIN MED J BEIJING, V114, P129
NR 21
TC 13
Z9 13
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2005
VL 1042
IS 
BP 48
EP 54
DI 10.1196/annals.1338.005
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics
GA BCR22
UT WOS:000230893400005
PM 15965044
DA 2024-11-01
ER

PT J
AU Smigrodzki, RM
   Khan, SM
AF Smigrodzki, RM
   Khan, SM
TI Mitochondrial microheteroplasmy and a theory of aging and age-related disease
SO REJUVENATION RESEARCH
LA English
DT Review
ID plasma-membrane oxidoreductase; electron-transport chain; mtdna point mutations; apoptotic cell-death; cytochrome-c-oxidase; alzheimers-disease; parkinsons-disease; oxidative stress; dna mutations; skeletal-muscle
AB We implicate a recently described form of mitochondrial mutation, mitochondrial microheteroplasmy, as a candidate for the principal component of aging. Microheteroplasmy is the presence of hundreds of independent mutations in one organism, with each mutation usually found in 1-2% of all mitochondrial genomes. Despite the low abundance of single mutations, the vast majority of mitochondrial genomes in all adults are mutated. This mutational burden includes inherited mutations, de novo germline mutations, as well as somatic mutations acquired either during early embryonic development or later in adult life. We postulate that microheteroplasmy is sufficient to explain the pathomechanism of several age-associated diseases, especially in conditions with known mitochondrial involvement, such as diabetes (DM), cardiovascular disease, Parkinson's disease (PD), and Alzheimer's disease (AD) and cancer. The genetic properties of microheteroplasmy reconcile the results of disease models (cybrids, hypermutable PolG variants and mitochondrial toxins), with the relatively low levels of maternal inheritance in the aforementioned diseases, and provide an explanation of their delayed, progressive course.
C1 Gencia Corp, Charlottesville, VA 22903 USA.
RP Gencia Corp, 706B Forest St, Charlottesville, VA 22903 USA.
EM rafal@genciabiotech.com
CR ACHIM CL, 2004, BETA AMYLOID HIV BRA, V226, P0
   Adams JD, 2001, CURR MED CHEM, V8, P809, DOI 10.2174/0929867013372995
   Alvarez G, 2003, J NEUROSCI RES, V73, P260, DOI 10.1002/jnr.10648
   Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   Arai T, 2003, AGING CLIN EXP RES, V15, P1
   Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003
   Arias C, 2002, EXP NEUROL, V176, P163, DOI 10.1006/exnr.2002.7912
   Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216
   Barrett TG, 2001, BEST PRACT RES CL EN, V15, P325, DOI 10.1053/beem.2001.0149
   Barrientos A, 1996, BIOCHEM BIOPH RES CO, V229, P536, DOI 10.1006/bbrc.1996.1839
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bhat HK, 2004, J BIOCHEM MOL TOXIC, V18, P180, DOI 10.1002/jbt.20024
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Bigl M, 2003, J NEURAL TRANSM, V110, P77, DOI 10.1007/s00702-002-0772-x
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Bowles Karla R, 2004, EXPERT REV CARDIOVASC THER, V2, P683
   Brahimi-Horn MC, 2005, INT REV CYTOL, V242, P157
   BRAND FN, 1992, J CLIN EPIDEMIOL, V45, P169, DOI 10.1016/0895-4356(92)90009-C
   Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, PC353, DOI 10.1152/ajpcell.00525.2002
   Brown GC, 2004, BBA-BIOENERGETICS, V1658, P44, DOI 10.1016/j.bbabio.2004.03.016
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Büchner M, 2002, NEUROSCIENCE, V114, P285, DOI 10.1016/S0306-4522(02)00280-4
   Burger G, 2003, IUBMB LIFE, V55, P205, DOI 10.1080/1521654031000137380
   Cardoso SM, 2004, J NEUROCHEM, V89, P1417, DOI 10.1111/j.1471-4159.2004.02438.x
   Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4
   Carrière A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7
   Cervin C, 2004, DIABETES, V53, P1894, DOI 10.2337/diabetes.53.7.1894
   Cetica P, 2002, REPRODUCTION, V124, P675, DOI 10.1530/rep.0.1240675
   Chaisson E, 2000, COSMIC EVOLUTION RIS, V0, P0
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Crentsil V, 2004, AGEING RES REV, V3, P153, DOI 10.1016/j.arr.2003.07.003
   Crouch PJ, 2005, J NEUROSCI, V25, P672, DOI 10.1523/JNEUROSCI.4276-04.2005
   Cuezva JM, 2002, CANCER RES, V62, P6674
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   de Grey ADNJ, 2004, REJUV RES, V7, P171, DOI 10.1089/rej.2004.7.171
   De Grey ADNJ, 2002, ANN NY ACAD SCI, V959, P452, DOI 10.1111/j.1749-6632.2002.tb02115.x
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Deleonardi G, 2004, BIOFACTORS, V20, P251
   Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027
   Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002
   Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7
   DU YS, 2000, J BIOL CHEM, V275, P27100
   Dufour E, 2004, BBA-BIOENERGETICS, V1658, P122, DOI 10.1016/j.bbabio.2004.04.020
   Eckert A, 2003, ANN NY ACAD SCI, V1010, P604, DOI 10.1196/annals.1299.113
   Edland SD, 1996, NEUROLOGY, V47, P254, DOI 10.1212/WNL.47.1.254
   El Meziane A, 1998, NAT GENET, V18, P350
   Emelyanov VV, 2003, EUR J BIOCHEM, V270, P1599, DOI 10.1046/j.1432-1033.2003.03499.x
   EPHRUSSI B, 1955, NATURE, V176, P1207, DOI 10.1038/1761207b0
   Eriksson JW, 1999, DIABETES, V48, P1572, DOI 10.2337/diabetes.48.8.1572
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Fischel-Ghodsian N, 2003, EAR HEARING, V24, P303, DOI 10.1097/01.AUD.0000079802.82344.B5
   Fosslien E, 2003, ANN CLIN LAB SCI, V33, P371
   Frost MT, 2005, AM J PHYSIOL-REG I, V288, PR394, DOI 10.1152/ajpregu.00504.2004
   Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x
   Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   Gibson GE, 2000, ANN NEUROL, V48, P297, DOI 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001
   Horenstein RB, 2004, REV ENDOCR METAB DIS, V5, P25, DOI 10.1023/B:REMD.0000016122.84105.75
   Huang Y, 2004, BRAIN RES REV, V46, P44, DOI 10.1016/j.brainresrev.2004.04.007
   Huettenbrenner S, 2003, MUTAT RES-REV MUTAT, V543, P235, DOI 10.1016/S1383-5742(02)00110-2
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Kang DC, 2005, CURR MED CHEM, V12, P429, DOI 10.2174/0929867053363081
   Kato Y, 2002, DIABETIC MED, V19, P784, DOI 10.1046/j.1464-5491.2002.00777.x
   Khan SM, 2004, J BIOENERG BIOMEMBR, V36, P387, DOI 10.1023/B:JOBB.0000041773.20072.9e
   Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7
   Kim JH, 2002, DIABETIC MED, V19, P681, DOI 10.1046/j.1464-5491.2002.00747.x
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   KNUDSON AG, 1978, SEMIN ONCOL, V5, P57
   Kraytsberg Y, 2003, MECH AGEING DEV, V124, P49, DOI 10.1016/S0047-6374(02)00169-0
   KRISTAL BS, 2003, SCI AGING KNOWLEDGE, V0, PPE3
   Lacy F, 1998, J HYPERTENS, V16, P291, DOI 10.1097/00004872-199816030-00006
   Larkin JE, 2004, PHYSIOL GENOMICS, V18, P152, DOI 10.1152/physiolgenomics.00057.2004
   LARM JA, 1994, J BIOL CHEM, V269, P30097
   Lee HC, 1997, J FORMOS MED ASSOC, V96, P770
   Lee HG, 2004, ANN NY ACAD SCI, V1019, P1, DOI 10.1196/annals.1297.001
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Lewis W, 2003, ANTIVIR RES, V58, P189, DOI 10.1016/S0166-3542(03)00069-X
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Liou CW, 2004, ANN NY ACAD SCI, V1011, P317, DOI 10.1196/annals.1293.031
   Liu L, 2002, AGING CELL, V1, P40, DOI 10.1046/j.1474-9728.2002.00004.x
   Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   LUSIS AJ, 2004, ANNU REV GENOM HUM G, V0, P5189
   Lüth HJ, 2005, CEREB CORTEX, V15, P211, DOI 10.1093/cercor/bhh123
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Maklashina E, 2004, AGING CELL, V3, P21, DOI 10.1111/j.1474-9728.2003.00078.x
   Maneiro E, 2005, ANN RHEUM DIS, V64, P388, DOI 10.1136/ard.2004.022152
   Maraganore DM, 2004, ANN NEUROL, V55, P512, DOI 10.1002/ana.20017
   Martin W, 2003, PHILOS T R SOC B, V358, P59, DOI 10.1098/rstb.2002.1183
   Mawrin C, 2004, NEUROSCI LETT, V357, P111, DOI 10.1016/j.neulet.2003.11.073
   Meeker AK, 2004, CURR OPIN ONCOL, V16, P32, DOI 10.1097/00001622-200401000-00007
   MENZIES RA, 1971, J BIOL CHEM, V246, P2425
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007
   Morelli L, 2004, J BIOL CHEM, V279, P56004, DOI 10.1074/jbc.M407283200
   Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241
   Mott JL, 2004, BIOCHEM BIOPH RES CO, V319, P1210, DOI 10.1016/j.bbrc.2004.05.104
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   Ong KK, 2004, EUR J ENDOCRINOL, V151, PU131, DOI 10.1530/eje.0.151U131
   Onyango IG, 2005, NEUROBIOL DIS, V19, P312, DOI 10.1016/j.nbd.2005.01.026
   Osborne C, 2004, ONCOLOGIST, V9, P361, DOI 10.1634/theoncologist.9-4-361
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   Pak JW, 2004, ANN NY ACAD SCI, V1019, P289, DOI 10.1196/annals.1297.049
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   Perez GI, 2000, NATURE, V403, P500, DOI 10.1038/35000651
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079
   Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Rasmussen UF, 2003, EXP GERONTOL, V38, P877, DOI 10.1016/S0531-5565(03)00092-5
   Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140
   REMPEL HC, 2004, DIFFUSE ABETA ACCUMU, V0, P0
   Reynaud K, 2000, MOL CELL ENDOCRINOL, V163, P101, DOI 10.1016/S0303-7207(99)00246-4
   ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB
   Russell MJ, 1996, NEUROBIOL AGING, V17, P269, DOI 10.1016/0197-4580(95)02072-1
   Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x
   Scatena R, 2004, IUBMB LIFE, V56, P477, DOI 10.1080/15216540400008416
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Schoeler S, 2005, BIOCHEM BIOPH RES CO, V332, P43, DOI 10.1016/j.bbrc.2005.04.086
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0
   Shiao YH, 2000, CANCER RES, V60, P2816
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923
   Shishido S, 2003, HEPATOLOGY, V37, P136, DOI 10.1053/jhep.2003.50014
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Sun FZ, 2003, AM J HUM GENET, V72, P1515, DOI 10.1086/375656
   Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918
   Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045
   Swerdlow RH, 2001, PARKINSONISM RELAT D, V7, P129, DOI 10.1016/S1353-8020(00)00029-8
   Szabados T, 2004, BEHAV BRAIN RES, V154, P31, DOI 10.1016/j.bbr.2004.01.016
   Szczesny B, 2003, P NATL ACAD SCI USA, V100, P10670, DOI 10.1073/pnas.1932854100
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   Takeda A, 1998, JPN CIRC J, V62, P695, DOI 10.1253/jcj.62.695
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Tatemoto H, 2000, BIOL REPROD, V63, P805, DOI 10.1095/biolreprod63.3.805
   Taylor DR, 2002, P NATL ACAD SCI USA, V99, P3690, DOI 10.1073/pnas.072660299
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Teng FYH, 2005, BIOCHEM BIOPH RES CO, V328, P1, DOI 10.1016/j.bbrc.2004.12.131
   Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015
   Thamer C, 2003, DIABETES CARE, V26, P2126, DOI 10.2337/diacare.26.7.2126
   Thouas GA, 2004, BIOL REPROD, V71, P1936, DOI 10.1095/biolreprod.104.033589
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Turcanu V, 1992, REV MED CHIR SOC MED NAT IASI, V96 Suppl, P13
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Van Blerkom J, 2004, REPRODUCTION, V128, P269, DOI 10.1530/rep.1.00240
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Remmen H, 2001, EXP GERONTOL, V36, P957
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10
   Velasquez Enrique M, 2003, J LA STATE MED SOC, V155, P314
   VICKERS JC, 1994, NEUROSCIENCE, V62, P1, DOI 10.1016/0306-4522(94)90310-7
   Wang X, 2004, INT J DEV NEUROSCI, V22, P175, DOI 10.1016/j.ijdevneu.2004.05.008
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Watson B, 2001, AM J KIDNEY DIS, V38, P529, DOI 10.1053/ajkd.2001.26848
   Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wirdefeldt K, 2004, NEUROLOGY, V63, P305, DOI 10.1212/01.WNL.0000129841.30587.9D
   Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
   Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102
   Yechoor VK, 2004, P NATL ACAD SCI USA, V101, P16525, DOI 10.1073/pnas.0407574101
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
   Zhang JL, 2005, AM J PHYSIOL-CELL PH, V288, PC840, DOI 10.1152/ajpcell.00325.2004
NR 211
TC 52
Z9 56
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD FAL 15
PY 2005
VL 8
IS 3
BP 172
EP 198
DI 10.1089/rej.2005.8.172
PG 27
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 964XR
UT WOS:000231914800007
PM 16144471
DA 2024-11-01
ER

PT J
AU Tovo, PA
   Chiapello, N
   Gabiano, C
   Zeviani, M
   Spada, M
AF Tovo, PA
   Chiapello, N
   Gabiano, C
   Zeviani, M
   Spada, M
TI Zidovudine administration during pregnancy and mitochondrial disease in the offspring
SO ANTIVIRAL THERAPY
LA English
DT Article
ID virus-uninfected infants; dna; toxicity
AB Prophylactic administration of zidovudine (ZDV) to mother-child pairs reduces HIV transmission. ZDV can impair mitochondrial (mt) DNA polymerase gamma, leading to mtDNA depletion. Signs of mitochondrial dysfunction have been observed in a few children with prenatal exposure to nucleoside analogues, although no mtDNA depletion was demonstrated. Other studies failed to confirm mitochondrial disorders in children who were exposed to antiretroviral agents in utero. A child, whose HIV-infected mother received ZDV from the fourth month of pregnancy, developed neonatal encephalomyopathy, anaemia and hyperlactataemia. At 2 weeks of age, a muscle biopsy exhibited red-ragged-like fibres, proliferation of abnormal mitochondria and a 90% depletion of mtDNA without qualitative abnormalities. At 6 months, the depletion was less profound (about 50% of normal values). Severe psychomotor delay and visual disturbances persisted at 30 months, but they were greatly reduced at 5-year follow-up. These laboratory and clinical findings clearly demonstrated that mtDNA alteration was acquired and not consequent to an inherited disorder. Fetal exposure to ZDV may have caused the mtDNA depletion, which, although temporary, led to irreversible but not progressive brain damage.
C1 Univ Turin, Dept Pediat, I-10124 Turin, Italy.
   Natl Neurol Inst C Besta, Div Mol Neurogenet, Milan, Italy.
C3 University of Turin; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Univ Turin, Dept Pediat, I-10124 Turin, Italy.
EM pierangelo.tovo@unito.it
CR Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74
   BEATRICE B, 2003, AIDS, V17, P1769
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   CHINNERY PF, 1999, LANCET S1, V354, P17
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   COOPER ER, 2004, 15 INT AIDS C BANGK, V0, P0
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006
   Noguera A, 2004, PEDIATRICS, V114, PE598, DOI 10.1542/peds.2004-0955
   *PER SAF REV WORK, 2000, J ACQ IMMUN DEF SYND, V15, P261
   Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
NR 13
TC 21
Z9 23
U1 0
U2 1
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
EI 
J9 ANTIVIR THER
JI Antivir. Ther.
PD JUN 15
PY 2005
VL 10
IS 6
BP 697
EP 699
DI 
PG 3
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 972IB
UT WOS:000232446400001
PM 16218167
DA 2024-11-01
ER

PT J
AU Chabi, B
   de Camaret, WM
   Chevrollier, A
   Boisgard, S
   Stepien, G
AF Chabi, B
   de Camaret, WM
   Chevrollier, A
   Boisgard, S
   Stepien, G
TI Random mtDNA deletions and functional consequence in aged human skeletal muscle
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE aging; mitochondria; mtDNA deletion; respiratory chain; oxidative phosphorylation
ID mitochondrial-dna deletions; respiratory-chain function; accumulation; sequence; mutation; decline; disease; tissue; organization; deficiency
AB Mitochondrial respiratory chain deteriorates with age, mostly in tissues with high energy requirements. Damage to mitochondrial DNA (mtDNA) by reactive oxygen species is thought to contribute primarily to this impairment. However, the overall extent of random mtDNA mutations has still not been evaluated. We carried out molecular and biochemical analyses in muscle biopsies from healthy young and aged subjects. Deleted mtDNA accumulation was followed by both quantitative PCR analysis to quantify total mtDNA, and Southern-blotting, to determine deleted to full length mtDNA ratio. Enzymatic activities of the mitochondrial respiratory chain were measured in all subjects. Randomly deleted mtDNA appeared mainly in the oldest subjects (beyond 80 years old), affecting up to 70% of mtDNA molecules. The activities of complexes III and IV of the respiratory chain, complexes with mtDNA encoded subunits, are lower in the aged subjects. Physical activity could be one major parameter modulating the mitochondrial respiratory chain activity in aged muscle. (C) 2005 Elsevier Inc. All rights reserved.
C1 Univ Auvergne, INSERM, U484, Clermont Ferrand, France.
   Univ Auvergne, INRA, U1019, Clermont Ferrand, France.
   Hop Debrousse, Biochim Lab, Lyon, France.
   Univ Angers, INSERM, U694, Angers, France.
   CHU Gabriel Montpied, Serv Chirurg Orthoped, Clermont Ferrand, France.
C3 Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; Universite Clermont Auvergne (UCA); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; CHU Clermont Ferrand
RP Univ Auvergne, INSERM, U484, Clermont Ferrand, France.
EM stepien@inserm484.u-clermont1.fr
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   BERTHON P, 1995, ACTA PHYSIOL SCAND, V154, P269, DOI 10.1111/j.1748-1716.1995.tb09908.x
   Biagini G, 1998, MECH AGEING DEV, V101, P269, DOI 10.1016/S0047-6374(97)00181-4
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X
   Ferlin T, 1997, MOL CELL BIOCHEM, V174, P221, DOI 10.1023/A:1006860508606
   Gerhard GS, 2002, MECH AGEING DEV, V123, P155, DOI 10.1016/S0047-6374(01)00328-1
   Geromel V, 1997, BIOCHEM BIOPH RES CO, V236, P643, DOI 10.1006/bbrc.1997.7024
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V226, P369, DOI 10.1006/bbrc.1996.1363
   HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HSIEH RH, 1994, BIOCHEM MOL BIOL INT, V32, P1009
   Khrapko K, 2003, MUTAT RES-FUND MOL M, V522, P13, DOI 10.1016/S0027-5107(02)00306-8
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MOUSSON B, 1995, ACTA NEUROL SCAND, V91, P488
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0
   Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8
   Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9
   REYNIER P, 1995, BIOCHEM BIOPH RES CO, V217, P59, DOI 10.1006/bbrc.1995.2745
   Rooyackers OE, 1996, CLIN SCI, V91, P475, DOI 10.1042/cs0910475
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158
NR 40
TC 27
Z9 33
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 1
PY 2005
VL 332
IS 2
BP 542
EP 549
DI 10.1016/j.bbrc.2005.04.153
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 932RY
UT WOS:000229572300033
PM 15896715
DA 2024-11-01
ER

PT J
AU Kornblum, C
   Schröder, R
   Müller, K
   Vorgerd, M
   Eggers, J
   Bogdanow, M
   Papassotiropoulos, A
   Fabian, K
   Klockgether, T
   Zange, J
AF Kornblum, C
   Schröder, R
   Müller, K
   Vorgerd, M
   Eggers, J
   Bogdanow, M
   Papassotiropoulos, A
   Fabian, K
   Klockgether, T
   Zange, J
TI Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions:: a placebo-controlled, double-blind <SUP>31</SUP>P-MRS crossover study
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE chronic progressive external ophthalmoplegia; creatine monohydrate; Kearns-Sayre syndrome; mitochondrial disorders; mtDNA deletion; P-31-MRS
ID magnetic-resonance-spectroscopy; transgenic animal-model; phosphocreatine resynthesis; quantitative-analysis; myotonic-dystrophy; mcardle-disease; supplementation; monohydrate; exercise; accumulation
AB The purpose of our randomized, double-blind, placebo-controlled crossover study in 15 patients with chronic progressive external ophthalmoplegia (CPEO) or Kearns-Sayre syndrome (KSS) because of single large-scale mitochondrial (mt) DNA deletions was to determine whether oral creatine (Cr) monohydrate can improve skeletal muscle energy metabolism in vivo. Each treatment phase with Cr in a dosage of 150 mg/kg body weight/day or placebo lasted 6 weeks. The effect of Cr was estimated by phosphorus-31 magnetic resonance spectroscopy (P-31-MRS), clinical and laboratory tests. P-31-MRS analysis prior to treatment showed clear evidence of severe mitochondrial dysfunction. However, there were no relevant changes in P-31-MRS parameters under Cr. In particular, phosphocreatine (PCr)/ATP at rest did not increase, and there was no facilitation of post-exercise PCr recovery. Clinical scores and laboratory tests did not alter significantly under Cr, which was tolerated without major side-effects in all patients. Cr supplementation did not improve skeletal muscle oxidative phosphorylation in our series of patients. However, one explanation for our negative findings may be the short study duration or the limited number of patients included.
C1 Univ Bonn, Dept Neurol, D-5300 Bonn, Germany.
   DLR, Inst Aerosp Med, Cologne, Germany.
   Ruhr Univ Bochum, Dept Neurol, D-4630 Bochum, Germany.
   Univ Bonn, Dept Med Biometr Informat & Epidemiol, D-5300 Bonn, Germany.
   Univ Zurich, Dept Psychiat Res, Zurich, Switzerland.
   Univ Dresden, Inst Sports Med, Dresden, Germany.
C3 University of Bonn; Helmholtz Association; German Aerospace Centre (DLR); Ruhr University Bochum; University of Bonn; University of Zurich; Technische Universitat Dresden
RP Univ Hosp Bonn, Dept Neurol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM cornelia.kornblum@ukb.uni-bonn.de
CR Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   ARNOLD DL, 1984, MAGNET RESON MED, V1, P307, DOI 10.1002/mrm.1910010303
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BALSOM PD, 1995, ACTA PHYSIOL SCAND, V154, P303, DOI 10.1111/j.1748-1716.1995.tb09914.x
   Brose A, 2003, J GERONTOL A-BIOL, V58, P11
   Casey A, 1996, AM J PHYSIOL-ENDOC M, V271, PE31, DOI 10.1152/ajpendo.1996.271.1.E31
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   COOKE WH, 1995, J APPL PHYSIOL, V78, P670, DOI 10.1152/jappl.1995.78.2.670
   DiMauro S, 2000, NEUROL SCI, V21, P0
   FITCH CD, 1969, P SOC EXP BIOL MED, V132, P219
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   GREENHAFF PL, 1994, AM J PHYSIOL, V266, PE725, DOI 10.1152/ajpendo.1994.266.5.E725
   Grehl T, 1998, NEUROMUSCULAR DISORD, V8, P480, DOI 10.1016/S0960-8966(98)00066-2
   Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925
   HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367
   Howell N, 1999, INT REV CYTOL, V186, P49
   Hultman E, 1996, J APPL PHYSIOL, V81, P232
   Jones B, 1989, DESIGN AND ANALYSIS OF CROSSOVER TRIALS, V0, P0
   KEMP GJ, 1993, NMR BIOMED, V6, P302, DOI 10.1002/nbm.1940060504
   Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, PC598, DOI 10.1152/ajpcell.1992.263.3.C598
   LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807
   Louis M, 2003, MUSCLE NERVE, V27, P604, DOI 10.1002/mus.10355
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   Matthews RT, 1998, J NEUROSCI, V18, P156
   MORGANHUGHES JA, 1995, MYOLOGY, V0, P1610
   OVERSTEEGEN HJ, 1987, CLIN CHEM, V33, P720
   Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   RADDA GK, 1982, NATURE, V295, P608, DOI 10.1038/295608a0
   RADDA GK, 1995, BBA-MOL BASIS DIS, V1271, P15, DOI 10.1016/0925-4439(95)00004-N
   Rico-Sanz J, 2000, J APPL PHYSIOL, V88, P1181, DOI 10.1152/jappl.2000.88.4.1181
   Robinson TM, 1999, J APPL PHYSIOL, V87, P598, DOI 10.1152/jappl.1999.87.2.598
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Smith SA, 1999, J APPL PHYSIOL, V87, P116, DOI 10.1152/jappl.1999.87.1.116
   Tarnopolsky M, 2004, MUSCLE NERVE, V29, P51, DOI 10.1002/mus.10527
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028.abs
   Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055
   Taylor D J, 1983, MOL BIOL MED, V1, P77
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   Vandenberghe K, 1999, MED SCI SPORT EXER, V31, P236, DOI 10.1097/00005768-199902000-00006
   Vandenberghe K, 1997, J APPL PHYSIOL, V83, P2055, DOI 10.1152/jappl.1997.83.6.2055
   Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5
   Vorgerd M, 2000, ARCH NEUROL-CHICAGO, V57, P956, DOI 10.1001/archneur.57.7.956
   Vorgerd M, 2002, ARCH NEUROL-CHICAGO, V59, P97, DOI 10.1001/archneur.59.1.97
   Walsh B, 2001, J PHYSIOL-LONDON, V537, P971
   Walter MC, 2002, J NEUROL, V249, P1717, DOI 10.1007/s00415-002-0923-x
   Walter MC, 2000, NEUROLOGY, V54, P1848, DOI 10.1212/WNL.54.9.1848
   WYSS M, 1994, MOL CELL BIOCHEM, V133, P51, DOI 10.1007/BF01267947
   Xu CJ, 1996, J BIOL CHEM, V271, P13435, DOI 10.1074/jbc.271.23.13435
   Yquel RJ, 2002, J SPORT SCI, V20, P427, DOI 10.1080/026404102317366681
   Zange J, 2002, ANN NEUROL, V52, P126, DOI 10.1002/ana.10197
NR 58
TC 52
Z9 57
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD APR 15
PY 2005
VL 12
IS 4
BP 300
EP 309
DI 10.1111/j.1468-1331.2004.00970.x
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 908GN
UT WOS:000227775600010
PM 15804248
DA 2024-11-01
ER

PT J
AU Apostolova, LG
   White, M
   Moore, SA
   Davis, PH
AF Apostolova, LG
   White, M
   Moore, SA
   Davis, PH
TI Deep white matter pathologic features in watershed regions - A novel pattern of central nervous system involvement in MELAS
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
AB Background: Myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome typically manifests in adults younger than 40 years with encephalopathy, stroke-like episodes, and lactic acidosis. Magnetic resonance imaging (MRI) abnormalities typically involve the cortical gray and the adjacent subcortical white matter. Objective: To describe a 58-year-old woman diagnosed with MELAS who was initially seen with acute myopathy, cardiac ischemia, psychosis, and MRI changes in a watershed distribution. Results: Initial MRI of the brain showed the characteristic parieto-occipital gray matter lesions involving the adjacent white matter. Follow-up MRI revealed striking deep white matter involvement in a watershed distribution. A cerebral angiogram and thorough hypercoagulable workup results were normal. Electromyography showed acute denervation and myopathy. A muscle biopsy specimen revealed ragged red and cytochrome-c oxidase-negative fibers. Mitochondrial DNA analysis revealed an A3243G mutation. Conclusions: Myopathy, encephalopathy, lactic acidosis, and stroke-like episodes should be considered in older patients with myopathy, cardiomyopathy, encephalopathy, and unaccountable MRI findings. Watershed pathologic features are a rare pattern of cerebral involvement in MELAS.
C1 Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA.
   Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA.
C3 University of California System; University of California Los Angeles; University of Iowa; University of Iowa; University of Iowa
RP Apostolova, LG (corresponding author), Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, RNRC 2-238,710 Westwood Blvd, Los Angeles, CA 90095 USA.
EM lapostolova@mednet.ucla.edu
CR BARKOVICH AJ, 1993, AM J NEURORADIOL, V14, P1119
   CASTILLO M, 1995, AM J NEURORADIOL, V16, P233
   FUJII T, 1990, PEDIATR NEUROL, V6, P253, DOI 10.1016/0887-8994(90)90116-I
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Kimata KG, 1998, ARCH NEUROL-CHICAGO, V55, P722, DOI 10.1001/archneur.55.5.722
   MATTHEWS PM, 1991, NEUROLOGY, V41, P1043, DOI 10.1212/WNL.41.7.1043
   MCKELVIE PA, 1991, J NEUROL SCI, V102, P51, DOI 10.1016/0022-510X(91)90093-M
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
NR 9
TC 28
Z9 30
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JUL 15
PY 2005
VL 62
IS 7
BP 1154
EP 1156
DI 10.1001/archneur.62.7.1154
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 945NG
UT WOS:000230508600023
PM 16009776
DA 2024-11-01
ER

PT J
AU Winterthun, S
   Ferrari, G
   He, L
   Taylor, RW
   Zeviani, M
   Turnbull, DM
   Engelsen, BA
   Moen, G
   Bindoff, LA
AF Winterthun, S
   Ferrari, G
   He, L
   Taylor, RW
   Zeviani, M
   Turnbull, DM
   Engelsen, BA
   Moen, G
   Bindoff, LA
TI Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase γ mutations
SO NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; dna deletions; polg; neuropathy; dominant; twinkle; merrf
AB Objective: To investigate three families and one sporadic case with a recessively inherited ataxic syndrome. Methods: Clinical and genetic studies were performed in six individuals. Southern blotting and real time PCR were used to detect deletions of mtDNA and mutations in the POLG gene were identified using a combination of DHPLC and direct DNA sequencing. Results: The patients have a distinctive, progressive disorder that starts with episodic symptoms such as migraine-like headache or epilepsy. Ataxia, which is a combination of central and peripheral disease, develops later as does ophthalmoplegia. The commonest form of epilepsy was focal and involved the occipital lobes. Myoclonus was common and patients have a high risk of status epilepticus. MRI typically shows signal changes in the central cerebellum, olivary nuclei, occipital cortex, and thalami. COX negative muscle fibers were found in four of six; in one patient these were rare and in another absent. Multiple mtDNA deletions were identified in all patients, although in two these were not apparent on Southern blotting and real time PCR was required to demonstrate the defect. Two families were homozygous for a previously described POLG mutation, G1399A (A467T). One family and the sporadic case had the same two new mutations, a G to C at position 1491 (Q497H) and a G to C at 2243 (W748S). Conclusions: Mutations in POLG cause a recessively inherited syndrome with episodic features and progressive ataxia. Characteristic changes on MRI are seen and although skeletal muscle may appear morphologically normal, multiple mtDNA deletions can be detected using real-time PCR.
C1 Univ Bergen, Haukeland Univ Hosp, Dept Neurol, Inst Clin Med & Mol Med, N-5021 Bergen, Norway.
   Univ Bergen, Haukeland Univ Hosp, Dept Radiol, N-5021 Bergen, Norway.
   Unit Mol Neurogenet Pierfranco, Milan, Italy.
   Luisa Mariani Ctr Study Childrens Mitochondrial D, Milan, Italy.
   Natl Neurol Inst C Besta, Milan, Italy.
   Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Fondazione IRCCS Istituto Neurologico Carlo Besta; Newcastle University - UK
RP Bindoff, LA (corresponding author), Univ Bergen, Haukeland Univ Hosp, Dept Neurol, Inst Clin Med & Mol Med, N-5021 Bergen, Norway.
EM laurence.bindoff@nevro.uib.no
FU Telethon [GGP030039] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline
CR Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HARDING AE, 1995, CURR OPIN NEUROL, V8, P306, DOI 10.1097/00019052-199508000-00010
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   vanDomburg PHMF, 1996, BRAIN, V119, P997, DOI 10.1093/brain/119.3.997
   Zhou L, 1997, J NEUROSCI, V17, P7746
NR 15
TC 186
Z9 199
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD APR 12
PY 2005
VL 64
IS 7
BP 1204
EP 1208
DI 10.1212/01.WNL.0000156516.77696.5A
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 915BO
UT WOS:000228272800021
PM 15824347
DA 2024-11-01
ER

PT J
AU Song, SW
   Pursell, ZF
   Copeland, WC
   Longley, MJ
   Kunkel, TA
   Mathews, CK
AF Song, SW
   Pursell, ZF
   Copeland, WC
   Longley, MJ
   Kunkel, TA
   Mathews, CK
TI DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
ID progressive external ophthalmoplegia; base excision-repair; rat cardiac-muscle; polymerase-gamma; point mutations; human-cells; mtdna; identification; accumulation; maintenance
AB The mutation rate of the mammalian mitochondrial genome is higher than that of the nuclear genome. Because mitochondrial and nuclear deoxyribonucleoside triphosphate (dNTP) pools are physically distinct and because dNTP concentrations influence replication fidelity, we asked whether mitochondrial dNTP pools are asymmetric with respect to each other. We report here that the concentrations of the four dNTPs are not equal in mitochondria isolated from several tissues of both young and old rats. In particular, in most tissues examined, mitochondrial dGTP concentrations are high relative to the other dNTPs. Moreover, in the presence of the biased dNTP concentrations measured in heart and skeletal muscle, the fidelity of DNA synthesis in vitro by normally highly accurate mtDNA polymerase gamma is reduced, with error frequencies increased by as much as 3-fold, due to increased formation of template T-dGTP mismatches that are inefficiently corrected by proofreading. These data, plus some published data on specific mitochondrial mutations seen in human diseases, are consistent with the hypothesis that normal intramitochondrial dNTP pool asymmetries may contribute to spontaneous mutagenesis in the mammalian mitochondrial genome.
C1 Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.
   NIEHS, Genet Mol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
   NIEHS, Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
C3 Oregon State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Oregon State Univ, Dept Biochem & Biophys, 2011 ALS, Corvallis, OR 97331 USA.
EM mathewsc@onid.orst.edu
FU NIEHS NIH HHS [P01 ES000040, ES00040] Funding Source: Medline
CR ANGELASTRO JM, 1992, J BIOL CHEM, V267, P25685
   BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946
   Bebenek K, 1995, METHOD ENZYMOL, V262, P217
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392
   Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   KUNKEL TA, 1988, J BIOL CHEM, V263, P4450
   KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011
   KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2
   Marin-Garcia J, 2001, CARDIOVASC RES, V49, P17, DOI 10.1016/S0008-6363(00)00241-8
   Mason PA, 2003, FEBS LETT, V554, P6, DOI 10.1016/S0014-5793(03)01169-4
   MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mole ML, 1998, ANAL BIOCHEM, V259, P245, DOI 10.1006/abio.1998.2647
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   PALMER JW, 1977, J BIOL CHEM, V252, P8731
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Regnier M, 2000, CIRC RES, V86, P1211, DOI 10.1161/01.RES.86.12.1211
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Suh JH, 2003, FREE RADICAL BIO MED, V35, P1064, DOI 10.1016/S0891-5849(03)00468-4
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vinnakota KC, 2004, AM J PHYSIOL-HEART C, V286, PH1742, DOI 10.1152/ajpheart.00478.2003
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   WHIPPS DE, 1984, BIOCHEM J, V221, P147, DOI 10.1042/bj2210147
   WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210
   YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146
NR 45
TC 133
Z9 157
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2005
VL 102
IS 14
BP 4990
EP 4995
DI 10.1073/pnas.0500253102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 914AC
UT WOS:000228195800015
PM 15784738
DA 2024-11-01
ER

PT J
AU White, HE
   Durston, VJ
   Seller, A
   Fratter, C
   Harvey, JF
   Cross, NCP
AF White, HE
   Durston, VJ
   Seller, A
   Fratter, C
   Harvey, JF
   Cross, NCP
TI Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing
SO GENETIC TESTING
LA English
DT Article
ID hereditary optic neuropathy; gradient-gel-electrophoresis; false-positive diagnosis; peptide nucleic-acid; mtdna control region; clinical-features; prenatal-diagnosis; dna heteroplasmy; a3243g mutation; quantification
AB Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.
C1 Salisbury Dist Hosp, Natl Genet Reference Lab Wessex, Salisbury SP2 8BJ, Wilts, England.
   Churchill Hosp, Oxford Med Genet Lab, Oxford OX3 7LJ, England.
C3 Salisbury District Hospital; University of Oxford
RP White, HE (corresponding author), Salisbury Dist Hosp, Natl Genet Reference Lab Wessex, Salisbury SP2 8BJ, Wilts, England.
EM H.E.White@soton.ac.uk
CR Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Boles RG, 2003, CLIN CHEM, V49, P198, DOI 10.1373/49.1.198
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Conley YP, 2003, BRAIN RES PROTOC, V12, P99, DOI 10.1016/j.brainresprot.2003.08.005
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   JUVONEN V, 1994, HUM GENET, V93, P16
   Kirby DM, 1998, MOL DIAGN, V3, P211, DOI 10.1016/S1084-8592(98)80042-8
   Lagerström-Fermér M, 2001, AM J HUM GENET, V68, P1299, DOI 10.1086/320115
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   MASHIMA Y, 1995, INVEST OPHTH VIS SCI, V36, P1714
   Mashima Y, 2004, CLIN BIOCHEM, V37, P268, DOI 10.1016/j.clinbiochem.2003.11.011
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   TANNO Y, 1995, MUSCLE NERVE, V18, P1390, DOI 10.1002/mus.880181208
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   Urata M, 2004, CLIN CHEM, V50, P2045, DOI 10.1373/clinchem.2004.033761
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   White SL, 1998, MOL DIAGN, V3, P113, DOI 10.1016/S1084-8592(98)80059-3
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Wong LJC, 1997, CLIN CHEM, V43, P1857
NR 33
TC 88
Z9 95
U1 0
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1090-6576
EI 
J9 GENET TEST
JI Genet. Test.
PD FAL 15
PY 2005
VL 9
IS 3
BP 190
EP 199
DI 10.1089/gte.2005.9.190
PG 10
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 977EG
UT WOS:000232784600003
PM 16225398
DA 2024-11-01
ER

PT J
AU Ferrari, G
   Lamantea, E
   Donati, A
   Filosto, M
   Briem, E
   Carrara, F
   Parini, R
   Simonati, A
   Santer, R
   Zeviani, M
AF Ferrari, G
   Lamantea, E
   Donati, A
   Filosto, M
   Briem, E
   Carrara, F
   Parini, R
   Simonati, A
   Santer, R
   Zeviani, M
TI Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA
SO BRAIN
LA English
DT Article
DE POLG; mitochondrial DNA polymerase; Alpers' hepatopathic poliodystrophy; valproate toxicity; mtDNA depletion
ID progressive external ophthalmoplegia; diffuse cerebral degeneration; autosomal-dominant; polg mutations; multiple deletions; thymidine kinase; depletion; quantification; disorders; myopathy
AB We studied nine infant patients with a combination of progressive neurological and hepatic failure. Eight children, including two sibling pairs and four singletons, were affected by Alpers' hepatopathic poliodystrophy. A ninth baby patient suffered of a severe floppy infant syndrome associated with liver failure. Analysis of POLG1, the gene encoding the catalytic subunit of mitochondrial DNA polymerase, revealed that all the patients carried different allelic mutations in this gene. POLG1 is a major disease gene in mitochondrial disorders. Mutations in this gene can be associated with multiple deletions, depletion or point mutations of mitochondrial DNA (mtDNA). In turn, these different molecular phenotypes dictate an extremely heterogeneous spectrum of clinical outcomes, ranging from adult-onset progressive ophthalmoplegia to juvenile ataxic syndromes with epilepsy, to rapidly fatal hepatocerebral presentations, including Alpers' syndrome.
C1 Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy.
   Meyer Childrens Hosp, Unit Child Neurol, Florence, Italy.
   Univ Verona, Inst Neurol, I-37100 Verona, Italy.
   Univ Hosp, Pediat Unit, Pierfranco & Luisa Mariani Ctr Study Childrens Me, Monza, Italy.
   Univ Hamburg, Childrens Hosp, Hamburg, Germany.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Verona; University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Divi RL, 2004, AIDS, V18, P1013, DOI 10.1097/00002030-200404300-00009
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Flemming K, 2002, AM J NEURORADIOL, V23, P1421
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Janes MS, 2004, J HISTOCHEM CYTOCHEM, V52, P1011, DOI 10.1369/jhc.3a6209.2004
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   von Wurmb-Schwark N, 2002, FORENSIC SCI INT, V126, P34, DOI 10.1016/S0379-0738(02)00026-9
   Walker UA, 2004, HEPATOLOGY, V39, P311, DOI 10.1002/hep.20074
   WINTERTHUN S, 2005, IN PRESS NEUROLOGY, V0, P0
   Wright DK, 1990, PCR PROTOCOLS GUIDE, V0, P153
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 238
Z9 246
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD APR 15
PY 2005
VL 128
IS 
BP 723
EP 731
DI 10.1093/brain/awh410
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 911BV
UT WOS:000227977200010
PM 15689359
DA 2024-11-01
ER

PT J
AU Cormio, A
   Milella, F
   Vecchiet, J
   Felzani, G
   Gadaleta, MN
   Cantatore, P
AF Cormio, A
   Milella, F
   Vecchiet, J
   Felzani, G
   Gadaleta, MN
   Cantatore, P
TI Mitochondrial DNA mutations in RRF of healthy subjects of different age
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE human skeletal muscle; ragged red fibers; mtDNA; point mutations; aging
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; muscle-fiber analysis; mtdna control region; point mutations; skeletal-muscle; replication; deletion; disease; cells
AB To obtain information on the mechanisms responsible of the generation of ragged red fibers (RRF) during aging, we analyzed the mitochondrial genotype of single skeletal muscle fibers of healthy individuals having an age comprised between 45 and 92 years. The sequencing of the D-loop region showed many sequence changes with respect to the Cambridge reference sequence (CRS), in both RRF and normal fibers. These changes were more abundant in RRF and their number increased between 50 and 60, and 61 and 70 years and then remained approximately constant. The analysis of the sequence changes showed that each subject contained one or more changes associated to RRF in positions of D-loop region that either do not change or that change very rarely. In general the same type of RRF-associated change was not found in more than one individual; exceptions were changes in positions 189, 295, 374 and 514, detected in 20-50% of analyzed subjects. In particular the A189G age-associated mutation was found only in old individuals and prevalently in RRE Sequencing of other two mtDNA regions showed no relevant changes in the 16S/ND1 region and two RRF-associated original mutations, G5847A and A5884C, in two very conserved positions of tRNA(Tyr). These results indicate that each subject has its own pattern of RRF-associated mutations in both coding and non-coding region of human mtDNA. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Bari, Dipartmento Biochim & Biol Mol, I-70125 Bari, Italy.
   Univ Chieti G Annunzio, Cattedra Malattie Infett, I-66013 Chieti, Italy.
   Univ Chieti G Annunzio, Dipartimento Med Interna & Sci Invecchiamento, I-66013 Chieti, Italy.
   CNR, Inst Biomembrane & Bioenerget, I-70125 Bari, Italy.
   Univ Bari, Ctr Eccellenza Genom Comparata Campo Biomed & Agr, Dipartimento Farmacobiol, I-70125 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro
RP Univ Bari, Dipartmento Biochim & Biol Mol, Via Orabona,4, I-70125 Bari, Italy.
EM p.cantatore@biologia.uniba.it
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   BYRNE E, 1985, J NEUROL SCI, V71, P257, DOI 10.1016/0022-510X(85)90064-4
   CANTATORE P, 1987, INT REV CYTOL, V108, P149, DOI 10.1016/S0074-7696(08)61438-2
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   DUBOWITZ UK, 1973, MUSLCE BIOPSY MODER, V0, P0
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Gadaleta Maria N, 1999, P693, V0, P0
   GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717
   Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Johns DR, 2003, ANN NEUROL, V54, P422, DOI 10.1002/ana.10771
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Pesole G, 2001, GENETICS, V157, P859
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
NR 41
TC 31
Z9 34
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAY 15
PY 2005
VL 26
IS 5
BP 655
EP 664
DI 10.1016/j.neurobiolaging.2004.06.014
PG 10
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 902QM
UT WOS:000227371600013
PM 15708440
DA 2024-11-01
ER

PT J
AU Barron, MJ
   Chinnery, PF
   Howel, D
   Blakely, EL
   Schaefer, AM
   Taylor, RW
   Turnbull, DM
AF Barron, MJ
   Chinnery, PF
   Howel, D
   Blakely, EL
   Schaefer, AM
   Taylor, RW
   Turnbull, DM
TI Cytochrome <i>c</i> oxidase deficient muscle fibres:: Substantial variation in their proportions within skeletal muscles from patients with mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
ID kearns-sayre syndrome; tissue distribution; dna deletions; mutation; accumulation; disorders
AB Mitochondrial DNA (mtDNA) disease is a common cause of myopathy and the presence of histochemically demonstrated cytochrome c oxidase (COX) deficiency is an extremely useful diagnostic feature. However, there is currently no quantitative information regarding the variability of COX deficiency within or between muscles. This study addresses this issue by studying a number of skeletal muscle samples obtained at post-mortem from three patients with mitochondrial disease due to established mitochondrial DNA defects. COX deficient muscle fibres were enumerated in sections of these muscles and analysed according to patient, individual muscle, position within a particular muscle and sample size. Descriptive statistics were generated followed by an analysis of variance (ANOVA) to assess the effect of these parameters on the mean percentage of COX deficient fibres. We observed statistically significant variation in the percentage of COX deficient fibres within individual muscles from each patient for samples sizes of between 100 and 400 fibres. Our results have implications for the way in which biopsies of skeletal muscle are used for the assessment of disease severity, progression and response to treatment. (C) 2005 Elsevier B.V. All rights reserved.
C1 Univ Newcastle Upon Tyne, Sch Neurol Neurosci & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Univ Newcastle Upon Tyne, Sch Neurol Neurosci & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR BARRON MJ, 2003, AGING MOL LEVEL, V0, P91
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horváth R, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.015024
   HOWEL D, 1988, STAT MED, V7, P1157, DOI 10.1002/sim.4780071108
   HOWEL D, 1987, J NEUROL SCI, V77, P49, DOI 10.1016/0022-510X(87)90205-X
   JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322
   Kirches E, 2001, J MED GENET, V38, P312, DOI 10.1136/jmg.38.5.312
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SELIGMAN AM, 1969, J CELL BIOL, V38, P1
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 20
TC 15
Z9 18
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV 15
PY 2005
VL 15
IS 11
BP 768
EP 774
DI 10.1016/j.nmd.2005.06.018
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 983GQ
UT WOS:000233219900004
PM 16198107
DA 2024-11-01
ER

PT J
AU Kakiuchi, C
   Ishiwata, M
   Kametani, M
   Nelson, C
   Iwamoto, K
   Kato, T
AF Kakiuchi, C
   Ishiwata, M
   Kametani, M
   Nelson, C
   Iwamoto, K
   Kato, T
TI Quantitative analysis of mitochondrial DNA deletions in the brains of patients with bipolar disorder and schizophrenia
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE bipolar disorder; deletions; frontal cortex; mitochondrial DNA; schizophrenia
ID progressive external ophthalmoplegia; phosphorus-metabolism; gene-expression; frontal-lobe; p-31; dysfunction; mutation; association; disease; cells
AB Several clinical, genetic and neuromaging studies implicate mitochondrial dysfunction in the pathophysiology of bipolar disorder and schizophrenia. It has been reported that a mitochondrial DNA (mtDNA) deletion of 4977 bp, known as the 'common deletion', is associated with both mental illnesses. A lack of normal age-related accumulation of this deletion in schizophrenia and increased occurrence of the common deletion in bipolar disorder have been reported. However, even in the affected bipolar samples, the levels of common deletion were relatively small, indicating that the common deletion did not play a pathophysiological role in respiratory function. We hypothesized that accumulation of multiple mtDNA deletions, rather than the common deletion alone, is involved in the pathophysiology of these two major mental disorders. To test this hypothesis, we assessed mtDNA deletion(s) by comparing the copy number of two re-ions in mtDNA - ND1 and ND4 - using real-time quantitative PCR in the frontal cortex of 84 subjects (30 control, 27 with bipolar disorder, and 27 with schizophrenia). We also assessed the relative amount of mtDNA vs. nuclear DNA and the expression level of DNA polymerase gamma (POLG), which is involved in replicating mtDNA. We observed no association between mtDNA deletions and the two major mental disorders in the frontal cortex, which did not support our hypothesis. We did, however, make the following observations, although they were not significant after Bonferroni correction: (1) the ratio of mtDNA to nuclear DNA was significantly higher in female patients with schizophrenia than in control females (p =0.040) and (2) in bipolar disorder, the relative amount of mtDNA decreased with age (p = 0.016). Furthermore, POLG expression was significantly up-regulated in bipolar disorder (p = 0.036). Our results suggest that abnormalities in the system maintaining replication of mtDNA may underlie bipolar disorder and schizophrenia.
C1 RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.
C3 RIKEN
RP RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Hirosawa 2-1, Wako, Saitama 3510198, Japan.
EM kakiuchi@brain.riken.jp
CR ALTSHULER LL, 1995, AM J PSYCHIAT, V152, P1139
   [Anonymous], 1994, AM PSYCHIATR ASSOC, V0, P0
   Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x
   CAVELIER L, 1995, GENOMICS, V29, P217, DOI 10.1006/geno.1995.1234
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   DEICKEN RF, 1995, AM J PSYCHIAT, V152, P915
   Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116
   FUJIMOTO T, 1992, ACTA PSYCHIAT SCAND, V86, P455, DOI 10.1111/j.1600-0447.1992.tb03297.x
   GOLDSTEIN JM, 1990, BRIT J PSYCHIAT, V156, P819, DOI 10.1192/bjp.156.6.819
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Iwamoto K, 2004, MOL PSYCHIATR, V9, P406, DOI 10.1038/sj.mp.4001437
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133
   Kato T, 1998, EUR ARCH PSY CLIN N, V248, P301, DOI 10.1007/s004060050054
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kato T, 2000, AM J MED GENET, V96, P182, DOI 10.1002/(SICI)1096-8628(20000403)96:2<182::AID-AJMG12>3.0.CO;2-Q
   Kegeles LS, 1998, BIOL PSYCHIAT, V44, P382, DOI 10.1016/S0006-3223(97)00425-3
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3
   Marchbanks RM, 2003, SCHIZOPHR RES, V65, P33, DOI 10.1016/S0920-9964(03)00011-2
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   MULCRONE J, 1995, SCHIZOPHR RES, V14, P203, DOI 10.1016/0920-9964(94)00040-F
   Murashita J, 2000, PSYCHOL MED, V30, P107, DOI 10.1017/S0033291799001439
   Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905
   Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P978
   Rango M, 2001, J CEREBR BLOOD F MET, V21, P85, DOI 10.1097/00004647-200101000-00011
   SHIMIZU A, 1987, JPN J PSYCHIAT NEUR, V41, P65
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   SOONG NW, 1992, NAT GENET, V2, P318
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Uranova N, 2001, BRAIN RES BULL, V55, P597, DOI 10.1016/S0361-9230(01)00528-7
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Volz HP, 2000, BIOL PSYCHIAT, V47, P954, DOI 10.1016/S0006-3223(00)00235-3
   Washizuka S, 2003, AM J MED GENET B, V120B, P72, DOI 10.1002/ajmg.b.20041
   WINOKUR G, 1970, COMPR PSYCHIAT, V11, P93, DOI 10.1016/0010-440X(70)90151-3
   WOLYNIEC PS, 1992, J PSYCHIAT RES, V26, P17, DOI 10.1016/0022-3956(92)90012-D
NR 43
TC 56
Z9 60
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD DEC 15
PY 2005
VL 8
IS 4
BP 515
EP 522
DI 10.1017/S1461145705005213
PG 8
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 986VB
UT WOS:000233476700004
PM 16202181
DA 2024-11-01
ER

PT J
AU Deschauer, M
   Hudson, G
   Müller, T
   Taylor, RW
   Chinnery, PF
   Zierz, S
AF Deschauer, M
   Hudson, G
   Müller, T
   Taylor, RW
   Chinnery, PF
   Zierz, S
TI A novel <i>ANT1</i> gene mutation with probable germline mosaicism in autosomal dominant progressive external ophthalmoplegia
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial disease; multiple mitochondrial DNA deletions; novel mutation; ANT1 gene
ID nucleotide translocator-1 gene; polg mutations; multiple deletions; ataxic neuropathy; mitochondrial-dna; mtdna; disorder; twinkle
AB Only four different mutations in the adenine nucleotide translocator 1(ANT1) gene have been found in families with progressive external ophthalmoplegia (PEO). We report a novel heterozygous C to A transversion at nucleotide 269 in the ANT1 gene in a German family with PEO, predicted to convert a highly conserved alanine at codon 90 to aspartic acid. The mutation was identified in three siblings with PEO, one of them additionally suffered from schizoaffective disorder. Microsatellite analysis showed that the mutation was dominant and inherited from the mother who did not carry the mutation in blood, indicating germ-line mosaicism. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Halle Wittenberg, Klin & Poliklin Neurol, D-06097 Halle Saale, Germany.
   Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Sch Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK
RP Deschauer, M (corresponding author), Univ Halle Wittenberg, Klin & Poliklin Neurol, Ernst Grube Str 40, D-06097 Halle Saale, Germany.
EM marcus.deschauer@medizin.uni-halle.de
CR Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 14
TC 53
Z9 68
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR 15
PY 2005
VL 15
IS 4
BP 311
EP 315
DI 10.1016/j.nmd.2004.12.004
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 917UP
UT WOS:000228495000008
PM 15792871
DA 2024-11-01
ER

PT J
AU Kariya, S
   Hirano, M
   Furiya, Y
   Ueno, S
AF Kariya, S
   Hirano, M
   Furiya, Y
   Ueno, S
TI Effect of humanin on decreased ATP levels of human lymphocytes harboring A3243G mutant mitochondrial DNA
SO NEUROPEPTIDES
LA English
DT Article
DE humanin; bax; ATP; MELAS; lymphocyte; serum deprivation
ID stroke-like episodes; amyloid precursor protein; lactic-acidosis; cell-death; alzheimers-disease; melas subgroup; mutation; expression; muscle; bax
AB Humanin (HN) was originally identified as an endogenous peptide that protects neuronal cells from apoptosis by mutant Alzheimer's disease genes. This 24-residue peptide has been recently shown to suppress apoptosis by interfering with activation of Bcl-2-associated X protein (Bax) in cytosol. In the present study, we showed that HN increases ATP levels in human lymphocytes, muscular TE671 cells, and neural SKN-MC cells, and protects these cells from serum deprivation-induced apoptosis. The suppressed apoptotic death of serum-deprived cells would be explained by the anti-Bax effect of HN; however, HN also increased ATP levels of serum-supplemented cells (non-apoptotic cells), in which Bax is likely to be inactive. This result suggests the presence of a certain mechanism independent of Bax inactivation to increase ATP levels of cells under non-apoptotic condition. By treatment with HN, the ATP levels of lymphocytes from patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) associated with A3243G mutant mtDNA were increased as well, suggesting that HN is able to prevent cells in MELAS from falling into ATP deficiency. Our quantitative PCR findings indicated that the HN-induced increase in ATP may not be a consequence of mitochondrial proliferation, because HN rather suppressed mtDNA replication. This suppression may be important in the treatment of affected cells in MELAS, since the mutant mtDNAs that increase during compensatory mtDNA replication for ATP deficiency cause excessive formation of reactive oxygen species, leading to further energy crisis. We thus propose that HN, which increases cellular ATP levels without inducing mtDNA replication, may be suited for the treatment of MELAS. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Nara Med Univ, Dept Neurol, Kashihara, Nara 6348522, Japan.
C3 Nara Medical University
RP Hirano, M (corresponding author), Nara Med Univ, Dept Neurol, 840 Shijocho, Kashihara, Nara 6348522, Japan.
EM hirano_makito@yahoo.co.jp
CR Belzacq AS, 2003, CANCER RES, V63, P541
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Ebstein RP, 1996, MOL BRAIN RES, V35, P260, DOI 10.1016/0169-328X(95)00227-J
   Filosto M, 2002, ACTA NEUROPATHOL, V103, P215, DOI 10.1007/s004010100455
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   ICHIKI T, 1988, ANN NEUROL, V23, P287, DOI 10.1002/ana.410230312
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   Kariya S, 2004, ANN NEUROL, V56, P0
   Kariya S, 2003, MOL CELL BIOCHEM, V254, P83, DOI 10.1023/A:1027372519726
   Kariya S, 2002, NEUROREPORT, V13, P903, DOI 10.1097/00001756-200205070-00034
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Lezza AMS, 2001, FEBS LETT, V501, P74, DOI 10.1016/S0014-5793(01)02628-X
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407
   Vander Heiden MG, 1999, MOL CELL, V3, P159
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
NR 27
TC 33
Z9 35
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4179
EI 
J9 NEUROPEPTIDES
JI Neuropeptides
PD APR 15
PY 2005
VL 39
IS 2
BP 97
EP 101
DI 10.1016/j.npep.2004.11.004
PG 5
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 909MC
UT WOS:000227863000005
PM 15752543
DA 2024-11-01
ER

PT J
AU Komlósi, K
   Kellermayer, R
   Maász, A
   Havasi, V
   Hollódy, K
   Vincze, O
   Merkli, H
   Pál, E
   Melegh, B
AF Komlósi, K
   Kellermayer, R
   Maász, A
   Havasi, V
   Hollódy, K
   Vincze, O
   Merkli, H
   Pál, E
   Melegh, B
TI Maternally inherited deafness and unusual phenotypic manifestations associated with A3243G mitochondrial DNA mutation
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE mtDNA A3243G; tRNA(Leu( UUR)); mitochondrial disease; MELAS; deafness
ID transfer rna(leu(uur)) gene; transfer rnaleu(uur) gene; stroke-like episodes; diabetes-mellitus; lactic-acidosis; clinical spectrum; melas mutation; point mutation; large pedigree; disease
AB The mitochondrial DNA A3243G transition is a fairly common mutation which often associates with a MELAS ( mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) phenotype, however, a broad variety in the associated clinical picture has also been described. The patient reported here developed a generalized seizure at age 12, which was followed by bilateral hearing loss and occasional fatigue. The maternal inheritance pattern of hearing loss pointed to a possible mitochondrial origin, which was confirmed by molecular analysis of the mitochondrial DNA, revealing a heteroplasmic A3243G transition. Interestingly, muscle biopsy showed ragged-red fibers in the proband, which is unusual in the deafness-associated forms of this mitochondrial disorder. In addition to hearing impairment in four generations of the family, fatal cerebral embolization in the mother and fatal heart attack in the maternal grandmother ( both at age 33) also occurred. On the contrary, diabetes, which usually accompanies the hearing loss variant, was specifically absent in all generations. The unusual manifestations associated with this mutation somewhat differentiate this family from the already known variants.
C1 Univ Pecs, Dept Med Genet & Child Dev, Pecs, Hungary.
   Univ Pecs, Dept Neurol, Pediat Clin, Pecs, Hungary.
   Cty Hosp Baranya, Kerpel Fronius Odon Childrens Hosp, Pecs, Hungary.
C3 University of Pecs; University of Pecs
RP Univ Pecs, Dept Med Genet & Child Dev, Pecs, Hungary.
EM Bela.Melegh@aok.pte.hu
CR Bene J, 2003, EUR J HUM GENET, V11, P375, DOI 10.1038/sj.ejhg.5200975
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2002, ADV NEUROL, V89, P217
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2000, NEUROL SCI, V21, P0
   Fischel-Ghodsian N, 1999, HUM MUTAT, V13, P261, DOI 10.1002/(SICI)1098-1004(1999)13:4<261::AID-HUMU1>3.0.CO;2-W
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   JACOBS HT, 1997, ANN MED, V29, P438
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOMLOSI K, 2004, ORV HETI, V35, P1805
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Pronicki Maciej, 2002, MED SCI MONIT, V8, P0
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   Takahashi K, 2003, LARYNGOSCOPE, V113, P1362, DOI 10.1097/00005537-200308000-00018
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506
   Yamasoba T, 1999, NEUROLOGY, V52, P1705, DOI 10.1212/WNL.52.8.1705
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 35
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUN 15
PY 2005
VL 11
IS 2
BP 82
EP 86
DI 10.1007/BF02893371
PG 5
WC Oncology; Pathology
SC Oncology; Pathology
GA 943XE
UT WOS:000230388000003
PM 15999151
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Radi, E
   Dotti, MT
   Federico, A
AF Cardaioli, E
   Da Pozzo, P
   Radi, E
   Dotti, MT
   Federico, A
TI A novel heteroplasmic tRNA <SUP>Leu(CUN)</SUP> mtDNA point mutation associated with chronic progressive external ophthalmoplegia
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mtDNA; tRNA(Leu(CUN)); CPEO
ID mitochondrial-dna; a3243g mutation; dilated cardiomyopathy; sporadic patient; skeletal-muscle; trna(leu(cun)); genes
AB We have sequenced all mitochondrial tRNA genes from a patient with chronic progressive external ophthalmoplegia (CPEO) and mitochondrial myopathy. who had no detectable large mtDNA deletions. Direct sequencing failed to detect previously reported mutations and showed a heteroplasmic mutation at nucleotide 12,276 in the tRNA(Leu(CUN)) gene, in the dihydrouridine stem, which is highly conserved through the species during evolution. RFLP analyses confirmed that 18% of muscle mtDNA harbored the mutation. while it was absent from DNA of fibroblasts and lymphocytes of the proband and in 110 patients with other encephalomyopathies. To date, besides large and single nucleotide deletions, several point mutations on mitochondrial tRNA genes have been reported in CPEO patients, but only three were in the gene coding for tRNA(Leu(CUN)). (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
C3 University of Siena
RP Univ Siena, Dept Neurol & Behav Sci, Via Laterina 8, I-53100 Siena, Italy.
EM federico@unisi.it
CR Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 11
TC 14
Z9 14
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 18
PY 2005
VL 327
IS 3
BP 675
EP 678
DI 10.1016/j.bbrc.2004.11.170
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 892UF
UT WOS:000226674800008
PM 15649400
DA 2024-11-01
ER

PT J
AU Miró, O
   López, S
   Cardellach, F
   Casademont, J
AF Miró, O
   López, S
   Cardellach, F
   Casademont, J
TI Mitochondrial studies in HAART-related lipodystrophy:: from experimental hypothesis to clinical findings
SO ANTIVIRAL THERAPY
LA English
DT Article; Proceedings Paper
ID hiv-infected patients; active antiretroviral therapy; blood mononuclear-cells; subcutaneous adipose-tissue; dna depletion; protease inhibitors; nucleoside analogs; lactic-acid; toxicity; lipoatrophy
AB Chronic use of antiretrovirals (ARVs) to treat HIV infection, along with more prolonged patient survival, has been associated with an increase in adverse drug effects in HIV-infected patients on treatment. It has been proposed that some of these adverse effects (including myopathy, cardiomyopathy, anaemia, hyperlactataemia/lactic acidosis, pancreatitis, polyneuritis and lipodystrophy) could be mediated by mitochondrial (mt) toxicity. From the experimental data, it has been proposed that nucleoside analogue reverse transcriptase inhibitors (NRTIs) also inhibit gamma-polymerase, the enzyme devoted to replicate (and, to a lesser extent, repair) mtDNA. It is now widely accepted that the use of most NRTIs in HIV-infected patients is associated with mtDNA depletion. Although cross-sectional studies suggest that certain ARVs, especially stavudine, are more toxic to mitochondria, the differences among different highly active ARV therapy (HAART) schedules detected in the analysis of longitudinal studies are not so clear. These types of study in previously untreated individuals suggest that the greatest mtDNA loss appears at the beginning of the treatment. Conversely, in ARV-experienced patients, the potential beneficial effects of HAART changes in terms of mtDNA content remain controversial and must be further investigated. Functional studies accompanying genetic investigations are needed for the correct pathogenic interpretation of the mtDNA abnormalities.
C1 Hosp Clin Barcelona, IDIBAPS, Dept Internal Med, Mitochondrial Res Lab, Barcelona, Catalonia, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Hosp Clin Barcelona, IDIBAPS, Dept Internal Med, Mitochondrial Res Lab, Barcelona, Catalonia, Spain.
EM omiro@clinic.ub.es
CR BADLEY AD, 2005, IN PRESS CELL DEAT D, V0, P0
   Barile M, 1997, BIOCHEM PHARMACOL, V53, P913, DOI 10.1016/S0006-2952(96)00831-3
   Caron M, 2004, AIDS, V18, P2127, DOI 10.1097/00002030-200411050-00004
   Casademont J, 2002, NEW ENGL J MED, V347, P217
   Chapplain JM, 2004, JAIDS-J ACQ IMM DEF, V37, P1477, DOI 10.1097/01.qai.0000138982.68106.6c
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113
   Christensen ER, 2004, CLIN INFECT DIS, V39, P1371, DOI 10.1086/424881
   Church JA, 2001, J PEDIATR-US, V138, P748, DOI 10.1067/mpd.2001.112653
   Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   Cossarizza A, 2002, J INFECT DIS, V185, P299, DOI 10.1086/338564
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   de Mendoza C, 2004, AIDS RES HUM RETROV, V20, P271, DOI 10.1089/088922204322996491
   Divi RL, 2004, AIDS, V18, P1013, DOI 10.1097/00002030-200404300-00009
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   GRAU JM, 1993, ANN NEUROL, V34, P206, DOI 10.1002/ana.410340217
   HALL ET, 1994, J BIOL CHEM, V269, P14355
   Hammond E, 2004, AIDS, V18, P815, DOI 10.1097/00002030-200403260-00015
   HOBBS GA, 1995, BIOCHEM PHARMACOL, V50, P381, DOI 10.1016/0006-2952(95)00141-L
   Hoy JF, 2004, J INFECT DIS, V190, P688, DOI 10.1086/422602
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   López S, 2004, ANTIVIR THER, V9, P47
   Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   Masanés F, 1998, J NEUROL SCI, V159, P226, DOI 10.1016/S0022-510X(98)00151-8
   McComsey G, 2004, JAIDS-J ACQ IMM DEF, V37, PS30, DOI 10.1097/01.qai.0000137004.63376.27
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   McComsey GA, 2005, AIDS, V19, P15, DOI 10.1097/00002030-200501030-00002
   Miró O, 2003, AIDS RES HUM RETROV, V19, P1027, DOI 10.1089/088922203322588387
   Miró O, 2000, AIDS, V14, P1855, DOI 10.1097/00002030-200008180-00024
   Miró O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176
   Miró O, 2003, ANTIVIR THER, V8, P333
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   Montaner JSG, 2004, CLIN INFECT DIS, V38, PS73, DOI 10.1086/381449
   Negredo E, 2005, JAIDS-J ACQ IMM DEF, V38, P47, DOI 10.1097/00126334-200501010-00009
   Nerurkar PV, 2003, CELL MOL BIOL, V49, P1205
   Nolan D, 2004, ANTIVIR THER, V9, P849
   Nolan D, 2003, ANTIVIR THER, V8, P617
   Pace CS, 2003, ANTIVIR THER, V8, P323
   Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000
   Petit C, 2003, JAIDS-J ACQ IMM DEF, V33, P461, DOI 10.1097/00126334-200308010-00006
   Phenix BN, 2001, BLOOD, V98, P1078, DOI 10.1182/blood.V98.4.1078
   Pilon AA, 2002, ANTIMICROB AGENTS CH, V46, P2687, DOI 10.1128/AAC.46.8.2687-2691.2002
   Polo R, 2003, JAIDS-J ACQ IMM DEF, V34, P32, DOI 10.1097/00126334-200309010-00004
   Reiss P, 2004, HIV MED, V5, P11, DOI 10.1111/j.1468-1293.2004.00178.x
   Roge BT, 2002, AIDS, V16, P973, DOI 10.1097/00002030-200205030-00003
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Valenti D, 2000, INT J MOL MED, V6, P93
   van der Valk M, 2004, ANTIVIR THER, V9, P385
   VANDERVALK M, 2004, HEPATOLOGY, V39, P311
   Villarroya F, 2005, TRENDS PHARMACOL SCI, V26, P88, DOI 10.1016/j.tips.2004.12.005
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002
   White DJ, 2001, AIDS, V15, P1061, DOI 10.1097/00002030-200105250-00017
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
NR 60
TC 26
Z9 29
U1 0
U2 1
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
EI 
J9 ANTIVIR THER
JI Antivir. Ther.
PD JUN 15
PY 2005
VL 10
IS 
BP M73
EP M81
DI 
PG 9
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 966QD
UT WOS:000232035000008
PM 16152708
DA 2024-11-01
ER

PT J
AU Crimi, M
   O'Hearn, SF
   Wallace, DC
   Comi, GP
AF Crimi, M
   O'Hearn, SF
   Wallace, DC
   Comi, GP
TI Molecular research technologies in mitochondrial diseases: The microarray approach
SO IUBMB LIFE
LA English
DT Review
DE mtDNA; mitochondrial diseases; heteroplosmy; microarray
ID l-arginine improves; gene-expression; oxidative-phosphorylation; skeletal-muscle; dna mutations; nuclear; dysfunction; apoptosis; diagnosis; responses
AB Mitochondria are ubiquitous in eukaryotic cells where they generate much of the cellular energy by the process of oxidative phosphorylation (OXPHOS). The approximately 1500 genes of the mitochondrial genome are distributed between the cytoplasmic, maternally-inherited, mitochondrial DNA ( mtDNA) which encodes 37 genes and the nuclear DNA (nDNA) which encompasses the remaining mitochondrial genes. The interplay between the mtDNA and nDNA encoded mitochondrial genes and their role in mitochondrial disorders is still largely unclear. One approach for elucidating the pathophysiology of mitochondrial diseases has been to look at changes in the expression of mtDNA and nDNA-encoded genes in response to specific mitochondrial genetic defects. Initial studies of gene expression changes in response to mtDNA defect employed blot technologies to analyze changes in the expression of individual genes one at a time. While Southern/Northern blot experiments confirmed the importance of nDNA - mtDNA interactions in the pathophysiology of mitochondrial myopathy, the methodology used limited the number of genes that could be analyzed from each patient. This barrier has been overcome, in part by the advent of DNA microarray technology. In DNA microarrays gene sequences or oligonucleotides homologous to gene sequences are arrayed on a solid support. The RNA from the subject is then isolated, the mRNA converted to cDNA and the cDNA labeled with a fluorescent probe. The labeled cDNA is hybridized on the microarray and the fluorescence bound to each array is then quantified. Recently, these technologies have been applied to mitochondrial disease patient tissues and the presence of coordinate changes in mitochondrial gene expression confirmed.
C1 Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Dept Biol Chem, Irvine, CA 92697 USA.
   Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci, Milan, Italy.
   IRCCS Osped Maggiore Policlin, Milan, Italy.
C3 University of California System; University of California Irvine; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Dept Biol Chem, Irvine, CA 92697 USA.
EM marco.crimi@gmail.com
FU NINDS NIH HHS [NS21328] Funding Source: Medline
CR Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   Bandelt HJ, 2005, SCHIZOPHR RES, V72, P267, DOI 10.1016/j.schres.2004.05.003
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, P0
   Behan A, 2005, MITOCHONDRION, V5, P173, DOI 10.1016/j.mito.2005.03.002
   Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Crimi Marco, 2002, HUM MUTAT, V20, P409, DOI 10.1002/humu.9079
   Danielson SR, 2005, BRAIN, V128, P1026, DOI 10.1093/brain/awh447
   Delsite Robert, 2002, MOL CANCER, V1, P6, DOI 10.1186/1476-4598-1-6
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Erdogan F, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.7.e36
   Everts HB, 2002, IUBMB LIFE, V54, P45, DOI 10.1080/15216540214316
   Gu GY, 2003, BIOCHEM BIOPH RES CO, V308, P197, DOI 10.1016/S0006-291X(03)01233-6
   HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2
   HEDDI A, 1993, J BIOL CHEM, V268, P12156
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Larsen NB, 2005, MITOCHONDRION, V5, P89, DOI 10.1016/j.mito.2005.02.002
   Li CH, 2005, J BIOL CHEM, V280, P26193, DOI 10.1074/jbc.M501371200
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Lobenhofer EK, 2001, ENVIRON HEALTH PERSP, V109, P881, DOI 10.2307/3454988
   Löhr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429
   Murray J, 2004, BBA-BIOENERGETICS, V1659, P206, DOI 10.1016/j.bbabio.2004.07.005
   Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Voisin V, 2005, NEUROBIOL DIS, V20, P123, DOI 10.1016/j.nbd.2005.02.010
   WALLACE D, 2004, BIOCHIM BIOPHYS ACTA, V1657, P4
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Zhang D, 2005, CARDIOVASC PATHOL, V14, P61, DOI 10.1016/j.carpath.2005.01.006
   Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138
NR 41
TC 16
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD DEC 15
PY 2005
VL 57
IS 12
BP 811
EP 818
DI 10.1080/15216540500460269
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 997EV
UT WOS:000234228700006
PM 16393784
DA 2024-11-01
ER

PT J
AU Richardson, C
   Smith, T
   Schaefer, A
   Turnbull, D
   Griffiths, P
AF Richardson, C
   Smith, T
   Schaefer, A
   Turnbull, D
   Griffiths, P
TI Ocular motility findings in chronic progressive external ophthalmoplegia
SO EYE
LA English
DT Article
DE ophthalmoplegia; mitochondrial myopathy
ID kearns-sayre syndrome; mitochondrial-dna; myopathy; deletions; disease; cataract; features; muscle
AB Aims To characterise the ocular motility features of chronic progressive external ophthalmoplegia by quantitative and semiquantitative means. To assess the prevalence of diplopia and the binocular adaptations to nonaligned visual axes. Method We studied 25 patients with chronic progressive external ophthalmoplegia. In each case muscle biopsies were consistent with mitochondrial myopathy. All patients underwent cover test in the primary position, assessment of binocular status, and measurement of uniocular fields of fixation using the Goldmann perimeter. Results A total of 23 (92%) patients had an exo-deviation, with six (26%) of those having an associated vertical deviation: 12 patients were binocular. Of the 13 patients with a manifest deviation seven had diplopia and six had suppression. Of all paired extra-ocular muscles (EOM), 68% had symmetry of movement within 51 of each other. Conclusion Almost all patients had an exo-deviation. Diplopia was more common than expected. The majority of patients had symmetry of EOM limitation.
C1 Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Univ Newcastle Upon Tyne, Dept Neurol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Royal Victoria Infirm, Dept Ophthalmol, Claremont Wing,Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM p.g.griffiths@ncl.ac.uk
CR BASTIAENSEN LAK, 1982, OPHTHALMOLOGICA, V184, P40, DOI 10.1159/000309183
   BOOTHE RG, 1985, ANNU REV NEUROSCI, V8, P485
   BORCHERT MS, 1994, PRINCIPLES PRACTICE, V0, P0
   DAROFF RB, 1966, NEUROLOGY, V16, P161, DOI 10.1212/WNL.16.2_Part_1.161
   Graefe VON, 1868, BERL KLIN WSCHR, V5, P125
   GUPTA SR, 1995, J NEURO-OPHTHALMOL, V15, P20
   HAGGERTY H, 2001, T EUR STRAB ASS 27 A, V0, P0
   HAMED LM, 1977, AM J OPHTHALMOL, V103, P741
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   JA B-E, 1988, STRUCTURAL ORG EXTRA, V2, P0
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Koutroumanidis M, 1996, MUSCLE NERVE, V19, P1586, DOI 10.1002/(SICI)1097-4598(199612)19:12<1586::AID-MUS8>3.0.CO;2-6
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Miller NR, 1985, WALSH HOYTS CLIN NEU, V0, P0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   PRATTJOHNSON JA, 1989, AM J OPHTHALMOL, V107, P23, DOI 10.1016/0002-9394(89)90809-X
   ROBINSON DA, 1970, J NEUROPHYSIOL, V33, P393, DOI 10.1152/jn.1970.33.3.393
   Salvan AM, 1998, EUR NEUROL, V40, P46, DOI 10.1159/000007955
   SHARKEY JA, 1994, J PEDIATR OPHTHALMOL, V31, P391
   Sherafat H, 2001, BRIT J OPHTHALMOL, V85, P1057, DOI 10.1136/bjo.85.9.1057
   Snell RS, 1989, CLIN ANATOMY EYE, V0, P0
   STANWORTH A, 1963, TRANS OPHTHALMOL SOC U K, V83, P515
   VAEGAN TD, 1979, T OPHTHAL SOC UK, V99, P432
   VONNOORDEN GK, 1985, INVEST OPHTH VIS SCI, V26, P1704
   VONNOORDEN GK, 1996, BINOCULAR VISION MOT, V0, P0
   WOOTEN GF, 1972, ARCH NEUROL-CHICAGO, V26, P350, DOI 10.1001/archneur.1972.00490100080008
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 28
TC 48
Z9 48
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR 15
PY 2005
VL 19
IS 3
BP 258
EP 263
DI 10.1038/sj.eye.6701488
PG 6
WC Ophthalmology
SC Ophthalmology
GA 902CZ
UT WOS:000227330300004
PM 15272295
DA 2024-11-01
ER

PT J
AU Schaefer, AM
   Blakely, EL
   Griffiths, PG
   Turnbull, DM
   Taylor, RW
AF Schaefer, AM
   Blakely, EL
   Griffiths, PG
   Turnbull, DM
   Taylor, RW
TI Ophthalmoplegia due to mitochondrial DNA disease: The need for genetic diagnosis
SO MUSCLE & NERVE
LA English
DT Article
DE chronic progressive external ophthalmoplegia; cytochrome c oxidase; deletion; histochemistry; mitochondrial DNA
ID progressive external ophthalmoplegia; cytochrome-c oxidase; mutation; mtdna; deletions
AB We describe a patient with chronic progressive external ophthalmoplegia (CPEO) who underwent muscle biopsy for suspected mitochondrial disease. In spite of normal histocytochemical cytochrome c oxidase (COX) activity and respiratory chain enzyme measurements in muscle, subsequent molecular genetic analysis revealed the presence of a single, large-scale deletion of mitochondrial DNA (mtDNA). The case serves to illustrate the importance of pursuing the proposed mitochondrial genetic abnormality, even in patients with normal biopsy findings.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Leigh RJ, 1999, NEUROLOGY EYE MOVEME, V3rd, P0
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 21
TC 18
Z9 19
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL 15
PY 2005
VL 32
IS 1
BP 104
EP 107
DI 10.1002/mus.20319
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 940BQ
UT WOS:000230119100013
PM 15795893
DA 2024-11-01
ER

PT J
AU Zeviani, M
   Carelli, V
AF Zeviani, M
   Carelli, V
TI Dominance in mitochondrial disorders
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article; Proceedings Paper
ID hereditary optic neuropathy; progressive external ophthalmoplegia; dynamin-related protein; sensorineural hearing-loss; autosomal-dominant; multiple deletions; dna polymerase; opa1 mutations; gene; atrophy
AB Dominant traits are rare in mitochondrial disorders but include important nosological entities such as alterations of organellar biogenesis and abnormalities in the structural integrity of the mitochondrial genome, determined by mutations in genes involved in its maintenance and propagation. Both haplo-insufficiency and 'gain-of-function' mechanisms underlie the pathogenesis of these disorders. Impairment in energy supply, abnormal mitochondrial trafficking, increased toxic damage by oxygen radicals, and mitochondrially driven apoptosis have been documented in different dominant syndromes. In addition, maternally inherited mutations of mitochondrial DNA can sometimes simulate dominant traits, mainly because of reduced penetrance and complex interaction with genetic and environmental factors.
C1 Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, Unit Mol Neurogenet, I-20126 Milan, Italy.
   Univ Bologna, Dept Neurol Sci, Neurogenet Lab, I-40126 Bologna, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Bologna
RP Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, Unit Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@tin.it
FU Telethon [GGP02323, GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   BENOTHMANE K, 1993, GENOMICS, V17, P370
   Borrás C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4
   BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198
   Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chalmers RM, 1996, AM J HUM GENET, V59, P103
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   CHEN JD, 1989, HUM GENET, V82, P203, DOI 10.1007/BF00291154
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   Delettre C, 2001, HUM GENET, V109, P584, DOI 10.1007/s00439-001-0633-y
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   Howell N, 1998, AM J HUM GENET, V63, P1220, DOI 10.1086/302049
   Hutchin T, 1999, ACTA OTO-LARYNGOL, V119, P48, DOI 10.1080/00016489950181927
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2
   KJER P, 1959, ACTA OPHTHALMOL S54, V37, P1
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Leber T, 1871, ARCH OPHTHALMOL-CHIC, V17, P249
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.e02-06-0330
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Macmillan C, 2000, AM J HUM GENET, V66, P332, DOI 10.1086/302716
   Man PYW, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011247
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200
   NEWMAN NJ, 1998, WALSH HOYTS CLIN NEU, V0, P753
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pegoraro E, 2003, AM J MED GENET A, V119A, P37, DOI 10.1002/ajmg.a.10211
   Pegoraro E, 1996, AM J MED GENET, V61, P356
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rojo M, 2002, J CELL SCI, V115, P1663
   Santel A, 2001, J CELL SCI, V114, P867
   Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715
   Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 67
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD JAN 15
PY 2005
VL 28
IS 3
BP 287
EP 299
DI 10.1007/s10545-005-0307-3
PG 13
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 923CD
UT WOS:000228885500005
PM 15868464
DA 2024-11-01
ER

PT J
AU Palmieri, L
   Alberio, S
   Pisano, I
   Lodi, T
   Meznaric-Petrusa, M
   Zidar, J
   Santoro, A
   Scarcia, P
   Fontanesi, F
   Lamantea, E
   Ferrero, I
   Zeviani, M
AF Palmieri, L
   Alberio, S
   Pisano, I
   Lodi, T
   Meznaric-Petrusa, M
   Zidar, J
   Santoro, A
   Scarcia, P
   Fontanesi, F
   Lamantea, E
   Ferrero, I
   Zeviani, M
TI Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; polymerase-gamma-a; adp/atp carrier; saccharomyces-cerevisiae; autosomal-dominant; bacterial expression; oxidative-phosphorylation; tissue distribution; yeast mitochondria; gene mutation
AB Multiple mitochondrial DNA deletions are associated with clinically heterogeneous disorders transmitted as mendelian traits. Dominant missense mutations were found in the gene encoding the heart and skeletal muscle-specific isoform of the adenine nucleotide translocator (ANT1) in families with autosomal dominant progressive external opthalmoplegia and in a sporadic patient. We herein report on a sporadic patient who presented with hypertrophic cardiomyopathy, mild myopathy with exercise intolerance and lactic acidosis but no ophthalmoplegia. A muscle biopsy showed the presence of numerous ragged-red fibers, and Southern blot analysis disclosed multiple deletions of muscle mitochondrial DNA. Molecular analysis revealed a C to A homozygous mutation at nucleotide 368 of the ANT1 gene. The mutation converted a highly conserved alanine into an aspartic acid at codon 123 and was absent in 500 control individuals. This is the first report of a recessive mutation in the ANT1 gene. The clinical and biochemical features are different from those found in dominant ANT1 mutations, resembling those described in ANT1 knockout mice. No ATP uptake was measured in proteoliposomes reconstituted with protein extracts from the patient's muscle. The equivalent mutation in AAC2, the yeast ortholog of human ANT1, resulted in a complete loss of transport activity and in the inability to rescue the severe Oxidative Phosphorylation phenotype displayed by WB-12, an AAC1/AAC2 defective strain. Interestingly, exposure to reactive oxygen species (ROS) scavengers dramatically increased the viability of the WB-12 transformant, suggesting that increased redox stress is involved in the pathogenesis of the disease and that anti-ROS therapy may be beneficial to patients.
C1 Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, I-20126 Milan, Italy.
   Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy.
   CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy.
   Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
   Univ Med Ctr, Dept Neurol, Ljubljana, Slovenia.
   Univ Med Ctr, Dept Anat, Ljubljana, Slovenia.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); University of Parma; University Medical Centre Ljubljana; University Medical Centre Ljubljana
RP Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP030039] Funding Source: Medline
CR Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   BULDER CJE, 1964, ANTON VAN LEE J M S, V30, P442, DOI 10.1007/BF02046758
   Chen XJ, 2004, GENETICS, V167, P607, DOI 10.1534/genetics.103.023655
   Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Doudican NA, 2005, MOL CELL BIOL, V25, P5196, DOI 10.1128/MCB.25.12.5196-5204.2005
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fagiolari G, 2002, MUSCLE NERVE, V26, P265, DOI 10.1002/mus.10172
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fiermonte G, 2004, J BIOL CHEM, V279, P30722, DOI 10.1074/jbc.M400445200
   FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293
   Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2
   KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928
   Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 40
TC 139
Z9 147
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2005
VL 14
IS 20
BP 3079
EP 3088
DI 10.1093/hmg/ddi341
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 972AG
UT WOS:000232425600013
PM 16155110
DA 2024-11-01
ER

PT J
AU Hance, N
   Ekstrand, MI
   Trifunovic, A
AF Hance, N
   Ekstrand, MI
   Trifunovic, A
TI Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; transcription factor; xenopus-laevis; accessory subunit; gene-expression; polg mutations; mice; biogenesis; nuclear; binding
AB Mitochondrial DNA (mtDNA) polymerase gamma (Polg) is a heterodimeric enzyme containing a Poll I-like catalytic core (PolgA) and an accessory subunit. Mutations in POLGA, affecting the stability of mtDNA, have been identified in several human pathologies such as progressive external ophthalmoplegia and Alpers' syndrome. Extensive literature shows mitochondrial toxicity effects nucleoside analogue reverse transcriptase inhibitors used in the treatment of HIV and chronic hepatitis B as a consequence of an inhibitory effect on Polg. We have previously shown that mice with an error-prone version of PolgA accumulate higher levels of somatic mtDNA mutations resulting in a premature aging phenotype. In the present paper, we demonstrate PolgA deficiency in mouse embryos causes an early developmental arrest between embryonic days 7.5 and 8.5 associated with severe mtDNA depletion. Heterozygous knockout mice have half the wild-type levels of PolgA transcripts and a slight reduction in mtDNA levels but develop normally. Surprisingly, amounts of PoIgA transcripts in heterozygous knockout mice are increased in response to artificially elevated mtDNA copy number, revealing a possible regulatory link between mtDNA maintenance and PoIgA expression. Our results show that Polg indeed is the only DNA polymerase capable of maintaining mtDNA in mammalian mitochondria. In addition, presence of Polg is absolutely essential for the organogenesis during mammalian embryonic development.
C1 Karolinska Inst, Novum, Dept Med Nutr, Stockholm, Sweden.
   Karolinska Inst, Novum, Dept Biosci, Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Karolinska Inst, Novum, Dept Med Nutr, Stockholm, Sweden.
EM aleksandra.trifunovic@mednut.ki.se
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671
   Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3
   Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753
   DAWID IB, 1972, J MOL BIOL, V63, P217, DOI 10.1016/0022-2836(72)90371-3
   EBERT KM, 1988, J REPROD FERTIL, V82, P145, DOI 10.1530/jrf.0.0820145
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h
   Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   HARDT N, 1980, EXP CELL RES, V127, P269, DOI 10.1016/0014-4827(80)90432-2
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   PIKO L, 1976, DEV BIOL, V49, P1, DOI 10.1016/0012-1606(76)90253-0
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846
   Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481
NR 38
TC 192
Z9 232
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2005
VL 14
IS 13
BP 1775
EP 1783
DI 10.1093/hmg/ddi184
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 950XJ
UT WOS:000230891700006
PM 15888483
DA 2024-11-01
ER

PT J
AU Jendrach, M
   Pohl, S
   Vöth, M
   Kowald, A
   Hammerstein, P
   Bereiter-Hahn, J
AF Jendrach, M
   Pohl, S
   Vöth, M
   Kowald, A
   Hammerstein, P
   Bereiter-Hahn, J
TI Morpho-dynamic changes of mitochondria during ageing of human endothelial cells
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE ageing; mitochondria; fusion; fission
ID degenerative diseases; oxidative stress; skeletal-muscle; dna mutations; in-vivo; apoptosis; fission; fusion; chain; complementation
AB Mitochondrial morphology is regulated in many cultured eukaryotic cells by fusion and fission of mitochondria. A tightly controlled balance between fission and fusion events is required to ensure normal mitochondrial and cellular functions. During ageing, mitochondria are undergoing significant changes on the functional and morphological level. The effect of ageing on fusion and fission of mitochondria and consequences of altered fission and fusion activity are still unknown although theoretical models on ageing consider the significance of these processes. Human. umbilical vein endothelial cells (HUVECs) have been established as a cell culture model to follow mitochondrial activity and dysfunction during the ageing process. Mitochondria of old and postmitotic HUVECs showed distinct alterations in overall morphology and fine structure, and furthermore, loss of mitochondrial membrane potential. In parallel, a decrease of intact mitochondrial DNA (mtDNA) was observed. Fission and fusion activity of mitochondria were quantified in living cells. Mitochondria of old HUVECs showed a significant and equal decrease of both fusion and fission activity indicating that these processes are sensitive to ageing and could contribute to the accumulation of damaged mitochondria during ageing. © 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Frankfurt, Kinemat Cell Res Grp, D-60439 Frankfurt, Germany.
   MPI Mol Genet, Kinet Modelling Grp, Berlin, Germany.
   Humboldt Univ, Inst Theoret Biol, Berlin, Germany.
C3 Goethe University Frankfurt; Humboldt University of Berlin
RP Jendrach, M (corresponding author), Univ Frankfurt, Kinemat Cell Res Grp, Marie Curie Str 9, D-60439 Frankfurt, Germany.
EM jendrach@zoology.uni-frankfurt.de
CR Arimura S, 2004, P NATL ACAD SCI USA, V101, P7805, DOI 10.1073/pnas.0401077101
   Barni S, 1996, BIOTECH HISTOCHEM, V71, P66, DOI 10.3109/10520299609117135
   Bereiter-Hahn J, 1996, EXP BIOL, V1, P4
   BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150
   Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200
   Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064
   Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hutter E, 2004, BIOCHEM J, V380, P919, DOI 10.1042/BJ20040095
   Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082
   KATAYAMA M, 1991, BIOCHEM INT, V25, P47
   Kiyonaga Hidetoshi, 2001, MEDICAL ELECTRON MICROSCOPY, V34, P41, DOI 10.1007/s007950100003
   Kowald A, 2000, J THEOR BIOL, V202, P145, DOI 10.1006/jtbi.1999.1046
   Li JQ, 2004, J CELL SCI, V117, P4673, DOI 10.1242/jcs.01339
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Lopes GS, 2004, BBA-BIOENERGETICS, V1658, P187, DOI 10.1016/j.bbabio.2004.05.011
   Mather MW, 2002, MECH AGEING DEV, V123, P707, DOI 10.1016/S0047-6374(01)00416-X
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Santos Janine H, 2002, METHODS MOL BIOL, V197, P159, DOI 10.1385/1-59259-284-8:159
   Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217
   Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058
   Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2
   Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Xiong H, 2004, NEUROBIOL AGING, V25, P349, DOI 10.1016/S0197-4580(03)00123-4
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
NR 40
TC 117
Z9 134
U1 1
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0047-6374
EI 
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUN-JUL 15
PY 2005
VL 126
IS 6-7
BP 813
EP 821
DI 10.1016/j.mad.2005.03.002
PG 9
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 932EC
UT WOS:000229536000023
PM 15888336
DA 2024-11-01
ER

PT J
AU Tay, SKH
   Shanske, S
   Crowe, C
   Shanske, A
   Schafer, I
   Pancrudo, J
   Lu, JS
   Bonilla, E
   DiMauro, S
AF Tay, SKH
   Shanske, S
   Crowe, C
   Shanske, A
   Schafer, I
   Pancrudo, J
   Lu, JS
   Bonilla, E
   DiMauro, S
TI Clinical and genetic features in two families with MELAS and the T3271C mutation in mitochondrial DNA
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID stroke-like episodes; lactic-acidosis; point mutation; encephalopathy; myopathy; neuropathy
AB The majority of patients with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes) have the A3243G point mutation. The much rarer T3271C mutation has been reported predominantly in Japanese subjects. Our objective was to better define the clinical phenotype and mutation load in patients with MELAS and the T3271C mutation in mitochondrial DNA. We present clinical and molecular genetic data in two pedigrees with the T3271C mutation. The age at onset was 8 years in one proband and 14 years in the other. Both patients had migrainelike headache, seizures, and strokelike episodes. Mutation loads were quantified in multiple tissues front the patients and from family members by polymerase chain reaction-restriction fragment length polymorphism analysis. The symptoms in both probands were typical of MELAS, and, contrary to previous reports, onset was early. Hearing loss was less common than in typical MELAS, and ragged red fibers were absent. The proportion of mutant genomes was consistently and markedly greater in DNA from urinary sediment than from blood. In the mother of one proband, mutant genomes were detected only in DNA from hair follicles and cheek mucosa. The phenotype of patients with the T3271C mutation might not be as distinct as that of the A3243G mutation, as previously described. Our data also suggest that urine is a better source of DNA than blood for diagnosis and that multiple tissues should be studied in maternal relatives, especially when the mutation cannot be detected in blood.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Metrohlth Med Ctr, Cleveland, OH 44109 USA.
   Montefiore Med Ctr, Ctr Congenital Disorders, Bronx, NY 10467 USA.
C3 Columbia University; MetroHealth System; Montefiore Medical Center; Albert Einstein College of Medicine
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St,4-420, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Barisic N, 2002, CROAT MED J, V43, P37
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   MARIE SKN, 1994, BIOCHEM MED METAB B, V52, P136, DOI 10.1006/bmmb.1994.1045
   Nagashima T, 2001, NEUROMUSCULAR DISORD, V11, P470, DOI 10.1016/S0960-8966(01)00190-0
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Suzuki Y, 2002, DIABETES CARE, V25, P407, DOI 10.2337/diacare.25.2.407
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Tsukuda K, 1997, DIABETIC MED, V14, P1032, DOI 10.1002/(SICI)1096-9136(199712)14:12<1032::AID-DIA504>3.0.CO;2-Y
NR 13
TC 9
Z9 12
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD FEB 15
PY 2005
VL 20
IS 2
BP 142
EP 146
DI 10.1177/08830738050200022301
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 907UA
UT WOS:000227742300012
PM 15794182
DA 2024-11-01
ER

PT J
AU Casademont, J
   Rodriguez-Santiago, B
   Miró, O
   Beato, A
   López, S
   Nunes, V
   Cardellach, F
AF Casademont, J
   Rodriguez-Santiago, B
   Miró, O
   Beato, A
   López, S
   Nunes, V
   Cardellach, F
TI Mitochondrial respiratory chain in brain homogenates:: activities in different brain areas in patients with Alzheimer's disease
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alzheimer's disease; dementia; free radicals; mitochondria; neurodegenerative disorders; respiratory chain
ID cytochrome-oxidase activity; oxidative-phosphorylation; dna; metabolism; mutations; muscle; association; deficiency; expression; radicals
AB Background and aims: The potential influence of impaired oxidative metabolism in the modulation of manifestations in sporadic Alzheimer's disease (AD) has attracted much attention in the last 50 years. Unfortunately, many clinical and experimental results aiming at proving this hypothesis are still controversial. The aim was to study the enzymatic activities of respiratory chain (RC) complexes I through V in three brain areas of a group of patients with definite AD, and to compare the results with a group of normal brains. We simultaneously assessed the lipid peroxidation of the samples as a measure of free radical damage. Methods: The specific activity of the individual complexes of the RC was measured spectrophotometrically, and the loss of cis-parinaric acid fluorescence was used to determine the chemical process of lipid peroxidation. Results: We were not able to detect differences in any of the analyzed RC enzymatic activities, or in the level of lipid peroxidation between patients with AD and controls. Instead, differences were found in the number of mitochondria and in the intrinsic enzymatic activities of complexes III and IV in various brain areas. Conclusions: Spectrophotometric enzymatic analyses of respiratory complexes in brain homogenates do not support the primary contribution of mitochondrial RC dysfunction in the pathogenesis of AD.
C1 Univ Barcelona, Fac Med, IDIBAPS, Hosp Clin,Dept Internal Med,Muscle Res Unit, E-08036 Barcelona, Spain.
   Hosp Duran & Reynals, Inst Recerca Oncol, Med & Mol Genet Ctr, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals
RP Univ Barcelona, Fac Med, IDIBAPS, Hosp Clin,Dept Med,Grp Invest Muscular, Villarroel 170, E-08036 Barcelona, Spain.
EM jordi@medicina.ub.es
CR BATTINO M, 1991, J BIOENERG BIOMEMBR, V23, P345, DOI 10.1007/BF00762227
   Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087
   Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   Curti D, 1997, NEUROSCI LETT, V236, P13, DOI 10.1016/S0304-3940(97)00741-6
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377
   Edland SD, 1996, NEUROLOGY, V47, P254, DOI 10.1212/WNL.47.1.254
   HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704
   Hensley K, 1996, ANN NY ACAD SCI, V786, P120, DOI 10.1111/j.1749-6632.1996.tb39057.x
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   Honig LS, 2001, AGING CLIN EXP RES, V13, P171, DOI 10.1007/BF03351476
   Hutchin TP, 1997, BIOCHEM BIOPH RES CO, V241, P221, DOI 10.1006/bbrc.1997.7793
   Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0
   KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Knight JA, 1998, ANN CLIN LAB SCI, V28, P331
   Lee HC, 1997, J BIOMED SCI, V4, P319, DOI 10.1007/BF02258357
   LIN FH, 1992, BIOCHEM BIOPH RES CO, V182, P238, DOI 10.1016/S0006-291X(05)80136-6
   Manfredi G, 2000, BRAIN PATHOL, V10, P462
   Mecocci P, 1997, AGING (MILANO), V9, P51
   Miró O, 1998, J NEUROSCI METH, V80, P107, DOI 10.1016/S0165-0270(97)00204-5
   MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132
   MIZUNO Y, 1990, J NEUROL SCI, V96, P49, DOI 10.1016/0022-510X(90)90056-S
   Molina JA, 1997, NEUROLOGY, V48, P636, DOI 10.1212/WNL.48.3.636
   MUTISYA EM, 1994, J NEUROCHEM, V63, P2179
   Nagy Z, 1999, ACTA NEUROPATHOL, V97, P346, DOI 10.1007/s004010050997
   PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   PETRUZZELLA V, 1992, BIOCHEM BIOPH RES CO, V186, P491, DOI 10.1016/S0006-291X(05)80834-4
   REICHMANN H, 1993, J NEUROL, V240, P377, DOI 10.1007/BF00839971
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SCHAGGER H, 1995, EUR J BIOCHEM, V227, P916, DOI 10.1111/j.1432-1033.1995.tb20219.x
   SCHEUERLE A, 1993, VIRCHOWS ARCH B, V63, P331, DOI 10.1007/BF02899280
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918
   Te Koppele JM, 1996, NEUROBIOLOGY OF AGING, V17, P819, DOI 10.1016/S0197-4580(96)00165-0
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   VANZUYLEN AJ, 1992, NEUROLOGY, V42, P1246, DOI 10.1212/WNL.42.6.1246
   Wallace DC, 1998, NAT GENET, V19, P105, DOI 10.1038/448
   Wragg MA, 1995, NEUROSCI LETT, V201, P107, DOI 10.1016/0304-3940(95)12146-3
NR 43
TC 11
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD FEB 15
PY 2005
VL 17
IS 1
BP 1
EP 7
DI 
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 906QA
UT WOS:000227655700001
PM 15847115
DA 2024-11-01
ER

PT J
AU Wang, LY
   Limongelli, A
   Vila, MR
   Carrara, F
   Zeviani, M
   Eriksson, S
AF Wang, LY
   Limongelli, A
   Vila, MR
   Carrara, F
   Zeviani, M
   Eriksson, S
TI Molecular insight into mitochondrial DNA depletion syndrome in two patients with novel mutations in the deoxyguanosine kinase and thymidine kinase 2 genes
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE deoxyguanosine kinase; thymidine kinase 2; mitochondrial DNA depletion; mitochondrial DNA depletion syndrome; mutation; mutagenesis; enzyme kinetic
ID mtdna depletion; deoxyribonucleoside kinases; substrate-specificity; tk2 deficiency; myopathy; expression; deletions
AB Thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) are the two key enzymes in mitochondrial DNA (mtDNA) precursor synthesis. Deficiencies in TK2 or dGK activity, due to genetic alteration, have been shown to cause tissue-specific depletion of mtDNA. In the case of TK2 deficiency, affected individuals suffer severe myopathy and, in the case of dGK deficiency, devastating liver or multi-systemic disease. Here, we report clinical and biochemical findings from two patients with mtDNA depletion syndrome. Patient A was a compound heterozygote carrying the previously reported T77M mutation and a novel mutation (R161K) in the TK2 gene. Patient B carried a novel mutation (L250S) in the dGK gene. The clinical symptoms of patient A included muscular weakness and exercise intolerance due to a severe mitochondrial myopathy associated with a 92% reduction in mtDNA. There was minimal involvement of other organs. Patient B suffered from rapidly progressive, early onset fatal liver failure associated with profoundly decreased mtDNA levels in liver and, to a lesser extent, in skeletal muscle. Site-directed mutagenesis was used to introduce the mutations detected in patients A and B into the TK2 and dGK cDNAs, respectively. We then characterized each of these recombinant enzymes. Catalytic activities of the three mutant enzymes were reduced to about 2-4% for TK2 and 0.5% for dGK as compared to the wild-type enzymes. Altered competition between dCyd and dThd was observed for the T77M mutant. The residual activities of the two mitochondrial enzymes correlated directly with disease development. (C) 2004 Elsevier Inc. All rights reserved.
C1 SLU, Biomed Ctr, Sect Vet Med Biochem, Dept Mol Biosci, SE-75123 Uppsala, Sweden.
   Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
   Columbia Univ, Dept Neurol, New York, NY 10032 USA.
C3 Swedish University of Agricultural Sciences; Fondazione IRCCS Istituto Neurologico Carlo Besta; Columbia University
RP Wang, LY (corresponding author), SLU, Biomed Ctr, Sect Vet Med Biochem, Dept Mol Biosci, POB 575, SE-75123 Uppsala, Sweden.
EM liya.wang@vmk.slu.se
FU Telethon [GGP030039] Funding Source: Medline
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cotter D, 2004, NUCLEIC ACIDS RES, V32, PD463, DOI 10.1093/nar/gkh048
   Darley-Usmar VM, 1987, MITOCHONDRIA PRACTIC, V0, P0
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sjoberg AH, 1998, MOL PHARMACOL, V53, P270, DOI 10.1124/mol.53.2.270
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WANG LY, 1993, J BIOL CHEM, V268, P22847
   Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0
NR 23
TC 60
Z9 71
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JAN 15
PY 2005
VL 84
IS 1
BP 75
EP 82
DI 10.1016/j.ymgme.2004.09.005
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 899VL
UT WOS:000227173700010
PM 15639197
DA 2024-11-01
ER

PT J
AU Möllers, M
   Maniura-Weber, K
   Kiseljakovic, E
   Bust, M
   Hayrapetyan, A
   Jaksch, M
   Helm, M
   Wiesner, RJ
   von Kleist-Retzow, JC
AF Möllers, M
   Maniura-Weber, K
   Kiseljakovic, E
   Bust, M
   Hayrapetyan, A
   Jaksch, M
   Helm, M
   Wiesner, RJ
   von Kleist-Retzow, JC
TI A new mechanism for mtDNA pathogenesis:: impairment of post-transcriptional maturation leads to severe depletion of mitochondrial tRNA<SUP>Ser(UCN)</SUP> caused by T7512C and G7497A point mutations
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID anticodon wobble nucleotide; higher-order structure; transfer-rna; cloverleaf structure; modification defect; lactic-acidosis; dna; aminoacylation; recognition; myopathy
AB We have studied the consequences of two homoplasmic, pathogenic point mutations (T7512C and G7497A) in the tRNA(Ser(UCN)) gene of mitochondrial (mt) DNA using osteosarcoma cybrids. We identified a severe reduction of tRNA(Ser(UCN)) to levels below 10% of controls for both mutations, resulting in a 40% reduction in mitochondrial protein synthesis rate and in a respiratory chain deficiency resembling that in the patients muscle. Aminoacylation was apparently unaffected. On non-denaturating northern blots we detected an altered electrophoretic mobility for G7497A containing tRNA molecules suggesting a structural impact of this mutation, which was confirmed by structural probing. By comparing in vitro transcribed molecules with native RNA in such gels, we also identified tRNA(Ser(UCN)) being present in two isoforms in vivo, probably corresponding to the nascent, unmodified transcripts co-migrating with the in vitro transcripts and a second, faster moving isoform corresponding to the mature tRNA. In cybrids containing either mutations the unmodified isoforms were severely reduced. We hypothesize that both mutations lead to an impairment of post-transcriptional modification processes, ultimately leading to a preponderance of degradation by nucleases over maturation by modifying enzymes, resulting in severely reduced tRNA(Ser(UCN)) steady state levels. We infer that an increased degradation rate, caused by disturbance of tRNA maturation and, in the case of the G7497A mutant, alteration of tRNA structure, is a new pathogenic mechanism of mt tRNA point mutations.
C1 Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany.
   Fac Med, Dept Biochem, Sarajevo, Bosnia & Herceg.
   Heidelberg Univ, Inst Pharm & Mol Biotechnol, D-69120 Heidelberg, Germany.
   Inst Clin Chem & Mitochondrial Genet, D-80804 Munich, Germany.
   Univ Cologne, CMMC, D-50931 Cologne, Germany.
   Univ Cologne, Dept Pediat, D-50924 Cologne, Germany.
C3 University of Cologne; Ruprecht Karls University Heidelberg; University of Cologne; University of Cologne
RP Univ Cologne, Inst Vegetat Physiol, Robert Koch Str 39, D-50931 Cologne, Germany.
EM rudolf.wiesner@uni-koeln.de
CR Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Christian EL, 2002, METHODS, V28, P307, DOI 10.1016/S1046-2023(02)00238-4
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   El Meziane A, 1998, NAT GENET, V18, P350
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   EUBANKS JH, 1991, GENOMICS, V11, P720, DOI 10.1016/0888-7543(91)90080-X
   Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153
   FRIEDERICH MW, 1995, P NATL ACAD SCI USA, V92, P4803, DOI 10.1073/pnas.92.11.4803
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Hao R, 2005, NUCLEIC ACIDS RES, V33, P3606, DOI 10.1093/nar/gki677
   Hayashi I, 1998, J MOL BIOL, V284, P57, DOI 10.1006/jmbi.1998.2151
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Helm M, 2004, J MOL BIOL, V337, P545, DOI 10.1016/j.jmb.2004.01.036
   Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636
   Hofhaus G, 1996, METHODS ENZYMOL, V264, P476, DOI 10.1016/S0076-6879(96)64043-9
   Huang Z, 1996, NUCLEIC ACIDS RES, V24, P4360, DOI 10.1093/nar/24.21.4360
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sambrook J, 1989, MOLECULAR CLONING: A LABORATORY MANUAL, V0, P0
   Schneider A, 1996, NUCLEIC ACIDS RES, V24, P1225, DOI 10.1093/nar/24.7.1225
   Shimada N, 2001, J BIOL CHEM, V276, P46770, DOI 10.1074/jbc.M105150200
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217
   Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200
   WATANABE Y, 1994, NUCLEIC ACIDS RES, V22, P5378, DOI 10.1093/nar/22.24.5378
   WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   Yokogawa T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101
NR 49
TC 27
Z9 32
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 15
PY 2005
VL 33
IS 17
BP 5647
EP 5658
DI 10.1093/nar/gki876
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 974LS
UT WOS:000232593700037
PM 16199753
DA 2024-11-01
ER

PT J
AU Zhang, D
   Ezekiel, UR
   Chang, SW
   Zassenhaus, HP
AF Zhang, D
   Ezekiel, UR
   Chang, SW
   Zassenhaus, HP
TI Gene expression profile in dilated cardiomyopathy caused by elevated frequencies of mitochondrial DNA mutations in the mouse heart
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Article
DE mitochondria; mutations; dilated cardiomyopathy; mice
ID smooth-muscle-cells; point mutations; fatty-acid; failure; disease; mice; phosphorylation; metabolism; microarray; connexin43
AB Background: Elevated mitochondrial DNA (mtDNA) mutations are associated with aging and age-related diseases, but their pathogenic potential is unclear. Methods: We performed expression profiling using an Incyte cDNA array of a mouse model of elevated mtDNA mutations wherein random mutations accumulate specifically in the heart. At frequencies of about 1 mutation/10,000 base pairs, these mice show apoptosis of cardiomyocytes and development of four-chamber dilated cardiomyopathy. Results: Significant Analysis of Microarrays (SAM) revealed that 117 genes were altered in their expression in the transgenic (Tg) heart at a threshold of less than one false positive, of which 34 were up-regulated and 83 were down-regulated. Some of the changes were confirmed by Northern and Western blots. By classification of these genes into functional categories, we identified changes that reflected cardiac pathology. The results indicated that cardiomyopathy caused by mtDNA mutations was largely characterized by gene expression changes indicative of increased fibrosis and cardiac remodeling of the extracellular matrix. Few changes were observed, suggesting an alteration in either mitochondrial energy production or generation of increased oxidative stress. Conclusions: Elevated frequencies of mtDNA mutations in the mouse heart lead to gene expression changes that are associated with remodeling of the extracellular matrix. Because cardiomyocytic death by apoptosis is also a feature of the dilated cardiomyopathy evident in these mice, extracellular remodeling may be a response to apoptotic signaling originating from the mitochondria with mtDNA mutations. (c) 2005 Elsevier Inc. All rights reserved.
C1 St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, St Louis, MO 63105 USA.
   GeneProTech, St Louis, MO 63144 USA.
C3 Saint Louis University
RP St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, 1402 S Grand Blvd, St Louis, MO 63105 USA.
EM zassenp@slu.edu
CR Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19
   Ausubel FM, 1995, CURRENT PROTOCOLS MO, V0, P0
   Barger PM, 1999, AM J MED SCI, V318, P36, DOI 10.1097/00000441-199907000-00006
   Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4
   Boluyt MO, 2000, CARDIOVASC RES, V46, P239, DOI 10.1016/S0008-6363(00)00043-2
   Burlew BS, 2002, HERZ, V27, P92, DOI 10.1007/s00059-002-2354-y
   Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758
   CAULFIELD JB, 1979, LAB INVEST, V40, P364
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CORTOPASSI G, 1995, BBA-MOL BASIS DIS, V1271, P171, DOI 10.1016/0925-4439(95)00025-Y
   CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754
   Dávila-Román VG, 2002, J AM COLL CARDIOL, V40, P271, DOI 10.1016/S0735-1097(02)01967-8
   Frank KF, 2002, BASIC RES CARDIOL, V97, P172
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333
   HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200
   Hwang JJ, 2002, PHYSIOL GENOMICS, V10, P31, DOI 10.1152/physiolgenomics.00122.2001
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Li P, 2003, CELL MOL LIFE SCI, V60, P2200, DOI 10.1007/s00018-003-3178-5
   Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1
   Mentlein R, 1996, PEPTIDES, V17, P709, DOI 10.1016/0196-9781(96)00066-6
   MORANO I, 1992, BASIC RES CARDIOL, V87, P129
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Müller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje
   Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053
   Schultz JEJ, 2004, AM J PHYSIOL-HEART C, V286, PH1146, DOI 10.1152/ajpheart.00720.2003
   Severs NJ, 2002, J CARD FAIL, V8, PS293, DOI 10.1054/jcaf.2002.129255
   Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181
   SWEENEY JL, 1986, AM J PHYSIOL, V250, P0
   Teng XW, 2003, CIRC RES, V92, P1065, DOI 10.1161/01.RES.0000073999.07698.33
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   WU KD, 1993, AM J PHYSIOL, V264, PC333, DOI 10.1152/ajpcell.1993.264.2.C333
   Yue HB, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.8.e41
   Záckova M, 2002, BIOSCIENCE REP, V22, P33, DOI 10.1023/A:1016009022186
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 39
TC 9
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-8807
EI 1879-1336
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD MAR-APR 15
PY 2005
VL 14
IS 2
BP 61
EP 69
DI 10.1016/j.carpath.2005.01.006
PG 9
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA 914XL
UT WOS:000228261300003
PM 15780797
DA 2024-11-01
ER

PT J
AU Peker, S
   Pamir, MN
AF Peker, S
   Pamir, MN
TI Trigeminal neuralgia in a patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE demyelination; mitochondrial neurogastrointestinal en-cephalomyopathy; trigerninal neuralgia
ID posterior cranial fossa; multiple-sclerosis; microvascular decompression; neurovascular relationships; cadaveric controls; linear pontine; root lesions; disorder; features; leukoencephalopathy
AB Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal-recessive disease associated with multiple deletions of mitochondrial DNA in skeletal muscle. MNGIE is a multisystem syndrome affecting muscle, peripheral, and central nervous systems and the gastrointestinal tract. A 25-year-old man is presented with 3 years history of right sided trigeminal neuralgia. He has been diagnosed as MNGIE based on clinical, neurophysiological and pathological findings. He had also received medical therapy and two radiofrequency thermocoagulations for the treatment of trigeminal neuralgia. Gamma Knife radiosurgery was performed and resulted in partial relief. To our knowledge, this is the first case in the literature of MNGIE with trigeminal neuralgia. An analogy is suggested between multiple sclerosis and MNGIE as a cause for trigeminal neuralgia in this patient. (c) 2004 Elsevier Ltd. All rights reserved.
C1 Marmara Univ, Dept Neurosurg, Inst Neurol Sci, Istanbul, Turkey.
C3 Marmara University
RP Peker, S (corresponding author), 48 Ada,Mimoza 2-17,D22, TR-34758 Istanbul, Turkey.
EM peker@atlas.net.tr
CR BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Broggi G, 2000, J NEUROL NEUROSUR PS, V68, P59, DOI 10.1136/jnnp.68.1.59
   Devor M, 2002, J NEUROSURG, V96, P532, DOI 10.3171/jns.2002.96.3.0532
   Ferroli P, 2001, ARCH NEUROL-CHICAGO, V58, P1311, DOI 10.1001/archneur.58.8.1311
   Gass A, 1997, NEUROLOGY, V49, P1142, DOI 10.1212/WNL.49.4.1142
   Ghezzi A, 2001, NEUROL SCI, V22, PS117, DOI 10.1007/s100720100048
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   GOODKIN DE, 1994, ARCH NEUROL-CHICAGO, V51, P505, DOI 10.1001/archneur.1994.00540170087020
   Hamlyn PJ, 1997, CLIN ANAT, V10, P371, DOI 10.1002/(SICI)1098-2353(1997)10:6<371::AID-CA1>3.0.CO;2-S
   Hamlyn PJ, 1997, CLIN ANAT, V10, P380, DOI 10.1002/(SICI)1098-2353(1997)10:6<380::AID-CA2>3.0.CO;2-T
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   HOOGE JP, 1995, NEUROLOGY, V45, P1294, DOI 10.1212/WNL.45.7.1294
   JENSEN TS, 1982, ACTA NEUROL SCAND, V65, P182
   Labauge P, 2002, NEUROLOGY, V58, P1862, DOI 10.1212/WNL.58.12.1862
   LAZAR ML, 1979, NEUROSURGERY, V5, P711, DOI 10.1227/00006123-197912000-00013
   Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347
   Love S, 2001, NEUROPATH APPL NEURO, V27, P238, DOI 10.1046/j.0305-1846.2001.00318.x
   MOULIN DE, 1988, NEUROLOGY, V38, P1830, DOI 10.1212/WNL.38.12.1830
   Nakashima I, 2001, ARCH NEUROL-CHICAGO, V58, P101, DOI 10.1001/archneur.58.1.101
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   Soykan I, 2002, J CLIN GASTROENTEROL, V34, P446, DOI 10.1097/00004836-200204000-00013
   Zvartau-Hind M, 2000, NEUROLOGY, V55, P1587, DOI 10.1212/WNL.55.10.1587
NR 24
TC 7
Z9 7
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0967-5868
EI 
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD FEB 15
PY 2005
VL 12
IS 2
BP 172
EP 174
DI 10.1016/j.jocn.2004.02.009
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 910JI
UT WOS:000227926900015
PM 15749422
DA 2024-11-01
ER

PT J
AU Hutchison, WM
   Thyagarajan, D
   Poulton, J
   Marchington, DR
   Kirby, DM
   Manji, SSM
   Dahl, HHM
AF Hutchison, WM
   Thyagarajan, D
   Poulton, J
   Marchington, DR
   Kirby, DM
   Manji, SSM
   Dahl, HHM
TI Clinical and molecular features of encephalomyopathy due to the A3302G mutation in the mitochondrial <i>tRNA</i> <SUP>Leu(UUR)</SUP> gene
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID respiratory-chain; dna; disorder
AB Background: The mitochondrial DNA mutation A3302G in the tRNA(Leu(UUR)) gene causes respiratory chain complex 1 deficiency. The main clinical feature appears to be a progressive mitochondrial myopathy with proximal muscle weakness. Objective: To report on clinical and molecular features in 4 novel patients with the A3302G mutation. Design: Case reports. Patients: Four patients (3 of whom are from the same family) with a myopathy caused by the A3302G mitochondrial DNA mutation. Main Outcome Measure: Identification of the A3302G mutation by DNA sequencing. Results: All 4 patients had an adult-onset progressive mitochondrial myopathy with proximal muscle weakness, resulting in exercise intolerance. In 2 unrelated patients, upper limb reflexes were absent with preservation of at least some lower limb reflexes. Other features including hearing loss, recurrent headaches, ptosis, progressive external oplithalmoplegia, and depression were present. Conclusion: While the dominant clinical features of the A3302G mutation were exercise intolerance and proximal muscle weakness, other features of mitochondrial encephalomyopathies, previously not described for this mutation, were present.
C1 Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia.
   Flinders Med Ctr, Dept Neurol, Bedford Pk, SA, Australia.
   John Radcliffe Hosp, Womens Ctr, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
C3 Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; Flinders Medical Centre; University of Oxford
RP Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM hen-rik.dahl@mcri.edu.au
CR BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025
   Gardner A, 2003, ACTA PSYCHIAT SCAND, V107, P233, DOI 10.1034/j.1600-0447.2003.02188.x
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Miyaoka H, 1997, BIOL PSYCHIAT, V42, P524, DOI 10.1016/S0006-3223(97)00280-1
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844
   SHOFFNER JM, 1993, AM J HUM GENET, V53, P949
   van den Bosch BJC, 2004, NEUROMUSCULAR DISORD, V14, P683, DOI 10.1016/j.nmd.2004.06.004
   WATMOUGH NJ, 1990, J CLIN INVEST, V85, P177, DOI 10.1172/JCI114409
NR 15
TC 16
Z9 16
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC 15
PY 2005
VL 62
IS 12
BP 1920
EP 1923
DI 10.1001/archneur.62.12.1920
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 991QC
UT WOS:000233827500016
PM 16344351
DA 2024-11-01
ER

PT J
AU Müller, T
   Deschauer, M
   Neudecker, S
   Zierz, S
AF Müller, T
   Deschauer, M
   Neudecker, S
   Zierz, S
TI Late-onset mitochondrial myopathy with dystrophic changes due to a G7497A mutation in the mitochondrial tRNA<SUP>Ser(UCN)</SUP>supercript stop gene
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE mitochondrial myopathy; muscular dystrophy; transfer RNA mutations
ID point mutation; exercise intolerance; respiratory-chain; muscle; mtdna; sequence; family; size
AB Mutations of mitochondrial tRNA genes are usually associated with multi-systemic disorders with onset of symptoms in childhood or early adulthood. Dystrophic myopathic changes are not typical features of these disorders. We report two siblings with a severe progressive myopathy of late onset without external ophthalmoplegia and without involvement of the central and peripheral nervous system. Muscle biopsy specimens showed severe myopathic changes similar to those found in muscular dystrophies. Molecular analysis revealed a G7497A mutation in the mitochondrial tRNA(Ser(UCN))supercript stop gene. In both patients, the proportion of mutated mitochondrial DNA in muscle was more than 97%. Mitochondrial disorder associated with the G7497A mutation has to be included into the differential diagnosis of severe progressive late-onset myopathy with histopathological dystrophic myopathic changes. Mitochondrial myopathy and high level of mutated mtDNA might be a characteristic of the G7497A tRNA(Ser(UCN)) mutation.
C1 Univ Halle Wittenberg, Univ Klin & Poliklin Neurol, D-06097 Halle Saale, Saale, Germany.
C3 Martin Luther University Halle Wittenberg
RP Müller, T (corresponding author), Univ Halle Wittenberg, Univ Klin & Poliklin Neurol, Ernst Grube Str 40, D-06097 Halle Saale, Saale, Germany.
EM tobias.mueller@medizin.uni-halle.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BEYENBURG S, 1991, NERVENARZT, V62, P506
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   *MIT, 2004, HUM MIT GEN DAT, V0, P0
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 17
TC 7
Z9 8
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0001-6322
EI 
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD OCT 15
PY 2005
VL 110
IS 4
BP 426
EP 430
DI 10.1007/s00401-005-1063-z
PG 5
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 985PV
UT WOS:000233391200009
PM 16133542
DA 2024-11-01
ER

PT J
AU Nakashima-Kamimura, N
   Asoh, S
   Ishibashi, Y
   Mukai, Y
   Shidara, Y
   Oda, H
   Munakata, K
   Goto, Y
   Ohta, S
AF Nakashima-Kamimura, N
   Asoh, S
   Ishibashi, Y
   Mukai, Y
   Shidara, Y
   Oda, H
   Munakata, K
   Goto, Y
   Ohta, S
TI MIDAS/GPP34, a nuclear gene product, regulates total mitochondrial mass in response to mitochondrial dysfunction
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE mitochondria; mitochondrial mass; cardiolipin; mitochondrial DNA; mitochondrial disease; Golgi apparatus
ID stroke-like episodes; transfer rnaleu(uur) gene; lactic-acidosis; skeletal-muscle; cell-death; saccharomyces-cerevisiae; respiratory-chain; oxidative stress; point mutation; dna-repair
AB To investigate the regulatory system in mitochondrial biogenesis involving crosstalk between the mitochondria and nucleus, we found a factor named MIDAS (mitochondrial DNA absence sensitive factor) whose expression was enhanced by the absence of mitochondrial DNA (mtDNA). In patients with mitochondrial diseases, MIDAS expression was increased only in dysfunctional muscle fibers. A majority of MIDAS localized to mitochondria with a small fraction in the Golgi apparatus in HeLa cells. To investigate the function of MIDAS, we stably transfected HeLa cells with an expression vector carrying MIDAS cDNA or siRNA. Cells expressing the MIDAS protein and the siRNA constitutively showed an increase and decrease in the total mass of mitochondria, respectively, accompanying the regulation of a mitochondria-specific phospholipid, cardiolipin. In contrast, amounts of the mitochondrial DNA, RNA and proteins did not depend upon MMAS. Thus, MIDAS is involved in the regulation of mitochondrial lipids, leading to increases of total mitochondrial mass in response to mitochondrial dysfunction.
C1 Nippon Med Coll, Dept Biochem & Cell Biol, Inst Dev & Aging Sci, Grad Sch Med, Kawasaki, Kanagawa 2118533, Japan.
   Tokyo Womens Med Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1628666, Japan.
   Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, NCNP, Kodaira, Tokyo 1878502, Japan.
C3 Nippon Medical School; Tokyo Women's Medical University; National Center for Neurology & Psychiatry - Japan
RP Nippon Med Coll, Dept Biochem & Cell Biol, Inst Dev & Aging Sci, Grad Sch Med, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.
EM ohta@nms.ac.jp
CR Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Asoh S, 1996, J BIOCHEM-TOKYO, V120, P600
   ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Bidlingmaier Scott, 2002, FUNCTIONAL AND INTEGRATIVE GENOMICS, V1, P345, DOI 10.1007/s10142-001-0043-1
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005
   BRUNK CF, 1981, EXP CELL RES, V136, P305, DOI 10.1016/0014-4827(81)90008-2
   Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450
   Dubowitz V, 1985, MUSCLE BIOPSY-A PRACTICAL APPROACH, VSecond, P19
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5
   Goglia F, 1999, FEBS LETT, V452, P115, DOI 10.1016/S0014-5793(99)00642-0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P6878
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Jishage M, 2003, ONCOGENE, V22, P41, DOI 10.1038/sj.onc.1206074
   Kanamori T, 2003, EMBO J, V22, P2913, DOI 10.1093/emboj/cdg299
   Kang D, 2002, CURR GENET, V41, P311, DOI 10.1007/s00294-002-0312-0
   KAWAHARA H, 1991, J SUBMICR CYTOL PATH, V23, P397
   KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Melov S, 2000, ANN NY ACAD SCI, V908, P219
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moyes CD, 1997, AM J PHYSIOL-CELL PH, V272, PC1345, DOI 10.1152/ajpcell.1997.272.4.C1345
   MULLERHOCKER J, 1986, J NEUROL SCI, V74, P199, DOI 10.1016/0022-510X(86)90105-X
   MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   Ohta S, 2003, CURR MED CHEM, V10, P2485, DOI 10.2174/0929867033456440
   Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   VOROBJEV IA, 1983, FEBS LETT, V163, P311, DOI 10.1016/0014-5793(83)80842-4
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Weber K, 2002, BIOL CHEM, V383, P283, DOI 10.1515/BC.2002.030
   WEI YF, 1995, MOL CELL BIOL, V15, P3206
   Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113
   Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901
   Wu CC, 2000, TRAFFIC, V1, P963, DOI 10.1034/j.1600-0854.2000.011206.x
   Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493
   ZELLER R, 1998, CELLS LAB MANUAL, V3, P0
NR 60
TC 57
Z9 64
U1 1
U2 5
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD NOV 15
PY 2005
VL 118
IS 22
BP 5357
EP 5367
DI 10.1242/jcs.02645
PG 11
WC Cell Biology
SC Cell Biology
GA 992KT
UT WOS:000233883500019
PM 16263763
DA 2024-11-01
ER

PT J
AU Sacher, M
   Fatterpekar, GM
   Edelstein, S
   Sansaricq, C
   Naidich, TP
AF Sacher, M
   Fatterpekar, GM
   Edelstein, S
   Sansaricq, C
   Naidich, TP
TI MRI findings in an atypical case of Kearns-Sayre syndrome: a case report
SO NEURORADIOLOGY
LA English
DT Article
DE mitochondrial deletion; diffusion; status spongiosus
ID stroke-like episodes; mitochondrial encephalomyopathy; external ophthalmoplegia; lactic-acidosis; mutation; encephalopathy; myopathy; melas
AB MR imaging features of mitochondrial encephalomyopathies, lactic acidosis, and stroke-like episodes, Kearns-Sayre/Pearson syndrome have been described in the literature. We describe extensive white matter changes with abnormal signal intensity lesions involving the deep gray nuclei and myelinated white matter tracts in an 18-year-old female with a large-scale 7.4 kb mitochondrial DNA deletion and a atypical presentation of Kearns-Sayre syndrome. Restricted diffusion due to status spongiosus at the involved sites is also discussed.
C1 Mt Sinai Med Ctr, Dept Radiol, New York, NY 10029 USA.
   Mt Sinai Med Ctr, Dept Med Genet, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Sacher, M (corresponding author), Mt Sinai Med Ctr, Dept Radiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM Michael.Sacher@mssm.edu
CR CASTILLO M, 1995, AM J NEURORADIOL, V16, P2333
   DIMAURO S, 1990, NEUROL CLIN, V8, P483, DOI 10.1016/S0733-8619(18)30332-3
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Mittal S, 2002, ARCH NEUROL-CHICAGO, V59, P128, DOI 10.1001/archneur.59.1.128
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Yonemura K, 2001, AM J NEURORADIOL, V22, P269
NR 10
TC 19
Z9 20
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0028-3940
EI 
J9 NEURORADIOLOGY
JI Neuroradiology
PD APR 15
PY 2005
VL 47
IS 4
BP 241
EP 244
DI 10.1007/s00234-004-1314-z
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 922QJ
UT WOS:000228852600001
PM 15789203
DA 2024-11-01
ER

PT J
AU Gilbert, J
   Ibdah, JA
AF Gilbert, J
   Ibdah, JA
TI Intestinal pseudo-obstruction as a manifestation of impaired mitochondrial fatty acid oxidation
SO MEDICAL HYPOTHESES
LA English
DT Article
ID trifunctional protein-deficiency; 3-hydroxyacyl-coa dehydrogenase-deficiency; liver-disease; pregnancy; family; subunit; defect; mngie
AB Intestinal pseudo-obstruction can be caused by mitochondrial disorders. Understanding the association between genetic alterations in mitochondrial function and development of intestinal pseudo-obstruction may provide insight into the pathogenesis of this disorder. Although the association between mitochondrial DNA defects and pseudo-obstruction is documented, Little is known about the relationship between mitochondrial beta-oxidation disorders, which are caused by defects in nuclear genes, and development of intestinal pseudo-obstruction. Mitochondrial beta-oxidation defects have emerged recently as an important group of recessively inherited inborn errors of metabolism with multiple phenotypes. Here we report the case history of a 25-year-old patient with mitochondrial trifunctional protein (MTP) deficiency, the eldest known living patient with this disorder. MTP is an enzyme complex that consists of 4alpha and 4beta subunits and catalyzes the Last three steps in the beta-oxidation cycle. The patient's MTP deficiency is secondary to a compound heterozygosity for two mutations in the MTP P-subunit. Over the past 5 years, the patient had worsening symptoms consistent with intestinal pseudo-obstruction associated with progressive skeletal myopathy and potyneuropathy. We hypothesize that impairment of mitochondrial beta-oxidation causes intestinal pseudo-obstruction secondary to accumulation of intracellular tong chain fatty acids, activation of extramitochondrial fatty acid oxidation pathways, and generation of excessive reactive oxygen species leading to visceral. myopathy. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Wake Forest Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Winston Salem, NC 27157 USA.
C3 Wake Forest University
RP Wake Forest Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM jibdah@wfubmc.edu
FU NIDDK NIH HHS [DK 56345] Funding Source: Medline
CR Chinnery PF, 1997, QJM-INT J MED, V90, P657, DOI 10.1093/qjmed/90.11.657
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Ibdah JA, 2004, GASTROENTEROLOGY, V126, P0
   Ibdah JA, 2003, GASTROENTEROLOGY, V124, PA707, DOI 10.1016/S0016-5085(03)83571-0
   Ibdah JA, 2001, J CLIN INVEST, V107, P1403, DOI 10.1172/JCI12590
   Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204
   Ibdah JA, 1998, J CLIN INVEST, V102, P1193, DOI 10.1172/JCI2091
   Ibdah JA, 1999, J INHERIT METAB DIS, V22, P811, DOI 10.1023/A:1005506024055
   Ibdah JA, 2001, J PEDIATR-US, V138, P396, DOI 10.1067/mpd.2001.111503
   ILJST L, 1996, J CLIN INVEST, V98, P1028
   JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983
   Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6
   KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302
   Kamm MA, 1996, SCAND J GASTROENTERO, V31, P91, DOI 10.3109/00365529609094758
   Mann SD, 1997, GUT, V41, P675, DOI 10.1136/gut.41.5.675
   Mansouri A, 1997, J HEPATOL, V27, P96, DOI 10.1016/S0168-8278(97)80286-3
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Saudubray JM, 1999, J INHERIT METAB DIS, V22, P488
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841
   Spiekerkoetter U, 2003, HUM MUTAT, V21, P598, DOI 10.1002/humu.10211
   UCHIDA Y, 1992, J BIOL CHEM, V267, P1034
   Ushikubo S, 1996, AM J HUM GENET, V58, P979
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0
   Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225
   Yang Z, 2002, AM J OBSTET GYNECOL, V187, P715, DOI 10.1067/mob.2002.125893
NR 27
TC 9
Z9 9
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUN 15
PY 2005
VL 64
IS 3
BP 586
EP 589
DI 10.1016/j.mehy.2004.07.032
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 899IX
UT WOS:000227139200030
PM 15617873
DA 2024-11-01
ER

PT J
AU Tulinius, M
   Moslemi, AR
   Darin, N
   Holme, E
   Oldfors, A
AF Tulinius, M
   Moslemi, AR
   Darin, N
   Holme, E
   Oldfors, A
TI Novel mutations in the thymidine kinase 2 gene (<i>TK2</i>) associated with fatal mitochondrial myopathy and mitochondrial DNA depletion
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA depletion; thymidine kinase-2; mitochondrial myopathy; infants; children
ID mtdna depletion; deficiency
AB We describe the clinical, morphological and genetic findings in two siblings with the myopathic form of mitochondrial DNA depletion syndrome (MIM 251880). Sequencing of the thymidine kinase-2 gene revealed two heterozygous missense mutations, a C -> T mutation at nucleotide 191 resulting in a change of threonine to methionine at residue 64 in exon 3, and a C -> T mutational nucleotide 547 resulting in an arginine to tryptophan amino acid change at residue 183 in exon 8. Both mutations changed highly conserved residues in the gene and neither one has been described previously. This report extends the phenotypic expression of mutations in the thymidine kinase-2 gene. (c) 2005 Elsevier B.V. All rights reserved.
C1 Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
   Univ Gothenburg, Sahlgrenska Hosp, Dept Clin Chem, Gothenburg, Sweden.
   Univ Gothenburg, Sahlgrenska Hosp, Dept Pathol, Gothenburg, Sweden.
C3 Queen Silvia Children's Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital
RP Tulinius, M (corresponding author), Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
EM mar.tulinius@vgregion.se
CR Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   OLDFORS A, 1989, ACTA NEUROPATHOL, V77, P267, DOI 10.1007/BF00687578
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
NR 11
TC 22
Z9 26
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN 15
PY 2005
VL 15
IS 6
BP 412
EP 415
DI 10.1016/j.nmd.2005.03.010
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 934UC
UT WOS:000229733100004
PM 15907288
DA 2024-11-01
ER

PT J
AU Stenqvist, L
   Paetau, A
   Valanne, L
   Suomalainen, A
   Pihko, H
AF Stenqvist, L
   Paetau, A
   Valanne, L
   Suomalainen, A
   Pihko, H
TI A juvenile case of MELAS with T3271C mitochondrial DNA mutation
SO PEDIATRIC RESEARCH
LA English
DT Article
ID stroke-like episodes; transfer rnaleu(uur) gene; lactic-acidosis; transfer rna(leu(uur)); clinical-features; mtdna mutation; point mutation; encephalopathy; myopathy; encephalomyopathy
AB We present here a patient with muscle fatigue and poor growth since the age of 6 y. The diagnosis of a mitochondrial disease was based on the presence of ragged red fibers in the muscle biopsy and on a combined defect of mitochondrial DNA-encoded respiratory enzymes. Epilepsia partialis continua with stroke-like episodes appeared 2 mo before death at the age of 18 and prompted a search for mitochondrial DNA mutations associated with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Minisequencing of the patient's DNA samples revealed a heteroplasmic T3271C mutation with a 78-94% mutation load in her fibroblasts or autopsy-derived tissue samples. This is the ninth reported non-Japanese patient with T3271C mutation. Our patient shows that despite very high proportion of mutant mtDNA, the T3271C mutation can give rise to mild symptoms in childhood and to a rapid terminal phase that simulates encephalitis.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Radiol, FIN-00029 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Dept Neurol, Haartmaninkatu 8,POB 63, FIN-00290 Helsinki, Finland.
EM laura.stenqvist@hus.fi
CR Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   CHEN CM, 1995, EUR NEUROL, V35, P281, DOI 10.1159/000117150
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225
   Shinde A, 2000, RINSHO SHINKEIGAKU, V40, P561
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SUOMALAINEN A, 1993, HUM MOL GENET, V2, P525, DOI 10.1093/hmg/2.5.525
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Takeda A, 1998, JPN CIRC J, V62, P695, DOI 10.1253/jcj.62.695
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VANDENOUWELAND JMW, 1995, MUSCLE NERVE, V0, PS124
   Yanagawa T, 1998, INTERNAL MED, V37, P780, DOI 10.2169/internalmedicine.37.780
NR 36
TC 13
Z9 19
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD AUG 15
PY 2005
VL 58
IS 2
BP 258
EP 262
DI 10.1203/01.PDR.0000169966.82325.1A
PG 5
WC Pediatrics
SC Pediatrics
GA 952HV
UT WOS:000230995500015
PM 16006433
DA 2024-11-01
ER

PT J
AU Chan, SSL
   Longley, MJ
   Naviaux, RK
   Copeland, WC
AF Chan, SSL
   Longley, MJ
   Naviaux, RK
   Copeland, WC
TI Mono-allelic <i>POLG</i> expression resulting from nonsense-mediated decay and alternative splicing in a patient with Alpers syndrome
SO DNA REPAIR
LA English
DT Article; Proceedings Paper
DE nonsense-mediated mRNA decay; exon skipping; Alpers syndrome; DNA polymerase gamma; premature termination codon; nonsense-associated alternative splicing
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; messenger-rna decay; gamma mutations; translation; depletion; degeneration; subunit; disease; cells
AB Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults. It is characterized by a progressive, fatal brain and liver disease. This syndrome has been associated with mutations in POLG, the gene encoding the mitochondrial DNA polymerase (pol gamma). Most patients with Alpers syndrome have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the POLG locus. POLG is a nuclear-encoded gene whose protein product is imported into mitochondria, where it is essential for mtDNA replication and repair. We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop/A467T. The E873stop mutation produces a premature termination codon (TAG) in exon 17. The A467T mutation produces a threonine to alanine substitution at a highly conserved site in exon 7. The allele bearing the stop codon (E873-TAG) is predicted to produce a truncated, catalytically inactive polymerase. However, only full-length pol gamma protein was detected by Western blot analysis. Here, we show that transcripts containing this stop codon undergo nonsense-associated alternative splicing and nonsense-mediated decay. More than 95% of the functional POLG mRNA was derived from the allele bearing the A467T mutation and less than 5% contained the E873stop mutation. These events ensured that virtually all POLG protein in the cell was expressed from the A467T allele. Therefore, the Alpers phenotype in this patient was a consequence of a single-copy gene dose of the A467T allele, and selective elimination of transcripts bearing the E873stop mutation. Published by Elsevier B.V.
C1 NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
   Univ Calif San Diego, Dept Med, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
   Univ Calif San Diego, Dept Pediat, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego; University of California System; University of California San Diego
RP NIEHS, Mol Genet Lab, NIH, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU Intramural NIH HHS Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5
   Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403
   Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5
   Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maquat LE, 2002, GENE DEV, V16, P1743, DOI 10.1101/gad.1014502
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   NGUYEN KV, 2005, IN PRESS NEUROLOGY, V65, P0
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Usuki F, 2004, ANN NEUROL, V55, P740, DOI 10.1002/ana.20107
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 30
TC 37
Z9 41
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-7864
EI 1568-7856
J9 DNA REPAIR
JI DNA Repair
PD DEC 8
PY 2005
VL 4
IS 12
BP 1381
EP 1389
DI 10.1016/j.dnarep.2005.08.010
PG 9
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 994NP
UT WOS:000234038800007
PM 16181814
DA 2024-11-01
ER

PT J
AU Okulla, T
   Kunz, WS
   Klockgether, T
   Schröder, R
   Kornblum, C
AF Okulla, T
   Kunz, WS
   Klockgether, T
   Schröder, R
   Kornblum, C
TI Diagnostic value of mitochondrial DNA mutation analysis in juvenile unilateral ptosis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID diseases; features
AB Purpose: To highlight the diagnostic relevance of mitochondrial DNA ( mtDNA) mutation analysis in acquired juvenile unilateral upper eyelid ptosis. Methods: A 13-year-old boy presented with acquired, slowly progressive unilateral ptosis. We performed ophthalmological and neurological examinations, laboratory testing, skeletal muscle biopsy including histological and histochemical investigations, biochemical analysis of respiratory chain enzymes in skeletal muscle homogenate and molecular genetic testing of skeletal muscle DNA. Results: Though clinical, laboratory, histological and biochemical analyses did not reveal any hints suggesting a mitochondrial cytopathy, molecular genetic testing by Southern blot analysis of total DNA from skeletal muscle tissue showed a 5.8 kb mtDNA deletion thus proving the diagnosis of mitochondrial chronic progressive external ophthalmoplegia ( CPEO). Conclusions: In patients with unexplained acquired juvenile unilateral ptosis, an underlying mitochondrial cytopathy should be considered even in cases of inconspicuous ancillary examinations comprising skeletal muscle histology and biochemistry. To establish the diagnosis, molecular genetic testing of DNA derived from skeletal muscle tissue is essential in those patients.
C1 Univ Bonn, Dept Neurol, D-53105 Bonn, Germany.
   Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Univ Bonn, Dept Neurol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM cornelia.kornblum@ukb.uni-bonn.de
CR Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   DiMauro S, 2001, SEMIN NEUROL, V21, P251, DOI 10.1055/s-2001-17942
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Goetz C, 1999, TXB CLIN NEUROLOGY, V0, P0
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Simon DK, 1999, ANNU REV MED, V50, P111
   Von Graefe A, 1867, SYMPTOMENLEHRE AUGEN, V0, P0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 10
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR 15
PY 2005
VL 243
IS 4
BP 380
EP 382
DI 10.1007/s00417-004-1000-1
PG 3
WC Ophthalmology
SC Ophthalmology
GA 922RW
UT WOS:000228856700016
PM 15864628
DA 2024-11-01
ER

PT J
AU Kuo, WW
   Chu, CY
   Wu, CH
   Lin, JA
   Liu, JY
   Ying, TH
   Lee, SD
   Hsieh, YH
   Chu, CH
   Lin, DY
   Hsu, HH
   Huang, CY
AF Kuo, WW
   Chu, CY
   Wu, CH
   Lin, JA
   Liu, JY
   Ying, TH
   Lee, SD
   Hsieh, YH
   Chu, CH
   Lin, DY
   Hsu, HH
   Huang, CY
TI The profile of cardiac cytochrome <i>c</i> oxidase (COX) expression in an accelerated cardiac-hypertrophy model
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE cytochrome c oxidase (COX); complete coarctation; cardiac hypertrophy; genetically hypertensive rats
ID dilated cardiomyopathy; mitochondrial-dna; gene-expression; heart; deficiency; pressure; rats; mutation; muscle; mtdna
AB The contribution of the mitochondrial components, the main source of energy for the cardiac hypertrophic growth induced by pressure overload, is not well understood. In the present study, complete coarctation of abdominal aorta was used to induce the rapid development of cardiac hypertrophy in rats. One to two days after surgery, we observed significantly higher blood pressure and cardiac hypertrophy, which remained constantly high afterwards. We found an early increased level of cytochrome c oxidase ( COX) mRNA determined by in-situ hybridization and dot blotting assays in the hypertrophied hearts, and a drop to the baseline 20 days after surgery. Similarly, mitochondrial COX protein level and enzyme activity increased and, however, dropped even lower than baseline 20 days following surgery. In addition, in natural hypertension- induced hypertrophic hearts in genetically hypertensive rats, the COX protein was significantly lower than in normotensive rats. Taken together, the lower efficiency of mitochondrial activity in the enlarged hearts of long-term complete coarcted rats or genetically hypertensive rats could be, at least partially, the cause of hypertensive cardiac disease. Additionally, the rapid complete coarctation-induced cardiac hypertrophy was accompanied by a disproportionate COX activity increase, which was suggested to maintain the cardiac energy-producing capacity in overloaded hearts.
C1 Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan.
   Chung Shan Med Univ, Sch Appl Chem, Taichung, Taiwan.
   Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan.
   Chung Shan Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan.
   Chung Shan Med Univ Hosp, Sch Phys Therapy, Taichung, Taiwan.
   Mackay Mem Hosp, Div Colorectal Surg, Taipei, Taiwan.
   China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; National Chung Hsing University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; Mackay Memorial Hospital; China Medical University Taiwan
RP Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan.
EM chuang1@csmu.edu.tw
CR BJORNTORP P, 1987, EUR HEART J, V8, P71, DOI 10.1093/eurheartj/8.suppl_B.71
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   DARLEYUSMAR VM, 1983, P NATL ACAD SCI-BIOL, V80, P5103, DOI 10.1073/pnas.80.16.5103
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Huang CY, 2003, CELL BIOCHEM FUNCT, V21, P355, DOI 10.1002/cbf.1040
   Huang CY, 1998, GENET ANAL-BIOMOL E, V14, P109, DOI 10.1016/S1050-3862(98)00003-5
   Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0
   Kunz WS, 2000, J BIOL CHEM, V275, P27741
   Leary SC, 2002, AM J PHYSIOL-HEART C, V283, PH540, DOI 10.1152/ajpheart.00032.2002
   LEGATO MJ, 1984, EUR HEART J, V5, P251, DOI 10.1093/eurheartj/5.suppl_F.251
   Lin CS, 2003, RES VET SCI, V74, P219, DOI 10.1016/S0034-5288(02)00189-3
   Minieri M, 2003, MOL CELL BIOCHEM, V252, P73, DOI 10.1023/A:1025542731335
   MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13
   Moslemi AR, 2000, CARDIOLOGY, V94, P68, DOI 10.1159/000007049
   NISHIO ML, 1995, CAN J PHYSIOL PHARM, V73, P630, DOI 10.1139/y95-080
   Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0
   Ruppert V, 2004, BIOCHEM BIOPH RES CO, V318, P535, DOI 10.1016/j.bbrc.2004.04.061
   SMITH L, 1955, METHODS BIOCHEM ANAL, V2, P427, DOI 10.1002/9780470110188.ch13
   Stanley WC, 2000, CARDIOVASC RES, V45, P805, DOI 10.1016/S0008-6363(99)00419-8
   STORRIE B, 1990, METHOD ENZYMOL, V182, P203
   Tanji K, 2000, BRAIN PATHOL, V10, P422
   Tokoro T, 1996, CLIN EXP HYPERTENS, V18, P595, DOI 10.3109/10641969609081769
   Wanagat J, 2002, J MOL CELL CARDIOL, V34, P17, DOI 10.1006/jmcc.2001.1483
   WHITE CR, 1990, CARDIOVASC RES, V24, P953, DOI 10.1093/cvr/24.12.953
   WIESNER RJ, 1994, AM J PHYSIOL, V267, PC229, DOI 10.1152/ajpcell.1994.267.1.C229
NR 25
TC 12
Z9 15
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD JUL 15
PY 2005
VL 12
IS 4
BP 601
EP 610
DI 10.1007/s11373-005-7373-2
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 985IR
UT WOS:000233371300003
PM 16132109
DA 2024-11-01
ER

PT J
AU Durham, SE
   Bonilla, E
   Samuels, DC
   DiMauro, S
   Chinnery, PF
AF Durham, SE
   Bonilla, E
   Samuels, DC
   DiMauro, S
   Chinnery, PF
TI Mitochondrial DNA copy number threshold in mtDNA depletion myopathy
SO NEUROLOGY
LA English
DT Article
ID thymidine kinase; mutations; gene; deficiency
AB The authors measured the absolute amount of mitochondrial DNA ( mtDNA) within single muscle fibers from two patients with thymidine kinase 2 (TK2) deficiency and two healthy controls. TK2 deficient fibers containing more than 0.01 mtDNA/mu m(3) had residual cytochrome c oxidase ( COX) activity. This defines the minimum amount of wild-type mtDNA molecules required to maintain COX activity in skeletal muscle and provides an explanation for the mosaic histochemical pattern seen in patients with mtDNA depletion syndrome.
C1 Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
C3 Newcastle University - UK; Columbia University; Virginia Polytechnic Institute & State University
RP Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU NICHD NIH HHS [HD32062] Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
NR 8
TC 40
Z9 43
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 9
PY 2005
VL 65
IS 3
BP 453
EP 455
DI 10.1212/01.wnl.0000171861.30277.88
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 953HM
UT WOS:000231067200022
PM 16087914
DA 2024-11-01
ER

PT J
AU Bannwarth, S
   Procaccio, V
   Paquis-Flucklinger, V
AF Bannwarth, S
   Procaccio, V
   Paquis-Flucklinger, V
TI Surveyor™ nuclease:: A new strategy for a rapid identification of heteroplasmic mitochondrial DNA mutations in patients with respiratory chain defects
SO HUMAN MUTATION
LA English
DT Article
DE mtDNA; surveyor endonuclease; heteroplasmic mutation; molecular screening; respiratory chain defects
ID diabetes secondary; genome; disorders; deletions; sequence; cardiomyopathy; variant; muscle; region; assay
AB Molecular analysis of mitochondrial DNA (mtDNA) is a critical step in diagnosis and genetic counseling of respiratory chain defects. No fast method is currently available for the identification of unknown mtDNA point mutations. We have developed a new strategy based on complete mtDNA PCR amplification followed by digestion with a mismatch-specific DNA endonuclease, Surveyor" Nuclease. This enzyme, a member of the CEL nuclease family of plant DNA endonucleases, cleaves double-strand DNA at any mismatch site including base substitutions and small insertions/deletions. After digestion, cleavage products are separated and analyzed by agarose gel electrophoresis. The size of the digestion products indicates the location of the mutation, which is then confirmed and characterized by sequencing. Although this method allows the analysis of 2 kb mtDNA amplicons and the detection of multiple mutations within the same fragment, it does not lead to the identification of homoplasmic base substitutions. Homoplasmic pathogenic mutations have been described. Nevertheless, most homoplasmic base substitutions are neutral polymorphisms while deleterious mutations are typically heteroplasmic. Here, we report that this method can be used to detect mtDNA mutations such as m.3243A > G tRNA(Leu) and m.14709T > C tRNA(Glu) even when they are present at levels as low as 3% in DNA samples derived from patients with respiratory chain defects. Then, we tested five patients suffering from a mitochondrial respiratory chain defect and we identified a variant (m16189T > C) in two of them, which was previously associated with susceptibility to diabetes and cardiomyopathy. In conclusion, this method can be effectively used to rapidly and completely screen the entire human mitochondrial genome for heteroplasmic mutations and in this context represents an important advance for the diagnosis of mitochondrial diseases. (c) 2005 Wiley-Liss, Inc.
C1 CHU Nice, Hop Archet 2, Dept Med Genet, F-06202 Nice, France.
   Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA USA.
   Univ Nice, Sch Med, CNRS, FRE,UNSA 2720, Sophia Antipolis, France.
C3 CHU Nice; University of California System; University of California Irvine; Centre National de la Recherche Scientifique (CNRS); Universite Cote d'Azur
RP CHU Nice, Hop Archet 2, Dept Med Genet, 151,Route St Antoine Ginestiere,BP 3079, F-06202 Nice, France.
EM paquis@unice.fr
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Barros F, 1997, ELECTROPHORESIS, V18, P52, DOI 10.1002/elps.1150180110
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   den Dunnen JT, 2003, HUM MUTAT, V22, P181, DOI 10.1002/humu.10262
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Hao HL, 1997, AM J HUM GENET, V60, P1363, DOI 10.1086/515474
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   Kulinski J, 2000, BIOTECHNIQUES, V29, P44, DOI 10.2144/00291bm07
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Narbonne H, 2001, EUR J ENDOCRINOL, V145, P541, DOI 10.1530/eje.0.1450541
   Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597
   Paul R, 1996, TRENDS GENET, V12, P131
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Qiu P, 2004, BIOTECHNIQUES, V36, P702, DOI 10.2144/04364PF01
   ROTIG A, 1989, LANCET, V1, P902
   Scaffino MF, 2004, TRANSGENICS, V4, P157
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   VIALETTES B, 1995, DIABETES CARE, V18, P1023, DOI 10.2337/diacare.18.7.1023
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 35
TC 59
Z9 62
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD JUN 15
PY 2005
VL 25
IS 6
BP 575
EP 582
DI 10.1002/humu.20177
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 930ZX
UT WOS:000229456700009
PM 15880407
DA 2024-11-01
ER

PT J
AU Blakely, EL
   Mitchell, AL
   Fisher, N
   Meunier, B
   Nijtmans, LG
   Schaefer, AM
   Jackson, MJ
   Turnbull, DM
   Taylor, RW
AF Blakely, EL
   Mitchell, AL
   Fisher, N
   Meunier, B
   Nijtmans, LG
   Schaefer, AM
   Jackson, MJ
   Turnbull, DM
   Taylor, RW
TI A mitochondrial cytochrome <i>b</i> mutation causing severe respiratory chain enzyme deficiency in humans and yeast
SO FEBS JOURNAL
LA English
DT Article
DE mitochondrial DNA (mtDNA); complex III; complex I; cytochrome b; yeast mutants
ID complex-iii deficiency; progressive exercise intolerance; stop-codon mutation; missense mutation; human-disease; saccharomyces-cerevisiae; mammalian mitochondria; dna mutations; gene; patient
AB Whereas the majority of disease-related mitochondrial DNA mutations exhibit significant biochemical and clinical heterogeneity, mutations within the mitochondrially encoded human cytochrome b gene (MTCYB) are almost exclusively associated with isolated complex III deficiency in muscle and a clinical presentation involving exercise intolerance. Recent studies have shown that a small number of MTCYB mutations are associated with a combined enzyme complex defect involving both complexes I and III, on account of the fact that an absence of assembled complex III results in a dramatic loss of complex I, confirming a structural dependence between these two complexes. We present the biochemical and molecular genetic studies of a patient with both muscle and brain involvement and a severe reduction in the activities of both complexes I and III in skeletal muscle due to a novel mutation in the MTCYB gene that predicts the substitution (Arg318Pro) of a highly conserved amino acid. Consistent with the dramatic biochemical defect, Western blotting and BN-PAGE experiments demonstrated loss of assembled complex I and III subunits. Biochemical studies of the equivalent amino-acid substitution (Lys319Pro) in the yeast enzyme showed a loss of enzyme activity and decrease in the steady-state level of bc(1) complex in the mutant confirming pathogenicity.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England.
   Radboud Univ Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Nijmegen, Netherlands.
   Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; University of London; University College London; Radboud University Nijmegen; Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008
   Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444
   Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200
   Bruno C, 2003, MUSCLE NERVE, V28, P508, DOI 10.1002/mus.10429
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053
   Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200
   Fisher N, 2004, EUR J BIOCHEM, V271, P1292, DOI 10.1111/j.1432-1033.2004.04036.x
   Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x
   Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003
   Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Lamantea E, 2002, NEUROMUSCULAR DISORD, V12, P49, DOI 10.1016/S0960-8966(01)00244-9
   LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626
   Mancuso M, 2003, J NEUROL SCI, V209, P61, DOI 10.1016/S0022-510X(02)00462-8
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Meunier B, 2001, BIOCHEM J, V354, P407, DOI 10.1042/0264-6021:3540407
   *MITOMAP, 2005, HUM MIT GEN, V0, P0
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Valnot I, 1999, HUM GENET, V104, P460, DOI 10.1007/s004390050988
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
NR 37
TC 78
Z9 87
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-464X
EI 
J9 FEBS J
JI FEBS J.
PD JUL 15
PY 2005
VL 272
IS 14
BP 3583
EP 3592
DI 10.1111/j.1742-4658.2005.04779.x
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 942PA
UT WOS:000230293100009
PM 16008558
DA 2024-11-01
ER

PT J
AU Young, TJ
   Shah, AK
   Lee, MH
   Hayes, DL
AF Young, TJ
   Shah, AK
   Lee, MH
   Hayes, DL
TI Kearns-Sayre syndrome: A case report and review of cardiovascular complications
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Review
DE Kearns-Sayre syndrome; conduction defects; cardiac pacing
ID progressive external ophthalmoplegia; mitochondrial-dna deletions; complete heart-block; pacemaker implantation; pyruvate metabolism; cardiac involvement; coenzyme-q10; improvement; guidelines; conduction
AB Kearns-Sayre syndrome (KSS) is a rare genetic abnormality. Classified as a mitochondrial cytopothy, the primary pathology of this syndrome is a disturbance of mitochondrial DNA, which codes for the proteins required for the respiratory chain reaction. Onset occurs before age 20, and is manifest as chronic progressive external ophthalmoplegia and retinal degeneration. Management issues of KSS include prophylactic cardiac pacing for conduction defects, which has been shown to improve survival. Other clinical considerations relate to dietary supplements to attempt to control the progressive effects of the disease.
C1 Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA.
   Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 1TN, England.
   Raffles Med Grp, Singapore, Singapore.
   Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Mayo Clinic
RP Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.
EM dhayes@mayo.edu
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ANAN R, 1992, EUR HEART J, V13, P1718, DOI 10.1093/oxfordjournals.eurheartj.a060129
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BRESOLIN N, 1988, NEUROLOGY, V38, P892, DOI 10.1212/WNL.38.6.892
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   Choi C, 2000, YONSEI MED J, V41, P676, DOI 10.3349/ymj.2000.41.5.676
   CLARK DS, 1975, CHEST, V68, P727, DOI 10.1378/chest.68.5.727
   DeCoo IFM, 1997, J NEUROL SCI, V149, P37, DOI 10.1016/S0022-510X(97)05366-5
   Fromenty B, 1997, AM J MED GENET, V71, P443, DOI 10.1002/(SICI)1096-8628(19970905)71:4<443::AID-AJMG14>3.0.CO;2-G
   GALLASTEGUI J, 1987, AM J CARDIOL, V60, P385, DOI 10.1016/0002-9149(87)90255-4
   Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325
   Gregoratos Gabriel, 2002, CIRCULATION, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   Hayes DL, 1998, AM J CARDIOL, V82, P1082
   Hayes DL, 2001, PACE 2, V24, P576
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   OGASAHARA S, 1985, NEUROLOGY, V35, P372, DOI 10.1212/WNL.35.3.372
   POLAK PE, 1989, EUR HEART J, V10, P281, DOI 10.1093/oxfordjournals.eurheartj.a059477
   REMES AM, 1992, BRIT HEART J, V68, P408
   ROBERTS NK, 1979, AM J CARDIOL, V44, P1396, DOI 10.1016/0002-9149(79)90459-4
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 23
TC 18
Z9 24
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0147-8389
EI 1540-8159
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD MAY 15
PY 2005
VL 28
IS 5
BP 454
EP 457
DI 10.1111/j.1540-8159.2005.40049.x
PG 4
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 927LM
UT WOS:000229195400017
PM 15869681
DA 2024-11-01
ER

PT J
AU Jakupciak, JP
   Wang, W
   Markowitz, ME
   Ally, D
   Coble, M
   Srivastava, S
   Maitra, A
   Barker, PE
   Sidransky, D
   O'Connell, CD
AF Jakupciak, JP
   Wang, W
   Markowitz, ME
   Ally, D
   Coble, M
   Srivastava, S
   Maitra, A
   Barker, PE
   Sidransky, D
   O'Connell, CD
TI Mitochondrial DNA as a cancer biomarker
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID mononucleotide repeat; prostate-cancer; mtdna mutations; primary tumors; genome; rearrangements; sequence; brain; muscle; loop
AB As part of a national effort to identify biomarkers for the early detection of cancer, we developed a rapid and high-throughput sequencing protocol for the detection of sequence variants in mitochondrial DNA. Here, we describe the development and implementation of this protocol for clinical samples. Heteroplasmic and homoplasmic sequence variants occur in the mitochondrial genome in patient tumors. We identified these changes by sequencing mitochondrial DNA obtained from tumors and blood from the same individual. We confirmed previously identified primary lung tumor changes and extended these findings in a small patient cohort. Eight sequence variants were identified in stage I to stage IV tumor samples. Two of the sequence variants identified (22%) were found in the D-loop region, which accounts for 6.8% of the mitochondrial genome. The other sequence variants were distributed throughout the coding region. in the forensic community, the sequence variations used for identification are localized to the D-loop region because this region appears to have a higher rate of mutation. However, in lung tumors the majority of sequence variation occurred in the coding region. Hence, incomplete mitochondrial genome sequencing, designed to scan discrete portions of the genome, misses potentially important sequence variants associated with cancer or other diseases.
C1 NIST, Div Biotechnol, Gaithersburg, MD 20899 USA.
   NCI, Early Detect Res Network, Rockville, MD USA.
   Geocenters Inc, Newton, MA USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 National Institute of Standards & Technology (NIST) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Geo-Centers Inc.; Johns Hopkins University
RP NIST, Div Biotechnol, 100 Bur Dr,MS 8311, Gaithersburg, MD 20899 USA.
EM johnj@nist.gov
FU NCI NIH HHS [Y1CN010309, Y1CN2020] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Attardi G, 2002, MITOCHONDRION, V2, P27, DOI 10.1016/S1567-7249(02)00032-6
   BAGGETTO LG, 1993, EUR J CANCER, V29A, P156, DOI 10.1016/0959-8049(93)90598-A
   BANDY B, 1990, FREE RADIC BIOL MED, V10, P515
   Barker PE, 2003, ANN NY ACAD SCI, V983, P142, DOI 10.1111/j.1749-6632.2003.tb05969.x
   Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6
   Chen JJZ, 2002, CANCER RES, V62, P6470
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Copeland WC, 2002, CANCER INVEST, V20, P557, DOI 10.1081/CNV-120002155
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Ha PK, 2002, CLIN CANCER RES, V8, P2260
   Hibi K, 2001, INT J CANCER, V94, P429, DOI 10.1002/ijc.1480
   Hirsch FR, 2001, CLIN CANCER RES, V7, P5
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Jazwinski SM, 2000, TRENDS GENET, V16, P506, DOI 10.1016/S0168-9525(00)02119-3
   Jerónimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646
   Jones JB, 2001, CANCER RES, V61, P1299
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Melov S, 1999, NEUROBIOL AGING, V20, P565, DOI 10.1016/S0197-4580(99)00092-5
   Meyer S, 2003, MOL BIOL EVOL, V20, P182, DOI 10.1093/molbev/msg019
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   NEUBERT D, 1981, ARCH TOXICOL, V48, P89, DOI 10.1007/BF00310481
   Nomoto S, 2002, CLIN CANCER RES, V8, P481
   Okochi O, 2002, CLIN CANCER RES, V8, P2875
   Opdal SH, 2002, PEDIATR NEUROL, V27, P23, DOI 10.1016/S0887-8994(02)00384-3
   Parrella P, 2003, CANCER LETT, V190, P73, DOI 10.1016/S0304-3835(02)00578-5
   Parrella P, 2001, CANCER RES, V61, P7623
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Richard SM, 2000, CANCER RES, V60, P4231
   Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015
   SCHUMACHER HR, 1973, LANCET, V2, P327
   SHAY JW, 1992, MUTAT RES, V275, P227, DOI 10.1016/0921-8734(92)90026-L
   Suzuki M, 2003, CLIN CANCER RES, V9, P5636
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Toescu EC, 2000, CELL CALCIUM, V28, P329, DOI 10.1054/ceca.2000.0167
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Wallace DC, 1999, P NATL ACAD SCI USA, V96, P1817, DOI 10.1073/pnas.96.5.1817
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 51
TC 70
Z9 86
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD MAY 15
PY 2005
VL 7
IS 2
BP 258
EP 267
DI 10.1016/S1525-1578(10)60553-3
PG 10
WC Pathology
SC Pathology
GA 921AP
UT WOS:000228736900014
PM 15858150
DA 2024-11-01
ER

PT J
AU Jafari, A
   Hosseinpourfaizi, MA
   Houshmand, M
   Ravasi, AA
AF Jafari, A
   Hosseinpourfaizi, MA
   Houshmand, M
   Ravasi, AA
TI Effect of aerobic exercise training on mtDNA deletion in soleus muscle of trained and untrained Wistar rats
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID mitochondrial-dna deletion; skeletal-muscle; human-leukocytes; metabolism; mutations
AB Background: According to the theory of mitochondrial aging, oxidative stress plays a major role in aging and age related degenerative diseases. Since oxygen consumption and reactive oxygen species rate increase during aerobic exercise, we hypothesised that heavy aerobic training could lead to enhanced mitochondrial DNA ( mtDNA) deletion in postmitotic tissues, leading in turn to premature aging and degenerative diseases. Methods: Sixty adult male 2 month old Wistar(14848) rats were divided into six equal groups. Two groups were trained for 3 months by running on a treadmill ( 5 days/week, incline 6 degrees; group 1: 40 m/min, 20 min/day; group 2: 20 m/min, 40 min/ day), while two sedentary groups participated in aerobic exercise only at the end of the study ( incline 6 degrees; group 3: 40 m/min; group 4: 20 m/min). To control for physical and physiological parameters, two groups of untrained animals were killed at the beginning ( group 6) and end ( group 5) of the study. Expand long PCR was used to investigate mtDNA deletion in soleus muscle and a sequencing method was used to confirm the mtDNA deletion break point. Results: Our results did not show any mtDNA deletion in untrained rats or in those that underwent moderate training ( group 2) We only found mtDNA deletion ( 4.6 kb) in the soleus muscle of heavily trained rats ( group 1). Conclusions: These results demonstrate that one session of aerobic exercise does not cause mtDNA deletion in skeletal muscle. The difference in results between heavy and moderate aerobic training may be due to low work rate or up-regulation of inducible antioxidant systems in moderate training.
C1 Tabriz Univ, Dept Phys Educ & Sport Sci, Tabriz 98, Iran.
   Natl Res Ctr Genet Engn & Biotechnol, Tehran, Iran.
C3 University of Tabriz
RP Tabriz Univ, Dept Phys Educ & Sport Sci, 29 Bahman St, Tabriz 98, Iran.
EM ajafari@tabrizu.ac.ir
CR AMES BN, 1991, OXIDATIVE DAMAGE & REPAIR, V0, P181
   ARMSTRONG RB, 1983, J APPL PHYSIOL, V55, P518, DOI 10.1152/jappl.1983.55.2.518
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Hartmann A, 1998, FREE RADICAL BIO MED, V24, P245, DOI 10.1016/S0891-5849(97)00249-9
   Iwai K, 2003, EUR J APPL PHYSIOL, V88, P515, DOI 10.1007/s00421-002-0745-7
   Jackson MJ, 1994, EXERCISE OXYGEN TOXI, V0, P49
   KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W
   La JH, 2000, FREE RADICALS EXERCI, V0, P35
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LAWLER JM, 1993, MED SCI SPORT EXER, V25, P1259
   Leeuwenburgh C, 1997, AM J PHYSIOL-REG I, V272, PR363, DOI 10.1152/ajpregu.1997.272.1.R363
   LINNANE AW, 1992, MUTAT RES, V275, P195, DOI 10.1016/0921-8734(92)90023-I
   McCurdy DT, 1996, J APPL PHYSIOL, V81, P326, DOI 10.1152/jappl.1996.81.1.326
   MEYDANI M, 1993, FREE RADICALS AGING, V0, P183
   MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x
   Ohishi S, 1997, CLIN EXP PHARMACOL P, V24, P326, DOI 10.1111/j.1440-1681.1997.tb01196.x
   Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425
   OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z
   Poulsen HE, 1996, J SPORT SCI, V14, P343, DOI 10.1080/02640419608727720
   POWERS SK, 1994, AM J PHYSIOL, V266, PR375, DOI 10.1152/ajpregu.1994.266.2.R375
   Radák Z, 2002, PFLUG ARCH EUR J PHY, V445, P273, DOI 10.1007/s00424-002-0918-6
   RADAK Z, 2000, FREE RADICALS EXERCI, V0, P177
   REZNICK AZ, 2000, FREE RADICALS EXERCI, V0, P73
   RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4
   Sakai Y, 1999, MUSCLE NERVE, V22, P258, DOI 10.1002/(SICI)1097-4598(199902)22:2<258::AID-MUS15>3.0.CO;2-1
   Sambrook J, 1989, MOLECULAR CLONING, V0, P0
   SEN CK, 1992, J APPL PHYSIOL, V73, P1265, DOI 10.1152/jappl.1992.73.4.1265
   Sumida S, 1997, FREE RADICAL RES, V27, P607, DOI 10.3109/10715769709097864
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
NR 33
TC 19
Z9 19
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
EI 1473-0480
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD AUG 1
PY 2005
VL 39
IS 8
BP 517
EP 520
DI 10.1136/bjsm.2004.014068
PG 4
WC Sport Sciences
SC Sport Sciences
GA 949AA
UT WOS:000230756000011
PM 16046334
DA 2024-11-01
ER

PT J
AU Minnerop, M
   Kornblum, C
   Joe, AY
   Tatsch, K
   Kunz, WS
   Klockgether, T
   Wüllner, U
   Reinhardt, MJ
AF Minnerop, M
   Kornblum, C
   Joe, AY
   Tatsch, K
   Kunz, WS
   Klockgether, T
   Wüllner, U
   Reinhardt, MJ
TI Dopamine transporter SPECT in patients with mitochondrial disorders
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID progressive external ophthalmoplegia; parkinsons-disease; deletions; dna
AB Background: Mitochondrial disorders may affect basal ganglia function. In addition, decreased activity of complex I of the mitochondrial electron transport chain has been linked to the pathogenesis of dopaminergic cell loss in Parkinson's disease. Objective: To investigate the dopaminergic system in patients with known mitochondrial disorders and complex I deficiency. Methods: Dopamine transporter density was studied in 10 female patients with mitochondrial complex I deficiency by I-123-FP-CIT (N-beta-fluoropropyl-2beta-carbomethyl-3beta-(4-iodophenyl)nortropane) SPECT. Results: No differences in I-123-FP-CIT striatal binding ratios were observed and no correlation of the degree of complex I deficiency and striatal binding ratios could be detected. Conclusions: These data argue against the possibility that mitochondrial complex I deficiency by itself is sufficient to elicit dopaminergic cell loss.
C1 Univ Bonn, Dept Neurol, D-53105 Bonn, Germany.
   Univ Bonn, Dept Nucl Med, D-5300 Bonn, Germany.
   Univ Bonn, Dept Epileptol, D-5300 Bonn, Germany.
   Univ Munich, Dept Nucl Med, Munich, Germany.
C3 University of Bonn; University of Bonn; University of Bonn; University of Munich
RP Univ Bonn, Dept Neurol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM wuellner@uni-bonn.de
CR Benamer HTS, 2000, MOVEMENT DISORD, V15, P503, DOI 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V
   Berendse HW, 2001, ANN NEUROL, V50, P34, DOI 10.1002/ana.1049
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Booij J, 1997, J NEUROL NEUROSUR PS, V62, P133, DOI 10.1136/jnnp.62.2.133
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   CHECCARELLI N, 1994, J NEUROL SCI, V123, P74, DOI 10.1016/0022-510X(94)90206-2
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279
   LERA G, 1994, MOVEMENT DISORD, V9, P642, DOI 10.1002/mds.870090610
   Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Radau P, 2003, J NUCL MED, V44, P0
   Schapira AHV, 1998, ANN NEUROL, V44, PS89, DOI 10.1002/ana.410440714
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#
   Tissingh G, 1998, J NUCL MED, V39, P1143
NR 19
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JAN 15
PY 2005
VL 76
IS 1
BP 118
EP 120
DI 10.1136/jnnp.2004.040220
PG 3
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 880GQ
UT WOS:000225777400026
PM 15608010
DA 2024-11-01
ER

PT J
AU Hanagasi, HA
   Ayribas, D
   Baysal, K
   Emre, M
AF Hanagasi, HA
   Ayribas, D
   Baysal, K
   Emre, M
TI Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE complex I; complex II/III; complex IV; familial Parkinson's disease; mitochondria; Parkinson's disease
ID electron-transport chain; respiratory-chain; skeletal-muscle; enzyme-activity; alpha-synuclein; platelet mtdna; gene; brain; dna; mutations
AB A possible role of initochondrial respiratory chain dysfunction in the pathogenesis of sporadic Parkinson's disease (PD) has been described. There are only a few reports concerning mitochondriall involvement in familial Parkinson's disease. The present study investigated mitochondrial complex I-IV activity in patients with sporadic and familial PD, compared to controls. Platelets were isolated from venous blood and platelet initochondria were obtained through sonication and differential centrifugation. Complex I, II/III, and IV activities were measured in 17 patients with family history of Parkinson's disease (PDF), 15 patients with sporadic Parkinson disease (PDS), and 17 age-matched, healthy controls. The mitochondrial enzyme activities did not differ significantly between patient groups and controls. In addition, there was no correlation between mitochondrial complex activities and age, severity of disease, or age at onset of disease in the patient groups. In this study, the data indicate no significant differences in mitochondrial complex I-IV activities in PDF and PDS.
C1 Istanbul Univ, Istanbul Fac Med, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey.
   TUBITAK, Res Inst Genet Engn & Biotechnol, Kocaeli, Turkey.
C3 Istanbul University; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
RP Istanbul Univ, Istanbul Fac Med, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey.
EM hasmet@yahoo.com
CR ANDERSON JJ, 1993, J NEUROL NEUROSUR PS, V56, P477, DOI 10.1136/jnnp.56.5.477
   Aomi Y, 2001, BIOCHEM BIOPH RES CO, V280, P265, DOI 10.1006/bbrc.2000.4113
   BARROSO N, 1993, CLIN CHEM, V39, P667
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   Blake CI, 1997, MOVEMENT DISORD, V12, P3, DOI 10.1002/mds.870120103
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   BRAVI D, 1992, MOVEMENT DISORD, V7, P228, DOI 10.1002/mds.870070307
   Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   DAPRADA M, 1994, EXPERIENTIA, V4, P115
   DIDONATO S, 1993, NEUROLOGY, V43, P2262, DOI 10.1212/WNL.43.11.2262
   Fahn S, 1987, RECENT DEVELOPMENTS IN PARKINSONS DISEASE, V0, P153
   Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81
   Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113
   Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207
   Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   KLAWANS HL, 1982, ARCH NEUROL-CHICAGO, V39, P302, DOI 10.1001/archneur.1982.00510170044012
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Krüger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Lansbury PT, 2002, CURR OPIN GENET DEV, V12, P299, DOI 10.1016/S0959-437X(02)00302-7
   Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066
   LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x
   Lodi R, 2002, FREE RADICAL RES, V36, P461, DOI 10.1080/10715760290021324
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858
   Martin MA, 1996, NEUROLOGY, V46, P1343, DOI 10.1212/WNL.46.5.1343
   McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067
   MENA I, 1995, HDB CLIN NEUROLOGY, V36, P217
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   NAKAGAWAHATTORI Y, 1995, J NEUROL SCI, V107, P29
   PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   REICHMANN H, 1994, EUR NEUROL, V34, P263, DOI 10.1159/000117053
   SANDY MS, 1993, MOVEMENT DISORD, V8, P74, DOI 10.1002/mds.870080114
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Schapira AHV, 1997, ANN NEUROL, V41, P556, DOI 10.1002/ana.410410421
   SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2
   Swerdlow RH, 2001, EXP NEUROL, V169, P479, DOI 10.1006/exnr.2001.7674
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Tanner CM, 1997, MOVEMENT DISORDERS N, V0, P137
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   VALENTE EM, 2004, SCIENCE 0415, V0, P0
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
NR 64
TC 36
Z9 43
U1 2
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD APR 15
PY 2005
VL 115
IS 4
BP 479
EP 493
DI 10.1080/00207450590523017
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 909RJ
UT WOS:000227878100004
PM 15809215
DA 2024-11-01
ER

PT J
AU Caer, M
   Viala, K
   Levy, R
   Maisonobe, T
   Chochon, F
   Lombès, A
   Agid, Y
AF Caer, M
   Viala, K
   Levy, R
   Maisonobe, T
   Chochon, F
   Lombès, A
   Agid, Y
TI Adult-onset chorea and mitochondrial cytopathy
SO MOVEMENT DISORDERS
LA English
DT Article
DE chorea; mitochondrial cytopathy; mitochondrial DNA; movement disorders
ID bilateral striatal necrosis; movement-disorders; dna mutation; dystonia; disease; gene
AB We report on 2 adult patients presenting with choreic movements as the main clinical feature of mitochondrial cytopathy. One patient exhibited a sensory neuronopathy and ophthalmoplegia. The other had ptosis, a proximal myopathy, and a sensory neuropathy. The diagnosis of mitochondrial cytopathy was established by the presence of ragged red fibers, cytochrome C oxydase-negative fibers, and a defect of the complex IV of the respiratory chain in muscle biopsy. No mutations in mitochondrial DNA were detected. The choreic movements observed in juvenile forms of mitochondrial cytopathy are rarely observed in adults. Although striatal vulnerability is commonly reported in patients with mitochondrial disorders, the mechanism by which the mitochondrial dysfunction leads to chorea is not known. (c) 2004 Movement Disorder Society.
C1 Grp Hosp Pitie Salpetriere, Federat Neurol, F-75013 Paris, France.
   Grp Hosp Pitie Salpetriere, Neurophysiol Lab, F-75013 Paris, France.
   Grp Hosp Pitie Salpetriere, INSERM, U523, F-75013 Paris, France.
C3 Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP
RP Grp Hosp Pitie Salpetriere, Federat Neurol, Blvd Hop, F-75013 Paris, France.
EM richard.levy@psl.ap-hop-paris.fr
CR DEMEIRLEIR L, 1994, ANN NEUROL, V36, P522
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Hanna MG, 1997, CURR OPIN NEUROL, V10, P351, DOI 10.1097/00019052-199708000-00012
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   LERA G, 1994, MOVEMENT DISORD, V9, P642, DOI 10.1002/mds.870090610
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Sudarsky L, 1999, MOVEMENT DISORD, V14, P488, DOI 10.1002/1531-8257(199905)14:3<488::AID-MDS1017>3.0.CO;2-4
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   TRUONG DD, 1990, MOVEMENT DISORD, V5, P109, DOI 10.1002/mds.870050204
   ZHOU L, 1997, J NEUROSCI, V17, P1746
NR 13
TC 12
Z9 12
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 15
PY 2005
VL 20
IS 4
BP 490
EP 492
DI 10.1002/mds.20363
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 918KI
UT WOS:000228540300015
PM 15597339
DA 2024-11-01
ER

PT J
AU Sciacco, M
   Prelle, A
   Fagiolari, G
   Bordoni, A
   Crimi, M
   Di Fonzo, A
   Ciscato, P
   Lamperti, C
   D'Adda, E
   Jann, S
   Bresolin, N
   Comi, GP
   Moggio, M
AF Sciacco, M
   Prelle, A
   Fagiolari, G
   Bordoni, A
   Crimi, M
   Di Fonzo, A
   Ciscato, P
   Lamperti, C
   D'Adda, E
   Jann, S
   Bresolin, N
   Comi, GP
   Moggio, M
TI A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE myoglobinuria; CPT deficiency; mitochondrial disorder; RRFs
ID ii deficiency; identification; rhabdomyolysis; gene
AB A 45-year-old male patient had all episode of acute renal failure with myoglobinuria, myalgias, weakness, and markedly increased serum CK levels. Similar episodes had occurred in the past. Carnitine palmitoyl-transferase II (CPT II) deficiency was documented both biochemically and genetically. Interestingly, muscle biopsy also showed some ragged red fibers (RRF) and complete mitochondrial DNA (mtDNA) sequence disclosed a homoplasmic T3394C point mutation. This mutation is described in Leber's hereditary optic neuropathy (LHON) or in patients with diabetes mellitus. (c) 2005 Elsevier B.V. All rights reserved.
C1 Fdn IRCCS, Osped Maggiore, Policlin Mangiagalli & Regina Elena, Dipartimento Neurosci,Ctr Dino Ferrari, I-20122 Milan, Italy.
   IRCCS, Ist E Medea, Bosisio Parini, LC, Italy.
   Osped Maggiore Niguarda, Div Neurol, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Eugenio Medea
RP Fdn IRCCS, Osped Maggiore, Policlin Mangiagalli & Regina Elena, Dipartimento Neurosci,Ctr Dino Ferrari, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM maurizio.moggio@unimi.it
FU Telethon [GTF02008] Funding Source: Medline
CR CAREY MP, 1987, J NEUROL NEUROSUR PS, V50, P1060, DOI 10.1136/jnnp.50.8.1060
   CRIMI M, 2002, HUM MUTAT, V50, P409
   Engel AGF-AC, 1994, MYOLOGY, V2nd, P0
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Smeets RJP, 2003, J HUM GENET, V48, P8, DOI 10.1007/s100380300001
   TARONI F, 1993, NAT GENET, V4, P314, DOI 10.1038/ng0793-314
   Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053
   Yang BZ, 1998, MOL GENET METAB, V64, P229, DOI 10.1006/mgme.1998.2711
NR 10
TC 11
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2005
VL 239
IS 1
BP 21
EP 24
DI 10.1016/j.jns.2005.07.008
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 989DC
UT WOS:000233652100004
PM 16168441
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Mjosund, KP
   Wanrooij, S
   Lappalainen, I
   Ylikallio, E
   Jalanko, A
   Spelbrink, JN
   Paetau, A
   Suomalainen, A
AF Tyynismaa, H
   Mjosund, KP
   Wanrooij, S
   Lappalainen, I
   Ylikallio, E
   Jalanko, A
   Spelbrink, JN
   Paetau, A
   Suomalainen, A
TI Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE mouse model; progressive external ophthalmoplegia; mitochondrial DNA replication
ID progressive external ophthalmoplegia; dna polymerase; respiratory-chain; crystal-structure; polg mutations; mouse; muscle; gene; t7; cells
AB Defects of mitochondrial DNA (mtDNA) maintenance have recently been associated with inherited neurodegenerative and muscle diseases and the aging process. Twinkle is a nuclear-encoded mtDNA helicase, dominant mutations of which cause adult-onset progressive external ophthalmoplegia (PEO) with multiple mtDNA deletions. We have generated transgenic mice expressing mouse Twinkle with PEO patient mutations. Multiple mtDNA deletions accumulate in the tissues of these mice, resulting in progressive respiratory dysfunction and chronic late-onset mitochondrial disease starting at 1 year of age. The muscles of the mice faithfully replicate all of the key histological, genetic, and biochemical features of PEO patients. Furthermore, the mice have progressive deficiency of cytochrome c oxidase in distinct neuronal populations. These "deletor" mice do not, however, show premature aging, indicating that subtle accumulation of mtDNA deletions and progressive respiratory chain dysfunction are not sufficient to accelerate aging. This model is a valuable tool for therapy development and testing for adult-onset mitochondrial disorders.
C1 Univ Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Neurosci Program, FIN-00290 Helsinki, Finland.
   Inst Med Technol, Tampere 33014, Finland.
   Tampere Univ Hosp, Tampere 33014, Finland.
   Natl Publ Hlth Inst, Dept Mol Med, Helsinki 00290, Finland.
   Univ Helsinki, Haartman Inst, Helsinki 00290, Finland.
   Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00290 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Univ Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
CR Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   Zapala MA, 2005, P NATL ACAD SCI USA, V102, P10357, DOI 10.1073/pnas.0503357102
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 31
TC 259
Z9 296
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 6
PY 2005
VL 102
IS 49
BP 17687
EP 17692
DI 10.1073/pnas.0505551102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 991XU
UT WOS:000233849000028
PM 16301523
DA 2024-11-01
ER

PT J
AU Atilano, SR
   Coskun, P
   Chwa, M
   Jordan, N
   Reddy, V
   Le, K
   Wallace, DC
   Kenney, MC
AF Atilano, SR
   Coskun, P
   Chwa, M
   Jordan, N
   Reddy, V
   Le, K
   Wallace, DC
   Kenney, MC
TI Accumulation of mitochondrial DNA damage in keratoconus corneas
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID hereditary optic neuropathy; human skeletal-muscle; mtdna control-region; hydrogen-peroxide; downs-syndrome; oxidative damage; penetrating keratoplasty; aldehyde dehydrogenase; pathological corneas; alzheimers-disease
AB PURPOSE. To determine whether keratoconus ( KC) corneas have more mitochondrial (mt) DNA damage than do normal corneas. METHODS. Thirty-three normal corneas and 34 KC corneas were studied. Immunohistochemistry for mitochondria-encoded cytochrome c oxidase ( complex IV) subunit 1 (CO-I) and porins was performed. Total DNA was isolated and mtDNA genome amplified by either long-extension -polymerase chain reaction (LX-PCR) or short-extension-PCR (SX-PCR). LX-PCR mtDNA was digested with restriction enzymes to confirm full-length mtDNA amplicon. SX-PCR mtDNA was probed by Southern blot analysis. The T414G mutation was analyzed by peptide nucleic acid directed clamping PCR. Real-time PCR measured the ratio of mtDNA to nuclear (n) DNA. RESULTS. KC corneas had decreased CO-I in areas of corneal thinning. LX-PCR mtDNA digested with restriction enzymes showed expected size bands except for PstI, which showed two additional bands in some KC corneas (2/18). By both LX-PCR ( 7.4 +/- 3.8 vs. 4.3 +/- 2.7, P < 0.04) and SX-PCR (5.5 +/- 0.55 vs. 2.4 +/- 2.0, P < 0.006), KC corneas had an increased number of smaller-sized bands ( representing mtDNA deletions/ mutations) compared with normal corneas. Southern blot analysis of SX-PCR products confirmed their mtDNA origin. The T414G mutation was not detected in either KC or normal corneas. KC corneas showed a trend of lower mtDNA-to-nDNA ratio (26%, P < 0.7) than did normal corneas. CONCLUSIONS. KC corneas exhibit more mtDNA damage than do normal corneas. The previously reported increased oxidative stress and altered integrity of mtDNA may be related to each other and may be important in KC pathogenesis.
C1 Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Orange, CA 92868 USA.
   Univ Calif Irvine, Dept Biol Chem, Orange, CA 92868 USA.
   Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Orange, CA 92868 USA.
   Univ Calif Irvine, Dept Pediat, Orange, CA 92668 USA.
   Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Orange, CA 92668 USA.
   Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Cedars Sinai Medical Center
RP Univ Calif Irvine, Med Ctr, Dept Ophthalmol, 101 City Dr,Bldg 55,Room 220, Orange, CA 92868 USA.
EM mkenney@uci.edu
FU NEI NIH HHS [EY06807] Funding Source: Medline
CR AMBROSIO G, 1993, J BIOL CHEM, V268, P18532
   *APPL BIOS, 2001, US B APPL BIOS, V2, P0
   Arbuzova S, 2002, BIOESSAYS, V24, P681, DOI 10.1002/bies.10138
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Behndig A, 2001, INVEST OPHTH VIS SCI, V42, P2293
   Brown DJ, 2004, MOL VIS, V10, P281
   BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9
   BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Christoph R, 1998, RESTOR NEUROL NEUROS, V12, P59
   CIBIS GW, 2001, FUNDAMENTALS PRINCIP, V2, P0
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Cristina Kenney M, 2003, CONT LENS ANTERIOR EYE, V26, P139
   Datta K, 2000, NATL MED J INDIA, V13, P304
   Druzhyna N, 1998, MUTAT RES-DNA REPAIR, V409, P81, DOI 10.1016/S0921-8777(98)00042-1
   GONDHOWIARDJO TD, 1993, CORNEA, V12, P146, DOI 10.1097/00003226-199303000-00010
   GONDHOWIARDJO TD, 1993, CORNEA, V12, P310, DOI 10.1097/00003226-199307000-00006
   Good PF, 1996, AM J PATHOL, V149, P21
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Haugen OH, 2001, ACTA OPHTHALMOL SCAN, V79, P616, DOI 10.1034/j.1600-0420.2001.790613.x
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kenney MC, 1997, CORNEA, V16, P345
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kim JH, 2002, EYE, V16, P710, DOI 10.1038/sj.eye.6700208
   Kim WJ, 1999, EXP EYE RES, V69, P475, DOI 10.1006/exer.1999.0719
   LIN FB, 1995, ARCH BIOCHEM BIOPHYS, V317, P7, DOI 10.1006/abbi.1995.1129
   Liu E, 1997, CORNEA, V16, P414
   LUM JK, 1994, HUM BIOL, V66, P567
   MAMALIS N, 1992, ARCH OPHTHALMOL-CHIC, V110, P1409, DOI 10.1001/archopht.1992.01080220071023
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MELTON T, 1995, AM J HUM GENET, V57, P403
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Ogawa O, 2002, DEV CELL, V2, P255, DOI 10.1016/S1534-5807(02)00139-9
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X
   PHILLIPS CI, 1991, SURV OPHTHALMOL, V35, P463, DOI 10.1016/0039-6257(91)90110-2
   *QIAG INC, 2004, CRIT FACT SUCC REAL, V0, P0
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K
   Rodríguez-Santiago B, 2001, EUR J HUM GENET, V9, P279, DOI 10.1038/sj.ejhg.5200629
   Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5
   Shen J, 2004, NEURON, V43, P301, DOI 10.1016/j.neuron.2004.07.012
   Spector A, 2002, INVEST OPHTH VIS SCI, V43, P3251
   TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421
   van Splunder J, 2004, OPHTHALMOLOGY, V111, P1457, DOI 10.1016/j.ophtha.2003.12.051
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2001, MENT RETARD DEV D R, V7, P158, DOI 10.1002/mrdd.1023
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wallace Douglas C, 1998, BIOFACTORS, V7, P187
   Winkler-Stuck K, 2004, J NEUROL SCI, V220, P41, DOI 10.1016/j.jns.2004.02.003
   Wong V, 1997, PEDIATR NEUROL, V16, P311, DOI 10.1016/S0887-8994(97)00029-5
   YAMADA M, 1991, DNA CELL BIOL, V10, P735, DOI 10.1089/dna.1991.10.735
   Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P
NR 62
TC 91
Z9 100
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR 15
PY 2005
VL 46
IS 4
BP 1256
EP 1263
DI 10.1167/iovs.04-1395
PG 8
WC Ophthalmology
SC Ophthalmology
GA 910DB
UT WOS:000227908900021
PM 15790887
DA 2024-11-01
ER

PT J
AU Yasukawa, T
   Kirino, Y
   Ishii, N
   Holt, IJ
   Jacobs, HT
   Makifuchi, T
   Fukuhara, N
   Ohta, S
   Suzuki, T
   Watanabe, K
AF Yasukawa, T
   Kirino, Y
   Ishii, N
   Holt, IJ
   Jacobs, HT
   Makifuchi, T
   Fukuhara, N
   Ohta, S
   Suzuki, T
   Watanabe, K
TI Wobble modification deficiency in mutant tRNAs in patients with mitochondrial diseases
SO FEBS LETTERS
LA English
DT Article
DE mitochondrial disease; mitochondrial tRNA; patient tissue; post-transcriptional modification; taurine
ID transfer rnaleu(uur) gene; cells lacking mtdna; modification defect; protein-synthesis; lactic-acidosis; wild-type; dna; mutation; myopathy; encephalopathy
AB Point mutations in mitochondrial (mt) tRNA genes are associated with a variety of human mitochondrial diseases. We have shown previously that mt tRNA(Leu(UUR)) with a MELAS A3243G mutation and mt tRNA(Lys) with a MERRF A8344G mutation derived from HeLa background cybrid cells are deficient in normal taurine-containing modifications [tau m(5)(s(2))U; 5-taurinomethyl-(2-thio)uridine] at the anticodon wobble position in both cases. The wobble modification deficiency results in defective translation. We report here wobble modification deficiencies of mutant mt tRNAs from cybrid cells with different nuclear backgrounds, as well as from patient tissues. These findings demonstrate the generality of the wobble modification deficiency in mutant tRNAs in MELAS and MERRF. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan.
   Nippon Med Coll, Grad Sch Med, Dept Biochem & Cell Biol, Inst Dev & Aging Sci, Kanagawa 2118533, Japan.
   MRC Dunn Human Nutr Unit, Cambridge CB2 2XY, England.
   Univ Tampere, Inst Med Technol, FI-33014 Tampere, Finland.
   Univ Tampere, Tampere Univ Hosp, FI-33014 Tampere, Finland.
   Saigata Natl Hosp, Dept Neuropathol, Ohgata Ku, Niigata 9493193, Japan.
   Saigata Natl Hosp, Dept Neurol, Ohgata Ku, Niigata 9493193, Japan.
C3 University of Tokyo; University of Tokyo; Nippon Medical School; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Tampere University; Tampere University; Tampere University Hospital
RP Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM ts@chembio.t.u-tokyo.ac.jp; kwatanab@jbirc.aist.go.jp
FU Medical Research Council [MC_U105663140] Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI
CR Bjork GR, 1995, TRNA, V0, P165
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251
   IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KIRINO Y, 2005, IN PRESS RNA BIOL, V1, P0
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200
   SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki T, 2005, TOP CURR GENET, V12, P23, DOI 10.1007/b106361
   Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200
   WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   Yokoyama Shigeyuki, 1995, P207, V0, P0
NR 35
TC 65
Z9 68
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD MAY 23
PY 2005
VL 579
IS 13
BP 2948
EP 2952
DI 10.1016/j.febslet.2005.04.038
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 931JX
UT WOS:000229482700034
PM 15893315
DA 2024-11-01
ER

PT J
AU Kärppä, M
   Herva, R
   Moslemi, AR
   Oldfors, A
   Kakko, S
   Majamaa, K
AF Kärppä, M
   Herva, R
   Moslemi, AR
   Oldfors, A
   Kakko, S
   Majamaa, K
TI Spectrum of myopathic findings in 50 patients with the 3243A&gt;G mutation in mitochondrial DNA
SO BRAIN
LA English
DT Article
DE mitochondrial myopathies; muscle fibres; ultrastructure; clinical laboratory techniques; MELAS
ID transfer rnaleu(uur) gene; stroke-like episodes; ragged-red fibers; muscle-fibers; skeletal-muscle; hearing impairment; lactic-acidosis; mtdna mutation; point mutation; melas
AB Myopathy is a typical clinical finding among patients with the 3243A > G mutation in mitochondrial DNA (mtDNA), but the variability in such findings has not been properly established. We have previously determined the prevalence of patients with 3243A > G in a defined population in northern Finland and characterized a group of patients who represent a good approximation to a population-based cohort. We report here on examinations performed on patients belonging to this cohort in order to determine the frequency of myopathy and to evaluate the clinical, histological, ultrastructural and single fibre mtDNA variability in muscle involvement. Fifty patients with 3243A > G underwent a thorough structured interview and clinical examination. Muscle histology, ultrastructure and single fibre analysis were examined in a subset of patients. A clinical diagnosis of myopathy was made in 50% of cases [95% confidence interval (CI), 36-64] and abnormalities in muscle histology were found in 72% (95% CI, 55-86). Moderate limb weakness leading to functional impairment was the most common myopathic sign, but mild weakness, ptosis and external ophthalmoplegia could also be found. The presence of intramitochondrial crystals and cytochrome c oxidase (COX)-negative fibres and variation in mitochondrial size and shape were more common in the muscles of the myopathic patients. Longitudinal variations in mutation heteroplasmy were examined in single muscle fibres from two severely affected patients. Although the total variation in mutation heteroplasmy along four ragged red fibres (RRFs) was small, the mutation heteroplasmy in five 10 mu m segments was clearly lower (median 68%, range 64-74%) than that in the neighbouring segments. There were also segments with deviant mutation load in histologically normal fibres in one patient. The highest incidence of myopathy was in the fifth decade of life, but, apart from age, no other clinical variables such as gender, muscle heteroplasmy, physical inactivity or diabetes were associated with an increased risk of myopathy. The clinical presentation of myopathy is highly variable in patients with 3243A > G.
C1 Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   Oulu Univ Hosp, Dept Internal Med, Oulu, Finland.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Univ Turku, Dept Neurol, FIN-20520 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu; Sahlgrenska University Hospital; University of Turku
RP Univ Oulu, Dept Neurol, POB 5000, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
CR BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Brierley EJ, 1997, ANN NEUROL, V41, P114, DOI 10.1002/ana.410410120
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Cwik Valerie A, 1996, P359, V0, P0
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Katirji B, 1900, P3, V0, P0
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MATSUOKA T, 1991, J NEUROL SCI, V106, P193, DOI 10.1016/0022-510X(91)90257-8
   MENDELL JR, 1990, MUSCLE NERVE S, V13, P16
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORGANHUGHES JA, 1994, MYOLOGY, V0, P1610
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 31
TC 28
Z9 29
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD AUG 15
PY 2005
VL 128
IS 
BP 1861
EP 1869
DI 10.1093/brain/awh515
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 948OB
UT WOS:000230724500014
PM 15857931
DA 2024-11-01
ER

PT J
AU Kazuno, AA
   Munakata, K
   Mori, K
   Tanaka, M
   Nanko, S
   Kunugi, H
   Umekage, T
   Tochigi, M
   Kohda, K
   Sasaki, T
   Akiyama, T
   Washizuka, S
   Kato, N
   Kato, T
AF Kazuno, AA
   Munakata, K
   Mori, K
   Tanaka, M
   Nanko, S
   Kunugi, H
   Umekage, T
   Tochigi, M
   Kohda, K
   Sasaki, T
   Akiyama, T
   Washizuka, S
   Kato, N
   Kato, T
TI Mitochondrial DNA sequence analysis of patients with 'atypical psychosis'
SO PSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
DE association study; 'atypical psychosis'; genetics; mitochondrial DNA; mitochondrial myopathy
ID genome database; transmission; disorder; mitomap; melas; polymorphisms; disease; update; japan; brain
AB Although classical psychopathological studies have shown the presence of an independent diagnostic category, 'atypical psychosis', most psychotic patients are currently classified into two major diagnostic categories, schizophrenia and bipolar disorder, by the Diagnostic and Statistical Manual of Mental Disorders (4th edn; DSM-IV) criteria. 'Atypical psychosis' is characterized by acute confusion without systematic delusion, emotional instability, and psychomotor excitement or stupor. Such clinical features resemble those seen in organic mental syndrome, and differential diagnosis is often difficult. Because patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) sometimes show organic mental disorder, 'atypical psychosis' may be caused by mutations of mitochondrial DNA (mtDNA) in some patients. In the present study whole mtDNA was sequenced for seven patients with various psychotic disorders, who could be categorized as 'atypical psychosis'. None of them had known mtDNA mutations pathogenic for mitochondrial encephalopathy. Two of seven patients belonged to a subhaplogroup F1b1a with low frequency. These results did not support the hypothesis that clinical presentation of some patients with 'atypical psychosis' is a reflection of subclinical mitochondrial encephalopathy. However, the subhaplogroup F1b1a may be a good target for association study of 'atypical psychosis'.
C1 RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Wako, Saitama 3510198, Japan.
   Univ Tokyo, Fac Med, Dept Neuropsychiat, Tokyo 113, Japan.
   Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.
   Teikyo Univ, Sch Med, Dept Psychiat, Tokyo 173, Japan.
   Natl Inst Neurosci, Dept Mental Disorder Res, Tokyo, Japan.
   Univ Tokyo, Dept Psychiat, Hlth Serv Ctr, Tokyo, Japan.
   NTT E Kanto Med Ctr, Dept Psychiat, Tokyo, Japan.
C3 RIKEN; University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Teikyo University; National Center for Neurology & Psychiatry - Japan; University of Tokyo; Kanto Medical Center NTT EC
RP RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Hirosawa 2-1, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.jp
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   CARROLL BT, 1994, J NEUROPSYCH CLIN N, V6, P122
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   ELLISON JM, 1984, ANN EMERG MED, V13, P521, DOI 10.1016/S0196-0644(84)80518-1
   Feddersen B, 2003, NEUROLOGY, V61, P1149, DOI 10.1212/01.WNL.0000092497.53706.1B
   Hatotani N, 1996, PSYCHIAT CLIN NEUROS, V50, P1, DOI 10.1111/j.1440-1819.1996.tb01656.x
   Husted J, 1998, AM J MED GENET, V81, P156, DOI 10.1002/(SICI)1096-8628(19980328)81:2<156::AID-AJMG6>3.0.CO;2-U
   JABLENSKY A, 1995, EUR ARCH PSY CLIN N, V245, P202, DOI 10.1007/BF02191798
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177
   Kogelnik AM, 1997, NUCLEIC ACIDS RES, V25, P196, DOI 10.1093/nar/25.1.196
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   MITSUDA H, 1965, ACTA PSYCHIAT SCAND, V41, P372, DOI 10.1111/j.1600-0447.1965.tb04996.x
   MORGANHUGHES JA, 1982, BRAIN, V105, P553, DOI 10.1093/brain/105.3.553
   Ojaimi J, 1998, CEREBROVASC DIS, V8, P102, DOI 10.1159/000015826
   SELTZER B, 1978, AM J PSYCHIAT, V135, P13
   Stöber G, 1998, PSYCHIATR GENET, V8, P213
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   Talbot-Stern JK, 2000, EMERG MED CLIN N AM, V18, P199, DOI 10.1016/S0733-8627(05)70118-8
   Tanaka M, 2004, ANN NY ACAD SCI, V1011, P7, DOI 10.1196/annals.1293.002
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Tanaka M, 1996, METHODS ENZYMOL, V264, P407, DOI 10.1016/S0076-6879(96)64037-3
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Yamazaki M, 1991, RINSHO SHINKEIGAKU, V31, P1219
NR 29
TC 32
Z9 32
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-1316
EI 1440-1819
J9 PSYCHIAT CLIN NEUROS
JI Psychiatry Clin. Neurosci.
PD AUG 15
PY 2005
VL 59
IS 4
BP 497
EP 503
DI 10.1111/j.1440-1819.2005.01404.x
PG 7
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 946LS
UT WOS:000230574300018
PM 16048457
DA 2024-11-01
ER

PT J
AU Bradshaw, PC
   Samuels, DC
AF Bradshaw, PC
   Samuels, DC
TI A computational model of mitochondrial deoxynucleotide metabolism and DNA replication
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE simulation; nucleotide phosphorylation; nucleoside transport; mitochondrial DNA
ID nucleoside-diphosphate kinase; rat-liver mitochondria; performance liquid-chromatography; gtp-amp phosphotransferase; thymidine kinase; deoxyribonucleoside kinases; deoxyguanosine kinase; triphosphate pools; depletion myopathy; thymidylate kinase
AB We present a computational model of mitochondrial deoxynucleotide metabolism and mitochondrial DNA (mtDNA) synthesis. The model includes the transport of deoxynucleosides and deoxynucleotides into the mitochondrial matrix space, as well as their phosphorylation and polymerization into mtDNA. Different simulated cell types (cancer, rapidly dividing, slowly dividing, and postmitotic cells) are represented in this model by different cytoplasmic deoxynucleotide concentrations. We calculated the changes in deoxynucleotide concentrations within the mitochondrion during the course of a mtDNA replication event and the time required for mtDNA replication in the different cell types. On the basis of the model, we define three steady states of mitochondrial deoxynucleotide metabolism: the phosphorylating state (the net import of deoxynucleosides and export of phosphorylated deoxynucleotides), the desphosphorylating state (the reverse of the phosphorylating state), and the efficient state (the net import of both deoxynucleosides and deoxynucleotides). We present five testable hypotheses based on this simulation. First, the deoxynucleotide pools within a mitochondrion are sufficient to support only a small fraction of even a single mtDNA replication event. Second, the mtDNA replication time in postmitotic cells is much longer than that in rapidly dividing cells. Third, mitochondria in dividing cells are net sinks of cytoplasmic deoxynucleotides, while mitochondria in postmitotic cells are net sources. Fourth, the deoxynucleotide carrier exerts the most control over the mtDNA replication rate in rapidly dividing cells, but in postmitotic cells, the NDPK and TK2 enzymes have the most control. Fifth, following from the previous hypothesis, rapidly dividing cells derive almost all of their mtDNA precursors from the cytoplasmic deoxynucleotides, not from phosphorylation within the mitochondrion.
C1 Virginia Polytech & State Univ, Virginia Bioinformat Inst, Bioinformat Facil I 0477, Blacksburg, VA 24061 USA.
C3 Virginia Polytechnic Institute & State University
RP Virginia Polytech & State Univ, Virginia Bioinformat Inst, Bioinformat Facil I 0477, Blacksburg, VA 24061 USA.
EM dsamuels@vbi.vt.edu
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   ATTARDI G, 1975, J CELL SCI, V19, P55
   BERK AJ, 1973, J BIOL CHEM, V248, P2722
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Camins A, 1996, LIFE SCI, V58, P753, DOI 10.1016/0024-3205(95)02353-4
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   COHEN A, 1983, J BIOL CHEM, V258, P2334
   COLLINS A, 1987, EUR J BIOCHEM, V169, P299, DOI 10.1111/j.1432-1033.1987.tb13612.x
   Copeland William C, 2003, SCIENTIFICWORLDJOURNAL, V3, P34
   Curbo S, 2003, BIOCHEM BIOPH RES CO, V311, P440, DOI 10.1016/j.bbrc.2003.10.018
   Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006
   DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861
   Erent M, 2001, EUR J BIOCHEM, V268, P1972, DOI 10.1046/j.1432-1327.2001.2076.doc.x
   ERIKSSON S, 1994, ADV ENZYME REGUL, V34, P13, DOI 10.1016/0065-2571(94)90006-X
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   Gaillard RK, 2002, ANTIMICROB AGENTS CH, V46, P1005, DOI 10.1128/AAC.46.4.1005-1013.2002
   GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925
   GEAR ARL, 1972, J CELL BIOL, V54, P325, DOI 10.1083/jcb.54.2.325
   GLAS U, 1966, J CELL BIOL, V29, P507, DOI 10.1083/jcb.29.3.507
   GREGER J, 1980, ENZYME, V25, P26, DOI 10.1159/000459211
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x
   HARMENBERG J, 1983, INTERVIROLOGY, V20, P48, DOI 10.1159/000149373
   Henneré G, 2003, J CHROMATOGR B, V789, P273, DOI 10.1016/S1570-0232(03)00099-0
   Huang D, 2003, J CHROMATOGR B, V784, P101, DOI 10.1016/S1570-0232(02)00780-8
   Iacobazzi V, 2001, CYTOGENET CELL GENET, V93, P40, DOI 10.1159/000056945
   JACKSON RC, 1980, CANCER RES, V40, P1286
   Jiménez A, 2000, EUR J PHARMACOL, V398, P31, DOI 10.1016/S0014-2999(00)00297-1
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Kacser H, 1973, SYMP SOC EXP BIOL, V27, P65
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050
   Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200
   Lambeth DO, 1997, J BIOL CHEM, V272, P24604, DOI 10.1074/jbc.272.39.24604
   LEE LS, 1977, J BIOL CHEM, V252, P5686
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Maher AD, 2003, EUR J BIOCHEM, V270, P3953, DOI 10.1046/j.1432-1033.2003.03783.x
   MARONGIU ME, 1990, BIOCHEM PHARMACOL, V39, P1523, DOI 10.1016/0006-2952(90)90516-N
   Martí R, 2003, CLIN CHEM LAB MED, V41, P845, DOI 10.1515/CCLM.2003.128
   Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4
   MAYBAUM J, 1980, J CHROMATOGR, V188, P149, DOI 10.1016/S0021-9673(00)88425-3
   Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9
   Mehus JG, 1999, HUM GENET, V104, P454, DOI 10.1007/s004390050987
   Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405
   MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032
   Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225
   PAK YK, 1990, J BIOL CHEM, V265, P14298
   Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783
   Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205
   PILLWEIN K, 1987, CANCER RES, V47, P3092
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   RAATIKAINEN MJP, 1992, BIOCHIM BIOPHYS ACTA, V1099, P238
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239
   REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025
   ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Sampol J, 2001, J AM SOC NEPHROL, V12, P1721, DOI 10.1681/ASN.V1281721
   Sjöberg AH, 2001, ANTIMICROB AGENTS CH, V45, P739, DOI 10.1128/AAC.45.3.739-742.2001
   SNYDER RD, 1988, MUTAT RES, V209, P51, DOI 10.1016/0165-7992(88)90110-8
   SNYDER RD, 1984, MUTAT RES, V131, P163, DOI 10.1016/0167-8817(84)90057-9
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   TAMIYA N, 1989, BIOCHIM BIOPHYS ACTA, V995, P28, DOI 10.1016/0167-4838(89)90229-X
   TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P257, DOI 10.1111/j.1432-1033.1979.tb12818.x
   TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P263, DOI 10.1111/j.1432-1033.1979.tb12819.x
   TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361
   Tsuiki H, 2000, J CELL BIOCHEM, V76, P254, DOI 10.1002/(SICI)1097-4644(20000201)76:2<254::AID-JCB9>3.0.CO;2-G
   Turner TE, 2004, COMPUT BIOL CHEM, V28, P165, DOI 10.1016/j.compbiolchem.2004.05.001
   Valdés R, 2002, BIOCHEM BIOPH RES CO, V296, P575, DOI 10.1016/S0006-291X(02)00919-1
   WALTERS RA, 1973, BIOCHIM BIOPHYS ACTA, V319, P336, DOI 10.1016/0005-2787(73)90173-1
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WATKINS LF, 1987, MOL CELL BIOCHEM, V77, P153
   WATKINS LF, 1987, MOL CELL BIOCHEM, V77, P71
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
NR 85
TC 24
Z9 27
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD MAY 15
PY 2005
VL 288
IS 5
BP C989
EP C1002
DI 10.1152/ajpcell.00530.2004
PG 14
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 917KY
UT WOS:000228461700005
PM 15634740
DA 2024-11-01
ER

PT J
AU Qiu, XZ
   Yu, L
   Zhang, LS
   Qin, JQ
   Liao, H
   Yang, J
   Ouyang, J
AF Qiu, XZ
   Yu, L
   Zhang, LS
   Qin, JQ
   Liao, H
   Yang, J
   Ouyang, J
TI A new mitochondrial RNA deletion fragment accelerated by oxidative stress in rat L6 cells
SO DNA SEQUENCE
LA English
DT Article
DE mitochondrial RNA; deletion; oxidative stress; L6 cells
ID alzheimers-disease; dna; mutagenesis; apoptosis; genome
AB RNA deletions may be easier to detect and more extensive than DNA deletions. Two large deletion fragments (1120 and 7811 bp) of mitochondrial RNA were observed in rat L6 muscle cells. At the site of the 1120 bp deletion, the remaining RNA fragment was re-linked by a short additional section (GGTATGAAGCT). These kinds of deletions were accelerated by oxidative stress and were not observed in mitochondrial DNA.
C1 So Med Univ, Dept Anat, Guangzhou 510515, Peoples R China.
C3 Southern Medical University - China
RP So Med Univ, Dept Anat, Guangzhou 510515, Peoples R China.
EM jouyang@fimmu.com
CR Aljanabi SM, 1997, NUCLEIC ACIDS RES, V25, P4692, DOI 10.1093/nar/25.22.4692
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Chamberlain JR, 1996, NUCLEIC ACIDS RES, V24, P3158, DOI 10.1093/nar/24.16.3158
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   Doetsch PW, 2002, MUTAT RES-FUND MOL M, V510, P131, DOI 10.1016/S0027-5107(02)00258-0
   Gibson GE, 2000, ANN NEUROL, V48, P297, DOI 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z
   Hanna MG, 1999, CELL MOL LIFE SCI, V55, P691, DOI 10.1007/s000180050327
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Lenaz G, 1999, ACTA BIOCHIM POL, V46, P1
   MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283
   Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427
   Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5
   SULIMAN HB, 2000, FREE RADIC BIOL MED, V32, P246
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   Xu JX, 2004, ANN NY ACAD SCI, V1011, P57, DOI 10.1196/annals.1293.006
NR 15
TC 0
Z9 0
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1042-5179
EI 
J9 DNA SEQUENCE
JI DNA Seq.
PD OCT 15
PY 2005
VL 16
IS 5
BP 335
EP 339
DI 10.1080/10425170500224495
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 978EB
UT WOS:000232855300003
PM 16323266
DA 2024-11-01
ER

PT J
AU Kato, T
AF Kato, T
TI Mitochondrial dysfunction in bipolar disorder:: From <SUP>31</SUP>P-magnetic resonance spectroscopic findings to their molecular mechanisms
SO INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL 63
LA English
DT Review
ID n-acetyl-aspartate; progressive external ophthalmoplegia; brain phosphorus-metabolism; wolfram-syndrome gene; mood disorders; synaptic plasticity; intracellular ph; dna deletion; frontal-lobe; phosphoinositide metabolism
CR BARBER D, 1993, EDUC TRAIN MENT RET, V28, P13
   Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273
   BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587
   Bertolino A, 2003, BIOL PSYCHIAT, V53, P906, DOI 10.1016/S0006-3223(02)01911-X
   BROOKE NSR, 1994, P NATL ACAD SCI USA, V91, P1903, DOI 10.1073/pnas.91.5.1903
   Cecil KM, 2002, BIPOLAR DISORD, V4, P357, DOI 10.1034/j.1399-5618.2002.02235.x
   Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x
   CHICUREL ME, 1992, J COMP NEUROL, V325, P169, DOI 10.1002/cne.903250204
   Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450
   DEICKEN RF, 1995, J AFFECT DISORDERS, V33, P195, DOI 10.1016/0165-0327(94)00089-R
   Deicken RF, 2003, AM J PSYCHIAT, V160, P873, DOI 10.1176/appi.ajp.160.5.873
   DEICKEN RF, 1995, AM J PSYCHIAT, V152, P915
   Evans KL, 2000, AM J MED GENET, V96, P158, DOI 10.1002/(SICI)1096-8628(20000403)96:2<158::AID-AJMG6>3.0.CO;2-8
   Furlong RA, 1999, NEUROSCI LETT, V277, P123, DOI 10.1016/S0304-3940(99)00865-4
   Goodwin FK, 2007, MANIC DEPRESSIVE ILL, V0, P0
   Hamakawa H, 2004, PSYCHIAT CLIN NEUROS, V58, P82, DOI 10.1111/j.1440-1819.2004.01197.x
   Hamakawa H, 1999, PSYCHOL MED, V29, P639, DOI 10.1017/S0033291799008442
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   Iwamoto K, 2004, MOL PSYCHIATR, V9, P406, DOI 10.1038/sj.mp.4001437
   IWAMOTO K, 2004, HUM MOL GENET 1124, V0, P0
   Jonas EA, 2003, J NEUROSCI, V23, P8423
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   KATO T, 1995, PSYCHOL MED, V25, P557, DOI 10.1017/S003329170003347X
   Kato T, 1998, J NEUROL SCI, V155, P182, DOI 10.1016/S0022-510X(97)00308-0
   Kato T, 1996, J AFFECT DISORDERS, V37, P67, DOI 10.1016/0165-0327(95)00050-X
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 1996, AM J MED GENET, V67, P546, DOI 10.1002/(SICI)1096-8628(19961122)67:6<546::AID-AJMG6>3.0.CO;2-F
   Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133
   KATO T, 1992, J AFFECT DISORDERS, V26, P223, DOI 10.1016/0165-0327(92)90099-R
   Kato T, 2000, INT J NEUROPSYCHOPH, V3, P83, DOI 10.1017/S1461145799001674
   Kato T, 2003, INT J NEUROPSYCHOPH, V6, P379, DOI 10.1017/S1461145703003717
   Kato T, 2003, NEUROSCI LETT, V338, P21, DOI 10.1016/S0304-3940(02)01334-4
   Kato T, 1998, EUR ARCH PSY CLIN N, V248, P301, DOI 10.1007/s004060050054
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   KATO T, 1991, J AFFECT DISORDERS, V22, P185, DOI 10.1016/0165-0327(91)90064-Y
   Kato T, 1997, BIOL PSYCHIAT, V42, P311, DOI 10.1016/S0006-3223(96)00377-0
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246
   Kirk R, 1999, AM J HUM GENET, V65, P508, DOI 10.1086/302507
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Lambert D, 2002, BIPOLAR DISORD, V4, P31, DOI 10.1034/j.1399-5618.4.s1.7.x
   Levy M, 2003, J BIOL CHEM, V278, P17727, DOI 10.1074/jbc.M212878200
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Manji H K, 2001, PSYCHOPHARMACOL BULL, V35, P5
   Matsuo K, 2002, PSYCHOL MED, V32, P1029, DOI 10.1017/S0033291702005974
   MATSUO K, 2004, WORLD FED SOC BIOL P, V0, P0
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   McMahon FJ, 2000, AM J PSYCHIAT, V157, P1058, DOI 10.1176/appi.ajp.157.7.1058
   Middle F, 2000, AM J MED GENET, V96, P154, DOI 10.1002/(SICI)1096-8628(20000403)96:2<154::AID-AJMG5>3.0.CO;2-F
   Miyaoka H, 1997, BIOL PSYCHIAT, V42, P524, DOI 10.1016/S0006-3223(97)00280-1
   Modica-Napolitano JS, 2004, BIOL PSYCHIAT, V55, P273, DOI 10.1016/S0006-3223(03)00784-4
   Moore CM, 2000, BIPOLAR DISORD, V2, P207, DOI 10.1034/j.1399-5618.2000.20302.x
   Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Murashita J, 2000, PSYCHOL MED, V30, P107, DOI 10.1017/S0033291799001439
   NAKASHIMA K, 1996, ACTA NEUROL SCAND S, V166, P96
   Nakatani N, 2004, PHARMACOGENOMICS J, V4, P114, DOI 10.1038/sj.tpj.6500234
   Ohtsuki T, 2000, J AFFECT DISORDERS, V58, P11, DOI 10.1016/S0165-0327(99)00099-3
   Öngür D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290
   Onishi H, 1997, BIOL PSYCHIAT, V41, P1137, DOI 10.1016/S0006-3223(97)00005-X
   Pfeiffer DR, 2001, IUBMB LIFE, V52, P205, DOI 10.1080/15216540152846019
   Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Rae C, 1996, P ROY SOC B-BIOL SCI, V263, P1061, DOI 10.1098/rspb.1996.0156
   Rae C, 2003, DEV NEUROSCI-BASEL, V25, P324, DOI 10.1159/000073509
   Rajkowska G, 2001, BIOL PSYCHIAT, V49, P741, DOI 10.1016/S0006-3223(01)01080-0
   Rango M, 2001, J CEREBR BLOOD F MET, V21, P85, DOI 10.1097/00004647-200101000-00011
   RENSHAW PF, 1987, MAGN RESON MED, V4, P221, DOI 10.1002/mrm.1910040303
   Riehemann S, 2002, PSYCHIAT RES-NEUROIM, V114, P113, DOI 10.1016/S0925-4927(02)00007-0
   Schroeter ML, 2002, NEUROREPORT, V13, P1675, DOI 10.1097/00001756-200209160-00021
   Serretti A, 2003, PSYCHIAT GENET, V13, P121, DOI 10.1097/01.ypg.0000056172.32550.f9
   Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Silverstone PH, 2003, INT CLIN PSYCHOPHARM, V18, P73, DOI 10.1097/00004850-200303000-00002
   Silverstone PH, 2002, HUM PSYCHOPHARM CLIN, V17, P425, DOI 10.1002/hup.434
   Soares JC, 1997, PSYCHOPHARMACOL BULL, V33, P685
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   STANTON PK, 1986, BRAIN RES, V382, P185, DOI 10.1016/0006-8993(86)90130-7
   STINE OC, 1993, BIOL PSYCHIAT, V42, P311
   Strakowski SM, 2000, BIPOLAR DISORD, V2, P148, DOI 10.1034/j.1399-5618.2000.020302.x
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D
   SWIFT RG, 1991, AM J PSYCHIAT, V148, P775
   Torres R, 2001, MOL PSYCHIATR, V6, P39, DOI 10.1038/sj.mp.4000787
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Volz HP, 1998, EUR ARCH PSY CLIN N, V248, P289, DOI 10.1007/s004060050052
   Washizuka S, 2004, BIOL PSYCHIAT, V56, P483, DOI 10.1016/j.biopsych.2004.07.004
   Washizuka S, 2003, INT J NEUROPSYCHOPH, V6, P421, DOI 10.1017/S1461145703003778
   Washizuka S, 2003, AM J MED GENET B, V120B, P72, DOI 10.1002/ajmg.b.20041
   Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200
   Winsberg ME, 2000, BIOL PSYCHIAT, V47, P475, DOI 10.1016/S0006-3223(99)00183-3
   Yamawaki S, 1998, LIFE SCI, V62, P1665, DOI 10.1016/S0024-3205(98)00125-8
   Yildiz A, 2001, BIOL PSYCHIAT, V50, P3, DOI 10.1016/S0006-3223(01)01069-1
   Yildiz A, 2001, PSYCHIAT RES-NEUROIM, V106, P181, DOI 10.1016/S0925-4927(01)00082-8
   Zazueta C, 2003, J MEMBRANE BIOL, V191, P113, DOI 10.1007/s00232-002-1047-z
   Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980
NR 100
TC 23
Z9 26
U1 0
U2 6
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0074-7742
EI 
J9 INT REV NEUROBIOL
PD JUN 15
PY 2005
VL 63
IS 
BP 21
EP 40
DI 10.1016/S0074-7742(05)63002-4
PG 20
WC Neurosciences
SC Neurosciences & Neurology
GA BBW53
UT WOS:000228146100002
PM 15797464
DA 2024-11-01
ER

PT J
AU Grazina, M
   Silva, F
   Santana, I
   Pratas, J
   Santiago, B
   Oliveira, M
   Carreira, I
   Cunha, LS
   Oliveira, C
AF Grazina, M
   Silva, F
   Santana, I
   Pratas, J
   Santiago, B
   Oliveira, M
   Carreira, I
   Cunha, LS
   Oliveira, C
TI Mitochondrial DNA variants in a Portuguese population of patients with Alzheimer's disease
SO EUROPEAN NEUROLOGY
LA English
DT Article
DE Alzheimer's disease; nitochondrial DNA; NADH dehydrogenase subunit 1; 16S rRNA; nucleotides
ID parkinsons-disease; point mutations; sequence; cardiomyopathy; dementia; region
AB Alzheimer's disease ( AD) is the most common neurodegenerative disorder associated with dementia in late adulthood. Mitochondrial respiratory chain impairment has been detected in the brain, muscle, fibroblasts and platelets of AD patients, indicating a possible involvement of mitochondrial DNA ( mtDNA) in the etiology of the disease. Several reports have identified mtDNA mutations in AD patients, but there is no consensual opinion regarding the cause of the impairment. We have studied mtDNA NADH dehydrogenase subunit 1 nucleotides 3337 - 3340, searching for mutations. Our study group included 129 AD patients and 125 healthy age- matched controls. We have found alterations in two AD patients: one had two already known mtDNA modifications ( 3197 T- C and 3338 T- C) and the other a novel transition ( 3199 T- C) which, to our knowledge, has not been described before. Copyright (C) 2005 S. Karger AG, Basel.
C1 Univ Coimbra, Fac Med, Inst Biochem, PT-30004504 Coimbra, Portugal.
   Univ Hosp Coimbra, Neurol Unit, Coimbra, Portugal.
   Univ Hosp Coimbra, Ctr Neurosci Coimbra, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)
RP Univ Coimbra, Fac Med, Inst Biochem, Rua Larga, PT-30004504 Coimbra, Portugal.
EM mgrazina@ci.uc.pt
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637
   BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   CHALMERS RM, 1995, J NEUROL, V242, P332, DOI 10.1007/BF00878877
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Grazina M, 2004, NEUROBIOL DIS, V15, P306, DOI 10.1016/j.nbd.2003.11.004
   Grazina M, 2003, EUR NEUROL, V50, P60, DOI 10.1159/000070863
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7
   HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   LIN FH, 1992, BIOCHEM BIOPH RES CO, V182, P238, DOI 10.1016/S0006-291X(05)80136-6
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   PETRUZZELLA V, 1992, BIOCHEM BIOPH RES CO, V186, P491, DOI 10.1016/S0006-291X(05)80834-4
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Swerdlow RH, 2002, INT REV NEUROBIOL, V53, P341
NR 20
TC 8
Z9 13
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0014-3022
EI 1421-9913
J9 EUR NEUROL
JI Eur. Neurol.
PD JUN 15
PY 2005
VL 53
IS 3
BP 121
EP 124
DI 10.1159/000085555
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 937JV
UT WOS:000229921300002
PM 15860916
DA 2024-11-01
ER

PT J
AU Crimi, M
   Bordoni, A
   Menozzi, G
   Riva, L
   Fortunato, F
   Galbiati, S
   Del Bo, R
   Pozzoli, U
   Bresolin, N
   Comi, GP
AF Crimi, M
   Bordoni, A
   Menozzi, G
   Riva, L
   Fortunato, F
   Galbiati, S
   Del Bo, R
   Pozzoli, U
   Bresolin, N
   Comi, GP
TI Skeletal muscle gene expression profiling in mitochondrial disorders
SO FASEB JOURNAL
LA English
DT Article
DE mt DNA; MELAS; PEO; real-time PCR; microarray
ID cluster-analysis; dna mutations; transcription; nuclear; variability; biogenesis; metabolism; activation; mechanisms; apoptosis
AB Extremely variable clinic and genetic features characterize mitochondrial encephalomyopathy (ME M). Pathogenic mitochondrial DNA(mtDNA) defects can be divided into large-scale rearrangements and single point mutations. Clinical manifestations become evident when a threshold percentage of the total mtDNA is mutated. In some MEM, the "mutant load" in an affected tissue is directly related to the severity of the phenotype. However, the clinical phenotype is not simply a direct consequence of the relative abundance of mutated mtDNA. Other factors, such as nuclear background, can contribute to the disease process, resulting in a wide range of phenotypes caused by the same mutation. Using Affymetrix oligonucleotide cDNA microarrays(HG-U133A), we studied the gene expression profile of muscle tissue biopsies obtained from 12 MEM patients[4 common 4977 bp deleted mtDNA and 8 A3243G:4 progressive external ophthalmoplegia (PEO) and 4 mitochondrial myopathy,encephalopathy, lactic cidosis, and stroke-like episodes syndrome (MELAS) phenotypes] compared with age matched healthy individuals. We found several differentially expressed genes: 35 were markedly up-regulated in the mtDNA macro-deletion group(vs. the control group) and 4 decreased; 56 genes were dysregulated in A3243G-related disorders(53 down-regulated in PEO and 3 upregulated in MELAS). Finally, 12 genes were similarly regulated in the majority of the MEM patients under study. Amongst these, we identified an increased expression of genes related to the metabolism of the amino groups, as well as of several genes involved in genetic information processing. Moreover, few genes were similarly decreased in MEM patients vs. the control group. Real-time PCR demonstrated excellent reproducibility of the microarray-based findings. The observed expression changes are likely to represent a molecular signature for mitochondrial disorders. Furthermore,the differential expression profile of MELAS(A3243G) vs. PEOA3243G may support a role of nuclear background in contributing to these different clinical phenotypes. MEM microarray data are available from GEO database (http://www.ncbi.nlm.nih.gov/geo/) wit h the access ion number: GSE1462.
C1 Univ Milan, Dept Neurol Sci, I-20122 Milan, Italy.
   IRCCS, Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy.
   CEND, I-20122 Milan, Italy.
   IRCCS E Medea La Nostra Famiglia, I-23842 Bosisio Parini, LC, Italy.
   Polytech Univ, Dept Biomed Engn, I-20133 Milan, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Eugenio Medea; Polytechnic University of Milan
RP Univ Milan, Dept Neurol Sci, Pad Ne Ponti,Via F Sforza 35, I-20122 Milan, Italy.
EM marcreamy@tiscali.it
CR ALESSI DR, 1993, ONCOGENE, V8, P2015
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x
   Bakay M, 2002, BMC BIOINFORMATICS, V3, P0, DOI 10.1186/1471-2105-3-4
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x
   Cerri C, 1983, MITOCHONDRIAL PATHOL, V0, P141
   Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324
   DELSITE R, 2002, MOL CANCER, V12, P6
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104
   Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Jiang DW, 2003, J BIOL CHEM, V278, P4763, DOI 10.1074/jbc.M210410200
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827
   Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X
   Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200
   Löhr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Morris SM, 1997, GENE, V193, P157, DOI 10.1016/S0378-1119(97)00099-1
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   RAO VLR, 1994, NEUROSCI LETT, V170, P27, DOI 10.1016/0304-3940(94)90230-5
   Raychaudhuri S, 2000, PAC SYMP BIOCOMPUT, V0, P455
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   SCRIVER CR, 1995, METABOLIC BASIS INHE, V0, P0
   SEIDEL U, 1988, GENE, V66, P135, DOI 10.1016/0378-1119(88)90231-4
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3
   Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200
   Yuen T, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/30.10.e48
NR 55
TC 52
Z9 54
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB 15
PY 2005
VL 19
IS 2
BP 866
EP +
DI 10.1096/fj.04-3045fje
PG 30
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology
GA 905TE
UT WOS:000227591900009
PM 15728662
DA 2024-11-01
ER

PT J
AU Kornblum, C
   Broicher, R
   Walther, E
   Herberhold, S
   Klockgether, T
   Herberhold, C
   Schröder, R
AF Kornblum, C
   Broicher, R
   Walther, E
   Herberhold, S
   Klockgether, T
   Herberhold, C
   Schröder, R
TI Sensorineural hearing loss in patients with chronic progressive external ophthalmoplegia or Kearns-Sayre syndrome
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE mitochondrial disorders; hearing loss; mtDNA deletion; CPEO; cochlear dysfunction
ID mitochondrial-dna; cochlear implantation; point mutation; melas syndrome; quantitative-analysis; defects; gene; impairment; features
AB In the present study we assessed the prevalence and nature of hearing loss in patients with chronic progressive external ophthalmoplegia (CPEO) or Kearns-Sayre syndrome (KSS) due to single large-scale mitochondrial DNA (mtDNA) deletion or mtDNA tRNA(Leu (UUR)) A3243G point mutation (A3243G PM). 14 patients with mtDNA deletion and three patients with A3243G PM underwent audiological evaluation comprising pure-tone and speech audiometry as well as transient evoked otoacoustic emissions (OAE). Audiological evaluation revealed hearing impairment in 10/17 patients. Hearing loss was mild to moderate predominantly affecting high frequencies in five patients with subjective hearing problems (three patients with mtDNA deletions, two patients with A3243G PM). Subclinical hearing deficits restricted to high frequencies were seen in further five asymptomatic patients (four patients with mtDNA deletions, one patients with A3243G PM). Audiological findings suggested a cochlear origin of hearing loss in all subjects. Our results demonstrate that CPEO or KSS patients due to mtDNA deletion or A3243G PM are at high risk of developing sensorineural hearing deficits.
C1 Univ Bonn, Dept Neurol, D-53105 Bonn, Germany.
   Univ Bonn, Dept Otorhinolaryngol, D-5300 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Univ Bonn, Dept Neurol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM cornelia.kornblum@ukb.uni-bonn.de
CR Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   DAVIS A, 1998, HEARING ADULTS, V0, P0
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Griffiths TD, 2001, JARO-J ASSOC RES OTO, V2, P172, DOI 10.1007/s101620010061
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   LINDSAY JR, 1976, ARCH OTOLARYNGOL, V102, P747
   LIU XZ, 1994, ANN OTO RHINOL LARYN, V103, P428, DOI 10.1177/000348949410300602
   MORGANHUGHES JA, 1995, MYOLOGY, V0, P1610
   Nishizaki K, 1999, ACTA OTO-LARYNGOL, V0, P34
   Oshima T, 1996, LARYNGOSCOPE, V106, P43, DOI 10.1097/00005537-199601000-00009
   Rosenthal EL, 1999, AM J OTOL, V20, P187
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Takahashi K, 2003, LARYNGOSCOPE, V113, P1362, DOI 10.1097/00005537-200308000-00018
   Tamagawa Y, 1997, ANN OTO RHINOL LARYN, V106, P338
   THALMANN R, 1981, ACTA OTO-LARYNGOL, V91, P535, DOI 10.3109/00016488109138539
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Usami S, 2000, J MED GENET, V37, P38, DOI 10.1136/jmg.37.1.38
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Warrick PD, 1997, J LARYNGOL OTOL, V111, P279, DOI 10.1017/S0022215100137089
   Yamaguchi T, 1997, ADV OTO-RHINO-LARYNG, V52, P321
   Yamasoba T, 1996, LARYNGOSCOPE, V106, P49, DOI 10.1097/00005537-199601000-00010
   Yamasoba T, 1999, NEUROLOGY, V52, P1705, DOI 10.1212/WNL.52.8.1705
   Zwirner P, 2001, LARYNGOSCOPE, V111, P515, DOI 10.1097/00005537-200103000-00024
NR 26
TC 13
Z9 17
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD SEP 15
PY 2005
VL 252
IS 9
BP 1101
EP 1107
DI 10.1007/s00415-005-0827-7
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 965TX
UT WOS:000231974300014
PM 15827867
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Gurgel-Giannetti, J
AF DiMauro, S
   Gurgel-Giannetti, J
TI The expanding phenotype of mitochondrial myopathy
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Article
DE coenzyme Q10 deficiency; homoplasmy; mitochondrial DNA; nuclear DNA; polymerase gamma
ID polg mutations; complex-i; dna; encephalomyopathy; deficiency; gene; cardiolipin
AB Purpose of review Our understanding of mitochondrial diseases (defined restrictively as defects in the mitochondrial respiratory chain) continues to progress apace. In this review we provide an update of information regarding disorders that predominantly or exclusively affect skeletal muscle. Recent findings Most recently described mitochondrial myopathies are due to defects in nuclear DNA, including coenzyme Q(10) deficiency, and mutations in genes that control mitochondrial DNA (mtDNA) abundance and structure such as POLG and TK2. Barth syndrome, an X-linked recessive mitochondrial myopathy/cardiopathy, is associated with altered lipid composition of the inner mitochondrial membrane, but a putative secondary impairment of the respiratory chain remains to be documented. Concerning the 'other genome', the role played by mutations in protein encoding genes of mtDNA in causing isolated myopathies has been confirmed. It has also been confirmed that mutations in tRNA genes of mtDNA can cause predominantly myopathic syndromes and - contrary to conventional wisdom - these mutations can be homoplasmic. Summary Defects in the mitochondrial respiratory chain impair energy production and almost invariably involve skeletal muscle, causing exercise intolerance, myalgia, cramps, or fixed weakness, which often affects extraocular muscles and results in droopy eyelids (ptosis) and progressive external ophthalmoplegia.
C1 Columbia Univ, Med Ctr, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA.
   Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
C3 Columbia University; Universidade Federal de Minas Gerais
RP Columbia Univ, Med Ctr, Dept Neurol, Coll Phys & Surg, 630 W 168th St,4-420, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hirano M, 2004, TOP CURR GENET, V8, P177
   Horváth R, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.015024
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LAMPERTI C, 2005, IN PRESS ARCH NEUROL, V0, P0
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Owczarek J, 2005, PHARMACOL REP, V57, P23
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   SALVIATI L, 2005, IN PRESS NEUROLOGY, V0, P0
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
NR 34
TC 31
Z9 32
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1350-7540
EI 1473-6551
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD OCT 15
PY 2005
VL 18
IS 5
BP 538
EP 542
DI 10.1097/01.wco.0000179761.63486.1a
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 977SP
UT WOS:000232823800008
PM 16155436
DA 2024-11-01
ER

PT J
AU Nikali, K
   Suomalainen, A
   Saharinen, J
   Kuokkanen, M
   Spelbrink, JN
   Lönnqvist, T
   Peltonen, L
AF Nikali, K
   Suomalainen, A
   Saharinen, J
   Kuokkanen, M
   Spelbrink, JN
   Lönnqvist, T
   Peltonen, L
TI Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID sensory neuropathy; dna deletions; gene; iron; friedreichs; expression; assignment; homolog; cloning; iosca
AB Infantile onset spinocerebellar ataxia (IOSCA) (MIM 271245) is a severe autosomal recessively inherited neurodegenerative disorder characterized by progressive atrophy of the cerebellum, brain stem and spinal cord and sensory axonal neuropathy. We report here the molecular background of this disease based on the positional cloning/candidate approach of the defective gene. Having established the linkage to chromosome 10q24, we restricted the critical DNA region using single nucleotide polymorphism-based haplotypes. After analyzing all positional candidate transcripts, we identified two point mutations in the gene C10orf2 encoding Twinkle, a mitochondrial deoxyribonucleic acid (mtDNA)-specific helicase, and a rarer splice variant Twinky, underlying IOSCA. The founder IOSCA mutation, homozygous in all but one of the patients, leads to a Y508C amino acid change in the polypeptides. One patient, heterozygous for Y508C, carries a silent coding region cytosine to thymine transition mutation in his paternal disease chromosome. This allele is expressed at a reduced level, causing the preponderance of messenger RNAs encoding Y508C polypeptides and thus leads to the IOSCA disease phenotype. Previously, we have shown that different mutations in this same gene cause autosomal dominant progressive external ophthalmoplegia (adPEO) with multiple mtDNA deletions (MIM 606075), a neuromuscular disorder sharing a spectrum of symptoms with IOSCA. IOSCA phenotype is the first recessive one due to Twinkle and Twinky mutations, the dominant PEO mutations affecting mtDNA maintenance, but in IOSCA, mtDNA stays intact. The severe neurological phenotype observed in IOSCA, a result of only a single amino acid substitution in Twinkle and Twinky, suggests that these proteins play a crucial role in the maintenance and/or function of specific affected neuronal subpopulations.
C1 Natl Publ Hlth Inst, Dept Mol Med, Helsinki 00290, Finland.
   Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Univ Tampere, Tampere Univ Hosp, Inst Med Technol, Tampere 33014, Finland.
   Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Dept Child Neurol, Helsinki 00250, Finland.
C3 Finland National Institute for Health & Welfare; University of Helsinki; Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital
RP Kings Coll London, MRC, Dev Neurobiol Ctr, New Hunts House,Guys Hosp Campus, London SE1 1UL, England.
EM kaisu.nikali@tiscali.co.uk
CR Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709
   Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200
   HARDING AE, 1983, ADV NEUROL, V61, P1
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Kuokkanen M, 2003, GUT, V52, P647, DOI 10.1136/gut.52.5.647
   Li HZ, 1999, MECH DEVELOP, V87, P169, DOI 10.1016/S0925-4773(99)00125-2
   Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   LONNQVIST T, 1995, THESIS U HELSINKI FI, V0, P0
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   NIKALI K, 1995, AM J HUM GENET, V56, P1088
   Nikali K, 1997, GENOMICS, V39, P185, DOI 10.1006/geno.1996.4465
   Nikali K, 2002, GENE, V299, P111, DOI 10.1016/S0378-1119(02)01019-3
   NIKALI K, 1998, THESIS NATL PUBLIC H, V0, P0
   NORIO R, 1973, ANN CLIN RES, V5, P109
   Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003
   Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913
   Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8
   Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Scarano V, 2001, NEUROLOGY, V57, P159, DOI 10.1212/WNL.57.1.159
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Tengan CH, 1996, BIOCHEM MOL MED, V58, P130, DOI 10.1006/bmme.1996.0040
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   VANDENPLAS S, 1984, J MED GENET, V21, P164, DOI 10.1136/jmg.21.3.164
   Varilo T, 1996, GENOME RES, V6, P870, DOI 10.1101/gr.6.9.870
   Wilson RB, 2000, ANN NEUROL, V47, P659, DOI 10.1002/1531-8249(200005)47:5<659::AID-ANA17>3.0.CO;2-T
   Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
NR 38
TC 150
Z9 160
U1 0
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2005
VL 14
IS 20
BP 2981
EP 2990
DI 10.1093/hmg/ddi328
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 972AG
UT WOS:000232425600003
PM 16135556
DA 2024-11-01
ER

PT J
AU Leshinsky-Silver, E
   Lev, D
   Tzofi-Berman, Z
   Cohen, S
   Saada, A
   Yanoov-Sharav, M
   Gilad, E
   Lerman-Sagle, T
AF Leshinsky-Silver, E
   Lev, D
   Tzofi-Berman, Z
   Cohen, S
   Saada, A
   Yanoov-Sharav, M
   Gilad, E
   Lerman-Sagle, T
TI Fulminant neurological deterioration in a neonate with Leigh syndrome due to a maternally transmitted missense mutation in the mitochondrial ND3 gene
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Leigh; mtDNA; complex I; ND3
ID complex-i deficiency; dna g13513a mutation; trna(trp) gene; disease; encephalopathy; insertion
AB Leigh syndrome can result from both nuclear and mitochondrial DNA defects. Mutations in complex V genes of the respiratory chain were considered until recently as the most frequent cause for mitochondrial inherited Leigh syndrome, while gene defects in complex I were related to recessive Leigh syndrome. Recently few reports of mutations in the mitochondrial-encoded complex I subunit genes causing Leigh syndrome have been reported. We describe a I-month-old baby who acutely deteriorated, with abrupt onset of brainstem dysfunction, due to basal ganglia lesions extending to the brainstem. A muscle biopsy demonstrated complex I deficiency. Subsequent analysis of the mitochondrial genome revealed a homoplastic T10191C mutation in the ND3 gene (in blood and muscle), resulting in a substitution of serine to proline. Hair root analysis revealed a 50% mutant load, reflecting heteroplasmy in early embryonic stages. The mutation was also detected in his mother (5%). Western blot analysis revealed a decrease of the 20 kDa subunit (likely ND6) and of the 30 kDa subunit (NDUFA9), which is probably due to instability attributed to the inability to form subcomplexes with ND3. This is the first description of infantile Leigh syndrome due to a maternally transmitted T 10 19 1 C substitution in ND3 and not due to a de novo mutation. This mutation is age and tissue dependent and therefore may not be amenable to prenatal testing. (c) 2005 Elsevier Inc. All rights reserved.
C1 Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
   Wolfson Med Ctr, Mitochondrial Dis Ctr, Holon, Israel.
   Wolfson Med Ctr, Inst Med Genet, Holon, Israel.
   Wolfson Med Ctr, Pediat Intens Care Unit, Holon, Israel.
   Wolfson Med Ctr, Pediat Neurol Unit, Holon, Israel.
   Shaare Zedek Med Ctr, Metab Unit, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Leshinsky-Silver, E (corresponding author), Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
EM leshinsky@wolfson.health.gov.il
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200
   BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Howell N, 1996, NEUROLOGY, V46, P219, DOI 10.1212/WNL.46.1.219
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Komaki H, 2003, MITOCHONDRION, V2, P293, DOI 10.1016/S1567-7249(03)00003-5
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   PASTORES GM, 1994, AM J MED GENET, V50, P265, DOI 10.1002/ajmg.1320500310
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2004, ANAL BIOCHEM, V335, P66, DOI 10.1016/j.ab.2004.08.015
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
NR 33
TC 31
Z9 40
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 26
PY 2005
VL 334
IS 2
BP 582
EP 587
DI 10.1016/j.bbrc.2005.06.134
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 950TI
UT WOS:000230880200040
PM 16023078
DA 2024-11-01
ER

PT J
AU Horváth, R
   Schoser, BGH
   Müller-Höcker, J
   Völpel, M
   Jaksch, M
   Lochmüller, H
AF Horváth, R
   Schoser, BGH
   Müller-Höcker, J
   Völpel, M
   Jaksch, M
   Lochmüller, H
TI Mutations in mtDNA-encoded cytochrome c oxidase subunit genes causing isolated myopathy or severe encephalomyopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial myopathy; cytochrome c oxidase deficiency; COII; COIII mutations
ID onset mitochondrial myopathy; stop-codon mutation; nonsense mutation; missense mutation; i gene; deficiency; microdeletion; patient; protein
AB We report on clinical, histological and genetic findings in two patients carrying novel heteroplasmic mutations in the mitochondrial cytochrome c oxidase subunit genes COII and COIII. The first patient, a 35 year-old man had a multisystemic disease, with clinical symptoms of bilateral cataract, sensori-neural hearing loss, myopathy, ataxia, cardiac arrhythmia, depression and short stature and carried a 7970 G > T (E129X) nonsense mutation in COII. A sudden episode of metabolic encephalopathy caused by extremely high blood lactate lead to coma. The second patient developed exercise intolerance and rhabdomyolysis at age 22 years. A heteroplasmic missense mutation 9789 T > C (S195P) was found in skeletal muscle, but not in blood and myoblasts pointing to a sporadic mutation. Our report of two patients with isolated COX deficiency and new mutations in COX subunit genes may help to draw more attention to this type of mtDNA defects and provide new aspects for counselling affected families. (C) 2005 Elsevier B.V. All rights reserved.
C1 Acad Hosp Schwabing, Metab Dis Ctr Munich Schwabing, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, D-80804 Munich, Germany.
   Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   Univ Munich, Inst Pathol, Munich, Germany.
   Hosp Krefeld, Inst Pathol, Krefeld, Germany.
C3 University of Munich; University of Munich
RP Acad Hosp Schwabing, Metab Dis Ctr Munich Schwabing, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, Kolner Pl 1, D-80804 Munich, Germany.
EM Rita.Horvath@lrz.uni-muenchen.de
CR Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   DAurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200
   DALAKAS MC, 1994, ANN NEUROL, V35, P482, DOI 10.1002/ana.410350418
   DiMauro S, 2003, NEW ENGL J MED, V349, P1294
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Horváth R, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.015024
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Macmillan CJ, 1996, PEDIATR NEUROL, V14, P203, DOI 10.1016/0887-8994(96)00018-5
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MULLERHOCKER J, 1989, HUM PATHOL, V20, P666, DOI 10.1016/0046-8177(89)90154-8
   MUNOZINFANTE JP, 2000, FEBS LETT, V468, P1
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 27
TC 43
Z9 47
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC 15
PY 2005
VL 15
IS 12
BP 851
EP 857
DI 10.1016/j.nmd.2005.09.005
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 998JD
UT WOS:000234313700006
PM 16288875
DA 2024-11-01
ER

PT J
AU Rylova, SN
   Albertioni, F
   Flygh, G
   Eriksson, S
AF Rylova, SN
   Albertioni, F
   Flygh, G
   Eriksson, S
TI Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE NRTI; mitochondrial toxicity; adipocytes; myoblasts; deoxynucleoside kinases; 5'-nucleotidases
ID reverse-transcriptase inhibitors; dna depletion; substrate-specificity; thymidine kinase-1; differentiation; mechanism; assays; pools
AB Nucleoside reverse transcriptase inhibitor (NRTI) treatment of HIV is associated with complications, including lipodystrophy (LD) and myopathy. Inhibition of mitochondrial DNA polymerase and depletion of mtDNA by NRTI triphosphates are believed to be key mechanisms in NRTI toxicity. Here, we determined the activities and mRNA levels of deoxynucleoside kinases (dNK) and 5'-nucleotidases (5'-NT) controlling the rate-limiting step in intracellular phosphorylation of NRTIs in cell models representing adipose, muscle tissue and peripheral blood cells using specific assays and Taqman RT-PCR. In vitro phosphorylation of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-didehydro-2',3'-dideoxythymidine (d4T) in extracts was also determined. 3T3-L1 adipocytes showed similar activity of mitochondrial thymidine kinase-2 (TK2) and deoxyguanosine kinase (dGK) but 3- to 36-fold lower levels of cytosolic deoxycytidine kinase (dCK), thymidine kinase-1 (TK1) and thymidine monophosphate kinase (TMPK) and higher levels of deoxyribonucleotidase activity compared to proliferating 3T3-L1. dCK, dGK and TK2 activities correlated with their mRNA levels in proliferating, resting and differentiating 3T3-L1. Differentiated L6 myoblasts had lower activities of cytosolic dNK's and TMPK, higher dGK and similar TK2 and deoxyribonucleotidases (dNT) activities compared to proliferating myoblasts. TK2 was the limiting dNK activity while dGK was predominant in adipocytes and myocytes. Activity profiles revealed limited capacity to phosphorylate dThd and dCyd in adipocytes and myocytes compared to proliferating cells and CEM lymphocytes. Phosphorylation of AZT and d4T was low in adipocytes and myocytes, and the presence of these analogs inhibited the phosphorylation of dThd by TK2 suggesting that mitochondrial toxicity of some NRTIs in adipocytes and myocytes is due to the depletion of normal mitochondrial dNTP pools. (c) 2005 Elsevier Inc. All rights reserved.
C1 Ctr Biomed, SLU, Sect Vet Med Biochem, Dept Mol Biosci, SE-75123 Uppsala, Sweden.
   Karolinska Univ Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden.
C3 Swedish University of Agricultural Sciences; Karolinska Institutet; Karolinska University Hospital
RP Ctr Biomed, SLU, Sect Vet Med Biochem, Dept Mol Biosci, POB 575, SE-75123 Uppsala, Sweden.
EM Svetlana.Rylova@bmc.uu.se
CR Anderson PL, 2004, CLIN INFECT DIS, V38, P743, DOI 10.1086/381678
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002
   Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Davison FD, 1996, J NEUROL, V243, P648, DOI 10.1007/BF00878661
   De Arcangelis V, 2003, MOL BIOL CELL, V14, P1392, DOI 10.1091/mbc.E02-03-0156
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   Elsner P, 1998, AM J PHYSIOL-ENDOC M, V275, PE925, DOI 10.1152/ajpendo.1998.275.6.E925
   ERIKSSON S, 1984, EXP CELL RES, V155, P129, DOI 10.1016/0014-4827(84)90774-2
   Eriksson S, 2002, RECENT ADVANCES IN NUCLEOSIDES: CHEMISTRY AND CHEMOTHERAPY, V0, PP455, DOI 10.1016/B978-044450951-2/50016-3
   Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200
   FROST SC, 1985, J BIOL CHEM, V260, P2646
   Ives D H, 1978, METHODS ENZYMOL, V51, P337
   Jacobsson B, 1998, BIOCHEM PHARMACOL, V56, P389, DOI 10.1016/S0006-2952(98)00032-X
   Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9
   McComsey Grace, 2002, AIDS REVIEWS, V4, P140
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Rampazzo C, 2002, BIOCHEM BIOPH RES CO, V293, P258, DOI 10.1016/S0006-291X(02)00206-1
   Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239
   Ropp PA, 1996, ARCH BIOCHEM BIOPHYS, V336, P105, DOI 10.1006/abbi.1996.0537
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WANG LY, 1993, J BIOL CHEM, V268, P22847
NR 39
TC 41
Z9 45
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2005
VL 69
IS 6
BP 951
EP 960
DI 10.1016/j.bcp.2004.12.010
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 907TW
UT WOS:000227741900008
PM 15748706
DA 2024-11-01
ER

PT J
AU Chien, KR
   Karsenty, G
AF Chien, KR
   Karsenty, G
TI Longevity and lineages: Toward the integrative biology of degenerative diseases in heart, muscle, and bone
SO CELL
LA English
DT Review
ID growth-factor-i; mitochondrial-dna deletions; skeletal-muscle; life-span; oxidative stress; mice; osteoclast; differentiation; hypertrophy; regulator
AB Human aging is characterized by debilitating diseases, including heart failure, cardiac pacemaker defects, muscle wasting, and osteoporosis, in heart, skeletal muscle, and bone. Recent studies are identifying pathways for these aging-related diseases by examining how the process of aging influences tissue-specific progenitors and differentiated cell lineages in these organ systems. These advances form a foundation for new therapeutic strategies to delay the onset of aging-related disorders.
C1 Univ Calif San Diego, Sch Med, Inst Mol Med, La Jolla, CA 92093 USA.
   Baylor Coll Med, Dept Genet, Houston, TX 77030 USA.
C3 University of California System; University of California San Diego; Baylor College of Medicine
RP Univ Calif San Diego, Sch Med, Inst Mol Med, La Jolla, CA 92093 USA.
EM kchien@partners.org; karsenty@bcm.tmc.edu
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2
   Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603
   Bernecker Oliver Y, 2003, SEMIN THORAC CARDIOVASC SURG, V15, P268, DOI 10.1016/S1043-0679(03)70006-9
   Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0
   Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3
   Cheng G, 1999, DEVELOPMENT, V126, P5041
   Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6
   Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991
   Cooper Cyrus, 1996, P419, V0, P0
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251
   Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101
   DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706
   Elefteriou F, 2003, ENDOCRINOLOGY, V144, P3842, DOI 10.1210/en.2003-0369
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219
   Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Harada T, 2003, PATHOL INT, V53, P382, DOI 10.1046/j.1440-1827.2003.01485.x
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701
   Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549
   Iwanaga Y, 2004, J CLIN INVEST, V113, P727, DOI 10.1172/JCI200418716
   Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255
   Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1
   Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200
   Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215
   Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836
   Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614
   Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457
   Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789
   Musarò A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101
   Musarò A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839
   Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2
   Perls T, 2003, ANN INTERN MED, V139, P445, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00013
   Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009
   Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355
   Ruiz-Lozano P, 2003, NAT GENET, V33, P8, DOI 10.1038/ng0103-8
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Schmidt U, 2000, CIRCULATION, V101, P790, DOI 10.1161/01.CIR.101.7.790
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   SCHWARTZ JB, 2005, BRAUNWALDS HEART DIS, V0, P1925
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Winn N, 2002, COLD SPRING HARB SYM, V67, P507, DOI 10.1101/sqb.2002.67.507
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
   YOSHIDA H, 1990, NATURE, V16, P391
   Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525
NR 83
TC 113
Z9 129
U1 2
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD FEB 25
PY 2005
VL 120
IS 4
BP 533
EP 544
DI 10.1016/j.cell.2005.02.006
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 901GR
UT WOS:000227271500010
PM 15734685
DA 2024-11-01
ER

PT J
AU Karadag, A
   Avci, Z
   Catal, F
   Odemis, E
AF Karadag, A
   Avci, Z
   Catal, F
   Odemis, E
TI Cytochrome c oxidase deficiency in a child with isolated myopathy
SO FETAL AND PEDIATRIC PATHOLOGY
LA English
DT Article
DE child; cytochrome c oxidase deficiency; isolated myopathy
ID infantile mitochondrial myopathy
AB Cytochrome c oxidase ( COX) deficiency is the most commonly recognized respiratory chain defect in childhood. The disease is clinically heterogeneous with phenotypes including Leigh syndrome, hepatic failure and myopathies. COX deficiency has been associated with mitochondrial DNA mutations in COX I, II, and III with large- scale deletions of the mitochondrial genome and with point mutations in mitochondrial tRNA genes. Here we report on a 3.5- year- old girl with a rare type of isolated myopathy due to COX deficiency.
C1 Fatih Univ, Fac Med, Dept Pediat, Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Pediat, TR-06490 Ankara, Turkey.
C3 Fatih University; Baskent University
RP Karadag, A (corresponding author), Hosdere Caddesi 145, TR-06540 Ankara, Turkey.
EM ahmetkaradag@gmail.com
CR Darin N, 2003, NEUROPEDIATRICS, V34, P311
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Liet JM, 2003, J PEDIATR-US, V142, P62, DOI 10.1067/mpd.2003.mpd0333
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   SAUNIER P, 1995, NEUROMUSCULAR DISORD, V5, P285, DOI 10.1016/0960-8966(94)00071-G
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   WU CM, 1992, MUSCLE NERVE, V15, P1258, DOI 10.1002/mus.880151107
   ZEVIANI M, 1986, ARCH NEUROL-CHICAGO, V43, P1198, DOI 10.1001/archneur.1986.00520110084025
NR 12
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1551-3815
EI 
J9 FETAL PEDIATR PATHOL
JI Fetal Pediatr. Pathol.
PD MAY-JUN 15
PY 2005
VL 24
IS 3
BP 149
EP 153
DI 10.1080/15227950500304218
PG 5
WC Pathology; Pediatrics
SC Pathology; Pediatrics
GA 992TH
UT WOS:000233906400003
PM 16338876
DA 2024-11-01
ER

